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Summary 
 
Candida infections of humans are an increasingly prevalent problem. Most candidal 
infections are superficial, occurring on mucosal surfaces, however, systemic 
infection can arise in immunocompromised individuals and these are life 
threatening. Candida is recognised by host immune cells through pattern 
recognition receptors e.g. dectin-1. The immune cells then produce cytokines to 
drive adaptive immune responses. The type of T-helper (Th) cell response that 
occurs is an important factor in whether candidal colonisation or clearance occurs.  
The overall focus of this research was to employ in vivo and in vitro studies to 
assess the nature of the immune response to Candida albicans. Increased pro-
inflammatory Th17 and Th1 responses were evident in denture stomatitis (DS) 
patients based on cytokine profiles. In chronic hyperplastic candidosis (CHC) tissues 
significantly higher levels of CD4+, IL-12A+, IL-17A+ and EBi3+ positive cells were 
detected by immunohistochemistry (IHC) compared to control tissues. This finding 
was indicative of an increased Th17 response in CHC. IHC detection of individual 
cytokine subunits in cells was more difficult to interpret, but suggested both IL-35 
and IL-12 cytokines were present, indicating Treg and Th1 cell responses, 
respectively. Challenge of a human monocyte cell line and human peripheral blood 
mononuclear cells (PBMCs) with C. albicans resulted in IL-23 cytokine expression 
indicative of a Th17 response. Interestingly, lipopolysaccharide (LPS) was important 
in enhancing the ability of dendritic cells to recognise and phagocytose C. albicans 
via dectin-1. The recall response from PBMCs stimulated with C. albicans resulted 
in a significant Th17 recall response.  
Extrapolation of these findings to the host interaction with Candida requires 
additional clinical studies and assessment of other forms of superficial mucosal 
candidosis. This research does however indicate that host recognition of C. albicans 
leads to a predominantly pro-inflammatory Th17 response.  
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Chapter 1: 
General Introduction 
  
2 
 
1.0 Introduction  
Numerous microorganisms come into contact with the human body and some of 
these including bacteria, viruses, fungi and protozoa are capable of causing disease. 
Given their eukaryotic nature, compared with bacteria and viruses it is only 
comparatively recently that the importance of fungi in human infection has been 
recognised. 
Fungi are ubiquitously found in the natural environment, however, few have been 
identified as residing in humans and most of these have been in the oral cavity 
(Köhler et al., 2015). Most frequently encountered are fungi of the genera Candida, 
Saccharomyces, Geotrichum and Cryptococcus, and these organisms are generally 
not involved in infection (Köhler et al., 2015). Candida species are the most 
prevalently encountered in humans, where they normally colonise mucosal 
surfaces without causing pathogenic insult (Kong and Jabra-Rizk, 2015). However, 
Candida species are also the most frequent causes of human fungal infections, 
particularly in debilitated patients. Collectively these infections are termed 
candidoses (pl) or a candidosis (sing.) and several distinct forms of infection types 
can result (Millsop and Fazel, 2016) (sections 1.1.3 and 1.1.4). Whilst systemic 
candidoses may occur in severely compromised individuals, most commonly, 
superficial mucosal candidoses are encountered. Mucosal infections generally 
occur when an individual is immunocompromised or debilitated by another means.  
Traditionally, much attention has focused on the role of host debilitation in 
determining whether candidal clearance, carriage or infection occurs. However, the 
mechanism by which the host recognises and responds to Candida on the mucosal 
surface remains an area of limited study. The research described in this thesis aims 
to assess these interactions and with focus given to T cell responses (section 1.2.4) 
to Candida during oral mucosal infection and in in vitro experiments.  
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1. 1 Candida  
In taxonomic terms, Candida species were all originally deemed to have the 
common feature of lacking a sexual reproductive cycle. Candida yeast cells 
(blastospores) are typical of other eukaryotic cells although their reproduction 
occurs through the process of budding. Candida may however exist in a variety of 
morphological forms, which develop depending on the local nutrient availability 
and other environmental factors. 
Over 17 different Candida species are associated with human infection (Sardi et al., 
2013), with C. albicans considered the most pathogenic species despite an 
apparent increasing prevalence of the non-C. albicans Candida species (McManus 
and Coleman, 2014). To highlight this, a dataset analysing invasive fungal infections 
in 2019 patients found that C. albicans was the most prevalent species being 
involved in 45.6% of cases (Horn et al., 2009). There was, however, an increasing 
number (54.4%) of non-Candida albicans Candida species reported in this study. 
 
1.1.1 Candida albicans 
Candida albicans is a polymorphic fungus able to grow as yeast, pseudohyphae and 
true hyphae (Gow et al., 2012). Yeast are eukaryotic, single cells that are about 5 
µm in size, and are readily cultured using standard laboratory media. 
Pseudohyphae are conjoined elongated yeast cells, and are produced by the most 
pathogenic Candida species (Erwig and Gow, 2016). True hyphae are long 
branching filamentous structures that can be differentiated from pseudohyphae by 
the presence of defined septa along their length. It is the ability of C. albicans to 
morphologically change from yeast to hyphae that has been implicated in tissue 
invasion of the host (Gow et al., 2012). In addition, Candida hyphae have an 
increased size and an elongated shape, which makes it more difficult for their 
eradication by phagocytosis (Erwig and Gow, 2016). Normally in infected human 
tissues, a mixture of both yeast and hyphae are seen.  
A distinguishing feature of C. albicans from most other species is its ability to 
generate germ tubes (rudimentary hyphae) when cultured in serum for 2-4 h at 
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37°C. Germ tubes are new true hyphal extensions produced by yeast (Odds, 1988). 
The only other Candida species known to form germ tubes is C. dubliniensis 
(Sullivan and Coleman, 1998) and the sharing of this phenotypic characteristic with 
C. albicans has often resulted in the misidentification of C. dubliniensis. 
Candida albicans is an extremely heterogeneous species whose strains differ 
markedly, both phenotypically and genotypically (Bartie et al., 2001). This variation 
can potentially be associated with different pathogenicity and resistance (Sherry et 
al., 2014). It is therefore interesting to speculate that candidal strain variation could 
determine which type of infection occurs, or whether the host manages to clear 
the colonising strain or retains it as a commensal. It is conceivable that strain 
variation could promote pathogenesis not only through elevated expression of 
virulence determinants (section 1.1.4), but also by affecting the nature of the hosts’ 
immune response. 
Candida albicans strains that are unable to form hyphae or maintain hyphal 
formation are non-invasive in vitro and in mucosal models and this indicates the 
key role that hyphae play in disease progression (Wächtler et al., 2011, Tang et al., 
2016). Importantly, there are relatively few studies on the influence of C. albicans 
strain variation on host responses (Chapter 3). 
 
1.1.1.1 Identification of Candida albicans 
Phenotypic and molecular methods can be used to identify Candida species. 
Identification methods include standard phenotypic analyses of sugar utilisation, 
enzyme production, morphological transformation, and more recently, molecular 
methods based on PCR. Strain typing approaches include multilocus sequence 
typing (MLST), pulsed-field gel electrophoresis (PFGE), random amplified 
polymorphic deoxyribonucleic acid (RAPD) analysis, repeat sequence amplification 
(REP) PCR, matrix-assisted laser desorption ionization-time of flight mass 
spectrometry (MALDI-TOF MS) and micro-array methods (Criseo et al., 2015). Of 
the diverse methods for typing C. albicans, MLST is considered the gold standard 
and has been used to characterise epidemiological relationships of C. albicans 
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(Bougnoux et al., 2002, McManus and Coleman, 2014) and identify clades (section 
1.1.1.2). MLST is based on PCR and subsequent sequencing of DNA sequences 
derived from multiple housekeeping genes. MLST is highly reproducible and has 
been developed as an optimal consensus for typing strains within the species 
(Bougnoux et al., 2003).  
 
1.1.1.2 Clade typing of Candida albicans  
A clade is a genetically related group of closely related strain types. Using MLST, 18 
distinct clades (1 to 18) have been recognised for C. albicans (McManus and 
Coleman, 2014). Clade analyses has revealed an extraordinary level of geographical 
specificity between C. albicans strains (Soll and Pujol, 2003, McManus and 
Coleman, 2014). Each clade and strain has equally inherited or evolved the ability 
of becoming either a commensal or pathogen. Clade 1 strains of C. albicans are 
found more frequently in superficial infections and there is a view that with time, 
clades may be identified that are more associated with invasive infection 
(McManus and Coleman, 2014). 
Currently, there are no global views of the population dynamics and epidemiology 
of C. albicans strains involved in nosocomial infection (Bougnoux et al., 2002). 
There has, however, been a particular clade identified where the C. albicans strains 
exhibit resistance to 5-flucytosine (5-FC). This result provided the first genetic 
evidence for clade-specific drug resistance (Pujol et al., 2004). In 2007, Odds, et al., 
examined a panel of 1391 C. albicans isolates and found 97% could be assigned to 
one of 17 clades. The five most populous clades differed significantly in their 
proportions of commensal and pathogenic isolates (Odds et al., 2007). This may be 
a potential reason for variation in the host immune response to different Candida 
strains (Chapter 3). 
 
1.1.2 Prevalence of Candida in the human body 
As previously mentioned, C. albicans normally colonises as a benign commensal 
fungal organism, but can become an opportunistic pathogen. The switch between 
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these interactions with the host is thought to be dependent on changes in host-
related factors (Kong and Jabra-Rizk, 2015). Candida colonises many body locations 
including the oral cavity, gastrointestinal tract, anus, and groin of healthy 
individuals, and the vagina and vulva of women. Candida albicans has been isolated 
from 30-70% of healthy individuals and from at least one of the above mentioned 
body locations (Perlroth et al., 2007) and is the most prevalent Candida species at 
these sites (Millsop and Fazel, 2016). The occurrence of Candida in biofilms on the 
surfaces of denture prostheses is notably high, with an incidence of 78.3% in 
complete denture wearers (Abu-Elteen and Abu-Elteen, 1998). 
 
1.1.3 Candidosis 
Infections caused by Candida have seemingly increased over recent decades, and 
this has been attributed to numerous factors including the AIDS epidemic, the 
increase in the average age of the population and the more widespread use of 
immunosuppressant medication (Silva et al., 2012b). Candidoses can be grouped 
into systemic or superficial infection with the former associated with high mortality 
rates. Superficial infections are however seen more frequently, and in certain 
patients can be a potential cause of systemic infections. 
 
1.1.3.1 Systemic candidosis 
Systemic candidosis, which is associated with deep organ infection, is much less 
frequent than superficial infection of mucous membranes and skin (Naglik et al., 
2014). To highlight this lower prevalence, the incidence of solid organ infection in 
transplant patients is estimated at less than 2% (Silveira et al., 2013).  
Systemic candidosis can manifest as localised primary disease or as disseminated 
candidosis, where several organs are simultaneously affected. In 
immunosuppressed patients, superficial colonisation can lead to extensive regional 
involvement leading to systemic infection and possible death (Section 1.1.3.1) 
(Epstein, 1990, Naglik et al., 2014). Candida is the fourth most common pathogen 
in blood stream infections in many intensive care units, with C. albicans the most 
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commonly isolated species (Mukherjee et al., 2003). Candida is also a leading cause 
of health-care associated infective endocarditis in children (Marom et al., 2011) 
and has been  associated with ventilator acquired pneumonia (Delle Rose et al., 
2016).  
Candidaemia is a significant cause of morbidity and mortality in hospitalised 
patients (Rajendran et al., 2016), with mortality rates estimated between 38 and 
49% (Wey et al., 1988, Rajendran et al., 2016). A study in the USA found that 
Candida was responsible for 9% of nosocomial infections, ranking joint third (along 
with enterococci) as the most common cause (Wisplinghoff et al., 2004). The true 
incidence of disseminated candidosis is likely to be under-estimated by datasets 
derived from blood cultures as it has been shown that approximately 30% of 
autopsy-proven disseminated candidosis cases were previously negative for 
Candida by blood culture (Perlroth et al., 2007). High mortality from candidaemia is 
linked to the organism’s ability to form biofilms on medical devices, particular 
central venous catheters and endotracheal tubes (Kojic and Darouiche, 2004, 
Rajendran et al., 2016).  
 
1.1.3.2 Superficial candidosis 
There are many examples of human mucosal candidoses (Table 1.1). Oral 
candidosis is one of the most prevalent mucocutaneous forms of candidosis and is 
caused by the presence of Candida on the oral mucosal surface, usually in an 
immunocompromised individual (Tang et al., 2016). Oral infections are mainly 
superficial and easily treated, but they can cause severe morbidity in an individual 
with a compromised immune response (Tang et al., 2016). 
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Table 1.1: Body locations for Candida infection and specific candidoses 
  
Candidosis location Disease  
Oral mucosa  Oral candidosis 
Genitalia Vulvovaginal candidosis 
 Candida balanoposthitis 
Skin Candida onychia 
 Candida paronychia 
Gastrointestinal tract Oesophageal candidosis 
Respiratory tract Laryngeal candidosis 
 Pulmonary candidosis 
Urinary tract Candida cystitis 
 Candida urethritis 
Eye Candida infections of the cornea 
 Candida conjunctivitis 
Bones and joints Candida arthritis 
 Candida osteomyelitis 
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1.1.3.3 Oral candidosis 
Oral candidosis can be recognised and classified based on the presence of clinical 
lesions colonised by Candida. Table 1.2 lists the Candida species most frequently 
encountered with oral health and infection. As previously mentioned, Candida is 
most frequently encountered as a harmless commensal, although oral carriage 
rates are dependent on the studied population (Rathod et al., 2015). Typically, 35-
55% of healthy mouths are colonised by Candida (De-la-Torre et al., 2016). In 
immunocompromised patients, such as those with acquired immunodeficiency, the 
incidence of oral Candida carriage can be as high as 90% (Ribeiro Ribeiro et al., 
2015).The underlying driver of change from commensal candidal carriage to 
infection is the cause for much debate and research (Patil et al., 2015). Oral 
candidosis has historically been referred to as a ‘disease of the diseased’ because 
of its high incidence in patients suffering from an identified debilitating and 
predisposing factor (Samaranayake and MacFarlane, 1990). There are four primary 
forms of oral candidosis as well as secondary oral lesions involving Candida. All 
forms of oral candidosis have specific characteristics with regards to lesion 
appearance and associated risk factors (Figure 1.1) (Section 1.1.3.12). 
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Table 1.2: The majority of the Candida species isolated from the oral cavity  
and estimated prevalence. 
Candida species Estimated prevalence Reference 
Candida albicans 61% 
 
38.8% 
(Muadcheingka and 
Tantivitayakul, 2015) 
(De-la-Torre et al., 2016) 
Candida glabrata 15.2% (Muadcheingka and 
Tantivitayakul, 2015) 
Candida tropicalis 10.4% (Muadcheingka and 
Tantivitayakul, 2015) 
Candida krusei 1.6% (Muadcheingka and 
Tantivitayakul, 2015) 
Candida dubliniensis 2% 
 
3.2% 
(Muadcheingka and 
Tantivitayakul, 2015) 
(De-la-Torre et al., 2016) 
Candida guilliermondii 0.4% 
 
1.6% 
(Muadcheingka and 
Tantivitayakul, 2015) 
(De-la-Torre et al., 2016) 
Candida parapsilosis 3.2% 
 
3.7% 
(Muadcheingka and 
Tantivitayakul, 2015) 
(De-la-Torre et al., 2016) 
Candida lusitaniae 2% (Muadcheingka and 
Tantivitayakul, 2015) 
Candida kefyr 3.6% (Muadcheingka and 
Tantivitayakul, 2015) 
Candida inconspicua <1% (De-la-Torre et al., 2016) 
Candida norvegenesis <1% (De-la-Torre et al., 2016) 
Candida rugosa 1.1% (Sardi et al., 2013) 
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1.1.3.4 Candida species in oral candidosis 
In the oral cavity, approximately 12 Candida species (Table 1.2) have been isolated 
(Muadcheingka and Tantivitayakul, 2015), with C. albicans the most prevalent 
(Deepa et al., 2014). Candida albicans is the predominant cause of oral infection, 
but there is evidence that non-C. albicans Candida species have increasing 
involvement. This apparent change in epidemiology could be an outcome of the 
increased use of immunosuppressive medications, illness and use of broad 
spectrum antibiotics (Sardi et al., 2013), but may also be due to the improvement 
in diagnostic tools and identification methods (Section 1.1.1.1).  
 
1.1.3.5 Classification of oral candidosis 
Classification of oral candidosis has been fraught with difficulties due to the many 
manifestations the disease takes and the multifaceted aetiology (Farah et al., 
2000). Oral candidosis can be subdivided into three basic types namely, acute, 
chronic and Candida-associated lesions. Further subdivisions into primary and 
secondary forms are also made, as are oral manifestations of systemic 
mucocutaneous candidosis (Table 1.3). As mentioned previously, four primary 
forms of oral candidosis are recognised and these are pseudomembranous 
candidosis, acute erythematous candidosis, chronic erythematous candidosis and 
chronic hyperplastic candidosis (Figure 1.1). 
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Figure 1.1: Clinical presentation of oral candidosis and Candida-associated lesions; 
a) pseudomembranous candidosis, b) acute erythematous candidosis, c) chronic 
erythematous candidosis, d) chronic hyperplastic candidosis, e) angular cheilitis 
and f) median rhomboid glossitis. (Photographs a), b), c), e) and f) reproduced 
courtesy of M.A.O. Lewis). 
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Table 1.3: Classification of oral candidosis as described by Axell (1997)  
 
Primary Oral Candidosis 
 
Secondary oral candidosis 
Acute Forms                                                                     
Pseudomembranous                                                               
Erythematous 
 
Chronic Forms 
Hyperplastic 
Erythematous 
Pseudomembranous 
 
Candida-associated lesions 
Angular cheilitis 
Median rhomboid glossitis 
 
Oral manifestations of chronic mucocutaneous 
candidosis 
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1.1.3.6 Pseudomembranous candidosis (thrush) 
Pseudomembranous candidosis is typified by white patches, which may occur at a 
range of oral sites including the buccal mucosa, tongue, gingivae, oropharynx and 
hard or soft palate (Figure 1.1a). The lesions can form confluent plaques that can 
be scraped or wiped off to reveal a erythematous, and sometimes bleeding base 
(Patil et al., 2015). The pseudomembranes consist of necrotic material and 
desquamated parakeratotic epithelium, penetrated by C. albicans yeast and 
hyphae, as well as polymorphonuclear leukocytes (PMNLs) and fibrin (Lalla et al., 
2013). Candida albicans hyphae can invade as far as the stratum spinosum in this 
infection (Farah et al., 2000).  
Pseudomembranous candidosis has the highest prevalence in infants, the elderly 
and in the terminally ill (Millsop and Fazel, 2016). The infection may also occur in 
association with underlying medical conditions and immunocompromised states, 
such as diabetes or HIV (Ribeiro Ribeiro et al., 2015). On occasion, 
pseudomembranous candidosis is associated with steroid inhaler use by asthmatics 
and in patients receiving radiotherapy for head and neck cancers (Akpan and 
Morgan, 2002). Both these factors may temporarily compromise the host immunity 
causing alterations in the oral microflora (Patil et al., 2015). Individuals with 
pseudomembranous candidosis are often asymptomatic, but may complain of 
altered taste or mild discomfort if extensive oral mucosal involvement (Lalla et al., 
2013).  
 
1.1.3.7 Acute erythematous candidosis 
Acute erythematous candidosis (also known as ‘antibiotic sore mouth’) is 
characterised by areas of erythema, often on the dorsum of the tongue, palate or 
buccal mucosa and these do not present as white plaques (Figure 1.1b). The 
erythematous areas are usually associated with soreness (Millsop and Fazel, 2016). 
The histology of acute erythematous candidosis is similar to other forms of the oral 
candidosis with C. albicans hyphae superficially penetrating the epithelium. An 
associated inflammatory process is characterised by the presence of neutrophils in 
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the epithelium and a lymphocytic infiltrate in the connective tissue (Farah et al., 
2000). The condition is related to use of broad-spectrum antibiotics and/or inhaled 
steroids (Lalla et al., 2013). Indeed, the erythematous lesions in this infection 
generally resolve after cessation of antibiotic therapy. The mechanisms behind the 
relationship with antibiotics is likely to be due to local reduction in commensal 
bacterial numbers (Soysa et al., 2008), which in turn lowers bacterial-derived 
competition for Candida for adherence sites and nutrition, thereby allowing 
Candida levels to increase (Soysa et al., 2008). Other predisposing factors 
associated with erythematous candidosis include use of corticosteroids inhalers, 
HIV infection, uncontrolled diabetes mellitus, iron deficiency anaemia and vitamin 
deficiency (Millsop and Fazel, 2016). 
 
1.1.3.8 Chronic erythematous candidosis (denture stomatitis) 
Denture stomatitis (also known as denture-related stomatitis, denture-induced 
stomatitis or chronic erythematous candidosis; CEC) is a well-described candidosis 
characterised by inflammation of the oral mucosa in contact with a denture (Figure 
1.1c). Chronic erythematous candidosis is most often seen in association with a 
complete upper acrylic denture and is usually asymptomatic, with only a minority 
of individuals reporting symptoms of itching, burning, discomfort and occasional 
bleeding (Millsop and Fazel, 2016).  
Candida readily forms recalcitrant biofilms on acrylic surfaces and these provide a 
constant delivery of infectious agents and products to the overlying palatal 
mucosa, which induce inflammation (Cannon and Chaffin, 1999). The denture base 
material and whether there is a soft lining also have a role to play on the 
development of erythematous candidosis (He et al., 2006, Bulad, 2004). Higher 
numbers of C. albicans have been observed on roughened surfaces of acrylic resin 
and silicone compared to smooth surfaces (Verran and Maryan, 1997). Smoking is 
also linked to more extensive inflammation of the mucosa (Barbeau et al., 2003). 
Few studies have assessed the inflammatory mediators associated with chronic 
erythematous candidosis. However, some evidence indicates that inflammation is 
17 
 
associated with increased levels of several interleukins and infiltration by 
inflammatory cells at affected oral mucosal sites. Cytokine profiling of saliva from 
patients with chronic erythematous candidosis has largely focussed on Th1 and Th2 
related cytokines (Section 1.2.4 and chapter 2) (Leigh et al., 2002) and reported no 
significant differences between infected and non-infected control patients. There is 
currently no data available that has assessed the Th1/2/17 cytokine profiles in this 
infection.  
 
1.1.3.9 Chronic hyperplastic candidosis 
Chronic hyperplastic candidosis (CHC) is seen as chronic, discrete, raised lesions, 
which vary from small, palpable, translucent, whitish areas to large, dense, opaque 
plaques (Patil et al., 2015) (Farah et al., 2000) (Figure 1.1d). CHC lesions can occur 
at several oral mucosal sites, but are most frequently seen at the commissure 
regions of the buccal mucosa, dorsum of the tongue and the hard palate (López et 
al., 2012). Histopathological features include hyperplasia and parakeratosis of the 
surface epithelium, which is invaded by C. albicans hyphae. Polymorphonuclear 
micro abscesses form in the epithelium beneath the hyphae and a poorly 
characterised chronic inflammatory infiltrate is evident in the lamina propria. The 
condition is important because of its potential for malignant change into squamous 
cell carcinoma (SCC) (Cawson and Lehner, 1968, López et al., 2012), with up to 15% 
of cases reported to undergo malignant change (Sitheeque and Samaranayake, 
2003).  
Studies have investigated the potential mechanism of Candida in inducing 
malignancy and have highlighted the ability of some species to convert nitrite and 
nitrate into nitrosamines, and other substances to produce acetaldehyde (Scardina 
et al., 2009, Gall et al., 2013). A biopsy is often required to confirm CHC diagnosis 
and rule out dysplasia. CHC is more prevalent in tobacco smokers, those who drink 
high levels of alcohol, and middle aged men (Arruda et al., 2016) (chapter 5). 
 
1.1.3.10 Candida-associated oral lesions 
18 
 
In addition to the four primary forms of oral candidosis described above, there are 
two Candida-associated lesions, namely, angular cheilitis and median rhomboid 
glossitis (Millsop and Fazel, 2016). Angular cheilitis manifests as sore, erythematous 
areas at the corners of the mouth and is associated with high levels of intra-oral 
Candida carriage (Figure 1.1f). Median rhomboid glossitis presents as a chronic 
symmetrical reddened area on the tongue, anterior to the circumvallate papillae 
(Figure 1.1e). This area is made up of atrophic filiform papillae and biopsy reveals 
the presence of Candida in over 85% of cases (Akpan and Morgan, 2002, 
McCullough and Savage, 2005). 
 
1.1.3.11 Chronic mucocutaneous candidosis 
Chronic mucocutaneous candidosis (CMC) is a complex disorder where patients 
have chronic and recurrent candidosis involving the skin, nails and mucous 
membranes (Kirkpatrick, 1994). CMC arises from an autosomal dominant severe 
primary immunodeficiency, which also leads to autoimmunity, cerebral aneurysms, 
oropharyngeal and oesophageal cancer (van de Veerdonk and Netea, 2016). CMC 
can be grouped into different syndromes and these are associated with a variety of 
disorders (Table 1.4). 
 
Table 1.4: Different syndromes of chronic mucocutaneous candidosis as described 
by Kirkpatrick (1994)  
 
CMC and polyendocrinopathy 
Localised CMC 
Diffuse CMC 
CMC with thymoma 
CMC with interstitial keratosis 
CMC with keratitis, ichthyosis, deafness 
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CMC syndromes are all related to a primary immune deficiency and particularly 
impairment of cell-mediated immunity (Kirkpatrick, 1989). There is thought to be 
dysfunction in cytokine production leading to the features of the disease, and the 
severity of CMC depends on the T cell defect and whether there is an abnormal 
response to the Candida antigen (Kirkpatrick, 1989). Candida albicans accounts for 
the majority of CMC (Odds, 1988). 
The specific defect in cell signalling has been linked to an error in the IL-17 pathway 
(Huppler, 2012). Different genetic aetiologies have been reported to underlie CMC 
disease but each gene defect has an impact in IL-17 signalling (Okada et al., 2016). 
1.1.3.12 Host-related factors associated with oral candidosis 
Host factors play a significant part in the relative prevalence of C. albicans found in 
patients and can be divided into local and systemic factors (Table 1.5).  
 
1.1.3.12.1 Local factors associated with oral candidosis 
Local factors implicated in oral candidosis include smoking, denture wearing, poor 
oral hygiene, defective diet, steroid inhaler use, hormonal imbalances and reduced 
saliva flow (Patil et al., 2015). Effective oral hygiene regimes can reduce the 
candidal load and ultimately lower incidence of oral candidosis, and in particular 
pseudomembranous candidosis (Section 1.1.3.5).  
Candidal carriage rates are lower in non-smoking people, although the precise 
mechanism by which smoking promotes candidal colonisation is not yet 
established. There are several theories for this difference in candidal carriage found 
between smokers and non-smokers including modified epithelial interactions 
(Arendorf and Walker, 1987) and suppression of local immunity (Patil et al., 2015). 
Wearing an acrylic denture increases the risk of developing chronic erythematous 
candidosis as it creates a favourable environment for Candida to grow (Patil et al., 
2015).  
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Table 1.5: Local and systemic host factors which predispose to oral candidosis  
 
Local factors Systemic factors  
 
Mucosal damage 
- endogenous epithelial 
changes (atrophy, 
hyperplasia, dysplasia) 
- exogenous epithelial 
changes (trauma, 
maceration) 
 
Physiological states 
- Infancy 
- Old age 
Saliva 
- quantitative change (e.g. 
Sjögren’s syndrome) 
- qualitative change (e.g. pH) 
Hormonal states 
- Diabetes 
- Hypothyroidism 
- Hypo-adrenocortism 
Other members of commensal  
microflora 
Nutritional state 
- Iron deficiency 
- malnutrition 
Local steroids 
-  Inhalers 
- Topical 
Immune mechanism 
- decreased number of phagocytes 
- intrinsic defect in cell-mediated 
immunity 
 
Local antibiotics Medication related (e.g. Antibiotics, 
systemic steroids, immunosuppressive 
therapy) 
Smoking  
Carbohydrate-rich diet  
pH= Power of hydrogen concentration 
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Oral hygiene interventions that are effective in denture cleaning can lower the 
candidal bioburden and subsequently reduce incidence of chronic erythematous 
candidosis (Chapter 2). 
Saliva has several mechanisms that can limit Candida colonisation of the oral 
epithelium (Feller et al., 2014). The physical flushing action of salivary flow plays a 
role in the removal of loosely adhered Candida from oral surfaces, and salivary 
mucin can bind to C. albicans reducing attachment to the oral epithelium (Feller et 
al., 2014). Saliva is the medium that facilitates interactions between the oral 
microbiome, host innate immune cells, and their secreted modulators and is also a 
carrier for salivary proteins. As a consequence saliva unifies host defences against 
C. albicans (Salvatori et al., 2016).  
Salivary proteins (proline rich proteins [PRPs], statherins, mucins) and oral 
epithelial transglutaminase (TGase) can promote C. albicans growth by enhancing 
adherence to oral tissues, or conversely can inhibit growth through immune 
exclusion by binding and aggregating fungal cells (mucins and secretory IgA [sIgA]) 
to enable clearance by swallowing. Antifungal proteins, including salivary histatin 5 
(Hst 5), calprotectin and β-defensins (secreted by oral tissues), are inhibitory to C. 
albicans growth (Salvatori et al., 2016). The importance of saliva in preventing oral 
candidoses is clearly evident when its quantity is reduced in systemic diseases such 
as Sjögren’s Syndrome (SS), and in these cases, patients are at elevated risk of oral 
candidosis.  
Saliva can also protect from oral infection by maintaining a normal pH which is 
between 6.2 and 7.6 (Baliga et al., 2013). An unbalanced diet with an increase in 
refined carbohydrates and dairy foods leads to a reduction in pH and this provides 
an environment within which Candida can thrive (Martins et al., 2014). Salivary pH 
can also be reduced when saliva levels are lowered, as in SS. An acidic environment 
promotes candidal colonisation of mucosal surfaces (Martins et al, 2014). The 
increased colonisation at low pH levels could be related to the enhanced candidal 
adherence in acidic conditions. Topical oral medications such as inhaled 
corticosteroids can suppress the local immunity and alter the local microflora 
favouring candidal growth (Patil et al., 2015). Inhaled corticosteroids, for example 
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beclomethasone inhaler, are used to treat respiratory conditions such as asthma or 
chronic obstructive airways disease (COPD) and function by lowering bronchial 
mucosal inflammation. Topical corticosteroids are also used to treat oral 
inflammatory conditions such as oral lichen planus or recurrent aphthous 
stomatitis. Oral candidosis can be prevented by asking the patient to gargle and 
rinse the mouth after use of the topical or inhaled corticosteroid. 
 
1.1.3.12.2 Systemic host factors associated with oral candidosis 
There are several systemic host factors associated with oral candidosis (Table 1.5). 
The function of the host’s immune system is central to the likelihood of developing 
oral candidosis. An immature or weakened immune system is thought to be a key 
factor in development of oral candidosis in individuals at extremes of age (Patil et 
al., 2015). Oral candidosis is frequently found in people whose immune system is 
compromised through immunosuppressant medication, chemotherapy or AIDS 
(Salvatori et al., 2016). Oral candidosis is one of the seven cardinal infections listed 
by the World Health Organisation as an oral manifestation strongly associated with 
HIV (Patton et al., 2013). HIV infection leads to increased incidence of 
pseudomembranous candidosis (Jabra-Rizk et al., 2016) and this is linked to the 
reduced mucosal protective function in HIV-infected patients that is normally 
afforded by CD4+ T cells (Fidel, 2011). HIV positive individuals treated with highly 
active antiretroviral (HAART) medication often exhibit resolution of their oral 
candidosis (Patton et al., 2013). Treatment with HAART stops HIV replication, 
lowers viral load and improves the CD4+ T cells. It is this improvement in the CD4+ T 
cells count that leads to reduced incidence of oral candidosis.  
Use of immunosuppressive treatments have increased in recent years and the side-
effects of such medication increases host susceptibility to previously harmless 
commensals including Candida (Jabra-Rizk et al., 2016). For example liver and renal 
transplant patients will be on long term immunosuppressive medications such as 
mycophenolate mofetil or azathioprine to prevent rejection of the transplant. 
Further examples include patients with chronic rheumatological disease such as 
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rheumatoid arthritis who may be on corticosteroids or alternative 
immunosuppressant medications. 
The use of broad spectrum antibiotics can reduce bacteria levels in the oral 
microflora and this has been implicated with increased prevalence of oral 
candidosis (Martins et al., 2014) (Section 1.1.3.6). 
Head and neck patients receiving radiotherapy have an oral C. albicans prevalence 
rate of 86% (Thaweboon, 2008). This high incidence of infection has, in part, been 
attributed to reduced saliva flow caused by the destruction of the normal salivary 
tissue during the radiotherapy treatment, and therefore reducing the protective 
role of saliva (Section 1.1.3.11.1). 
Up to 77% of diabetic patients harbour Candida in their mouths (Willis et al., 2000). 
Saliva in diabetic patients has been found to contain higher glucose levels, which 
could enhance the growth of Candida in the correct environment. Glycaemic 
control in diabetic patients is highly instrumental in affecting candidal colonisation 
(Shenoy et al., 2014). However, in diabetic patients, other local factors, such as 
denture wearing, may have a greater influence than diabetic status on the amount 
and species of Candida (Manfredi et al., 2002). 
 
1.1.3.13 Management of oral candidosis 
Oral candidosis is initially managed by addressing any underlying local and systemic 
host factors. When these factors can be improved, eliminated or treated then the 
oral candidosis may resolve (Martins et al., 2014). This can be seen in cases where 
oral hygiene and denture cleaning is improved in cases of denture stomatitis 
(Chapter 2). Where an adjunct is required to reduce the microbial load 
chlorhexidine has been prescribed for use as an antiseptic oral rinse (Ellepola., 
2001). Chlorhexidine has been shown to have anti-microbial activity against 
Candida and can be used as a mouth rinse or has been shown to be effective in 
elimination of Candida from denture surfaces (Ramage et al., 2010, McCourtie et 
al., 1986).  
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In some patients with chronic autoimmune conditions such as rheumatoid arthritis 
or pemphigus vulgaris, the underlying systemic immunosuppressive medication 
cannot be altered. In these patients, topical or systemic antifungals may be 
considered to control oral candidosis. 
If medical management is required, there are several different categories of 
antifungal therapy that can be used. The two major groups of antifungals are the 
polyenes (e.g. nystatin and amphotericin) and azoles (e.g. miconazole and 
fluconazole). Depending on the drug, antifungals can be used topically for localised 
oral candidosis e.g. chronic erythematous candidosis, or systemically e.g. treatment 
of chronic hyperplastic candidosis (Williams and Lewis, 2011) (Table 1.6). 
Polyene antifungals work by interacting with the ergosterol component in the 
fungal cell membrane and generating membrane pores leading to cell leakage and 
loss of cytoplasmic content. Polyene antifungals are fungicidal which differs from 
the fungistatic activity of azole antifungals. Azole antifungals interfere with the 
fungal enzyme, lanosterol demthylase, and thus inhibit the biosynthesis of 
ergosterol, depleting it in the fungal cell membrane. Fluconazole used to treat oral 
candidosis is delivered systemically and the benefits are that it is secreted in saliva. 
In contrast itraconazole is lipid based and achieves high levels in the tissues. 
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Table 1.6: Antifungals used in the management of oral candidosis 
 
 
 
  
Antifungal Mode of action Administration 
Polyenes 
Nystatin 
 
Azoles 
Miconazole 
Fluconazole 
Itraconazole 
Ketoconazole 
 
Disruption of cell 
membrane 
 
 
Inhibition of ergosterol 
synthesis 
Topical 
 
 
 
Topical 
Systemic 
Systemic 
Systemic 
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1.1.4 Virulence factors of Candida  
Candida albicans has a number of traits which promote host colonisation and 
infection (Höfs et al., 2016). Whilst no single predominant virulence factor has been 
recognised, several putative virulence factors have been proposed (Williams and 
Lewis, 2011) (Table 1.7). It is probable that it is a combination of host factors 
(Section 1.1.3.11) and candidal factors that ultimately determine whether oral 
candidosis occurs. 
The ability of Candida to form biofilms is a key contributor to its virulence. Biofilms 
are defined as structured microbial communities that are attached to a surface and 
encased in a matrix of exopolymeric substances (EPS) (Ramage et al., 2006). 
Biofilms protect Candida from host immune mechanisms, increase resistance to 
antifungal treatment and are able to withstand competitive pressure from 
exogenous microorganisms (Sardi et al., 2013).  
Candida has to adhere and persist on oral surfaces in order to cause oral 
candidosis, therefore adherence is vital for successful host colonisation and 
pathogenicity. The initial adherence between Candida and an epithelial cell or 
prosthetic surface is medicated by simple hydrophobic and electrostatic 
interactions. Subsequent long term adhesion requires interaction of candidal 
adhesions with specific host receptor molecules (Höfs et al., 2016). The most 
studied group of adhesions are the agglutinin-like sequence (ALS) proteins, hyphal 
wall protein (Hwp1) and the enhanced adherence to polystyrene (EAP1) protein. 
Als3 and Ssa1 (an invasin and a HSP70 heat shock protein expressed on hyphal 
surfaces) mediate binding to host epithelial surface receptors, which enable 
attachment and invasion of host cells. Host ligands include the epidermal growth 
factor (EGF) receptor on oral epithelial cells (da Silva Dantas et al., 2016). 
Hyphal development can lead to the expression of genes for a variety of hydrolytic 
enzymes. Secreted aspartyl proteinases (SAPs) and phospholipases are the most 
frequently implicated enzymes in C. albicans virulence. It is thought that SAPs are 
involved in degrading tissue barriers and immunoglobulins, and also facilitating 
adherence (Mayer et al., 2013). The phospholipase enzyme may contribute to 
candidal virulence by a variety of mechanisms including; host cell membrane 
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damage, promoting cell lysis or exposure of receptors to facilitate adherence 
(Mayer et al., 2013). 
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Table 1.7: Potential virulence factors of Candida albicans  
 
Virulence Factor Effect 
Adherence 
 Cell surface hydrophobicity 
 Expression of cell surface 
adhesins 
Promotes retention in the mouth 
 Non-specific adherence 
 Specific adherence 
Evasion of host defences 
 Phenotypic switching 
 Hyphal formation 
 Secreted aspartyl proteinase 
production 
 Binding of complement 
Promotes retention in the mouth 
 Antigenic modification 
 Reduces phagocytosis 
 Secretory IgA destruction 
 Antigenic masking 
Invasion and destruction of host tissue 
 Hyphal production 
 Hydrolytic enzyme production 
Enhances pathogenicity 
 Promotes invasion of oral 
epithelium 
 Host cell and extracellular matrix 
damage 
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1.1.4.1 Morphology of C. albicans and effect on host responses 
It is generally thought that both morphological forms of C. albicans are important 
in virulence and infection. The yeast form of C.albicans is likely to be important in 
disseminated blood stream infections and the formation of filamentous hyphae 
which then contribute to the invasion of host cells (Wilson et al., 2016).  
The hyphal form of C. albicans is a critical feature of pathogenicity at the mucosal 
surface (Naglik et al., 2014) and murine dendritic cells can discriminate between C. 
albicans yeast and hyphae.  
Hyphae can evade host phagocytes and macrophage killing by initiation of 
pyroptosis and piercing of the macrophage membrane (Krysan et al., 2014, Wilson 
et al., 2016). The specific C.albicans factor that directly induces cell damage and 
lysis has been identified as a cytolytic toxin called candidalysin (Wilson et al., 2016). 
Studies have demonstrated that phagocytoses of yeasts results in induction of 
interleukin (IL) 12, whereas phagocytoses of hyphae inhibits IL-12 and induces IL-4 
(d'Ostiani et al., 2000). Yeast induction of IL-12 is more likely to result in a pro-
inflammatory Th1 response (Section 1.2.4), whereas inhibition of IL-12 by hyphae 
inhibits an inflammatory response. Oral epithelial cells can also orchestrate innate 
responses to C. albicans via nuclear factor NF-κB and a biphasic mitogen-activated 
protein kinase (MAPK) response (Moyes et al., 2010, Naglik et al., 2014). The first 
MAPK response is independent of Candida morphology, but the second phase is 
dependent on hyphal formation and fungal burden. This correlates with a pro-
inflammatory response and cytokine release (Moyes et al., 2010). The lack of 
surface β-glucan exposure by hyphae may also influence immune detection and 
prevent a pro-inflammatory response (Netea et al., 2008). Yeast and hyphae 
therefore initiate different C. albicans-induced cell-signalling, resulting either in 
inflammatory mediators being released and epithelial cell activation resulting in a 
pro-inflammatory response or not (Naglik et al., 2014, Tang et al., 2016). The 
mucosal immune response is therefore variable and dependent on the 
morphological status of C. albicans and relates to the ability of epithelial cells 
differentiating between commensal and pathogenic forms of the fungus (Naglik et 
al., 2014). 
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1.2 Candida albicans and recognition by the host 
The human immune system consists of three main components: the physical 
barrier, the innate immune system and adaptive immune system (Tang et al., 
2016). This host-Candida interaction can be considered at the level of the host 
immune cells in systemic immunity and the mechanisms involved in mucosal-
candidal interactions (Moyes et al., 2015).  
Superficial mucosal interactions with Candida occur at any human mucosal surface, 
however oral candidoses are among the most easily accessible to study. Oral 
mucosal immunity can also be affected by local and systemic host factors (Section 
1.1.3.12).  
The morphology of C. albicans also has a role to play in the host response and the 
immune response to the different forms can vary. When yeast cells are 
encountered the mucosal tissues typically recognises these cells as benign 
colonisers, but when hyphae are encountered this initiates a danger response 
pathway as the epithelial cells recognise candidalysin (Wilson et al., 2016). This 
ultimately results in inducing epithelial cytokine production and recruitment of 
immune cells (phagocytes and dendritic cells) (Wilson et al., 2016). 
Ultimately, it is the balance between the different T helper (Th) cell responses and 
associated cytokines that are integral to host immune responses and whether the 
resulting infection is resolved. 
The importance of identifying cytokines involved in host defence against C. albicans 
may in turn have future therapeutic value for the treatment of severely 
immunocompromised individuals and their fungal infections (Dongari-Bagtzoglou 
and Fidel, 2005).  
The type of recognition receptor involved in detecting C. albicans, the phagocyte 
type, the anatomical site of infection and the type of infection will all effect how 
the host responds to the organism (Krysan et al., 2014). 
The following sections and experimental chapters mainly focus on oral mucosa-C. 
albicans interactions by the cell mediated immune response. 
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1.2.1 Pathogen associated molecular patterns  
The immune response against C. albicans begins with the recognition of pathogen 
associated molecular patterns (PAMPS) by pattern-recognition receptors (PRRs). 
The C. albicans cell wall is composed of two layers, the outer cell wall layer is 
mainly composed of glycoproteins that consist of mannose (O-linked, N-linked and 
phosphorylated mannans), whereas the inner layer contains β-1,6- glucan, β-1,3-
glucan and chitin which gives strength and shape to the cell (Figure 1.2) (Netea et 
al., 2015). The cell wall composition is dynamic because of the morphological 
variability of C. albicans, which can influence which immune cell recognises the 
different PAMPs through engaging with different PRRs (Erwig and Gow, 2016). 
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1.2.2 Pattern Recognition Receptors  
Initial antigen recognition by immune surveillance cells is mediated through 
expression of PRRs on the surface of the cell. The nature of the interaction 
between the innate immune cell and Candida is a key factor in determining the 
subsequent immune response (Bonifazi et al., 2009). PRRs are receptor proteins 
found mostly on immune cells and epithelial cells and bind to PAMPs to trigger host 
cell signals leading to the secretion of cytokines and activation of the innate 
immune response (Erwig and Gow, 2016). 
There are four major families of PRRs: 1) C-type lectin receptors (CLRs), 2) Toll-Like 
receptors (TLRs), 3) Nucleotide-binding Oligomerisation Domain (NOD)-like 
receptors (NLRs) and 4) Retinoic-acid-Inducible-Gene I (RIGI) receptors (Palucka et 
al., 2010). CLRs are thought to be the most important family of PRRs for the 
recognition of Candida species (Netea et al., 2015). Recognition of Candida by 
innate immune cells and the different PRRs are shown in figure 1.3 
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1.2.2.1 C-type lectin receptors 
C-type lectin receptors (CLRs) recognise carbohydrates expressed by 
microorganisms as well as glycoproteins. CLRs function as PRRs or as adhesion 
receptors (Geijtenbeek and Gringhuis, 2016) and are expressed by myeloid cells, in 
particular macrophages and dendritic cells. There are several CLRs that recognise 
fungal PAMPs, and include, dectin-1, dectin-2, DC-SIGN (DC-specific ICAM3-
grabbing non-integrin), mannose-receptor and MINCLE (macrophage-induced C-
type lectin receptor) (Hardison and Brown, 2012). 
Dectin-1 is a β-1,3-glucan receptor and plays an essential role in the innate 
response against fungal pathogens (Taylor et al., 2007). Recognition of fungal β-1,3-
glucan by dectin-1 can induce phagocytosis, respiratory burst and production of 
numerous cytokines (Brown et al., 2003). Dectin-1 is believed to be primarily 
involved in the detection and inflammatory response to C. albicans yeast rather 
than to hyphae, and this is thought to arise from β-glucan being exposed at a 
greater level during yeast budding (Goodridge and Underhill, 2007).  
It has recently been suggested that host defence relies more on lectin receptors 
than on TLRs, a notion compatible with the clinical picture seen in individuals 
deficient in MyD88/TLRs or dectin 1/CARD 9 (Netea et al., 2010). Other studies 
have demonstrated dectin-1 as a cell surface non-TLR receptor that is necessary for 
antifungal immunity and the induction of a protective immune response (Taylor et 
al., 2007, Ferwerda et al., 2008). Dectin-1 may amplify cytokine production by 
stimulating TLR 2 and TLR 4 and may therefore have synergistic effects with these 
TLRs (Ferwerda et al., 2008). 
Dectin-1 has been found to be expressed on airway epithelial cells and induced by 
mycobacteria (Lee et al., 2009) and expressed in human corneal epithelial cells in 
response to fungal stimuli (Peng et al., 2015). Dectin-1 has been shown to be 
expressed by a human gingival epithelial cell line and human gingival fibroblasts 
after stimulation with C.albicans (Tamai et al., 2011). 
Dectin-1 binding to C. albicans β-glucan components triggers host immune cell 
responses and signalling, and this is thought to be mediated via the spleen tyrosine 
kinase (SYK) pathway and the caspase activation and recruitment domain 9 (CARD 
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9) leading to induction of the cytokines IL-23 and IL-6, but not IL-12 (LeibundGut-
Landmann et al., 2007). 
Dectin- 2 is a α-1,2-mannose receptor that can couple to the Syk-CARD 9 innate 
pathway and regulate the immune response to fungal infection (Robinson et al., 
2009, Geijtenbeek and Gringhuis, 2016). Dectin-2 selectively activates c-rel, 
signifying a specialised Th17 (T helper cell 17) enhancing function for this CLR 
(Gringhuis et al., 2011).  
DC-SIGN is a CLR expressed by DCs and macrophages, and recognises mannose-
containing structures on the fungal pathogen. This can trigger a Th1 (T helper cell 1) 
and a Th17 protective immune response to C. albicans (Geijtenbeek and Gringhuis, 
2016) (section 1.2.4).  
It is thought that there is interaction between the PRRs to recognise different 
pathogens, all of which are required for optimal antifungal response (Hardison and 
Brown, 2012).  
1.2.2.2 Toll like receptors (TLRs) 
To date, 11 TLRs have been identified in humans, with TLR2, TLR3, TLR4, TLR6 and 
TLR9 implicated in host recognition of C. albicans. TLRs can be divided into two 
groups depending on subcellular localisation. One group, which includes TLR2, 4 
and 6 are located in the plasma membrane of cells and the second group, including 
TLR3 and 9 are localised to intracellular compartments (Gil and Gozalbo, 2009). 
TLRs are type 1 membrane proteins and are either homodimer or heterodimer 
receptors, recognising various PAMPs, including proteins, cell wall sugars or 
DNA/RNA molecules (Wei et al., 2010).  
The TLRs can recognise different fungal components. TLR2 interacts with 
phospholipomannan, TLR4 recognises O-linked mannans, TLR6 recognises zymosan 
and TLR9 detects fungal DNA (Netea et al., 2008). The interaction of TLRs with C. 
albicans is a complex process, as these receptors may function as homodimers or 
heterodimers and may have synergistic effects with other PRRs, triggering 
intracellular signalling pathways (Gil and Gozalbo, 2009). It has also been found 
that yeast and hyphal forms of C. albicans stimulate TLR2 and TLR4 differently (van 
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der Graaf et al., 2005). Yeast stimulates both TLR2 and TLR4 resulting in IFNγ 
production and a pro-inflammatory response. In contrast, hyphae are not 
recognised by TLR4 and do not stimulate IFNγ. Candida albicans has also been 
reported to evade host defences through TLR2 mediated signals, as the IL-10 that is 
secreted can be followed by a Th2 response (Netea et al., 2004). 
TLR3 may have a protective role against Candida, as patients with a mutated 
variant of TLR3 have decreased levels of interferon-γ (IFNγ) resulting in increased 
susceptibility to cutaneous candidosis (Nahum et al., 2011, Netea et al., 2015). 
TLR9 recognises chitin in the fungal cell wall and this can lead to the secretion of IL-
10 and an anti-inflammatory response, and may help in regulating the immune 
response (Wagener et al., 2014). 
1.2.2.3 Nod-like receptors 
Nod-like receptors (NLRs) are cytoplasmic receptors that recognise chitin (NOD2) 
and β-1,3-glucans (NLRP3) in the fungal cell wall (Erwig and Gow, 2016). Along with 
TLR9 and the mannose receptor, NOD2 receptors are essential in recognising fungal 
chitin leading to the secretion of IL-10 and the anti-inflammatory response 
(Wagener et al., 2014). Chitin recognition is therefore important for immune 
homeostasis. 
A further important role of NLRs are their function as components of the 
inflammasome (Netea et al., 2015). The inflammasome is a group of proteins that 
are found in myeloid cells that are involved in innate immunity and trigger the 
release of inflammatory cytokines such as IL-1 and IL-18, resulting in programmed 
cell death (Erwig and Gow, 2016). NLRP3 is an important NLR family member in 
mammalian host defence against fungal infections, with NLRP3-deficient mice 
being hyper susceptible to C. albicans infection (Gross et al., 2009). 
 
1.2.3 Immune cell and non-immune cells contributing to antifungal response 
After recognition of a C. albicans PAMP by one of the PRRs, mechanisms are set in 
place to initiate clearance of the fungal pathogen (Netea et al., 2015). The anti-
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fungal response is brought about by a number of different mechanisms and cell 
types.  
1.2.3.1 Epithelial cells 
Epithelial cells serve as important mechanical barriers against tissue invasion by C. 
albicans (Netea et al., 2015). The morphological change that C. albicans undergoes 
from yeast to hyphae enables penetration of the epithelium and ultimately 
activation of a pro-inflammatory cytokine response (section 1.1.4.1). Epithelial cells 
also release small antimicrobial peptides (AMPs) which exert direct microbicidal 
effects (Tomalka et al., 2015). Reduced salivary AMP levels are associated with oral 
candidosis and mice deficient in the AMP β-defensin 1, have an elevated oral and 
systemic fungal burden (Tomalka et al., 2015).  
1.2.3.2 Macrophages 
After Candida has penetrated the epithelium, the first cell encountered is the 
resident macrophage. Macrophages act to clear Candida by phagocytoses and 
release cytokines to recruit further immune cells serving to direct a pro-
inflammatory response at the site of infection (Netea et al., 2015). Macrophages 
are more proficient at phagocytosis compared to dendritic cells (DC), which are the 
main activators of the adaptive T cell response (Galli et al., 2011). 
Macrophages are heterogeneous in phenotype and exhibit plasticity to adapt to 
different tissue environments. Several types of macrophages have been identified 
in infection and are referred to as M1 and M2 subtypes, which can have different 
functions in the immune response (Galli et al., 2011). M1 macrophages are usually 
associated with release of pro-inflammatory cytokines and simulate Th1 and Th17 
immune responses and M2 macrophages are implicated in the release of anti-
inflammatory cytokines and suppress the T cell response (Zheng et al., 2013). 
1.2.3.3 Neutrophils 
Neutrophils are as important as macrophages in phagocytosis and clearance of 
Candida (Erwig and Gow, 2016) and both of these innate immune cells can kill 
Candida through release of reactive oxygen species (ROS). When macrophages and 
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neutrophils compete to kill Candida, neutrophils have been shown to migrate more 
rapidly towards the fungal pathogen and have a higher number of C. albicans 
uptake events compared with macrophages (Rudkin et al., 2013). It has also been 
shown that patients with impaired neutrophil function and neutropenic patients 
are highly susceptible to systemic candidoses (Maertens et al., 2001). Neutrophils 
are also the only host cell able to successfully inhibit C. albicans hyphal formation 
(Brown, 2011). 
1.2.3.4 Natural killer cells 
Natural killer (NK) cells along with the macrophages and neutrophils already 
mentioned also play a role in the control of infection by Candida (Netea et al., 
2015). Human NK cells have been shown to be able to recognise C. albicans, 
resulting in degranulation and secretion of granulocyte-macrophage colony-
stimulating factor (GM-CSF), interferon (IFN) γ, and tumor necrosis factor (TNF) α. 
This NK cell interaction with C.albicans therefore leads to a pro-inflammatory 
response and activation of polymorphonuclear neutrophils (PMNs) resulting in 
increased fungicidal activity (Voigt et al., 2014). 
1.2.3.5 Dendritic cells 
Dendritic cells (DCs) can ingest and kill Candida but their main role is as antigen 
presenting cells (APCs), which can drive naive T cells towards different T helper (Th) 
cell responses including Th1, Th2, Th17 and regulatory T cell (Treg). It is still 
controversial as to which type of Th cell response and cytokine production is 
beneficial and detrimental for the host clearance of Candida. 
Large numbers of DCs and macrophages are found in mucosa where they play a key 
role in immune surveillance. DCs are innate immune cells, which respond to 
pathogen stimulation, mediated through the PRRs on the DC surface (section 
1.2.2). This stimulation initiates an adaptive immune response through antigen 
presentation and subsequent cytokine production. Activation of the PRRs by the 
filamentous forms of C. albicans activates intracellular signalling pathways 
including those involving NF-kB, MAPK and interferon regulatory factors (IRFs) 
(Feller et al., 2014). 
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Many pathogens, particularly those that are opportunistic, exist in a commensal 
state with the host by inducing host immune tolerance. Immune tolerance can be 
achieved by stimulating the production of immune suppressing cytokines or 
inhibiting immune stimulatory cytokines. Candida has been shown to be a 
commensal with immunoregulatory activity resulting from the orchestrated use of 
multiple, yet functionally distinct receptor-signalling pathways in DCs (Bonifazi et 
al., 2009). 
DCs exist in distinct functional states i.e. resting and activated, and this feature is 
classically described as the morphological and functional alteration associated with 
the activation of the DC by microbial stimuli (Palucka et al., 2010). 
Candida may be phagocytosed and fragments presented on the cell surface via 
major histocompatibility complex (MHC) molecules to provide the first signal for T 
cell activation. Cell-surface receptors that act as co-receptors in T cell activation 
such as CD80 (B7.1), CD86 (B7.2), and CD40, greatly enhance the ability of DCs to 
activate T cells by providing the second signal for T cell activation. DCs migrate to 
the draining lymph nodes where the Candida antigen is processed and presented 
to naive CD4+ T cells, which in turn differentiate into mature effective T cells under 
direction of the DCs (Ryan et al., 2008). The cytokines produced by DCs and 
surrounding cells in T cell activation region of lymph node act as a third signal for T 
cell activation and direct T cell differentiation into Th1, Th2, Th17 or Treg.  
Figure 1.4 illustrates examples of differentiated T cells and the variety of cytokines, 
especially related to the IL-12 family, that are generated.  
DCs regulate CD4+ T cell differentiation through a variety of molecules that belong 
to three major families, namely IL-12, Tumour Necrosis Factor (TNF) and B7 
(Palucka et al., 2010). The IL-12 cytokine family appears to play an important role in 
the differentiation of T cells (Tang et al., 2004, Zelante et al., 2007, Dongari-
Bagtzoglou and Fidel, 2005). 
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Figure 1.4: A simplified diagram to show how the different cytokines are involved 
in the naïve CD4+ T Cell development and the subsequent T cell response after 
antigen presenting cell (APC) activation with the pathogen Candida albicans. 
IL=interleukin, TNFα= Tumour necrosis factorα, TGFβ= Transforming growth 
factorβ, IFNγ= Interferon γ, Treg= Regulatory T cell, Th= T helper cell.  
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1.2.3.6 Innate lymphoid cells (ILC) 
Innate lymphoid cells (ILCs) are a recently described group of innate lymphocytes 
that are found at mucosal surfaces (Spits and Di Santo, 2011). ILCs are thought to 
be similar to Th cells, but lack T cell receptors (Section 1.2.4). ILCs are thought to 
play a protective role at mucosal sites through production of tissue protective 
factors. Subsets of ILCs are recognised which exhibit different functionalities. ILC1 
express the transcription factor T-bet and also produce Interferon-γ (IFN-γ). ILC2 
express the transcription factor GATA3 and produce IL-5 and IL-13. ILC3 cells 
express the transcription factor RAR-related orphan receptor gamma t (RORγt) and 
produce IL-17 and IL-22 (Becker et al., 2015). In a mouse model ILCs were shown to 
be the main source of IL-17 (Section 1.2.5.1) during oropharyngeal candidosis and 
thus thought to be an important in the instigation of antifungal defences (Gladiator 
et al., 2013). It is, however, unclear whether these cells are involved in human oral 
mucosal antifungal defence. 
 
1.2.4 T cell immunity in controlling candidosis 
T cells are derived from the thymus and some of the different T cell sub 
populations can show plasticity with features of one subset capable of acquiring 
the phenotypic and functional characteristics of another T cell, in particular 
plasticity of Treg and Th17 has been shown (Galli et al., 2011). 
The normal protective T cell response may be a mechanism by which the host can 
control Candida infection. The type of cytokine released from the APC, and thus 
involved in signalling the naïve CD4+ T cell, will play a key role in directing the type 
of T cell response. This can result in different response types, currently classified as 
Th1, Th2, Th17 or regulatory T cell (Treg) responses. These responses can be 
categorised based on the types of cytokines generated and their effects on the 
immune system. Each particular Th cell has unique cell signalling cytokines related 
to it. A Th1 response is associated with a pro-inflammatory response leading to 
fungicidal effects (Netea et al., 2015) (section 1.2.4.1). This is countered by the Th2 
response, which is associated with immune suppression (section 1.2.4.2). Th17 cells 
43 
 
are believed to be particularly important in the immune response against oral 
candidosis (Netea et al., 2015) (section 1.2.4.3), whilst Treg cells are immune 
suppressing cells involved in immune tolerance (Romagnani, 2006).  
Three signals are provided by the APC to drive the naive CD4+ T cell. The first is 
through interaction of the presented antigen on MHC II and the T cell receptor 
(TCR). The second occurs by costimulatory molecules on the APC binding to the 
costimulatory receptors on the T cell. The last signal involves the production of 
cytokines by the APC, which activates the cytokine receptors on T cells to induce T 
cell differentiation into Th1, 2, 17 or Treg (Baumgartner and Malherbe, 2010). 
1.2.4.1 Th1 response 
It is widely reported that cytokines produced by Th1 cells activate macrophage and 
neutrophils to a candidacidal state (Romani, 1999, Romani, 2004). A Th1 cell has 
the ability to respond to an antigen and produce the cytokines IFNγ, IL-2 and TNF. 
A study in mice, showed the direct requirement for T lymphocytes in recovery from 
oral candidosis and suggested that this was associated with the production of 
cytokines related to Th1 responses in particular IL-12 driving the Th1 differentiation 
and the release of IFNγ cytokines (Farah et al., 2002). A recent clinical trial involving 
a small number of patients with systemic candidosis demonstrated an 
improvement in their immune function and an enhanced capacity of leucocytes to 
produce to produce pro inflammatory cytokines after treatment with recombinant 
IFNγ (Delsing et al., 2014). 
1.2.4.2 Th2 response 
The development of Th2 responses underlines susceptibility to infection as Th1 cell 
development is inhibited and phagocytic cells deactivated (Romani, 1999). Th2 cells 
are CD4+ T cells that produce the cytokines IL-4, IL-5, IL-13 and IL-25. 
There is less evidence that the Th2 response plays a significant function during 
mucosal candidosis (Farah et al., 2002). Although in a study in mice, production of 
IL-4 and a Th2 response was associated with a high fungal load, whereas IL-12 and 
IFNγ were produced early in the infection regardless of fungal load (Mencacci et al., 
1996). Another study in mice showed that Th2 cytokines such as IL-4 were required 
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for the maintenance and efficiency of Th1-mediated antifungal resistance 
(Montagnoli et al., 2002). The Th2 cytokines have been reported to have conflicting 
roles in coordinating the responses to Candida (Netea et al., 2015). 
1.2.4.3 Th17 response 
In 2005, the Th17 cell was discovered and changed how CD4-dependent immunity 
was viewed and differed from the Th1/Th2 hypothesis of T cell mediated tissue 
damage (Steinman, 2007). Th17 cells are part of the lineage of the T cell effector 
response and appear to be specialised for enhanced host protection against 
extracellular bacteria and some fungi (Weaver et al., 2007). Th17 cells produce the 
cytokines IL-17A, IL-17F, IL-21 and IL-22 (Ouyang et al., 2008), as well as GM-CSF. 
Th17 cells differentiate through a combination of TGFβ, IL-6, IL-1 and IL-23. IL-23 is 
essential for Th17 cell expansion and function (Conti et al., 2009). 
Th17 cells mediate inflammatory pathology in numerous models of inflammatory 
auto-immunity, and Th17 differentiation can be primed following C. albicans 
infection in mice (LeibundGut-Landmann et al., 2007). Furthermore, human 
peripheral blood monocytes (PBMCs) can consist of both memory and effector 
Th17 cells, and some of the memory Th17 cells exhibit specificity for C. albicans 
(Zhou et al., 2008). A further mouse study has demonstrated that IL-23 and IL-17A 
were required for effective resistance to oropharyngeal candidosis, whereas IL-12 
and IL-22 played less critical roles (Conti et al., 2009). This has been supported by 
studies confirming the role of Th17 cells in the control of candidosis (Conti et al., 
2014, Kagami et al., 2010, Huppler et al., 2014). Conversely, PBMCs from CMC 
patients produced significantly lower amounts of IL-17 and IL-22 both mRNA and 
protein, when stimulated with C. albicans compared with matched healthy 
controls. In these studies, the levels of IL-6 and IL-23 were not altered and the 
inability to overcome infection was thought to be an immune defect of the Th17 
cells (Eyerich et al., 2008).  
IL-22 has been shown to be produced by Th17 cells and along with TNFα effectively 
inhibits the growth of C. albicans and conserves epithelial integrity (Eyerich et al., 
2011).  
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A study by Lilac et al (1996) showed that Candida antigens trigger a predominantly 
Th2 rather than a Th1 response in CMC patients. This may be why CMC patients 
have increased susceptibility to Candida infections. Conversely, a recent study 
showed that CMC patients had reduced response to IL-17F and IL-22 (Kisand et al., 
2010). This is more in keeping with a Th17 response being implicated in protection 
against Candida antigens. In this study, there was an increased production in 
autoantibodies detected and the researchers concluded that the immunodeficiency 
underlying CMC had an autoimmune basis (Kisand et al., 2010). 
1.2.4.4 Regulatory T cell response 
Regulatory T cells (Tregs) play a major role in immune suppression by preventing 
proliferation of effector T cells (Sutmuller et al., 2006). A lack of Tregs may result in 
autoimmune disease, but enhanced Treg function may lead to an infection such as 
candidosis not being eliminated. Tregs have been shown to have a diverse immune 
response depending on the infection (Whibley and Gaffen, 2014). Similarly, the 
location of the infection can also have a bearing on response. In oral candidosis, 
Tregs are thought to play a protective role (Pandiyan et al., 2011), whereas in 
disseminated infection, Tregs promote Th17 responses and an inflammatory 
response (Whibley and Gaffen, 2014, Whibley et al., 2014). These opposing roles of 
Tregs may be partially explained by T helper cell plasticity with regards to different 
T helper cell subsets. 
Tregs are induced during C. albicans infection in mice and it may be that they have 
a role in determining the antifungal response in terms of magnitude and quality, 
and avoiding unnecessary inflammatory responses (Montagnoli et al., 2002). Tregs 
have been shown to express TLR2 and proliferate under stimulation with TLR2 
ligands, which may mean that Tregs can be modulated directly by the pathogen. 
Furthermore, in mice infected with fungi, TLR2 triggering on Tregs, prevents 
suppressive activity and allows an increase in IFNγ production and a decrease in 
fungal infection (Sutmuller et al., 2006).  
 
 
46 
 
1.2.5 The role of cytokines in host immunity to C. albicans 
1.2.5.1 IL-17 family 
The IL-17 cytokine family consists of six related members: IL-17A, IL-17B, IL-17C, IL-
17D, IL-17E and IL-17F. IL-17A and IL-17F have been the most widely studied and 
reported to play a role in protection against candidosis (Conti et al., 2015). IL-17 is 
thought to be a mediator of neutrophil recruitment to the site of fungal infection 
and therefore plays a role in the restriction of the invading fungal pathogen (Becker 
et al., 2015). IL-17 is expressed predominantly by Th cells, but is also generated by 
ILCs and neutrophils. 
Genetic defects in the IL-17 pathway are associated with CMC, as seen in patients 
with CMC having complete autosomal recessive deficiency in the IL-17A receptor, 
or partial autosomal dominant IL-17F deficiency (Puel et al., 2011). This reinforces 
the role for IL-17A and IL-17F in mucocutaneous immunity against C. albicans. 
Furthermore, in a mouse model of oropharyngeal candidosis, IL-17A was found to 
be the main cytokine mediator in immunity, and a co-operative relationship 
between IL-17A and IL-17F was evident (Whibley et al., 2016).  
The precise mechanism(s) by which IL-17 cytokines protect the host are not clear. A 
recent study in mice showed that the protective effects of IL-17 were independent 
of neutrophil function (Trautwein-Weidner et al., 2015). Whilst neutrophils were 
involved in restricting the fungal infection, neutrophil activity and recruitment was 
not impaired in IL-17A receptor deficient or IL-17C receptor deficient mice, or mice 
depleted of IL-17A and IL-17F cytokines (Trautwein-Weidner et al., 2015). Mucosal 
immunity against C. albicans may be mediated by regulating expression of 
antimicrobial peptides (AMPs) in the oral epithelium, which eliminates Candida 
from the oral mucosa. Again, the exact role of IL-17 signalling in this process is not 
clear (Trautwein-Weidner et al., 2015). 
It has recently been demonstrated that IL-17R signalling in the oral epithelium of 
mice is necessary for defence against candidosis, although the IL-17 responsive cell 
type that plays a role in this protection is unknown (Conti et al., 2016).  
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1.2.5.2 IL-12 cytokine family 
Members of the IL-12 cytokine family (Figure. 1.5) are produced by human DCs and 
macrophages in response to pathogen challenge, and appear to be significant in 
controlling T cell differentiation. Four main cytokines have been identified in the IL-
12 family and these are IL-12, IL-23, IL-27 and IL-35 (Trinchieri et al., 2003, Collison 
and Vignali, 2008). The IL-12 cytokine family are all heterodimeric soluble proteins 
varying with the type of protein sub-units present (Figure 1.5). 
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Figure 1.5:  Protein subunits of the four members of the IL-12 cytokine family. The 
blue ellipse represents the Ig-like domain. The yellow and orange ellipses represent 
the cytokine receptor domain. The ellipses of p35, p19 and p28 are four helix 
bundle cytokines. The IL-12 and IL-23 subunits are linked by a disulphide bond but 
IL-27 and IL-35 are not. 
IL=interleukin, EBi3= Epstein-Barr virus induced gene 3. 
 
1.2.5.2.1 IL-12 cytokine 
IL-12 is a heterodimeric cytokine produced by inflammatory myeloid cells. IL-12 is 
composed of two subunits called p40 and p35. IL-12 p40 monomers and 
homodimers, although secreted, are not biologically active, and the IL-12 p35 chain 
is never independently secreted (van Seventer, et al, 2002). IL-12 is mostly 
produced by activated hematopoietic phagocytic cells (monocytes, macrophages, 
neutrophils) and DCs (Trinchieri, 2003). IL-12 acts at three stages in the response to 
pathogen challenge. The first stage, after initial infection, is the induction of IFNγ, 
which contributes to macrophage activation and inflammation. Secondly, IL-12 and 
IL-12-induced IFNγ then favour Th1 cell differentiation by priming Th1 cells to 
p35
p40 p40
p19
EBI3
p28
IL-23
EBI3
IL-27 IL-35IL-12
p35
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produce large amounts of IFNγ. Finally, IL-12 contributes to proliferation of 
antigen-specific differentiation to Th1 cells in response to APCs and optimising IFNγ 
production (Holscher, 2004).  
IL-12 plays a key role in mediating Candida clearance through induction of IFNγ, 
which in turn activates the phagocytic action of macrophages. This mechanism was 
initially thought to be the primary host defence against Candida infection based on 
increased IL-12 detection in the lymph nodes of mice recovering from challenge 
with C. albicans (Farah et al., 2001). It is now thought that the IL-23/IL-17 axis also 
has an important role in protection against oropharyngeal candidosis (Saunus et al., 
2010). Using IL-12p40 knockout mice challenged with C. albicans, it has been 
shown that IL-12p40 is essential for recovery from oral, but not systemic candidosis 
(Farah et al., 2006). IL-12 is a heterodimeric cytokine and the p40 component is 
common to both IL-12 and IL-23, so from the results of this study, IL-23 could also 
be required in protection against oral candidosis. 
 
1.2.5.2.2 IL-23 cytokine  
The IL-23 cytokine shares the same p40 subunit as IL-12, but this is combined with 
a p19 subunit. IL-23 is thought to be involved in the later stages of Th1 
differentiation and also plays a role in Th17 effector function (Zelante et al., 2007).  
IL-23 induces lower amounts of IFN-γ compared with IL-12 from activated Th1 cells 
(Oppmann et al., 2000). IL-23 is also required for expansion and lineage 
commitment of the CD4+ T cell subset, Th17, which secretes cytokines (including IL-
17A, IL-17F and IL-22) involved in neutrophil-mediated immunity against 
extracellular pathogens (Saunus et al., 2010).  
In humans, resident memory T cells specific for C. albicans are mainly of the Th17 
subset. Candida albicans hyphae have been shown to stimulate APCs for priming of 
Th17 responses in vitro and production of IL-23, but not IL-12 (Acosta-Rodriguez et 
al., 2007). Conversely, the IL-23/IL-17 developmental pathway has been shown to 
act as a negative regulator of the Th1-mediated immune resistance to fungi, 
resulting in promotion of inflammation and infection (Zelante et al., 2007). 
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IL-23 is produced by DCs earlier than other directive cytokines in response to 
Candida stimuli, and is particularly evident in conditions of high-level fungal growth 
(Zelante et al., 2007). Since IL-12 and IL-23 share the common p40 subunit, it may 
be that the results from experiments on IL-12p40 knockout mice may also be due 
to IL-23 deficiencies. Indeed, it has been reported that IL-23 knockout mice are 
profoundly more susceptible to oral candidosis, whereas IL-12p35 knockout mice 
show lower burdens and no overt disease (Conti et al., 2009), however the IL-12 
knockout mice used in this study were IL-12p35-/- mice which may also have lost 
IL-35 due to IL-35 shared protein subunit of IL-12p35 with IL-12. These recent 
studies indicate that IL-23 is required for effective resistance to candidosis, 
whereas IL-12 has a less critical role. Moreover, IL-23 may have a role in the early 
induction of IL-22, which has been shown to be crucial in the early control of C. 
albicans infection (De Luca et al., 2010). 
 
1.2.5.2.3 IL-27 cytokine 
The cytokine IL-27 comprises of a p40-related protein referred to as EBi3 (Epstein-
Barr virus induced gene 3) together with a subunit known as p28 (Pflanz et al., 
2002). It has been suggested that IL-27 synergises with IL-12 in inducing IFNγ 
production by T cells and NK cells and activating naive T cells (Trinchieri et al., 
2003). In contrast, IL-27 has also been shown to have an immunosuppressive 
feature by suppressing Th17 differentiation and IL-17 production (Yoshida and 
Yoshiyuki, 2008). Further study has shown that IL-27 induces production of IL-10 
from human CD4+ T cells and inhibits IL-17 secretion. Increased IL-10 secretion 
would suggest the promotion of Treg cells and inhibition of Th17 cells and may 
indicate a mechanism to control autoimmunity and tissue inflammation 
(Murugaiyan et al., 2009). 
IL-27 has a dual role in immune regulation, in that it induces a Th1 pro-
inflammatory response and also an immunosuppressive effect (Yoshida and 
Yoshiyuki, 2008). It has also been suggested that IL-27 can inhibit expansion of IL-17 
producing cells (Murugaiyan et al., 2009), which may indicate a role for IL-27 in 
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controlling Th17 responses to candidal infection. To date, there has been limited 
laboratory research into the role that IL-27 may have in the immune response to 
candidosis. 
 
1.2.5.2.4 IL-35 cytokine  
The EBi3 subunit can also couple with p35 protein and this cytokine is known as IL-
35 (Niedbala and Wei, 2007). EBi3 is a gene first reported in 1996, that is expressed 
by EBV-transformed lymphocytes and encodes a member of the hematopoietin 
receptor family related to IL-12 p40 (Devergne et al., 1996). It has been reported 
that IL-35 has a similar (to IL-27) dual role in host immune response. IL-35 may 
suppress the immune response by expanding Tregs and limiting the differentiation 
of Th17 cells (Niedbala and Wei, 2007). The role of IL-35 in immune regulation in 
humans remains unclear and still is an area which requires further study (Collison 
and Vignali, 2008, Banchereau et al., 2012). 
IL-12p35 knockout mice tend to have lower fungal burden and no overt disease 
during oral candidosis (Conti et al., 2009). Since the p35 subunit is a component of 
IL-35, this may indicate that IL-35 does not play a major role in protection against 
oral candidosis. Conversely, it could be that over expression of IL-35 may result in 
chronic infection. Again, there is limited research to date on the role of IL-35 in oral 
Candida infections. However the role of IL-35 in induction of immune tolerance by 
promoting Treg development may contribute to maintain a commensal stage of C. 
albicans.  
 
1.3 Aims 
The overall aim of this project was to study the potential of C. albicans to regulate 
the host immune response in different forms of oral candidoses. Candidal 
colonisation and the immune response in chronic erythematous candidosis will 
firstly be studied to provide an understanding of the cytokines, and hence T helper 
response, involved in vivo. A second clinical study will be undertaken to identify 
immune cells in chronic hyperplastic candidosis in biopsy samples compared to 
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control tissue. This will be supported by considering the production of the IL-12 
family cytokines by a human monocyte cell line and human dendritic cells (DCs) 
after stimulation with clinical isolates of C. albicans in vitro. Specific components of 
the research are listed below. 
 
1.  Determine the extent of Candida colonisation in denture wearing patients, 
with and without CEC.  
2. Identify the local cytokine response in patients with CEC compared with 
control subjects, in order to determine the T helper cell response  
3.  Identify the host immune cells involved in C. albicans infected biopsy tissue 
from chronic hyperplastic candidosis patients to determine the T cell 
response.  
4. Examine the IL-12 family cytokine expression in an activated or inactivated 
human monocyte cell line, DCs and human PBMC after C. albicans 
stimulation. This will be indicative of the type of T cell response that may be 
directed by the DC after challenge with different strains of C.albicans in 
vitro. 
5.  To determine the recall response of T helper cells in healthy individuals 
after stimulation of PBMCs with C. albicans in vitro. 
 
 
*As part of the literature review a manuscript has been published: 
  
 WEI, X., ROGERS, H., LEWIS, M. A. O. & WILLIAMS, D. W. (2010) The role of the IL-
12 cytokine family in directing T cell responses in Oral Candidosis. Clinical and 
Developmental Immunology, 2011, 10 pages. 
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Chapter 2: 
Candida colonisation and the 
immune response in chronic 
erythematous candidosis  
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2.1 Introduction 
2.1.1 Denture stomatitis  
Oral candidosis can be classified into several distinct clinical forms, which can 
manifest as white lesions as in acute pseudomembranous candidosis and chronic 
hyperplastic candidosis (Chapter 5) or as red lesions as encountered in chronic 
erythematous candidosis (CEC) (Millsop and Fazel, 2016) (Section 1.1.3.5) (Figure 
1.1). Chronic erythematous candidosis is also known as denture stomatitis (DS), 
denture-related stomatitis or denture-induced stomatitis.  
DS is the most prevalent form of oral candidosis, with an incidence ranging 
between 15% and 70% in denture wearers (Gendreau and Loewy, 2011). The 
association between DS and Candida as a causative agent was first made by Cahn in 
1936 (Cahn, 1936).  
 
2.1.1.1 Clinical presentation 
DS clinically presents as erythematous and inflamed areas of the oral mucosa, 
which are exclusively limited to sites covered by a denture. Whilst DS is usually 
asymptomatic, some patients may complain of itching, burning, discomfort, 
soreness and occasional bleeding. Newton described DS as ‘denture sore mouth’ 
and also classified it into three categories dependent on clinical severity (Newton, 
1962). 
The infection primarily manifests on the upper palatal mucosa under the fitting 
surface of a complete acrylic denture (Figure 2.1). The denture bearing surface of 
the hard palate is most frequently involved (Salerno et al., 2011) and it is not 
usually encountered beneath a lower complete denture, possibly due to greater 
exposure to the protective effects of saliva. Given the higher incidence of denture 
wearing with increasing age, it is unsurprising that the condition is most prevalent 
in the older population (Gendreau and Loewy, 2011). The problem of edentulism 
(absence of teeth) is often considered to be one that will increase in the future 
based on higher growth in the population and elevated life expectancy (Felton et 
al., 2011). However, this problem may be negated with improved prevention, 
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education and dental care. Some reports indicate that DS is more prevalent in 
females (Figueiral et al., 2007, Gendreau and Loewy, 2011). 
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…A 
…B 
…C 
Figure 2.1: Clinical appearances of an edentulous hard palate. An example of a 
normal appearance of a hard palate (A) (Newton’s score 0), a mildly inflamed hard 
edentuolous palate (B) (Newton’s score 1) and widespread inflammation of and 
edentulous palate (C) affecting the palatal mucosa (Newton’s score 3) 
(Photographs reproduced courtesy of M.A.O. Lewis)..  
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2.1.1.2 Aetiology of denture stomatitis 
The aetiology of DS has multiple factors. In its mildest form, DS may arise purely 
from frictional irritation caused by a poorly fitting denture (Figueiral et al., 2007). 
However, the aetiology of DS is likely to be complex in more clinically severe cases. 
Table 2.1 lists some of the associated factors in DS and their management; as with 
other forms of oral candidosis, addressing these risk factors have to be considered 
when treating DS. 
DS is primarily instigated by poor denture hygiene, which promotes the formation 
of biofilm (Sakki et al., 1997, Gendreau and Loewy, 2011). The biofilm can 
penetrate the denture surface and when in contact with the mucosa can cause the 
characteristic clinical palatal inflammatory response (Ramage et al., 2004).  
Another important risk factor in DS is the continuous wearing of the prosthesis 
(Figueiral et al., 2007). The wearing of a denture overnight results in the palatal 
mucosa not being cleansed by the normal saliva flow and the retained biofilm on 
the denture surface leads to an increased contact time of the denture biofilm with 
the palatal mucosa. 
Other factors associated with DS include a low salivary pH and regular sugar 
consumption (Martori et al., 2014). All of these factors can result in an increased 
ability for C. albicans to colonise the denture and oral mucosa (Gendreau and 
Loewy, 2011) (Section 2.1.1.3). 
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Table 2.1: Aetiology and potential risk factors of denture stomatitis 
 
Category of factor 
 
Precipitating factor 
 
Reference 
 
Denture factors Poor denture hygiene 
Poor fit 
Continuous wear 
Hypersensitivity to 
material 
Trauma/irritation 
Increased denture age 
Denture 
material/roughness 
(Kulak-Ozkan et al., 2002) 
(Emami et al., 2008) 
(Kossioni, 2011) 
 
(Emami et al., 2008) 
(Figueiral et al., 2007) 
 
(Jackson et al., 2014) 
 
Patient factors  Gender 
Diet 
Immunocompromised 
Diabetes mellitus 
 
Tobacco use 
Reduced salivary flow 
Steroid usage 
Low saliva pH 
Hyposalivation 
(Figueiral et al., 2007) 
(Sakki et al., 1997) 
(Spiechowicz et al., 1994) 
(Dorocka-Bobkowska et al., 
2010) 
(Shulman et al., 2005) 
(Glazar et al., 2010) 
(Shulman et al., 2005) 
(Martori et al., 2014) 
(Sakki et al., 1997) 
Microbial factors Candida presence 
Candida species  
Candida morphology 
Bacteria present 
Biofilm deposit 
(Ramage et al., 2004) 
(Pereira et al., 2013) 
 
(Chopde et al., 2012) 
(Ramage et al., 2004) 
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2.1.1.3 Denture stomatitis and Candida 
The majority of DS cases are caused by infection with Candida species, and 
particularly C. albicans. Other species including C. glabrata, C parapsilosis, C. 
tropicalis, C. krusei, C. dubliniensis and C. guilliermondii are also linked to the 
infection, albeit less frequently (Pereira et al., 2013, Ramage et al., 2004, Coco et 
al., 2008). There may be an association between the different Candida species 
found on the denture and the severity of DS. Coco et al, (2008) found that C. 
glabrata and C. albicans were co-isolated in 80% of DS patients with the highest 
grades of clinical inflammation. Whether there is a pathogenic difference between 
specific strains or a variation in clinical host response still remains to be determined 
(Coco et al., 2008). Silva et al found that co-infection of C. albicans and C. glabrata 
was more invasive and caused more tissue damage in a reconstituted human 
epithelial tissue model than C. glabrata alone (Silva et al., 2011). One hypothesis 
(which is tested in the current research) is that individuals who generate 
inappropriate immune responses to candidal presence on the palatal mucosa, 
might be at increased risk of chronic DS infection  
Using a rodent experimental model, DS was induced in rats using acrylic prostheses 
colonised with Candida. A significant increase in peripheral blood neutrophils 
occurred in the DS group of rats and a decrease in lymphocytes was also 
encountered. Linked to the infection, was higher expression of Candida-derived 
secreted aspartyl proteinases (SAPs) from the acrylic biofilm (Lie Tobouti et al., 
2015). The increase in virulence potential of C. albicans was demonstrated at day 4 
and not at day 6 in this study. As this was a relatively short experimental period and 
involved animals, it may not reflect the clinical picture seen in humans. 
2.1.1.4 Denture stomatitis and biofilms 
In the oral cavity, including the denture surface, microorganisms are typically found 
as part of a complex structured microbial community referred to as a biofilm. DS is 
an unusual type of oral candidosis in that it is perpetuated by the presence of a 
candidal biofilm on the acrylic denture (Ramage et al., 2004). Both yeast and 
bacteria can grow within this denture biofilm (Ramage et al., 2006). A study by 
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Pereira et al., (2013) analysed the denture biofilm of 50 patients with DS, and 50 
without DS, and found C. albicans was the most frequently encountered fungal 
species, followed by C. tropicalis and C. glabrata. The most prevalent bacterial 
species were Staphylococcus aureus and S. epidermidis. This study sampled a 
relatively large group of patients, but did not assess the degree of inflammation 
and the type of microorganisms detected. 
The acrylic denture surface is hard and non-shedding, and therefore biofilms 
cannot be removed by surface turn-over, which occurs with oral mucosa (Section 
1.1.4). In addition to promoting inflammation, the denture biofilm promotes 
survival of Candida in the presence of immune defences and administered 
antifungals (Ramage et al., 2004). It is this protective nature of the biofilm that 
means that unless physical/chemical cleaning of the denture is appropriately 
implemented, resolution of the infection will be problematic.  
The surface roughness and topography of the denture acrylic can affect the type 
and extent of the biofilm. Biofilms primarily consisting of C. albicans hyphae are 
reportedly thicker and less easily removed from rougher acrylic surfaces, compared 
with C. albicans yeast (Jackson et al., 2014). The presence or absence of natural 
teeth has a significant impact on the overall microbial composition of denture 
biofilms, with the oral microbiome being more diverse in dentate patients 
(O’Donnell et al., 2015). O’Donnell’s group found that the microbial composition 
was different at denture and mucosa sites compared to the dental plaque. 
Actinobacteria and Bacilli are the two predominant classes of bacteria found on 
dentures and oral mucosa, comprising 75.2% and 66.4%, respectively, of the overall 
composition. However, Actinobacteria and Bacilli only contributed 30% to dental 
plaque (O’Donnell et al., 2015).  
 
2.1.1.5 Treatment of denture stomatitis 
DS is usually managed by improved oral hygiene through denture cleansing, 
removal of dentures whilst sleeping, smoking cessation and the use of topical 
antimicrobial agents (Walsh et al., 2015). Removing the denture whilst sleeping 
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allows saliva flow to combat microorganisms colonising the palatal surface as well 
as facilitating healing of the mucosa. However, in a study looking at DS and non-DS 
patients there was no association with dry mouth or xerostomia (Altarawneh et al., 
2013).  
Denture cleansing agents (Section 2.1.1.5.1) are varied and frequently patients 
have been known to use diluted household bleach as well as commercially 
developed denture cleansing agents (Emami et al., 2014). Natural products have 
been also used to combat denture biofilms including garlic containing agents, tea 
tree oil, propolis, pomegranate and salt (Santos et al., 2008), citric acid (Faot et al., 
2014), and apple cider vinegar (Mota et al., 2015). 
Topical antifungal agents for treating DS include nystatin suspension and 
miconazole gel (Section 1.1.3.14). In severe cases, systemic antifungals including 
fluconazole, itraconazole or ketoconazole may be indicated. Although previous 
studies (DePaola et al., 1986, Cross et al., 2004, Kulak et al., 1994) have evaluated 
treatment options in DS, there is no single accepted or totally effective treatment 
(Manfredi et al., 2013). Fully effective treatments of DS typically involve attempts 
to simultaneously reduce inflammation of the oral mucosa and microbial 
colonisation of the denture.  
A meta-analysis of randomised controlled trials showed no significant difference 
between antifungal treatment and disinfection methods in clinical or 
microbiological outcomes for DS (Emami et al., 2014). This study, reported a 
significant improvement in microbiological outcome with use of the antifungal 
compared to the placebo, however no difference in clinical outcome was evident 
between the two treatment groups. There was, however, some heterogeneity 
between studies which was explained by a lack of standardisation regarding 
microbiological analyses, and this may bias results (Emami et al., 2014). 
The frequency denture cleanser use may affect C. albicans’ ability to regrow on the 
denture surface and DS occurrence. Daily, compared with alternative day use of a 
denture cleanser has been shown to be more effective in reducing denture biofilm 
(Ramage et al., 2012). 
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Alternative methods of denture cleansing have involved use of microwave 
disinfection where both heat and microwave irradiation have microbicidal effects 
(Neppelenbroek et al., 2008). Microwaving has the advantage of being cost 
effective and avoids use of medications. Indeed, it has been shown to be as 
effective as nystatin antifungal therapy in reducing clinical signs and Candida 
colonisation in DS (Silva et al., 2012a). This study did not, however, compare 
microwave disinfection to denture cleansers. The disadvantage of microwave usage 
is that if high temperatures are generated then they have the potential to damage 
the acrylic by distortion of the poly (methylmethacrylate) (PMMA) polymer matrix 
(Senna et al., 2013). Conceivably, this would be detrimental to the denture fit and 
could lead to palatal irritation. 
Importantly, it has been shown that visible mucosal inflammatory changes 
associated with DS actually reduces following treatment with either topical or 
systemic antifungal therapy (Bergendal and Isacsson, 1980). This response provides 
strong evidence for the role of Candida in the aetiology of DS. However, 
inflammation often rapidly reoccurs following cessation of antifungal treatment, an 
observation that, in part, probably reflects the failure to completely eradicate 
Candida from the denture surface. Therefore, to fully control DS, it is likely 
necessary to simultaneously reduce mucosal inflammation and the microbial 
colonisation of the denture.   
 
2.1.1.5.1 Denture cleansers 
It has been suggested that the ideal denture cleaner should be antibacterial, 
antifungal, non-toxic and compatible with the denture material, and should not 
modify or degrade the surface of the denture. Additionally, it should be easy for 
the patient to use and cost effective (Felton et al., 2011). Three denture cleansers, 
including Polident®, Efferdent and Fittydent have previously been compared against 
two mouthwashes (CloSYSII and Corsodyl) for inhibition of Candida on acrylic resin. 
The three denture cleansers were found to be less effective than the mouthwashes 
for reducing Candida number (Işeri et al., 2011). 
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Denture cleansers can lower biofilm activity and load, but residual biofilm regrowth 
can lead to further Candida colonisation (Jose et al., 2010). This indicates that 
mechanical cleaning of the denture is also important along with the denture 
cleaning agents. 
A further in vitro study compared Polident with a common dentifrice and brushing. 
It was shown that sequential use of the denture cleaner was required to inhibit 
Candida regrowth and reduce the biofilm viability (Ramage et al., 2012). Whether a 
chemical denture cleanser is as effective in vivo where other microorganisms may 
be present and the local host response plays a role has yet to be determined 
(section 1.2). 
 
2.1.2 Immune responses in denture stomatitis 
Key factors involved in protecting the oral mucosa from infection by Candida are 
those associated with cell-mediated immunity. Innate immune cells are present in 
the palatal mucosa and contribute to the immune response generated in palatal 
secretions. It is not, however, known how T helper (Th) cells respond to Candida on 
the palate in DS, nor the type of immune response generated. 
An appropriate host immune response is considered essential for the control of 
Candida at oral mucosal surfaces. Host cells first recognise Candida through the 
presence of pathogen-associated molecular patterns (PAMPs) on the surface of 
Candida and this is facilitated by pattern recognition receptors (PRRs), such as 
Dectin-1, TLR2 and TLR4 on host cells including those of the oral epithelium 
(Takahara et al., 2012, Gasparoto et al., 2010) (Section 1.2).  
Host immune cells in the oral mucosa, particularly those involved in innate 
immunity, (dendritic cells, macrophages and neutrophils) recognise Candida PAMPs 
and produce cytokines to drive adaptive immune responses involving T-cells and B-
cells in candidosis (Wei et al., 2011). All these cells produce cytokines and create a 
tissue environment that either promotes or suppresses immune mechanisms 
involved in controlling Candida. CD4+ T cells are the most influential host immune 
cells in this respect, and dictate immunity against Candida by secreting cytokines, 
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such as those associated with Th1 (IFNγ and IL-2), Th17 (IL-17A and IL-22) and Treg 
cells (IL-10 and TGF-β1) (Carvalho et al., 2012). 
 
2.1.2.1 Cytokine expression in denture stomatitis 
Previous studies have used various methods to assess cytokine secretion in 
individuals with and without DS. Whole saliva has been analysed, but this will not 
reflect the immune response specifically at palatal mucosal sites. Indeed, this may 
not only represent responses from the entire oral mucosa, but also from other sites 
in the body. In one study, there was no significant differences between adult and 
elderly patients (n=64 in each group) with and without DS, when analysing several 
cytokines from whole saliva including IL-17 (Pesee and Arpornsuwan, 2013). A 
further study analysed IL-6 and TGFβ in whole saliva, and both were found to be 
significantly elevated in DS compared to non-DS patients (Gasparoto et al., 2012c). 
As IL-6 is secreted by T cells and macrophages and is typically raised during 
infection, these findings indicate a pro-inflammatory immune response in DS. 
Conversely, production of TGFβ indicates an immune regulatory response and 
activation of Treg cells. The same researchers analysed levels of IL-4, IL-10, IL-12 
and IFNγ cytokines in whole saliva in DS and non-DS patients. Results showed that 
DS patients had significantly higher IL-4 levels compared with non-DS patients 
(Gasparoto et al., 2012b). This finding could indicate chronic inflammation, with a 
Th2 response in DS. Whilst there was no significant difference in the levels of other 
cytokines, they did find differences in cytokines for patient groups when age was 
used as a variable. The elderly group (age range 60-85 years old) with DS had lower 
IL-12 levels compared with the elderly non-DS group.  This was not, however, the 
case in the younger DS group (age range 25-50 years old). This finding would fit 
with a typical Th2 response. A further study by the same group, identified patients 
with DS as having ‘affected’ neutrophils, and the damage was intensified by age 
(Gasparoto et al., 2012a). These ‘affected’ neutrophils exhibited higher production 
of IL-4 and IL-10 when challenged with C. albicans, which would result in a Th2 anti-
inflammatory response. 
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Ramage et al., (2006) examined inflammatory responses in an epithelial cell co-
culture model induced by zymosan, and the subsequent effect of denture cleanser 
treatment. This showed that IL-8 increased over time with zymosan exposure, and 
was reduced after treatment with the denture cleanser (Ramage et al., 2012). IL-8 
is generally thought to be a pro-inflammatory cytokine and its reduction after 
denture cleanser treatment may indicate that the denture cleanser reduced the 
biofilm and thus inflammation, as evident by lowered IL-8 levels (Ramage et al., 
2012). 
 
2.1.2.2 Identification of cytokines and prediction of T cell response 
In acute Candida infection of immunocompetent individuals, as might be expected 
to occur in the early stages of DS, it would be hypothesised that elevated Th1 
and/or Th17 responses would occur, compared with Th2 responses. As such, 
increased production of IFNγ, IL-2 and TNFα, together with simultaneously low 
levels of IL-4, IL-5 and IL-10 cytokines (associated with Th2 responses) might be 
anticipated. Conversely, for DS patients with chronic inflammation induced by 
Candida, a Th2 response might be anticipated (indicating an inability to raise a 
protective immune response) with an appropriate cytokine profile reflecting this.  
Inflammatory and anti-inflammatory cytokine production may fluctuate, resulting 
in a delicate balance between host immunity and pathogen growth. Importantly, 
excessive Th1 and Th17 responses could also contribute to inflammation and tissue 
damage. 
In a recent study, patients with DS had peripheral blood taken to assess systemic 
inflammatory responses. Compared with non-DS patients, the relative proportions 
of peripheral lymphocytes, T cells and monocytes were similar. Interestingly, the 
median percentage of CD4 T cell and CD8 T cell subsets were found to be 
significantly lower in the DS group than the controls. This may indicate a limited 
host response and ability to resolve DS (Maciąg et al., 2016). Additionally, there 
was no significance difference in IL-17, IL-4, IFNγ or TNFα production between DS 
and control groups. 
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However, despite a relatively broad knowledge base of host immune responses 
during Candida infection, limited studies have been undertaken concerning local 
inflammatory response in DS associated.  
 
2.2 Aims 
The primary purpose of this study was to assess the type of cytokines present in 
palatal secretions in DS patients and then extrapolate this to the T-helper cell 
response generated.  
The mechanism by which Candida is recognised by the host in the oral mucosa has 
not been studied specifically in DS. The hypothesis of this study was that subjects 
with DS would have higher colonisation of Candida and produce a protective T 
helper, i.e. Th1 and Th17 cell response. As a secondary component of this study, 
Candida levels in DS patients were lowered using a proprietary denture cleanser 
and the effect of this on immune responses was assessed along with the efficacy of 
the treatment. 
 
To meet these key aims, the following objectives were determined: 
 
1. The clinical parameters of patients with DS compared to a control group. 
2. The extent of Candida colonisation in denture wearing patients, with and 
without DS.   
3. The local cytokine response in patients with DS compared to control 
subjects in order to determine the T helper cell response. 
4. The number of Candida, clinical parameters and local cytokine response 
when the dentures of patients with DS and controls were treated with a 
denture cleanser compared to tap water over a 28 day period. 
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Aspects of this research have been published: 
 
Rogers, H., Wei, X-Q., Lewis, M.A.O., Patel, V., Rees, J.S., et al. (2013) Immune 
Response and Candidal Colonisation in Denture Associated Stomatitis. Journal of 
Clinical and Cellular Immunology 4: 178. doi:10.4172/2155-9899.1000178 
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2.3 Materials and Methods 
2.3.1 Patients studied 
Patients (n=104) from Cardiff and Vale NHS Trust were recruited through an 
existing subject database, clinician referrals and the local media. The study had 
previously received ethical approval (main REC reference number 09/H0206/32) 
and all subjects provided written informed consent. The study population 
comprised of 55 males (mean age 69.4 years) and 38 females (mean age 69.1 
years). All patients wore a complete upper maxillary denture and the majority 
(n=91) were Caucasian. Of the recruited patients, 46 and 47 were, respectively, 
randomly assigned to receive treatment with a proprietary denture cleanser 
(Polident) or tap water. Of these 93 individuals, 88 (94.6%) completed the study 
with 2 subsequently withdrawing consent, 2 deviated from protocol and 1 
experienced an adverse event (musculoskeletal chest pain, not related to the 
research).  
2.3.1.1 Inclusion and exclusion criteria 
Subjects were included if they were aged 18 years or older, wore a full upper 
conventional denture and were able to provide consent, as evidenced by a 
voluntary written informed signed and dated consent form (Appendix II). Patients 
needed to be willing to comply with all study procedures and restrictions. Subjects 
were included if they had good general health with no clinically significant and 
relevant abnormalities of their medical history. In brief, the subjects were excluded 
if they were pregnant, had a known allergy to any study materials, had used an 
antibiotic in the last 30 days, or had used a medication that may impact on 
outcome (e.g. corticosteroid or immunosuppressant medication), and if they had 
participated in a separate clinical study in the last 30 days (full details of exclusion 
criteria in Appendix II). 
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2.3.2 Classification of DS 
Following removal of the patient’s upper denture, the appearance of the palatal 
mucosa was scored according to Newton’s classification scale (Newton, 1962). The 
scored categories were defined as 0=no evidence of erythema on palatal mucosa, 
1=pin-point hyperaemic lesions (localised palatal erythema), 2=diffuse erythema 
(generalised simple palatal inflammation), and 3=hyperplastic granular surface 
(inflammatory papillary hyperplasia on palatal mucosa) (Figure 2.2).  
2.3.3 Calibration of examiners 
Whilst I was responsible for the majority of these investigations, there were 
occasions (see thesis acknowledgements) when another examiner was involved in 
clinical assessments. It was therefore necessary to undertake initial calibration of 
examiners. All examiners were trained and calibrated to use an Inflammation Index 
(DePaola et al., 1986), an Erythema Meter Index, and assessment of the area of 
erythema (palatal percentage coverage) to grade area and intensity of palatal 
inflammation in maxillary edentulous subjects. The recording of the Kapur Indices, 
denture cleanliness index as well as techniques for taking imprint culture and 
inflammatory marker collection were also reviewed and standardised. A total of 8 
patients were involved in this calibration exercise and were asked to attend an 
initial screening visit, a training and calibration visit and a final visit to repeat the 
assessment of the indices. Intra-class correlation (ICC), R-squares and kappa 
statistics were used to evaluate the intra-assessor repeatability for each examiner. 
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Figure 2.2: The different clinical appearances of denture stomatitis. This can be 
scored according to the Newton’s classification scale (Newton, 1962). A- 0=none 
(no evidence of erythema, normal palatal mucosa), B- 1=pin-point hyperaemic 
lesions (localised erythema), C- 2=diffuse erythema (generalised simple 
inflammation), and D-3=hyperplastic granular surface (inflammatory papillary 
hyperplasia). (Photographs reproduced courtesy of M.A.O. Lewis).. 
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2.3.4 Classification of clinical measurements 
2.3.4.1 Clinical Inflammation Index 
Scales to grade the relative area (extent) and intensity (severity) of inflammation 
have previously been developed (DePaola et al., 1986). These scales were recorded 
for each patient. The maxillary oral soft tissue was scored using a predefined scale 
for area of inflammation (0=no inflammation; 1=inflammation (erythema, oedema) 
of the palatal denture bearing tissue, extending to 20 mm; 2=inflammation 
(erythema, oedema) of the palatal denture bearing tissue, extending >20 mm on 
denture bearing tissue, but exhibiting no hyperplastic changes; 3=severe 
inflammation exhibiting hyperplastic projections covering more than 50% of the 
palatal denture bearing tissue). Intensity of inflammation was scored according to 
the following scale: 0=normal mucosa- tissue had pink colour with stippling and 
texture that was considered healthy; 1=mild inflammation- slight redness, no 
swelling or oedema, normal size and shape; 2=moderate inflammation- redness 
with some oedema, loss of stippling and slight change from normal shape; 
3=severe inflammation- acutely inflamed redness, oedema, definite change in size, 
shape and consistency; hyperplastic projections) (DePaola et al., 1986). 
2.3.4.2 Erythema Index 
Palatal erythema was assessed visually and objectively using an erythema meter 
(Multi Skin Center® MC750; Enviroderm, Evesham, UK). The erythema meter 
operates based on white light reflection off a mucosal surface. When this occurs, 
haemoglobin in the vasculature of the tissue selectively absorbs green light, but has 
little effect on red light. An erythema index was generated based on the ratio of 
red to green reflected light and was recorded for each patient over the course of 
the study. Readings were taken from each side of the palate, repeated three times 
and averaged to obtain an ‘erythema index’. 
2.3.4.3 Area of erythema (percentage coverage) 
The proportion of the right and left halves of the palate that were covered by 
erythema was estimated. The palate was viewed and the mid-palatal suture 
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running from the incisive papilla to the fovea palante was used as the anatomical 
landmark to demarcate the right and left halves of the palate that corresponded to 
the subject’s right and left hand side. An estimation of the proportion of each half 
of the palate covered by erythema was established by mentally summing any 
individual erythematous areas observed clinically and recording this as a value 
between 0-100 %. 
2.3.4.4 Denture stability and retention score 
A score of the retention and stability of the upper and lower denture (if applicable) 
was made (Olshan et al., 1992). The denture retention criteria included the 
following score: 0= no retention, the denture was seated in place and displaced 
itself; 1= poor retention- the denture offered slight resistance to vertical pull, and 
little or no resistance to lateral force; 2=fair retention- the denture offered 
moderate resistance to vertical pull, and little or no resistance to lateral force; 
3=good retention- the denture offered moderate resistance to vertical pull and 
lateral force; 4=very good retention- the denture offered very good resistance to 
vertical pull and lateral force; 5=excellent retention- the denture offered excellent 
resistance to vertical pull and lateral force.  
The denture stability criteria were based on the following scores: 0=no stability, the 
denture base demonstrated extreme rocking on its supporting structures under 
pressure; 2=some stability, the denture base demonstrated moderate rocking on 
its supporting structures under pressure; 2=sufficient stability, the denture base 
demonstrated slight or no rocking on its supporting structures under pressure. 
2.3.4.5 Denture Bearing Tissue Score (Kapur Index) 
The upper and lower denture (if applicable) were removed and the supporting 
tissues scored using the scales detailed in table 2.2 (Kapur, 1967). 
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Table 2.2: Denture bearing tissue score (Kapur Index) 
 
  
Ridge shape Tissue resiliency Location of border tissue 
attachment 
1= Flat 
2= V-shaped 
3= Shaped between U & V 
4= U Shaped 
 
1= Flabby 
2= Resilient 
3= Firm 
 
Maxillary  
1= Low  
2= Medium  
3= High  
Mandibular 
1= High 
2= Low 
3= Medium 
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2.3.4.6 Denture cleanliness index 
The denture was removed and its cleanliness graded (Blair et al., 1995). The fit 
surface of the denture was graded using the following scale: 0=no visible plaque- 
no matter adherent to flat plastic instrument on light scraping of fitting surface; 
1=no visible plaque; matter adherent to flat plastic instrument on light scraping of 
fitting surface; 2=deposits of plaque just visible on careful examination without 
need to confirm by scraping; 3=deposits of plaque clearly visible; 4=gross plaque 
deposits (‘velvet appearance’). 
2.3.4.7 Salivary survey questionnaire 
Responses to a questionnaire were recorded. Questions were based on denture 
comfort and perception of dryness of mouth (Appendix II).  
2.3.5 Isolation and identification of Candida 
The presence of Candida on the fitting surface of the denture, the palate and the 
tongue was determined using an imprint culture technique that also permitted 
quantification of Candida at the test site (Williams and Lewis, 2000). Briefly, sterile 
foam squares (2 cm2) were initially moistened in sterile water and placed on the 
fitting surface of the denture, the palate and the tongue for 30 s. The foam squares 
were then transferred to CHROMagar® Candida medium (CHROMagar, Paris, 
France) for 30 min and then removed.  Agar plates were incubated at 37°C for 48 h 
and the number of Candida colony forming units (CFUs) recorded and expressed 
per cm2. Representative colony types were selected for definitive identification 
based on standard morphological testing (germ-tube test), biochemical profiling 
using the Auxocolor 2 system (Bio-Rad), and sequence analysis of PCR amplified 
ribosomal DNA, as previously described (ITS1 and ITS4) (Williams et al., 1996). 
2.3.6 Cytokine collection and analysis 
Fluid from the palatal mucosa was collected by absorption on to filter paper strips. 
A piece of filter paper (2×3 cm, Whatman chromatography grade No. 3 mm) was 
fixed on each side of the fitting surface of the upper denture, which was then 
placed in the mouth for 5 min (Figure 2.3). The denture was removed and filter 
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paper placed in a microcentrifuge tube containing 400 µl of phosphate buffered 
saline, 5% fetal bovine serum (FBS), 0.05% sodium azide w/v, protease inhibitor 
and Tween (0.002% (v/v). The vial was gently agitated for 2 h at 4°C and 
contaminating particles removed by centrifugation. The solution was stored at -
70°C until analysed.  
2.3.5.1 Cytokine Bead Array (CBA) for cytokine detection 
To determine efficiency of cytokine recovery from the filter paper, positive controls 
of buffer, which had been artificially contaminated with a known quantity of 
specific cytokines was analysed. The BD™ Cytometric Bead Array (CBA; BD) Human 
Th1/Th2/Th17 Cytokine Kit was used to quantify cytokines (IFNγ, IL-2, TNFα, IL-4, IL-
6, IL-10, IL-17A) in single tissue fluid samples (minimum sensitivity estimated at 2 
pg/ml for the cytokines). The capture beads were prepared by mixing in a capture 
bead tube, and these were then aliquoted into sterile microcentrifuge tubes before 
adding 32 µl of sample palatal fluid. The preparation was then mixed prior to 
adding 35 µl of phycoerythrin (PE) detection agent and then incubating overnight 
at 2-8C. The tubes were brought to room temperature before adding 700 µl of BD 
wash buffer and centrifuging for 5 min. The remaining pellet was resuspended in 
210 µl of wash buffer before placing in a tube ready for fluorescence-activated cell 
sorting (FACS) analysis. The CBA samples were analysed on a FACS Calibur machine 
(BD Biosciences).  
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Figure 2.3: Placement of filter paper on the denture surface. Filter paper (2 × 3 cm, 
Whatman Chromatography grade No. 3mm) was positioned on the left and right 
side of the fitting surface of an upper complete acrylic denture before placing in 
the subject’s mouth for 5 minutes. 
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2.3.5.2 Single plex flex kit for cytokine detection 
Single plex flex kits (Becton) were used to quantify TGFβ and IL-5 in the palatal 
fluid. In sterile microcentrifuge tubes, 35 µl of each sample was added to an equal 
volume of diluted capture beads. The diluted PE detection reagent was then added 
to each assay tube. The tubes were incubated at 2-8°C overnight, after which they 
were incubated at room temperature for approximately 1 h. The beads were then 
washed by adding 700 µl of BD wash buffer and centrifuging for 5 min, the resulting 
pellet was then resuspended in 210 µl of BD wash buffer and vortexed to 
resuspend the beads. The sample was then measured using a FACs Calibur machine 
(BD biosciences). 
2.3.5.3 Enzyme Linked Immunosorbent Assay for cytokine detection 
An Enzyme-Linked Immunosorbent Assay (ELISA; eBioscience) was used to quantify 
IL-22 and for selected samples of TGFβ in the palatal fluid samples. The wells of a 
NUNC Maxisorp 96-well ELISA plate were incubated overnight, at 4°C, with 100 
μl/well of capture IL-22 antibody (eBioscience) in coating buffer. The wells were 
then aspirated and washed (5) with wash buffer (250 μl/well) allowing time for 
soaking (1 min) during each wash step to increase the effectiveness of the washes. 
The plate was blotted on absorbent paper to remove residual buffer. The wells 
were blocked with 200 μl/well of assay diluent (1) and incubated at room 
temperature for 1 h. The wells were aspirated and washed as previously described. 
Assay diluent (1) was used to dilute the standards as recommended by the 
manufacturer (standard 0 to 500pg/ml), sensitivity 3pg/ml) (eBioscience). Standard 
concentrations of antigen were added (100 μl) to the appropriate wells in a 2-fold 
dilution series. 
Samples of palatal secretion fluid (100 μl) were added to the appropriate wells. The 
plate was sealed and incubated overnight for maximal sensitivity. The wells were 
aspirated and washed (5) as previously described. Detection antibody (biotin-
conjugate anti-human IL-22 eBioscience) was diluted in assay diluent (1) and 
added to each well (100 μl/well). The plate was sealed and incubated at room 
temperature for 1 h. The wells were aspirated and washed (5) as previously 
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described. Avidin-horse radish peroxidase (100 μl/well) in assay diluent (1) was 
then added to each well. The plate was incubated at room temperature for 30 min, 
after which, the wells were aspirated and washed (7) allowing the wash buffer to 
soak in the wells for 1 min prior to aspiration. Substrate solution (100 μl/well) was 
added to each well, and the plate incubated at room temperature for 15 min. Stop 
solution (50 μl/well) was added and the absorbance read at 450 nm using a 
FLUOstar spectrophotometer (BMG, FLUOstar optima). 
2.3.7 Antimicrobial denture cleanser to reduce Candida levels 
Denture wearing patients with and without DS were randomised to treatment of 
dentures with a denture cleanser (Polident® GSK; GlaxoSmithKline) or tap water. 
Polident® was administered as an effervescent denture cleanser tablet, which was 
dissolved in water and used to soak and brush dentures outside the mouth. 
Dentures were rinsed thoroughly before being placed back in the mouth. 
Selected clinical, microbiological and cytokine parameters were studied in patients 
over 28 days. Patients were asked to return at weekly intervals (+/- one day) for 
assessment. The groups were randomised at baseline (day 0) into either receiving 
Polident® to use between weekly visits, or the control tap water group. The two 
groups were further divided into using daily 15 min or overnight soaks in the 
Polident® or water.  
3.3.8 Statistical analysis 
Summary statistics (means, standard deviation (SDs), medians, maxima, minima) 
were obtained for the study parameters at days 0, 7, 14, 21 and 28. Non-
parametric Wilcoxon Rank Sum tests determined patient differences in logarithmic 
Candida counts, as well as cytokine levels. Changes from baseline for palatal 
inflammation, Candida colonisation and cytokines were used to compare 
effectiveness of treatments. Analysis of Covariance (ANCOVA) was undertaken in 
mixed model using Statistical Analysis System (SAS; Marlow, UK). The mixed 
model included treatment as fixed effect, baseline, smoking status, age of denture 
and denture adhesive as covariates. All tests were performed at a 5% significance 
level and 95% confidence intervals were used. Separate analyses were performed 
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for each patient group (DS and non-DS). Correlation between different cytokines 
were also calculated. All the randomised patients were included in the statistical 
intention to treat analysis, that is analysis was carried out according to the group 
they were randomised to even if they did not actually receive the treatment. 
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2.4 Results 
2.4.1 Demographics of subjects studied 
Of the recruited patients, 30 males and 21 females had no clinical evidence of DS 
(Newton score 0), whilst 25 males (mean age 59.5 years) and 17 females (mean age 
40.5 years) had varying degrees of erythematous changes in the palate consistent 
with DS (Newton score 1, 2 and 3). Baseline demographics (Table 2.3) of the 
patients studied also revealed that of the 93 patients, 22 were smokers (10/42 with 
DS and 12/51 without DS).   
2.4.2 Calibrations of examiners 
A total of eight subjects participated in the calibration exercise, three males and 
five females (mean age 73.1 years; SD=7.55). Examiner 1 showed good 
repeatability on both erythema index and percent coverage scoring based on Intra 
Class Correlation (ICC) coefficient of 0.81 and 0.94, respectively. Examiners 2 and 3 
had an ICC of 0.95 and 0.88 for percent coverage, respectively, but failed to achieve 
good repeatability for erythema index based on the ICC value of 0.66 and 0.32, 
respectively. From the simple linear regression results, intensity scores were well 
explained by erythema index on day 2 (R2= 69%, 79% and 64% for examiner 1, 2 
and 3, respectively) by each examiner, but relatively less on day 3 (R2= 41%, 75% 
and 53% for examiner 1, 2 and 3, respectively). Based on the linear regression of 
inflammation area index against percentage coverage, variability in inflammation 
area scores were recorded consistently on day (R2= 90%, 78% and 90% for 
examiner 1, 2 and 3, respectively) by each examiner and on day 3 (R2= 95%, 80% 
and 79% for examiner 1, 2 and 3, respectively. Examiner 1 showed good agreement 
based on the Kappa analysis results for area and intensity indices at day 3 
(Weighted Kappa=0.77 for Area and 0.83 for Intensity). Similarly, examiner 2 and 3 
also demonstrated high agreement (Weighted Kappa=1.00 and 0.80 of area and 
intensity for examiner 2 and Weighted Kappa=0.86 and 0.86 for examiner 3, 
respectively)  
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Table 2.3: Baseline demographics and clinical measurements in the denture 
stomatitis and non-stomatitis study groups 
 Non-stomatitis 
group (n=51) 
Denture stomatitis 
group (n=42) 
Mean age (years) 69.4 (SD 10.3) 69.1 (SD 9.3) 
Sex Male 30 
Female 21 
Male 25 
Female 17 
Smokers 12 10 
Area score of inflammation index 0.0 1.4 
Intensity score of inflammation index 0.0 1.6 
Percentage coverage of palate (left 
side palate) 
0.0% 37.3% 
Percentage coverage of palate (right 
side palate) 
0.0% 38.5% 
Newton’s classification Class 0=51 Class 1=27 
Class 2 and 3=15 
N= number, SD= standard deviation 
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2.4.3 Clinical measurements in the study group at baseline 
Subject demographics and clinical measurements at baseline (Table 2.3) showed 
that the inflammation, the area score, intensity score, percentage coverage were 
all higher in the DS compared with non-DS group. The erythema meter did not 
work consistently through the study and it was concluded that this data would not 
be included in the rest of the study analyses.  
There was no difference in the denture cleanliness index and salivary survey 
questionnaire at baseline between the DS and non-DS groups. 
Newton’s classification of the two treatment groups at baseline is shown in figure 
2.4. 
2.4.4 Isolation and identification of Candida 
The isolation and identification of Candida colonisation was examined at baseline 
in the group with DS and without. Table 2.4 and figure 2.5 summarise the extent of 
Candida colonisation at specific sites and relationship with Newton’s classification 
of DS. Candida was isolated from 48 patients (29/42 with DS, and 19/51 without 
DS). The mean Candida count for non-DS patients (Newton’s Classification=0) was 
9.97 cfu/cm2 on the palate, 12.8 cfu/cm2 on the tongue, and 9.93 cfu/cm2 on the 
denture. In comparison, for patients with DS (Newton’s class=1, 2 and 3), the mean 
palatal count was 8.46 cfu/cm2, the tongue count was 16.64 cfu/cm2 and the fitting 
surface of denture count was 24.23 cfu/cm2. A statistically higher Candida count 
was evident on the tongue (P=0.0043) and fitting surface of the denture (P=0.0113) 
for patients with DS compared to those without DS (Figure 2.6). Interestingly, the 
palatal Candida count for DS patients was significantly lower (P=0.0301) compared 
with non-DS patients (Figure 2.6). 
The summary data of the Candida species isolated from the oral three sites in DS 
and non-DS patients at baseline is shown in figure 2.7. It was evident that C. 
albicans was the most prevalent species in DS patients (24/42; 57%), with C. 
glabrata (5/42; 12%), C. tropicalis (4/42; 10%) and C. parapsilosis (2/42; 5%) also 
encountered. Mixed Candida species were recovered from 7 (17%) of the 42 DS 
patients. In patients without DS, the recovered Candida species were C. albicans 
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(11/51; 22%), C. glabrata (4/51; 8%), C. parapsilosis (5/51; 10%), and C. krusei 
(2/51; 4%). Four patients (8%) without DS were colonised with mixed Candida 
species. In several patients, different Candida species were found at multiple sites.  
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Figure 2.4: Newton’s classification of all subjects randomised into the two 
treatment groups at baseline. There were small numbers of patients with Newton’s 
class 2 and 3 in both groups. The numbers with class 0 were similar for the two 
treatment groups (Polident and Tap water).  
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Figure 2.5: Candida counts at three sampled sites (fit surface of denture, palate and 
tongue) per Newton’s classification at baseline in the total subjects (n=96). Bars 
represent mean and standard deviation of the Candida count (cfu/cm2). 
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Table 2.4: Candida levels (cfu/cm2) at three sites and Newton’s classification of 
denture stomatitis in 93 patients. 
  Newton’s classification 
Sample site Statistical 
measure 
0 1, 2 & 3 1 2 &3 
Fit surface of 
denture 
 
 
denture 
N 51 42 27 15 
 mean 9.93 24.23 (P=0.01) 19.44 32.85 
 SD 22.74 31.67 30.67 32.65 
CV (%) 229.1 130.7 157.8 99.4 
 median 0.00 5.00 0.50 24.50 
 minimum 0.00 0.00 0.00 0.0 
 maximum 75.0 75.0 75.0 75.0 
Palate      
 mean 9.97 8.46 (P=0.03) 5.32 14.12 
 SD 24.26 19.84 15.44 25.63 
 CV (%) 243.3 234.4 290.0 181.5 
 median 0.00 1.00 0.25 1.50 
 minimum 0.00 0.00 0.0 0.0 
 maximum 75.0 75.0 75.0 75.0 
Tongue      
 mean 12.80 16.64 (P=0.0043) 13.35 22.55 
 SD 27.27 26.11 24.747 28.31 
 CV (%) 213.1 157.0 185.3 125.5 
 median 0.00 4.38 3.00 10.50 
 minimum 0.00 0.00 0.0 0.0 
 maximum 75.0 75.0 75.0 75.0 
SD=standard deviation, N= number, CV (%)= coefficient of variation, P-value is 
based on the Wilcoxon Rank Sum test 
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Figure 2.6: Candida counts from the three different sites in the two groups. 
Candida counts from the fit surface of the denture (P=0.0113) and tongue (P= 
0.0043) were significantly higher in the patients with denture stomatitis 
compared to the non-stomatitis group. Candida counts from the palate 
(P=0.0301) were significantly higher in the patients without denture stomatitis 
compared to the stomatitis group. Bars represent mean and standard deviation.  
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Figure 2.7: Summary of Candida species isolated from the oral three sites in 
denture stomatitis and non-stomatitis patients at baseline. It was evident that C. 
albicans was the most prevalent species in DS patients (24/42; 57%), with C. 
glabrata (5/42; 12%), C. tropicalis (4/42; 10%) and C. parapsilosis (2/42; 5%) also 
encountered.  
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 2.4.5 Cytokine profiling at the mucosal surface of DS and non-DS patients  
A summary of the level of detected cytokines is presented in Table 2.5. Statistical 
analysis showed that the following cytokines were significantly elevated in patients 
with DS (Newton’s class=1, 2 and 3) compared with those non-DS patients 
(Newton’s class=0): IFN (P=0.0004), IL-6 (P<0.0001), IL-10 (P<0.0001), IL-17A 
(P=0.026), IL-22 (P=0.0004), TGFβ (P<0.0001) and TNFα (P=0.0009). Grouping the 
cytokines associated with Th1 (IFN-, TNFα, and IL-2), Th2 (IL-4, IL-5 and IL-10) and 
Th17 (IL-17A, IL-22 and TGFβ) responses, showed significant increases in Th1 
(P=0.0008), Th2 (P=0.0028) and TH17 (P<0.0001) responses in DS patients. Of the 
cytokines in the Th2 group, only IL-10 was significantly elevated in DS. The Treg 
cytokines IL-10 and TGFβ were also significantly elevated in the DS group. The most 
significant changes were, however, with Th1 and Th17 responses. 
2.4.6 Correlation between the different cytokine levels in DS patients 
In the DS group, it was evident that the levels of IL-17A strongly correlated with 
those of IL-22 (R2=0.556). Associations were also seen between levels of IFNγ and 
IL-17A (R2=0.590), and levels of IFNγ and IL-22 (R2=0.541). There was no correlation 
between the cytokine levels in DS patients for TNFα and IFNγ (R2=0.101), nor for 
TNFα and IL-10 (R2=0.247). Although IL-10 and TGFβ may both originate from Treg 
cells, in DS patients, IL-10 levels were not associated with TGFβ (R2=0.001).  
2.4.7 Candida counts at different visits in different treatment groups 
Figure 2.8 and table 2.6 show that for palate and tongue imprint culture counts, a 
statistically significant (p< 0.05) change occurred with the Polident® denture 
cleanser compared with use of tap water for all visits except for day 7. In subgroup 
analysis of pre-existing DS, Polident® was significantly effective in reducing the CFUs 
from baseline compared with tap water at all visits.  
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Table 2.5: Level of 10 cytokines and Newton’s classification of denture stomatitis in 
93 patients at baseline  
  Newton’s Classification 
Cytokine 
(pg/ml) 
statistic 0 (n=47) 1, 2 & 3 (n=42) 1 (n=27) 2, 3 (n=15) 
IFN mean 0.24 3.83 (P=0.0004) 0.47 9.88 
 SD 1.39 11.9 1.39 18.71 
 CV (%) 590.9 310.8 298.9 189.4 
 median 0.00 0.07 0.00 0.74 
 minimum 0.0 0.0 0.0 0.0 
 maximum 9.6 64.4 6.8 64.4 
IL-2 mean 0.22 0.42 (P=0.058) 0.36 0.55 
 SD 0.40 0.54 0.49 0.63 
 CV (%) 180.5 127.9 136.5 115.5 
 median 0.00 0.00 0.00 0.46 
 minimum 0.0 0.0 0.0 0.0 
 maximum 1.2 2.2 1.7 2.2 
IL-4 mean 0.33 0.46 (P=0.139) 0.52 0.34 
 SD 0.56 0.566 0.622 0.444 
 CV (%) 168.3 124.1 119.9 129.5 
 median 0.00 0.16 0.00 0.32 
 minimum 0.0 0.0 0.0 0.0 
 maximum 2.0 1.6 1.6 1.4 
IL-5 mean 0.56 0.80 (P=0.0744) 0.68 1.01 
 SD 0.76 0.74 0.77 0.640 
 CV (%) 136.3 92.4 113.6 63.3 
 median 0.00 0.16 0.63 1.09 
 minimum 0.0 0.0 0.0 0.0 
 maximum 2.6 1.6 2.6 2.4 
IL-6 mean 3.48 28.32 (P<0.0001) 9.16 62.82 
 SD 5.21 40.06 10.64 63.40 
 CV (%) 149.8 162.6 116.2 100.9 
 median 2.08 8.63 5.49 37.67 
 minimum 0.0 0.0 0.0 3.7 
 maximum 30.5 215.7 41.9 215.7 
IL-10 mean 0.08 1.06 (P<0.0001) 0.47 2.13 
 SD 0.16 2.14 0.92 3.15 
 CV (%) 204.9 200.8 195.7 147.4 
 median 0.00 0.17 0.00 1.09 
 minimum 0.0 0.0 0.0 0.0 
 maximum 0.6 10.2 3.9 10.2 
IL-17A mean 1.02 8.35 (P=0.026) 2.78 18.39 
 SD 2.37 18.45 4.67 28.07 
 CV (%) 233.1 220.9 168.3 152.7 
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 median 0.00 0.00 0.00 6.89 
 minimum 0.0 0.0 0.0 0.0 
 maximum 9.0 89.2 13.7 89.2 
IL-22 mean 9.90 76.70 (P=0.0004) 33.39 154.65 
 SD 13.66 124.13 74.50 157.14 
 CV (%) 138.0 161.8 223.1 101.6 
 median 0.00 24.72 7.81 91.11 
 minimum 0.0 0.0 0.0 0.0 
 maximum 39.3 411.4 321.8 411.4 
TGF mean 258.67 360.39(P<0.0001) 
(P<0.0001) 
321.37 430.64 
 SD 495.52 308.77 297.32 326.81 
 CV (%) 191.6 85.7 92.5 75.9 
 median 186.89 280.11 273.48 343.90 
 minimum 10.1 93.4 93.4 167.1 
 maximum 3537.0 1705.5 1705.5 1335.7 
TNF mean 0.02 0.69 (P=0.0009) 0.61 0.84 
 SD 0.048 2.079 2.26 1.765 
 CV (%) 301.3 300.0 371.6 209.1 
 median 0.00 0.00 0.00 0.15 
 minimum 0.0 0.0 0.0 0.0 
 maximum 0.2 11.6 11.6 6.1 
CV (%), coefficient of variation, SD=standard deviation, IFN=interferon, 
IL=interleukin, n=number, TNF=tumour necrosis factor, TGF=transforming growth 
factor 
P-value comparing non-stomatitis (Newton’s 0) with DS (Newton’s 1, 2, and 3) 
patients for each of the 10 cytokines (calculated using Wilcoxon Rank Sum test). 
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Figure 2.8: Candida counts at weekly intervals isolated at each site (fit surface of 
denture, palate and tongue) in the two different treatment groups (Polident and 
tap water) including both non-stomatitis and stomatitis patients in each treatment 
group. There was a significant reduction in Candida counts in the Polident® group 
compared to the tap water group at days 14, 21 and 28 (p<0.05) in all three sites. 
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Table 2.6: Analysis of change from baseline in log-transformed imprint culture 
(cfu/cm2) levels (Polident® vs. tap water) 
 LS-Means# Ratio1 95% CI# P-value# 
Fit Surface: Day 7 0.26/1.21 0.22 0.11,0.43 <0.0001 
Fit Surface: Day 14 0.18/1.65 0.11 0.06,0.20 <0.0001 
Fit Surface: Day 21 0.22/1.35 0.16 0.08,0.33 <0.0001 
Fit Surface: Day 28 0.17/1.36 0.13 0.06,0.26 <0.0001 
Palate: Day 7 0.52/0.77 0.67 0.39,1.17 0.1589 
Palate: Day 14 0.39/1.12 0.34 0.21,0.56 <0.0001 
Palate: Day 21 0.49/1.06 0.46 0.27,0.80 0.0062 
Palate: Day 28 0.33/1.05 0.32 0.17,0.58 0.0003 
Tongue: Day 7 0.44/0.79 0.55 0.30,1.04 0.0654 
Tongue: Day 14 0.29/1.21 0.24 0.13,0.44 <0.0001 
Tongue: Day 21 0.47/1.28 0.37 0.19,0.72 0.0038 
Tongue: Day 28 0.27/0.97 0.27 0.14,0.53 0.0002 
 
Low scores were favourable. Negative change indicates an improvement from 
baseline. 
[1] Represent the Ratio of the relative change from baseline. # From ANCOVA with 
factors, treatment as fixed effect, baseline, smoking status, age of denture and 
denture adhesive as covariates. Statistical analysis was performed on log 
transformed data; all the results were exponentiated for presentation purpose.  
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Statistically significant reductions in the presence of Candida were observed for the 
fit surface of the denture, the palate and tongue in subjects with pre-existing DS 
and those without pre-existing DS following use of Polident® denture cleanser (14, 
21 and 28 days. No statistically significant reduction in Candida occurred for the fit 
surface of the denture, the palate and tongue in DS and non-DS following use of 
tap water at any time point. 
2.4.8 Clinical measurements for different treatment groups 
Polident® was significantly effective in reducing the percentage coverage of 
erythema compared with tap water at all visits and at each side of dentures except 
at day 14 for both left and right fit surfaces of the dentures (day 28 left side p<0.05, 
right side p<0.05) (Figure 2.9). 
A significant change (baseline to day 28; left side, p=0.0142 and right side 
p=0.0175) in area of erythema occurred using Polident compared with tap water. 
Analysis of the two groups individually showed there was no significant reduction 
in erythema in the non-DS group, but there was in the DS group at day 28 (left side, 
p=0.0087 and right side, p=0.0188).  
Statistically significant reductions in palatal inflammation (as determined by the 
inflammation index) were observed in area and intensity, area only, and intensity 
only scores in DS-patients using Polident® denture cleanser (day 7). No significant 
change in palatal inflammation was observed in non-DS patients using Polident® at 
any time point as would be expected as there is no initial inflammation by 
definition. No statistically significant reduction in palatal inflammation occurred in 
tap water treated DS and non-DS patients at any time point. A statistically 
significant reduction in area of palatal inflammation (as determined by area of 
erythema; percent coverage) at all-time points with Polident® compared with tap 
water treatment. 
There was a significant improvement in the cleanliness of both maxillary and 
mandibular dentures for the group treated with Polident® compared with tap water 
(figure 2.10). Polident® showed a statistically significant reduction in denture 
cleanliness from baseline as compared to tap water (p=0.0062 and 0.0121 at day 21 
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and 28, respectively for maxillary dentures, whereas p=0.0305 at day 28 for 
mandibular dentures. There was no statistically significant change observed based 
on the sub group analysis (pre-existing DS and no pre-existing DS) except for the 
maxillary denture at day 21 and 28 for pre–existing DS group.  
Based on the salivary survey questionnaire, most subjects (71.7% in Polident® group 
and 78.7% in tap water group) reported that no noticeable change in amount of 
saliva they produced. Most of the subjects (95.7% in Polident® group and 87.2% in 
tap water group) did not feel dryness of the mouth while eating.  
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Figure 2.9: Percentage area of palatal erythema at weekly intervals in the two 
different treatment groups (Polident® and tap water) including both the non-
stomatitis and stomatitis patients in each treatment group. Polident® was 
statistically significant in reducing the percentage coverage of erythema as 
compared with tap water at both left and right sides of the palate at all visits 
except at day 14. (Day 28 left side p<0.05, right side p<0.05).  
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Figure 2.10: Denture cleanliness index for the maxillary and mandibular denture at 
weekly intervals in the two treatment groups (Polident® and tap water) including 
both the non-stomatitis and stomatitis patients in each treatment group.  
There was a significant improvement in the cleanliness of both the maxillary and 
mandibular dentures for the group treated with Polident® compared to tap water. 
Polident® showed statistically significant reduction in denture cleanliness from 
baseline as compared to Tap water (p=0.0062 and 0.0121 at day 21 and 28, 
respectively for maxillary dentures, whereas p=0.0305 at day 28 for mandibular 
dentures.   
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2.4.9 Cytokine levels in the different treatment groups over time  
Summary statistics of the different cytokine levels at different time points are 
shown in table 2.7. IL-17A was significantly lower at day 14 in the pre-existing 
stomatitis group when Polident® was compared with tap water treatment (table 
2.8). There was no difference in IL-6 levels in the two treatment groups, but a 
reducing trend was seen for the mean of DS patients treated with Polident® 
compared with tap water. The remaining cytokine levels were mainly below the 
detectable threshold and no significant differences were seen. There was no 
difference in the overall change in the cytokine levels for the two groups 
(treatment and non-treatment) from baseline (Table 2.9).   
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Table 2.7: Summary (mean ± SD) of inflammatory cytokines (pg/ml) at different 
times 
 Day Polident®  
(N=46) 
Tap Water 
(N=47) 
IFNγ 0 2.17 ± 9.795 1.70 ± 6.828 
14 0.03 ± 0.107 0.29 ± 1.309 
28 0.15 ± 0.651 0.33 ± 0.912 
IL-2 0 0.26± 0.477 0.37 ± 0.486 
14 0.28 ± 0.409 0.28 ± 0.416 
28 0.30 ± 0.437 0.35 ± 0.491 
TNFα 0 0.38 ± 1.789 0.29 ± 1.063 
14 0.03 ±0.097 0.62 ± 2.835 
28 0.68 ±4.388 1.28 ±7.620 
IL-4 0 0.37 ±0.565 0.41 ± 0.570 
14 0.40 ± 0.515 0.46 ± 0.584 
28 0.39 ± 0.540 0.40 ± 0.567 
IL-5 0 0.58 ± 0.660 0.76 ± 0.831 
14 0.55 ±0.602 0.67 ± 0.780 
28 0.58 ±0.692 0.86 ±1.900 
IL-10 0 0.53 ±1.495 0.56 ±1.607 
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14 0.15 ± 0.210 0.33 ± 0.985 
28 0.14 ± 0.209 0.37 ±0.833 
IL-17A 0 3.75 ±9.864 5.19 ±15.936 
14 1.36 ±2.456 2.09 ± 4.589 
28 1.61 ±2.906 2.27 ± 4.089 
IL-22 0 39.75 ± 83.971 43.05 ± 99.529 
14 12.37 ± 32.848 25.66 ±65.705 
28 27.32± 77.343 27.78 ±45.942 
TGF 0 284.11 ±245.528 328.74 ±539.291 
14 269.39 ± 158.406 274.36 ± 236.587 
28 283.36 ±201.015 302.54 ± 320.146 
IL-6 0 16.28 ± 38.316 14.15 ±29.654 
14 4.30 ± 6.146 9.80 ± 26.115 
28 5.13 ±10.020 14.99 ±61.081 
IFN=interferon, IL=interleukin, N=number, TNF=tumour necrosis factor, 
TGF=transforming growth factor, SD= standard deviation. 
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Table 2.8: Analysis of change from baseline in inflammatory cytokines (pg/ml) – 
pre-existing Stomatitis (Polident vs. Tap water) 
 LS-Means# Difference1 95% CI# P-value# 
IFNγ: Day 14 -4.06/-3.43 -0.63 -1.50,0.25 0.1533 
IFNγ: Day 28 -3.73/-3.42 -0.31 -0.95,0.33 0.3315 
IL-2: Day 14 0.01/-0.12 0.13 -0.04,0.29 0.1286 
IL-2: Day 28 0.08/-0.07 0.15 -0.07,0.37 0.1830 
TNF: Day 14 -1.18/0.23 -1.42 -3.29,0.45 0.1334 
TNF: Day 28 -0.38/1.00 -1.38 -7.04,4.28 0.6239 
IL-4: Day 14 0.02/0.11 -0.09 -0.29,0.11 0.3593 
IL-4: Day 28 0.04/-0.03 0.08 -0.10,0.25 0.3686 
IL-5: Day 14 -0.09/-0.04 -0.05 -0.30,0.20 0.7006 
IL-5: Day 28 -0.31/0.05 -0.36 -1.39,0.67 0.4835 
IL-10: Day 14 -1.04/-0.58 -0.47 -1.05,0.12 0.1124 
IL-10: Day 28 -1.03/-0.66 -0.37 -0.84,0.10 0.1182 
IL-17A: Day 14 -7.40/-4.41 -2.99 -5.96,-0.01 0.0492 
IL-17A: Day 28 -6.23/-5.14 -1.09 -3.71,1.53 0.4060 
IL-22: Day 14 -77.52/-42.78 -34.74 -80.25,10.77 0.1303 
IL-22: Day 28 -50.60/-47.19 -3.41 -61.43,54.61 0.9058 
TGF: Day 14 -70.05/-24.55 -45.50 - 0.5479 
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197.62,106.62 
TGF: Day 28 -34.56/-15.99 -18.57 -
208.72,171.59 
0.8442 
IL-6: Day 14 -28.00/-14.83 -13.17 -30.07,3.73 0.1226 
IL-6: Day 28 -31.81/-9.06 -22.75 -63.99,18.49 0.2706 
IFN=interferon, IL=interleukin, N=number, TNF=tumour necrosis factor, 
TGF=transforming growth factor, CI=confidence intervals 
LS- Means= low score means of the change in the Polident and tap water groups 
from baseline, where low scores were favourable and a negative change indicated 
improvement from baseline. 
Difference was first named treatment (Polident) minus second named treatment 
(tap water), such that a negative difference favoured Polident. 
# From ANCOVA with factors, treatment as fixed effect, baseline, smoking status, 
age of denture and denture adhesive as covariates 
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Table 2.9: Analysis of change from baseline in inflammatory cytokines (pg/ml) –
Non- stomatitis group (Polident® vs. Tap water) 
 LS-Means# Difference1 95% CI# P-value# 
IFNγ: Day 14 -2.01/-1.75 -0.26 -0.67,0.15 0.2046 
IFNγ: Day 28 -1.88/-1.72 -0.16 -0.49,0.17 0.3307 
IL-2: Day 14 -0.01/-0.09 0.08 0.00,0.17 0.0571 
IL-2: Day 28 0.00/-0.02 0.02 -0.13,0.18 0.7616 
TNFα: Day 14 -0.46/0.11 -0.57 -1.45,0.31 0.2029 
TNFα: Day 28 0.00/0.42 -0.41 -3.07,2.25 0.7580 
IL -4: Day 14 0.01/0.04 -0.03 -0.14,0.09 0.6720 
IL -4: Day 28 0.01/-0.02 0.03 -0.10,0.17 0.6417 
IL - 5: Day 14  -0.09/-0.11 0.01 -0.15,0.18 0.8710 
IL - 5: Day 28 -0.15/-0.09 -0.07 -0.58,0.45 0.8013 
IL - 10: Day 14 -0.43/-0.27 -0.16 -0.46,0.13 0.2725 
IL - 10: Day 28 -0.47/-0.24 -0.24 -0.50,0.03 0.0778 
IL – 17A: Day 14 -2.87/-2.21 -0.66 -2.26,0.94 0.4121 
IL – 17A: Day 28 -2.61/-2.03 -0.58 -2.00,0.85 0.4228 
IL - 22: Day 14 -35.80/-22.92 -12.87 -34.88,9.09 0.2469 
IL - 22: Day 28 -20.97/-22.53 1.55 -25.29,28.40 0.9086 
TGF: Day 14 -53.94/-59.80 5.86 -77.57,89.28 0.8893 
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TGF: Day 28 -30.44/-34.28 3.84 -88.31,95.99 0.9342 
IL-6: Day 14 -12.86/-6.84 -6.02 -14.12,2.08 0.1432 
IL-6: Day 28 -14.08/-3.53 -10.51 -29.45,8.43 0.2729 
IFN=interferon, IL=interleukin, N=number, TNF=tumour necrosis factor, 
TGF=transforming growth factor, CI=confidence intervals 
LS- Means= low score means of the change in the Polident and tap water groups 
from baseline, where low scores were favourable and a negative change indicated 
improvement from baseline. 
Difference was first named treatment (Polident) minus second named treatment 
(tap water), such that a negative difference favoured Polident. 
# From ANCOVA with factors, treatment as fixed effect, baseline, smoking status, 
age of denture and denture adhesive as covariates 
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2.5 Discussion 
Denture stomatitis (DS) is considered the most prevalent form of oral candidosis, 
reportedly occurring in 65% of all denture wearers, often without clinical symptoms 
(Arendorf and Walker, 1987). Understanding the host response to this form of oral 
candidosis may have important clinical implications in terms of future management 
and treatment of the condition. The research presented in this Chapter 
investigated the relationship between the presence of Candida and the T helper 
(Th) cell response in DS.  
In this research, it was hypothesised that the DS group of patients would have 
higher colonisation of Candida leading to a protective Th cell response compared 
with non-DS controls. Research previously undertaken assessing DS and associated 
Th cell responses in human have been limited. In general, it is considered that Th1 
and Th17 responses are protective against mucosal infection by Candida, and that 
Th2 and Treg responses are associated with infection (Richardson and Moyes, 
2015, Netea et al., 2015). Based on the underlying hypothesis of this research, it 
was anticipated that an elevation of Th1 and Th17 would occur leading to a pro-
inflammatory response. It could, however, be argued that because DS is generally a 
chronic condition that it is associated with an immune response that is impaired 
and allows persistence of chronic infection, which might be indicated by a Th2 or 
Treg response. Th2 responses have been shown in atopic diseases such as asthma, 
and in chronic mucocutaneous candidosis (CMC) a Th2 defect has been reported 
(Becker et al., 2016). It was therefore not known whether the host immune system 
recognises Candida as a commensal or pathogen each time it is presented to the 
host and which Th cell subset will result. To date, there have been limited 
published studies that have elucidated the specific and localised immune response 
in DS. Whole saliva has been analysed for cytokine expression, but no difference 
was found in cytokine levels between patients with or without DS (Pesee and 
Arpornsuwan, 2013). A separate study reported an increase in the pro-
inflammatory cytokine IL-6 in elderly DS patients in one study (Gasparoto et al., 
2012c). However, contrary to this, in a separate study, the same group found an 
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increase in the anti-inflammatory cytokine IL-4 in elderly DS patients (Gasparoto et 
al., 2012b). So far, these limited studies have only been performed on whole saliva 
and serum in DS patients, and have not yielded conclusive data regarding the 
localised host immune response in DS.  
The principle objective of this research was to determine the relationship between 
DS and the ensuing Th cell response. This Th cell response was determined for two 
patient groups (DS and non-DS) at baseline and over the 28-day treatment period. 
It has previously been reported that elevation of IL-4 in the serum of elderly DS 
patients is coupled with reduced levels of IL-12 in saliva. In younger DS patients, an 
increase in salivary IL-10 has also been reported, together with higher levels of IFNγ 
in both saliva and serum (Gasparoto et al., 2012a). At baseline, the levels of several 
cytokines, including IFNγ, IL-10, IL-17A, IL-22, TGFβ and TNFα were all found to 
locally be increased in DS. When grouped according to the type of T helper cell 
response, perhaps unsurprisingly, compared with patients without inflammatory 
responses, Th1 (IFNγ and IL-2), and Th17 (IL-17A and IL-22) responses were 
significantly elevated. The levels of the anti-inflammatory cytokines (IL-10 and 
TGFβ), were also found to have increased in the palatal fluid sampled from the 
mucosa. These cytokines may be associated with increased numbers of Treg cells 
during infection. Treg cell (CD4+CD25+Foxp3+ T cell) responses are normally 
considered to suppress Th1 and Th17 responses. A recent study has, however, 
shown that Treg cells can promote Th17 cells for production of IL-17 and IL-22 in 
oral candidosis in mice (Pandiyan et al., 2011). This present study is the first to 
suggest that this same phenomenon also occurs during DS in humans. These results 
imply that patients with DS generate a local Th cell response involving Th1, Th17 
and Treg cells that would be considered protective against Candida infection. 
Indeed, it was interesting to note that significantly higher numbers of Candida 
occurred on the dentures of DS patients, although on the palate itself, lower counts 
were reported compared with non-DS patients. This finding could support the view 
that in the DS patients, whilst an effective and appropriate local inflammatory 
response was indeed present to combat palatal colonisation by Candida, this was 
not able to limit candidal levels on the denture. Importantly however, such a 
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response might effectively block Candida penetration into the mucosa and limit 
systemic infection. The likely situation of poor denture hygiene would contribute to 
the high Candida colonisation of dentures in DS patients, which could then provide 
a continuous reservoir of infecting Candida or their virulence factors to the palatal 
mucosa. Since by definition, the non-DS patients had no palatal inflammation, a 
protective immune response was not being raised, potentially allowing higher 
palatal Candida colonisation in these patients.  
The cytokines were studied at baseline (prior to treatment) to assess any 
correlation with DS and this was evident for both IL-17A and IL-22. As both of these 
cytokines are produced by Th17 cells, this finding was anticipated. Association with 
DS was also seen between the levels of IFNγ and IL-17A, and IFNγ and IL-22. As IFNγ 
production is strongly associated with Th1 cells, this would further suggest that Th1 
and Th17 responses against Candida were in simultaneous operation in DS 
patients. There was no correlation in DS patients between TNFα and IFNγ levels, 
nor between TNFα and IL-10 levels. Although IL-10 and TGFβ may both originate 
from Treg cells, in DS patients, IL-10 levels were not associated with TGFβ. This may 
indicate that TGFβ and IL-10 in DS patient samples had been generated by other 
cells within the oral mucosa, such as fibroblasts, keratinocytes or macrophages.  
Over the 28-day study period, the individual cytokines were also measured at 
different time points, and IL-17A was shown to be significantly reduced at day 14 
and reduced at day 28 (not significant) in the DS group when comparing Polident® 
treatment with tap water. This may indicate that with a lower Candida count there 
was less stimulation of the Th17 response. IL-17A (along with IL-22) is a cytokine 
produced by Th17 cells in response to Candida, leading to a protective effect, as 
Th17 cells drive a pro-inflammatory response (Kashem et al., 2015). IL-22 levels 
generally lowered in both the DS and non-DS groups over the study period, 
although this reduction was not significant.  
IL-6 is a non-specific inflammatory cytokine (Ataie-Kachoie et al., 2014) and its level 
would be expected to be elevated in areas of inflammation. There was no 
significant increase in IL-6 levels in either the treated or non-treated DS or non-DS 
groups, but there was a decreasing trend in mean level for DS patients treated with 
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Polident® compared with DS patients in the tap water group. The remaining 
cytokines analysed did not show any significant difference between the DS and 
non-DS groups over the time period measured, or the cytokine level was below the 
detection threshold. This may reflect the low number of Newton’s class three 
patients that were included in the study, so the patients had a generally lower level 
of inflammation to detect. This research could be developed further by increasing 
the period of study and increasing the number of participating subjects to 
determine if significant changes in cytokines exhibiting tends could be detected. In 
the few studies that have considered the saliva or serum, but not the local cytokine 
profile of DS patients (Gasparoto et al., 2012b, Pesee and Arpornsuwan, 2013), 
whole saliva and serum have been evaluated to compare local responses with the 
systemic response, and this is an area that may warrant future investigation to 
further support this study’s findings.  
Candida identification and involvement in DS has been widely studied to gain 
further insight into the aetiology of DS. Generally, C. albicans is reported as being 
the most prevalent Candida species on the dentures of DS patients, with an 
incidence ranging between 54-75%. A lower incidence of C. albicans occurs on the 
dentures of the patients without DS (39%) (Naik and Pai, 2011, Coco et al., 2008, 
Chopde et al., 2012). In the present study, similar findings were reported, with a 
57% incidence of oral colonisation by C. albicans isolated from the three sites 
(palate, tongue and denture) in DS patients and a 22% incidence in non-DS 
patients. The two most prevalent species isolated in DS in this present investigation 
were C. albicans and C. glabrata, which also supports the study by Coco et al, which 
reported the recovery of these two species in combination when the highest 
degrees of clinical inflammation were evident in DS (Coco et al., 2008).  
Candida glabrata along with the other non-albicans Candida species is thought to 
have a higher level of antifungal resistance to certain antifungals, which may 
promote persistence when in a mixed candidosis infection (Silva et al., 2012b, 
Gonzalez et al., 2008). It has been shown in a vaginal epithelial model that C. 
albicans enhances the colonisation and invasion of C. glabrata indicating enhanced 
tissue damage when these two species are combined in an infection (Alves et al.), 
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which may lead to greater tissue inflammation. This same enhanced invasion and 
increased tissue damage caused by mixed C. glabrata and C. albicans infections has 
been shown in reconstituted human oral epithelium (Silva et al., 2011). 
Of additional interest was the apparent absence of Candida in the oral cavity of 13 
(31%) DS patients. This finding supports the view that other microorganisms apart 
from Candida could contribute to DS and indeed previous studies have implicated a 
range of Gram-negative (Budtz-Jorgensen, 1990) and Gram-positive bacteria 
(Koopmans et al., 1988) with DS. A recent study found S. aureus and S. epidermis to 
be the most prevalent bacteria in a group of DS patients and C. albicans was the 
most frequently isolated yeast (Pereira et al., 2013). In the present study, bacterial 
presence was not evaluated as it was not part of the overall aims of this thesis 
however this would be an area of future research. The analyses in this study also 
did not factor in whether patients had any natural teeth, as the main focus was on 
complete denture wearing individuals who would be edentulous in the upper arch, 
but any existing lower teeth may have had a further influence on the 
microorganisms present and the extent of DS. To highlight this, O’Donnell et al 
showed that the oral microflora was more diverse in dentate patients than those 
who were completely edentulous (O’Donnell et al., 2015). 
Candida levels were significantly higher on the tongue and denture in the DS group 
compared to the non-DS group. However, the palatal site had lower Candida levels 
in the DS group (8.46 cfu/cm2 compared to 9.97 cfu/cm2 in the non-DS group). This 
finding might be explained by the host immune response of DS patients being 
effective in clearing the Candida from the palate, but unable to access the acrylic 
surface of the denture to lower numbers at that site. An alternative explanation 
could be that damaged epithelium is less conducive to candidal adherence. In this 
event, the Candida on the denture surface may serve to rapidly and continuously, 
recolonise the palatal surface, which in turn is sufficient to maintain an 
inflammatory palatal response, resulting in the clinical findings of DS and erythema. 
The palatal surface may not need to be colonised by Candida to cause palatal 
inflammation, as this may be caused by candidal virulence factors from the denture 
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biofilm which can protect Candida from the host immune system (Sardi et al., 
2013). 
From the results of this study, it may be possible to predict a diagnostic threshold 
for the number of colonies of Candida recorded in patients with DS. However, 
there was a large standard deviation for the numbers of Candida colonies from the 
different areas, tongue, palate and denture. Other factors that could preclude the 
extrapolation of candidal numbers to infection status include the impact of host 
factors such as previous antibiotic therapy, steroid usage, renal failure and 
neutropenia that are known to predispose to candidosis (Eggimann et al., 2003). 
The level of Candida in whole saliva was not taken into account in this study which 
may have been higher than in the palatal imprint sample taken, particularly if 
dental plaque was present and hence a potential added source of candida 
(Rautemaa et al., 2006). It has been shown that an increase in the cfu of Candida 
has an association with an increase in severity of oral candidosis, although this 
study considered tongue papillae atrophy, angular cheilitis and buccal mucosa 
atrophy, but not DS as measures of oral candidosis (Shinozaki et al., 2012). As 
shown in figure 2.5, it would seem that at candidal levels above 10 cfu/cm2 it was 
more likely that inflammation was detected by clinical examination, evidenced by 
the existence of palatal erythema, and a Newton’s score of one and above. This 
may have useful clinical diagnostic implications to indicate when it would be 
possible to predict DS.  
Previous studies have shown that denture cleansers can be effective in reducing 
Candida numbers on denture surfaces. Some studies have assessed overnight 
treatment with commercially available denture cleansers (Dentural, Medical™ 
Interporous®, Steradent Active Plus, and Boots Smile denture cleansers) (Jose et al., 
2010). In an in vitro study of three alkaline peroxide-type denture cleansers 
(including Polident, Efferdent, Fittydent) there was some reduction in C. albicans 
colonisation of the acrylic resin surfaces, but mouth rinses showed complete 
reduction after 60 min (Işeri et al., 2011). A further in vitro study over a 72 h period 
showed sequential use of a denture cleanser (Polident) to remove the C. albicans 
biofilm (Ramage et al., 2012). There are limited studies looking at denture cleansers 
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in patients over a prolonged period and their effect on Candida colonisation. At 
baseline, I compared the Candida counts for the DS and non-DS groups and then 
compared the change over a 28 day period after the two groups were randomised 
to treatment, denture cleanser group or placebo group. At days 14, 21 and 28, the 
denture cleanser was effective at significantly (p<0.05) reducing the Candida load 
on the fitting surface of the denture, the palate and tongue in patients with and 
without DS. This effect was not evident with control patients using tap water 
treatment. These results would be in keeping with earlier studies reported, albeit 
with fewer patients (Ramage et al., 2012, Işeri et al., 2011, Jose et al., 2010). 
In this study, an important outcome was the comparison of clinical parameters 
between DS and non-DS groups. It was found that at baseline, DS patients had a 
higher level of clinical inflammation as evidenced by the higher area score, 
intensity score and percentage of coverage of erythema. Interestingly, the dentures 
in the DS group were not deemed to be less clean than the non-DS group (as 
determined by the cleanliness index) as might have been expected as one of the 
casual factors in DS (Kulak-Ozkan et al., 2002). The second clinical factor that 
showed no difference between the two studied groups at baseline was the 
patient’s assessment of their saliva quantity. This is in contrast to studies that have 
reported that dry mouth is a risk factor for DS (Glazar et al., 2010). However, this 
part of the study was limited by only asking the patients simple questions about 
their subjective assessment of whether they felt their mouth was dry. If a more 
accurate causal relationship was warranted the study could have been improved by 
doing additional sialometery studies to determine if there was clear evidence of dry 
mouth (Villa et al., 2015).  
The research also determined whether use of a denture cleanser impacted on the 
clinical measurements. Over the 28 days of the study, Polident antibacterial was 
shown to be effective at significantly reducing the area of erythema and 
inflammation. It was also shown to improve the cleanliness of the denture 
compared to tap water. This denture cleanser compares favourably to some of the 
treatment methods discussed in a systematic review where the reduction in clinical 
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signs of inflammation and the reduction in Candida colony forming units were also 
used as an outcome measure (Emami et al., 2014). 
There was some potential for selection and recruitment bias within this study, as it 
was a hospital-based study. To minimise this, subjects were recruited by various 
methods including posters and radio advertising. Nevertheless, the subjects 
recruited may not have been representative of the whole population. A total of five 
patients that were randomised did not complete the study, two patients were lost 
to follow to follow up, two deviated from the study design and were not included 
and one patient had an adverse event unrelated to the study and had to withdraw. 
These patients were unlikely to be different to those that were not lost to follow-
up, therefore it was unlikely that there was any attrition bias in this study. There 
may have been confounding factors that were not accounted for in this study such 
as smoking, alcohol and dietary factors. As the study was primarily a clinical 
investigation, some of these factors are hard to account for completely, but by 
randomising the treatment groups, this would have minimised potential effects on 
the results. 
The importance of managing DS in the community is also justified based on the 
potential link between oral mucosal inflammation and other systemic 
manifestations. A large cross-sectional US survey found that participants with oral 
mucosal inflammation, including DS, had a greater chance of subsequently having 
systemic inflammation and cardiovascular disease, independent of common 
confounding factors (Fedele et al., 2011). Oral health and potentially, denture use, 
has also been linked as a potential risk factor in aspiration pneumonia in vulnerable 
older people (van der Maarel-Wierink et al., 2011). 
This study is important, as determining whether or not an appropriate immune 
response is being generated in DS provides key information in understanding the 
pathology of the condition. This in turn may enhance our understanding and ability 
to manage DS by better understanding the local immune and Th cell response. This 
in vivo study into DS in this chapter will be further supported by the subsequent 
chapters considering the immune response to C.albicans in vitro and by identifying 
the immune cells in biopsy samples of chronic hyperplastic candidosis.  
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2.6 Conclusions 
Based on the results of this Chapter, the importance of reducing the number of 
Candida on the denture is clearly evident as being beneficial to reduce the palatal 
inflammation. The results of this study showed that whilst Th1/Th17/Treg local 
mucosal immune responses may be of benefit in controlling Candida levels at 
mucosal sites in DS, these responses alone do not facilitate resolution of the 
infection.   
1. The DS group had higher clinical inflammation and percentage coverage of 
erythema in the group with DS compared to the control group as would be 
expected.  
2. The extent of Candida colonisation in denture wearing patients was 
significantly higher on the tongue and fitting surface of the denture in the 
group with DS at baseline compared to the group without DS, however it 
was lower on the palatal mucosa in the DS group. Candida albicans was the 
most prevalent species in both groups.  
3. The local cytokine response in patients with DS showed that there was a 
significant increase in the Th1 (IFNγ, TNFα, IL-2), Th17 (IL-17A, IL-22 and 
TGFβ) and Th2 (IL-4, IL-5, IL-10) cytokines in the DS group compared to the 
control group. 
4. Use of a denture cleanser reduced the number of Candida in the DS group 
compared to tap water. The denture cleanser also significantly reduced the 
area of erythema in the DS group from baseline to day 28.  
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Chapter 3: 
In vitro induction of cytokine 
expression following challenge by C. 
albicans, with emphasis on the IL-12 
family 
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3.1 Introduction  
The recognition of Candida by host cells and the subsequent immune response is 
likely to be a key factor in determining whether infection, colonisation or clearance 
of Candida occurs. Whilst infection by Candida is often superficial and managed by 
appropriate treatment, in severely debilitated and immunocompromised 
individuals, systemic candidosis may arise, which is associated with high morbidity 
and mortality (Pfaller and Diekema, 2007). Increasing our understanding of how the 
host recognises and then responds to Candida has important clinical implications in 
terms of both prognosis and the development of future management strategies 
(Höfs et al., 2016). Chapter 2, investigated how the human immune system 
responded to C. albicans, with emphasis on the cytokine profile present on the oral 
mucosa in denture stomatitis. In Chapter 2, the work sought to predict which Th 
cell response was being driven. In this chapter, consideration will be made to see if 
this immune response to C. albicans was supported through in vitro investigation, 
in particular considering the IL-12 family (Section 3.1.3.1), which includes IL-23, a 
key cytokine in Th17 expansion and function in oral candidosis (Conti et al., 2009) 
(Section 1.2.4.3). 
 
3.1.1 Candida infections in humans 
Candida species are the most frequently encountered human fungal pathogens, 
causing both superficial and systemic infection (Höfs et al., 2016) (Section 1.1.3.1). 
There are over 200 Candida species, however, only around 17 of these have been 
associated with human disease (Sardi et al., 2013). Candida albicans is the most 
prevalent Candida species encountered in humans, although there has been an 
increase in the incidence of non-C. albicans Candida species in human infection in 
recent years (McManus and Coleman, 2014). A recent study of Candida prevalence 
on the tongue found C. albicans in 53.4% and non-C. albicans Candida species 
isolated in 23.7% of 266 participants (Sato et al., 2017).  
Candida albicans possesses a number of putative virulence factors that, depending 
on the local environment, can promote host colonisation and infection (Höfs et al., 
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2016). These virulence factors include phenotypic switching, hyphal formation, 
expression of adhesins and invasins on the cell surface, and production of 
hydrolytic enzymes capable of degrading host proteins and lipids (Mayer et al., 
2013) (Section 1.1.4). Strains of C. albicans vary both genotypically and 
phenotypically (Bartie et al., 2001) and such variation has been associated with 
differences in inherent pathogenicity and resistance to antifungal agents (Sherry et 
al., 2014). It is highly probable that strain variation of C. albicans and the extent of 
hyphal production can also mean that host cells differ in their ability to recognise 
them and therefore the ensuing immune response will also differ (Naglik et al., 
2014). It is now possible to assign C. albicans strains to designated clades based on 
the sequences of several specific genes (Section 1.1.1.2).  
 
3.1.1.1 Identification of Candida albicans and clade designation  
There are over 17 Candida species that have been associated with human infection 
(Sardi et al., 2013) (section 1.1). However, given the fact that C. albicans is 
considered the most prevalent Candida species in human infection (Noble et al., 
2017), the research in this Chapter has focused on C. albicans. Several phenotypic 
and molecular approaches can be used to differentiate Candida species and some 
of these were employed in this research to initially confirm identity of the C. 
albicans isolates studied. 
CHROMagar® Candida is a chromogenic agar medium that presumptively identifies 
three Candida species (C. albicans, C. krusei and C. tropicalis) based on the colour 
and appearance of colonies (Willinger et al., 2001). It has been reported that this 
medium also differentiates between C. albicans and C. dubliniensis as colonies of 
the latter reportedly have a darker green colour compared C. albicans on primary 
culture (Williams and Lewis, 2000). The specificity of Candida species identification 
using CHROMagar Candida has been reported to be 96% (Rousselle et al., 1994). 
Candida albicans and C. dubliniensis are the only two Candida species that produce 
germ tubes (Sullivan and Coleman, 1998), which are rudimentary hyphal elements 
generated by yeast cells (Section 1.1.1). This trait can be exploited for identification 
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of C. albicans/C. dubliniensis using the ‘germ-tube test’. The germ tube test 
involves induction of germ tubes by culture of test isolates in horse serum at 37°C 
for 2-4 h.  
Identification of C. albicans by molecular methods is arguably more reliable than 
analysis of phenotypic criteria (Byadarahally Raju and Rajappa, 2011) (Section 
1.1.1.1). Species-specific PCR approaches can target C. albicans genes to enable 
detection. Identification of C. albicans can then be achieved by detecting the 
amplicon using standard gel electrophoresis, or by its direct sequencing 
(Byadarahally Raju and Rajappa, 2011). One of the target sequences used to 
identify Candida species has been nuclear ribosomal DNA (rDNA) and the first and 
second internal transcribed spacers (ITS-1 and ITS-2) of rDNA have been shown to 
be reliable species-specific genetic markers for fungal pathogens (Dunyach et al., 
2008, Zhang et al., 2016). More recently, real-time PCR assays have been 
developed to identify medically important Candida species that may aid the rapid 
detection of different species (Zhang et al., 2016).  
A newer detection method employs species-specific peptide nucleic acid (PNA) 
probes, which are complementary to DNA sequences of C. albicans. Hybridisation 
of these probes can then be detected by fluorescent in situ hybridisation (FISH). 
This technique of PNA-FISH often targets species-specific sequences of the rRNA 
gene and the benefit of this approach is that cells can be detected without the 
need for amplification (Byadarahally Raju and Rajappa, 2011). PNA-FISH is, 
however, more expensive than PCR and arguably more labour intensive. Having 
confirmed identity of C. albicans, it is then possible to differentiate strains, and 
again this can be achieved by phenotypic (biochemical) or molecular methods. In 
the case of C. albicans, the gold-standard strain typing approach is Multilocus 
Sequence Typing (MLST) (Bougnoux et al., 2003) which analyses the sequences of 
PCR fragments derived from the amplification of 10 published housekeeping genes. 
MLST has previously been discussed in Section 1.1.1.2. Using MLST, strains of C. 
albicans can be categorised into specific clades. A clade is defined as a genetically 
related group of closely related strain types. Importantly, strains within a specific 
clade are increasingly thought to share common features with regards to virulence 
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traits, antifungal resistance and potentially therefore the way the host will 
recognise and respond to them (MacCallum et al., 2009) (Section 1.1.1.2).  
The diverse genomic backgrounds and karyotypes of different C. albicans isolates 
has been shown to modulate pathogenic potential particularly with regards to 
morphological transition, internalisation by macrophages, resisting intracellular 
killing and escape from macrophages (Tavanti et al., 2006). This would suggest that 
different strains may be more virulent than others. In 2007, Odds et al examined 
1391 C. albicans isolates and assigned 97% of them to 17 clades. Five of the most 
frequent clades were found to differ significantly in their proportion of commensal 
and pathogenic C. albicans isolates (Odds et al., 2007). 
 
3.1.2 Recognition of Candida albicans by host immune cells 
Recognition of C. albicans by host immune cells can lead to the release of cytokines 
with subsequent generation of different T-helper cell responses. Depending on the 
type of T-cell response, clearance or tolerance of C. albicans can occur (Erwig and 
Gow, 2016).  
The host response to C. albicans involves both innate and adaptive mechanisms 
(Höfs et al., 2016). Innate defence to C. albicans is initiated through detection of 
pathogen associated molecular patterns (PAMPs) (Section 1.2.1) expressed by C. 
albicans. This detection is mediated by specific pattern recognition receptors 
(PRRs) (Section 1.2.2) on host cells, such as toll like receptors (TLRs) and C-type 
lectin receptors (CLRs) (Gow et al., 2007, Netea et al., 2010). 
Dectin-1 is a type of CLR and functions as a PRR or an adhesion receptor (Section 
1.2.2.1). Dectin-1 is expressed on myeloid cells such as macrophages, dendritic cells 
and phagocytes (Goodridge et al., 2011) where it recognises components of the β-
glucan molecule that are present in the cell wall of C. albicans (Gow et al., 2007). 
Dectin-1 is also expressed by epithelial cells found in the airway (Lee et al., 2009), 
cornea (Peng et al., 2015) and in a human gingival epithelial cell line (Tamai et al., 
2011).  
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Binding of dectin-1 to β-glucan leads to an induction of an immune cell response 
and production of receptor sinuses that increase phagocytosis of Candida 
(Goodridge et al., 2011). Of note is that β-(1,3) glucan represents 40% of the C. 
albicans cell wall (Gow et al., 2007), but importantly it is exposed at higher levels 
during yeast budding (Goodridge and Underhill, 2007). Thus, dectin-1 is thought to 
be more involved in the recognition of yeast cells than C. albicans hyphae. 
PRRs, such as dectin-1, will be expressed on different immune cells including 
macrophages and dendritic cells (DCs). The PRRs at epithelial surfaces promote 
secretion of antimicrobial peptides such as β defensins and cathelicidin (LL-37) to 
clear the fungal infection as part of the innate immune response (Höfs et al., 2016). 
The release of pro inflammatory cytokines such as IL-12 leads to the trafficking of 
phagocytes including macrophages and DCs to the site of infection. 
Although initial interaction between the fungal PAMP and host PRR is primarily an 
innate one, it is essential in the chain of events that lead to the development of an 
adaptive response (Richardson and Moyes, 2015). Phagocytosis of C. albicans 
results not only in the potential killing of the organism, but also in the processing 
and presentation of C. albicans specific antigens on the phagocytic cell. In this 
regard, DCs are a critical link between the innate and adaptive immune system 
(Richardson and Moyes, 2015). DCs phagocytose, kill, process and degrade C. 
albicans cells and the processed antigen is then recognised by T cells (Newman and 
Holly, 2001). The DC acts as a classical antigen presenting cell (APC) and has the 
following features: it is phagocytic, expresses PRRs, localises to the T cell zone of 
lymph nodes following activation (DCs), constitutively expresses high levels of MHC 
class II molecules and antigen processing machinery and expresses co-stimulatory 
molecules following activation (Kambayashi and Laufer, 2014). The fungal pathogen 
is processed at the site of the infection into antigenic peptides which are 
assembled onto class II molecules of the major histocompatibility complex (MHC II) 
and then transported to the surface of the activated DC (Richardson and Moyes, 
2015). These ‘activated’ DCs then migrate to the draining lymph node, where the C. 
albicans antigen is presented to the naïve CD4+ T helper (Th) cell. It is the 
121 
 
presentation of these antigens to the naïve Th cell which drives different Th cell 
responses (Ryan et al., 2008, Tang et al., 2016).  
CD4+ Th cells play a crucial role in the immune response to C. albicans. There are at 
least four distinct Th cell subsets (termed Th1, Th2, Th17, and inducible T-
regulatory cells; Tregs). Each of these subsets have specialised functions involved in 
the control of immune responses (Yamane and Paul, 2013). Which Th cell subset is 
favoured is largely driven by the T cell receptor (TCR)-mediated stimulation and the 
unique set of cytokines produced from the antigen presenting cell (Yamane and 
Paul, 2013). The different Th cell responses driven by the C. albicans antigen is 
discussed in sections 1.2.4 and 4.1 and the recall response was analysed in Chapter 
4 of this Thesis. 
Briefly, a Th1 response is one that responds to an antigen with production of IFNγ, 
IL-2 and TNFα cytokines. It is thought that this response activates macrophages 
leading to a candidacidal state (Romani, 2004). A Th2 response results in the 
production of IL-4, IL-5, IL-13 and IL-25 cytokines, which may have conflicting roles 
in the response to C. albicans (Netea et al., 2015). Th2 cells were originally thought 
to inhibit and deactivate phagocytic cells, conceivably therefore, increasing 
susceptibility to infection (Romani, 1999). In mice, the IL-4 cytokine has since been 
shown to be required for an efficient Th1-mediated antifungal response 
(Montagnoli et al., 2002). Another more recent study showed that peripheral blood 
mononuclear cells (PBMCs) of patients with chronic mucocutaneous candidosis 
(CMC) had significantly impaired production of Th2 cytokines (IL-5 and IL-13) 
(Becker et al., 2016) and this likely contributed to mucosal candidosis in these 
patients. A Th17 response leads to production of IL-17A, IL-17F, IL-21 and IL-22 
cytokines (Ouyang et al., 2008) and several studies have confirmed the role of Th17 
cells in controlling candidosis (Conti et al., 2014, Huppler et al., 2014, Kagami et al., 
2010).  
A Treg response leads to release of TGFβ, IL-10 and IL-35 cytokines and results in a 
diverse immune response depending on the site of infection (Whibley and Gaffen, 
2014).  
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Ultimately, it is the type of Th cell response and cytokines outlined above that are 
generated, which will determine if C. albicans is effectively phagocytosed and 
ultimately cleared from the infection site or tolerated so that colonisation occurs.  
 
3.1.2.1 Phagocytosis of C. albicans 
Phagocytosis is an important facet of the innate immune response and is a process 
that ultimately leads to the killing of C. albicans cells. Phagocytic cells (neutrophils, 
macrophages, monocytes and DCs) will phagocytose C. albicans following its 
recognition by appropriate cell receptors. Different PRRs recognise distinct 
components expressed on the surface of C. albicans, which may can be dependent 
on it morphological form (Brown, 2011). Macrophages are more effective at 
phagocytosis than DCs, whose main role is to serve as an antigen presenting cell 
(APC) (Galli et al., 2011) (Section 3.1.2). Once C. albicans has been recognised by 
the phagocyte’s PRR, it is internalised through the actin-dependent process of 
phagocytosis, during which cellular membranes enclose the fungal particle. The 
process results in the formation of an intracellular vacuole called the phagosome 
(Brown, 2011). The phagosome matures through several steps leading to the 
development of a compartment called the phagolysosome which has antimicrobial 
properties and the fungal particle is killed and ultimately digested (Brown, 2011). 
Phagocytosis can further enhance the pro-inflammatory response through release 
of cytokines and recruitment of further innate immune cells (Netea et al., 2015). 
 
3.1.2.2 Microbial interactions and host recognition of C. albicans 
The oral microbiota is comprised of a diverse range of bacteria along with fungal 
species. Although this study is focused on the role of C. albicans in host 
interactions, there will also be an interaction and an effect on immune modulation 
caused by the local bacteria present. It may be that interaction between fungi and 
bacteria result in a balanced oral microbiota and promotion of a healthy oral 
environment rather than leading to pathology (Krom et al., 2014).  
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In systemic candidaemia, over 20% of cases are polymicrobial infections, involving 
bacteria along with Candida. Importantly, these polymicrobial infections are 
associated with higher mortality rates than those only involving Candida (Klotz et 
al., 2007). The effect of the bacteria on mortality rates could be due to the added 
pathogenicity of the bacteria or may arise through synergistic effects upon the 
Candida. These synergistic effects could relate to production of virulence factors or 
might involve modulation of the immune response to Candida.  
In previous studies of immune response to bacteria, most emphasis has been given 
to the effects of lipopolysaccharide (LPS; endotoxin), which is a key inflammatory 
mediator present in cell walls of Gram-negative bacteria (Tan and Kagan, 2014). LPS 
plays a role in the induction of bacterial sepsis through the release of pro-
inflammatory cytokines (Tan and Kagan, 2014). 
In a recent study, Fusobacterium nucleatum was found to inhibit growth and 
hyphal morphogenesis of C. albicans in a contact dependent manner (Bor et al., 
2016). A similar effect was also found with P. gingivalis on C. albicans (Cavalcanti et 
al., 2015). The yeast form of C. albicans was also found to reduce the levels of TNFα 
produced by macrophages in response to F. nucleatum (Bor et al., 2016). This study 
exemplified a typical bacterial-candidal interaction that can arise, which would 
modulate both the virulence of C. albicans and the ensuing immune responses 
thereby promoting commensal existence.  
 
3.1.2.3 LPS and immune modulation 
There is an array of bacterial factors that can be used in in vitro studies and LPS is a 
common bacterial factor employed to promote a pro-inflammatory response. The 
disadvantage of LPS is that it is not produced by Gram-positive bacteria. Other 
examples of bacterial factors that can induce an immune response include; 
enzymes (e.g. collagenase, hyaluronidase), lipoteichoic acid, bacterial capsule and 
cytotoxins (such as amines and ammonia).  
LPS is recognised by TLR4 on leukocytes (Medzhitov et al., 1997) and when TLR4 is 
activated it signals through either a MyD88 (myeloid differentiation primary 
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response gene 88)-dependent or a MyD88-independent pathway leading to the 
release of pro-inflammatory cytokines (Ramachandran, 2014).  
LPS can induce inflammatory cells to express a number of pro-inflammatory 
cytokines including IL-8, IL-6, IL-1β, IL-1, IL-12, and IFNγ (Ramachandran, 2014). This 
release of pro-inflammatory cytokines and increase in inflammatory cells such as 
neutrophils and monocytes, provides an environment which protects the host 
against the bacterial LPS challenge (Mifsud et al., 2014). 
 
3.1.3 Role of cytokines in orchestrating the immune response 
Cytokines are small, soluble, non-structural proteins that are crucial intercellular 
regulators and mobiliser of cells that can affect nearly every biological process 
(Dinarello, 2007, Oppenheim, 2001). Cytokines are generally classified according to 
their cell source, structure or biological function (Fietta et al., 2015). Cytokines 
include chemokines, interleukins, interferons, tumour necrosis factors and 
mesenchymal growth factors (Dinarello, 2007). Cytokines can be released from 
several different cell types and result in various immune responses. Interleukins 
(ILs) are a multifunctional group of immunomodulators that mainly regulate 
immune cell proliferation, differentiation, growth, survival, activation, and function 
(Fietta et al., 2015). Up to 38 interleukins have been identified to date, and these 
are numbered based on their order of discovery. Interleukins are also grouped in 
different subsets, determined by distinguishing structural/functional features 
(Fietta et al., 2015). One of these subsets is the IL-12 family of cytokines, which 
given their importance in T cell differentiation, is a focus of this Chapter.  
 
3.1.3.1 IL-12 cytokines family  
The IL-12 cytokine family is thought to play an important role in the differentiation 
of T helper cells (Tang et al., 2004, Zelante et al., 2007). Figure 3.1 illustrates how 
the IL-12 family of cytokines may be involved in driving a Th1, Th17 or Treg 
response (Section 1.2.5.2 and Figure 1.4). 
125 
 
Four heterodimeric soluble proteins are involved in the construction of IL-12 
cytokines. The IL-12 cytokines include IL-12, IL-23, IL-27 and IL-35 (Collison and 
Vignali, 2008) (Figure 1.4 and section 1.2.5.2). IL-12 promotes a Th1 response 
leading to a pro-inflammatory outcome. IL-23, together with TGFβ and IL-1β 
promote Th17 differentiation, which leads to IL-17 expression and an ensuing pro-
inflammatory response.  
Several studies have confirmed the role of Th17 cells in the control of candidosis 
(Conti et al., 2014, Kagami et al., 2010, Huppler et al., 2014). IL-27 is thought to 
have a dual role in immune regulation (Yoshida and Yoshiyuki, 2008) and can inhibit 
expansion of IL-17 producing cells (Murugaiyan et al., 2009). It has also been 
suggested that IL-27 synergises with IL-12 which results in a Th1 pro-inflammatory 
response (Trinchieri et al., 2003). 
IL-35 is the latest discovered member of the IL-12 cytokine family and is thought to 
have a dual role in the immune response through promoting expansion of Treg 
cells and limiting differentiation of Th17 cells, leading to suppression of the 
immune response (Niedbala and Wei, 2007). The Th2 response releases IL-4, IL-5 
and IL-13 cytokines and therefore none of the IL-12 cytokine family are directly 
involved in the Th2 immune response.  
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Figure 3.1: A schematic illustrating how the IL-12 family of cytokines (IL-12, IL-23, 
IL-27 and IL-35) are involved in the development of the different naïve CD4+ T cell 
responses. As illustrated, none of the IL-12 family cytokines are directly involved in 
the development of a Th2 response. 
IL=interleukin, Th=T Helper cell, Treg= Regulatory T cell and APC= antigen 
presenting cell. 
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3.1.4 Experimental approaches used to study immune responses  
3.1.4.1 THP-1 monocyte cells to study immune response 
THP-1 is a human monocyte cell line originally derived from a patient with acute 
monocytic leukaemia. THP-1 cells have been used extensively to study 
monocyte/macrophage functions, mechanisms and signalling pathways (Chanput 
et al., 2014). The advantages of using THP-1 cells include their high growth rate 
compared with monocytes derived from peripheral blood mononuclear cells 
(PBMCs) (section 3.1.4.2) and the fact that they are relatively easy and safe to use 
and store (Chanput et al., 2014). Compared with PBMCs from healthy volunteers, 
THP-1 cells have a homogenous genetic background, which limits phenotypic 
variation and enhances reproducibility during experimental use (Cousins et al., 
2003, Rogers et al., 2003, Chanput et al., 2014). 
One disadvantage of using a cell line and particularly one that has a malignant 
background is that the cultivation and response of the cells is likely to be different 
than primary cells (Schildberger et al., 2013). Indeed in the study of Schilberger et 
al 2013, monocytes, PBMCs and THP-1 cells were all shown to lead to different 
cytokine expression profiles (TNF-α, IL-8, IL-6 and IL-10) after stimulation with LPS 
(Schildberger et al., 2013). 
In this present chapter, both THP-1 cells and PBMCs were selected for study in an 
in vitro monocyte/macrophage cell model.   
 
3.1.4.2 Use of PBMCs to study the immune response in vitro  
PBMCs typically have a rounded nucleus and include both lymphocytes and 
monocytes. These cells are frequently used to evaluate in vitro immunological 
function (Yang et al., 2016). PBMCs are derived from whole blood and therefore 
one concern over their use is the loss of cells during harvesting, which could 
influence subsequent cell-mediated responses observed in cell culture (Hartmann 
et al., 2016). A comparison of three different cell isolation techniques including 
density centrifugation with Ficoll®-Paque, and isolation by cell preparation tubes 
(CPTs) and SepMate tubes with Lymphoprep, showed that cell viability was 100% 
128 
 
for all three methods (Grievink et al., 2016). There was, however, a difference in 
cell recovery using the SepMate and CPT which were 70% higher than Ficoll 
isolation. However use of CPTs led to increased erythrocyte contamination 
(Grievink et al., 2016).  
 
3.1.4.3 Generation of dendritic cells from PBMCs 
Dendritic cells (DCs) play a key role in the immune system, but represent a sparsely 
distributed cell population which is derived from bone marrow cells. Immature DCs 
are located in peripheral tissues beneath mucosal surfaces and are recruited to 
sites of infection by chemokines (Richardson and Moyes, 2015). DCs process and 
present antigens to naïve T helper cells and can exist as many subsets which differ 
in terms of surface markers and function (Conti and Gessani, 2008). PBMCs are 
commonly used to generate DCs for in vitro use, as low numbers exist in 
physiological conditions. GM-CSF and IL-4 are cytokines which normally drive 
maturation of DCs from human PBMC (Guan et al., 2004). This method has been 
widely used and characterised (Pickl et al., 1996, Chapuis et al., 1997), and is 
employed in this chapter. Dendritic cells can have different properties depending 
on how they are matured from circulating human PBMCs (Conti and Gessani, 
2008).  
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3.2 Aims 
This in vitro work develops upon the previous in vivo studies described in Chapter 
2, and aimed to gain further insight on how C. albicans is both recognised by 
specific immune cell types (monocytes and dendritic cells) and how this influences 
subsequent immune cell responses (cytokine expression and phagocytosis). 
 
Specific objectives of the research in this Chapter were as follows: 
 
1. To assess the IL-12 family cytokine response to C. albicans by THP-1 cells, and 
activated and non-activated human PBMCs.  
2. To determine whether distinct strains of C. albicans lead to differential effects on 
expression of IL-12 cytokines from THP-1 cells and PBMCs. 
3. To assess expression of dectin-1 by THP-1 cells and PBMCs after stimulation with 
LPS and C. albicans. 
 
 
 
Aspects of this research have been published: 
Rogers, H., Williams, D, W., Feng, G., Lewis, M, A, O., Wei, X. (2013). Role of 
bacterial Lipopolysaccharide in enhancing host immune response to Candida 
albicans. Clinical and developmental immunology, 320168. 
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3.3 Materials and Methods  
3.3.1. Identification of Candida albicans for in vitro studies 
3.3.1.1. Culture of Candida albicans 
Nineteen clinical isolates (S1-S19) (Appendix III) of C. albicans were cultured on 
Sabouraud dextrose agar (SDA; LabM, Bury, UK) at 37°C for 48 h in aerobic 
conditions. Isolates were then stored on agar plates at 4C and regularly sub-
cultured prior to experimental use. 
3.3.1.2 Chromogenic agar 
CHROMagarTM Candida (Paris, France) was used for the presumptive identification 
of C. albicans by colony colour and appearance. The 19 strains were cultured on 
CHROMagarTM Candida plates for 48 h and the colour of colonies recorded. 
3.3.1.3 Germ-tube test 
The germ tube test was applied to the C. albicans isolates to determine 
rudimentary hyphal morphology (germ tube) production. Briefly, isolates were 
incubated in 3 ml of horse serum (TCS microbiology, UK) at 37°C in a water bath for 
2-3 h. A portion of the culture was then examined by light microscopy for the 
presence of germ tubes. 
3.3.1.4 Identification of clinical isolates using species specific PCR 
DNA extraction from Candida species was based on a previously described method 
(Scherer and Stevens, 1987) and later modified by Williams et al., (2001). Briefly, 
Candida (1-5 colonies) was sub cultured overnight at 37°C in single strength Yeast 
Nitrogen Base (YNB; Becton Dickinson, Le Pont de Claix, France) medium 
supplemented with 0.5% (w/v) glucose (Sigma, Poole, UK) per 100 ml. A 1.5-ml 
volume of the broth was then centrifuged 12500×g for 10 min. The supernatant 
was discarded, the pelleted cells resuspended in 1 ml of 1 M sorbitol (Sigma, St 
Louis, USA) and the centrifugation repeated. The supernatant was removed and 
the cells resuspended in 1 ml of lyticase buffer (1 M sorbitol plus 50 mM potassium 
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phosphate buffer (BDH chemicals, Poole, UK) with 0.1% (v/v) 2-mercaptoethanol 
(Sigma, St Louis, USA) and 0.2 mg of lyticase; pH 7.5) and incubated for 30 min at 
30°C. The resulting spheroplasts (yeast devoid of their cell walls) were pelleted by 
centrifugation, the supernatant was discarded and the spheroplasts resuspended in 
0.5 ml of 50 mM sodium ethylenediaminetetraacetic acid (EDTA, Sigma, St Louis, 
USA) buffer (pH 8.5) with 2 mg/ml sodium dodecyl sulphate (BDH chemicals, Poole, 
UK). After mixing, the preparation was incubated at 70°C for 30 min. A 50-μl 
volume of 5 M potassium acetate was added, and incubated at 0°C for 30 min. The 
mixture was clarified by centrifugation and the supernatant decanted into a clean 
microcentrifuge tube with 1 ml of 70% (v/v) ethanol and mixed gently. The mixture 
was then centrifuged at 12,500×g for 10min and the supernatant discarded. To the 
precipitate, several volumes of 70% (v/v) ethanol were added and then removed. 
The DNA pellet was dried and resuspended in 100 μl of 10 mM tris chloride (Sigma) 
buffer and 1 mM EDTA (TE solution). The presence of DNA was confirmed by 
electrophoresis in a 1% (w/v) agarose gel run for 30 min at 110 V/cm2 and 
visualised under UV light (Gel DocTM, Bio-Rad). The extracted DNA was stored at -
20°C prior to use as template for subsequent polymerase chain reactions (PCRs). 
3.3.1.5 Polymerase Chain Reactions (PCR) 
All PCRs were performed using the C. albicans DNA, extracted as described above, 
and a thermal cycler PCR machine (G-Storm, Somertone, UK) (Table 3.1 primer 
details). 
3.3.1.6 PCR for Candida identification 
PCR mixtures were prepared in a final reaction volume of 50 μl and comprised of 
0.5 μM of each primer (Table 3.1 primer details), 0.2 mmol/L of each 
deoxynucleoside triphosphate (dNTP), 1.5 mmol/L MgCl2, 2.5 units of GoTaq® Flexi 
DNA polymerase (Promega, Southampton, UK), working concentration of Green 
GoTaq® Flexi Buffer (Promega), and 5 μl of candidal DNA. Thirty PCR cycles each 
consisting of 95°C for 1 min, 55°C for 1 min and 72°C for 2 min were performed. 
Negative controls of sterile DNA-free water in place of template DNA were included 
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with each PCR. All PCR products were confirmed for size by standard 
electrophoresis in a 1.5% (w/v) agarose gel and stained with ethidium bromide (0.5 
µg/ml; Sigma). A 100 bp molecular weight ladder was included with each gel. The 
gel was run at 70 V/cm2 for 1 h and visualised under UV light (Gel DocTM, Bio-Rad). 
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Table 3.1: Primers used for PCR  
 
Primer target 
 
Primer sequences 5’-3’ Product size (bp) 
C. albicans rDNA ITS1:-TCCGTAGGTGAACCTGCGG  
ITS2:-TCCTCC GCTTATTGATATGC  
540  
β-actin P1:AGGGCAGTGATCTCCTTCTGA TCCT  
P2:CCACACTGTGCCCATCTACGAGGGGT  
500  
p-40 P1:-CATTCAGTGTCAAAAGCAGCAGAGGCT 
P2:ATCAGAACCTAACTGCAGGGCACAGATG 
541  
P-35 P1:ACGTGTCACCGAGAAGCTGATGTAGAG 
P2:GCCAGGCAACTCCCATTAGTTATGAAA 
545  
Ebi3 P1:TTCGTGCCTTTCATAACAGAGCACATCA 
P2:CTCCAGTCACTCAGTTCCCCGTAGTCTG 
302  
p-19 P1:GAGAGAATCAGGCTCAAAGCAAGTGG 
P2:GAGCAGAGAGGCTCCCCTGTGAAAATA 
449  
p-28 P1:GGCCCCAAGACAATAAATAAACCATCA- 
P2:GCTGCACTCCTTGGAGCTCGTCTTATCT- 
346  
TLR2 P1:CCTGAAACTTGTCAGTGGCCAGAAAAGA 
P2:CATCCCGCTCACTGTAAGAAACAAATGC  
670  
TLR4 P1:GAGGAAGAGAAGACACCAGTGCCTCAGA 
P2:ATAGTCCAGAAAGGCTCCCAGGGCTAA  
486  
Dectin-1 
 
P1:GTTTCAGAGAAAGGATCGTGTGCTGCAT 
P2:TTGGAGATGGGTTTTCTTGGGTAGCTGT 
427  
IL-27RA P1: GTTCTGATCTGCCAGTTCCACTACCGAA 
P2:TGAATCCAAGCAGACCAAAGAGAGGTTG 
477  
IL-27RB P1:GAGAATGAAATTGGGAAGGTTACATCAG 
P2:AAAGGAGGCAATGTCTTCCACACGAGTT 
470  
IL-17A P1:GAAACAACGATGACTCCTGGGAAGACCT 
P2:GTCCGAAATGAGGCTGTCTTTGAAGGAT 
577  
bp= base pairs, IL= interleukin, ITS= internal transcribed spacer, TLR= toll like 
receptor; all primers manufactured by Sigma, except β-actin primers produced by 
Gibco. C. albicans rDNA primers described by Williams et al., 2001.  
134 
 
3.3.1.7 Multilocus Sequence Typing (MLST) of Candida albicans to determine 
Clade designation  
MLST of the 19 test C. albicans isolates was performed as described previously 
(Bougnoux et al., 2003, Tavanti et al., 2003). This first involved genomic DNA 
extraction, as described by (Hoffman and Winston, 1987). Briefly, the C. albicans 
cultures were grown overnight in 5 ml YPD at 30°C. The cells were harvested and 
centrifuged for 5 min at 1200xg and the supernatant discarded. The cells were 
suspended in 500 µl of sterile H2O and transferred cells to 1.5 ml screw-capped 
microcentrifuge tubes. The cells were then centrifuged for 2 min at 14,000×g and 
the supernatant discarded. To the cell pellet, 0.3 g of acid washed 0.5mm glass 
beads (Sigma), 200 µl of DNA extraction buffer and 200 µl of phenol: chloroform 
alcohol (1:1) mix were added. The cells were disrupted with a mini-bead beater for 
40 s and then vortex mixing for 5 min. TE buffer (0.2 ml) was added and the tube 
mixed and centrifuged for 5 min at 14,000×g. The aqueous layer was transferred to 
a new microcentrifuge tube before 1 ml of 100% ethanol was added. This was 
centrifuged for 2 min at 14,000× g and the supernatant discarded. The pellet was 
resuspended in 400 µl of TE buffer plus 10 µl of RNase A (10 mg ml-1) and incubated 
for 15-60 min at 37°C. Twenty-µl of 3 M sodium acetate and 1 ml of 100% ethanol 
was added and mixed by inversion before centrifuging for 10 min at 14,000× g. The 
supernatant was discarded and the pellet air-dried before it was finally 
resuspended in 50 µl of TE. 
The PCR was performed using the primers listed in Table 3.2. Purification of PCR 
products and DNA sequencing was then performed. This aspect of study was 
undertaken with collaboration from the Aberdeen fungal research group.  
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Table 3.2: Primer sequences for MLST of C. albicans 
Gene 
fragment 
Gene target Primer sequence 5’-3’ Product 
size (base 
pairs; bp) 
AAT1a Aspartate 
aminotransferase 
ACTCAAGCTAGATTTTTGGC (F) 
CAGCAACATGATTAGCCC (R) 
478  
ACC1 Acetyl-coenzyme A 
carboxylase 
GCAAGAGAAATTTTAATTCAATG (F) 
TTCATCAACATCATCCAAGTG (R) 
519  
ADP1 ATP dependent 
permease 
GAGCCAAGTATGAATGATTTG (F) 
TTGATCAACAAACCCGATAAT (R) 
537  
MPI Mannose 
phosphate 
isomerase 
ACCAGAAATGGCCATTGC (F) 
GCAGCCATGCATTCAATTAT (R) 
486  
SYA1 Alanyl-RNA 
synthetase 
AGAAGAATTGTTGCTGTTACTG (F) 
GTTACCTTTACCACCAGCTTT (R) 
543  
VPS13 Vacuolar protein 
sorting protein 
TCGTTGAGAGATATTCGACTT (F) 
ACGGATGGATCTCCAGTCC (R) 
741  
ZWF1 Glucose-6-
phosphate 
dehydrogenase 
GTTTCATTTGATCCTGAAGC (F) 
GCCATTGATAAGTACCTGGAT (R) 
703  
F=forward, R=reverse, bp=base pairs 
  
136 
 
3.3.1.8 Preparation of heat killed C. albicans (HKC) antigen for in vitro cell 
stimulation experiments 
Colonies of C. albicans (S1-S19) were obtained from SDA plates using a standard 
wire loop and resuspended in a 1.5 ml microcentrifuge tube containing 1 ml of PBS. 
The preparation was placed in a water bath at 95°C for 30 min. To confirm that 
heat killing was successful, a portion of the sample was inoculated on SDA and 
incubated overnight at 37°C to establish no Candida growth. All the Candida 
isolates used in the following cell culture experiments were heat-killed. In most of 
the following experiments, C. albicans S1 was used and where indicated, strains of 
C. albicans S2, S3, S4, S5, S6, S10, S11 and S12 were also used. The strains 
employed were from different clades (Table 3.5). 
3.3.2. In vitro cytokine expression by a human monocyte cell line following 
challenge with heat killed C. albicans (HKC) 
The human monocyte cell line, THP-1 (ATCC® TIB-202™), was used in the following 
experiments. THP-1 cells were cultured in RPMI 1640 medium (Lonza 
BiowhittakerTM, Castleford, UK) with 10% (v/v) Foetal Bovine Serum (FBS), and 
streptomycin and gentamicin 10,000 U/ml (Invitrogen, California, USA). Cultured 
cells were passaged at regular intervals throughout experiments. 
3.3.2.1 Challenge of THP-1 cells with LPS and/or heat killed C. albicans (HKC) or 
Curdlan 
THP-1 cells (1x106) in RPMI 1640 medium were cultured at 37oC in a 5% (v/v) CO2 
enriched atmosphere and then were stimulated for 0, 24 and 48 h with increasing 
concentrations (0, 10, 100, 1000 ng/ml) of lipopolysaccharide (LPS) extracted from 
Escherichia coli (Sigma Ltd., UK) or Porphyromonas gingivalis (PG). The culture 
supernatant was harvested at the different time points and stored at -20oC until 
used for measurement of IL-12, IL-23 and IL-27 cytokines by ELISA (Section 
3.3.2.1.1). In additional experiments, THP-1 cells were also stimulated for 24 h with 
increasing concentrations (0, 5x104, 5x105 and 5x106 cells/ml) of HKC (S1-S6) or 
curdlan 1, 10, 100 µg/ml or LPS (E. coli or PG) 10 and 100ng/ml. Candida albicans 
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cell concentration was determined using a haemocytometer. The culture 
supernatant was harvested as described for ELISA. In further experiments the THP-
1 cells were stimulated with LPS (E. coli) 100ng/ml for 2 or 24 h and then HKC (S1-
S5, S10 and S11) 5x104 cells/ml 5x105 cells/ml or 5x106 cells/ml or curdlan (10, 
100ng/ml) added for a further 24 h. In all these experiments a THP-1 cells only 
control was used. The culture supernatant was harvested as described for ELISA. 
3.3.2.1.1. Enzyme Linked Immunosorbent Assay (ELISA) detection of human IL-
12p70, IL-23 and IL-27 cytokines  
The ELISA system for IL-12 p70, IL-23 and IL-27 was used to detect the respective 
targeted cytokines (eBiosciences, Aachen, Germany) (Table 3.3). A NUNC Maxisorp 
96-well ELISA plate was coated with 100 μl/well of capture antibody (IL-12p70, IL-
23 and IL-27, respectively; eBiosciences) in coating buffer. The plate was sealed and 
incubated overnight at 4oC. The wells were aspirated and washed (5) with wash 
buffer (>250 μl/well) allowing time for soaking (1 min) during each wash step to 
increase the effectiveness of adsorption of the washes. The plate was blotted on an 
absorbent paper to remove any residual buffer. The wells were ‘blocked’ with 200 
μl/well of assay diluent (1 strength) and incubated at room temperature for 1 h. 
The wells were aspirated and washed as previously described. Assay diluent (1 
strength) was used to dilute the standards as described by the manufacturer. 
Standard concentrations of antigen were added (100 μl) to the appropriate wells in 
a 2-fold dilution series. 
Tissue culture fluid (100 μl) was prepared as described in section 3.3.2.1 and added 
to appropriate wells. The plate was sealed and incubated overnight at 37oC in a 5% 
(v/v) CO2 enriched atmosphere for maximal sensitivity. The wells were aspirated 
and washed (5) as previously described. Detection antibody (biotin-conjugate 
anti-human IL-12 p70, IL-23 or IL-27; eBiosciences) was diluted in assay diluent (1 
strength) and added to appropriate wells (100 μl/well) (Table 3.3). The plate was 
sealed and incubated at room temperature for 1 h. The wells were aspirated and 
washed (5) as previously described. Avidin-horse radish peroxidase (100 μl/well) 
in assay diluent (1 strength) was then added to each well. The plate was 
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incubated at room temperature for 30 min, after which the wells were aspirated 
and washed (7), allowing the wash buffer to soak in the wells for 1 min prior to 
aspiration. Substrate solution (100 μl/well) was added to each well and the plate 
was incubated at room temperature for 15 min. Stop solution (50 μl/well) was 
added to each well and the absorbance of each well read at 450 nm using a 
FLUOstar spectrophotometer (BMG, FLUOstar optima). 
 
 
Table 3.3: Concentration of antibody and standards for ELISA  
ELISA Capture 
antibody 
Standard Detection 
antibody 
Company 
IL-12 4µl/ml 0 to 250 pg/ml 4µl/ml eBiosciences 
IL-23 4µl/ml 0 to 500 pg/ml 4µl/ml eBiosciences 
IL-27 2ul/ml 0 to 10ng/ml 2ul/ml eBiosciences 
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3.3.2.2. Reverse Transcriptase-PCR analysis of cytokine gene expression by THP-1 
cells 
THP-1 cells (1x106 cells/well in a 24 well plate) were stimulated with either HKC 
5x106 (S1) or LPS (E. coli) 100 ng/ml for different time intervals (0, 2, 6, 24 or 48 h 
stimulation). Cells were harvested at each time point by centrifugation (Heraeus 
PICO 27, Thermoscientific) at 2862g for 5 min in a 1.5 ml microcentrifuge tube. 
Cell pellets were lysed with 350 µl of RLT buffer from an RNeasy kit (Qiagen, 
Manchester, UK). The cell lysate was stored at -80oC prior to purification of total 
RNA with the RNeasy kit as recommended by the manufacturer. Briefly, the cell 
lysate was homogenised using a QIAshredderTM column by pipetting the lysate 
directly into the shredder tube and centrifugation at 9600×g for 2 min. One volume 
of 70% (v/v) ethanol was added to the lysate. The sample was then added to an 
RNeasy column and centrifuged at ≥8000xg for 15 s. RW1 buffer (700 l) was 
added and centrifuged at ≥8000xg for 15 s. The column was transferred to a new 2 
ml collection tube and 500 l of RPE buffer added before centrifugation at ≥8000xg 
for 15 s. RPE buffer (500 l) was added and centrifuged as previously described. 
The flow through liquid was discarded and the tube centrifuged at ≥8000xg for 2 
min to dry the column. The column was transferred to a clean 1.5 ml 
microcentrifuge tube and 40 l of diethylpyrocarbonate (DEPC; 0.1% v/v) treated 
water added. The preparation was again centrifuged at ≥8000xg for 1 min. The 
recovered RNA concentration was determined by measuring optical absorbance at 
260 and 280 nm in a Nanodrop spectrophotometer (GE healthcare, 
Buckinghamshire, UK). The total RNA extract was then frozen at -80oC. 
Total RNA was standardised to the same concentration as the lowest concentration 
of RNA in the samples and 1-5 g of total mRNA was then added to each reaction. 
DEPC treated water was added to the RNA sample to make a total volume of 11 µl, 
to which 1 l of random primer (50 ng/l) (Qiagen) was added. This solution was 
heated to 70oC for 10 min and then placed on ice for 5 min. A final reaction volume 
of 20 µl was prepared, which included 12 µl of the RNA sample, first strand buffer 
(5 strength), 0.1 mM DTT, 10 mM dNTP and 1 µl of Superscript (200 U/µl) 
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(Invitrogen, California, USA). The reaction tubes were placed in a thermal cycler 
and heated at 25oC for 10 min, 42oC for 50 min and 70oC for 5 min. 
PCR mixtures were prepared at a final reaction volume of 25 µl and comprised of 
1.5 µl of each primer (0.04 µg/ml; table 3.1), 0.5 l of 10 mM dNTPs, 1 µl of 25 mM 
MgCl2, 0.5 µl of GoTaq® Flexi DNA polymerase (5 U/µl; Promega, Southampton, 
UK), 5 µl of 5x Green GoTaq® Flexi Buffer (Promega), 1 µl of RNA and 14 µl of RNase 
free water. Thirty PCR cycles consisting of 96°C for 1 min, 62°C for 1 min and 72°C 
for 1 min were then performed. The annealing temperature was adjusted 
depending on the melting temperature of each primer. Negative controls of sterile 
DNA-free water in place of template DNA were included in each PCR.  
All amplicons were confirmed for size by standard electrophoresis in a 1.5% (w/v) 
agarose gel using ethidium bromide (0.5 µg/ml; Sigma) and a 100 bp ladder. The gel 
was run at 100 V/cm2 for 30 min and visualised under UV light (Gel DocTM, Bio-Rad). 
3.3.2.3 Real-Time RT-PCR (Q RT-PCR) for cytokine gene expression by Thp-1 cells 
3.3.2.3.1 Real-Time RT-PCR using GAPDH and SYBRGreen  
Total RNA was prepared using a RNeasy Mini Kit with the QIAshredder spin 
columns (Qiagen) and ‘on-column’ degradation of genomic DNA with 340 U/mL of 
RNase-free DNase I (Invitrogen) for 15 min. Total RNA (1 µg) was reverse 
transcribed to cDNA using Superscript II RNase H reverse transcriptase (200 units, 
Invitrogen) and 100 ng of random primers (Invitrogen) in a total volume of 20 µL 
for 50 min at 42C, following the manufacturer’s recommended method. Primer 
pairs were used to determine expression of human dectin-1, p40, p35, p28, EBi3 
and p19 mRNA in comparison to the human ‘housekeeping’ GAPDH gene (Table 3.4 
primers). Levels of mRNA for dectin-1, p40, p35, p28, EBi3 and p19 gene expression 
were then quantified using an ABI PRISM 7000 Sequence Detection System 
(Applied Biosystems, Paisley, UK). To quantify mRNA levels, relative gene 
expression was determined using a SYBR Green qPCR kit (Bio-Rad, USA), and all 
samples were run in triplicate. The threshold cycles (CTs) for each sample was used 
to calculate the 2−ΔΔCT and relative gene expression levels for the different samples. 
The data was expressed as expression-fold relative to the control. 
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3.3.2.3.2 Real time RT PCR (RT-qPCR) using primer design perfect probe 
In some experiments, instead of SYBR green being used to determine the relative 
gene expression, a hydrolysis probe-based detection solution (Perfect Probe) 
(Primer design, Southampton, UK) was used. 
Total RNA was prepared as described above using the RNeasy mini kit. The 
precision nanoscript reverse transcriptase kit (Primer Design) was used for these 
experiments. Each RNA sample was made up to 10 µl by adding 1 µl of RT primer 
(mixed 50:50 oligo (dT) primer and random nonamer primers (Primer Design), 
RNase/DNase free water and 500 ng/ml RNA. Each sample was heated to 65°C for 5 
min before being cooled on ice. A 10-µl volume of master mix comprising qScript 
10x Buffer, dNTP 10 mM, DTT 100 mM, RNase/DNase free water and 1 µl qScript 
enzyme (200units/µl) was added to each 10 µl sample on ice. The preparations 
were briefly mixed by vortexing followed by a pulsed spin. The mixtures were 
incubated at 25°C for 5 min, followed by 55°C for 20 min and finally heat 
inactivated at 75°C for 15 min. The cDNA was stored at -20°C until used. 
The primer/probe pairs used in these experiments for the EBi3, p35, p40, p28, p19 
and the human housekeeping gene GAPDH genes are presented in Table 3.4. 
Briefly, relative gene expression was determined using 5 µl of cDNA (10 ng/µl) 
sample and 15 µl of primer master mix (1µl primer/probe, 10 µl of primer design 
master mix and 4 µl of RNase/DNase free water). Triplicate qPCRs were performed 
in a 96-well plate and gene expression was quantified on the ABI PRISM 7000 
Sequence Detection System. The thermal cycle profile comprised of initial 
denaturation at 95oC for 10min, followed by 50 cycles of denaturation at 95oC for 
15 s, primer annealing at 55oC for 30 s and primer extension at 72oC for 30 s.  A 
dissociation stage at 65°C was used to generate a melting curve for verification of 
the amplified product. The RT-qPCR threshold was adjusted according to the 
amplification curves of all evaluated genes. The expression of the targeted genes 
was normalised according to the housekeeping reference gene (GAPDH).  
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Table 3.4: Primers used for RT qPCR (primer design, perfect probe, UK and SYBR 
Green) 
IL=interleukin, tm= melting temperature, EBI3= Epstein Barr induced virus 3, 
GAPDH= Glyceraldehyde 3-phosphate dehydrogenase 
  
Primer name Product size 
(base pairs) 
tm Sequence (5’-3’) 
 
IL12 A- p35 127 71.4 ACATGCTGGCAGTTATTGATGA 
TGAAGAAGTATGCAGAGCTTGAT 
IL12B-p40 114 74.1 TGAAGAAAGATGTTTATGTCGTAGAAT 
GGTCCAAGGTCCAGGTGATA 
EBI3 102 78.6 GCTTCGTGCCTTTCATAACAG 
GCTCCCACTGCACCTGTA 
p19,IL23A 82 76.2 AGCTTCATGCCTCCCTACT 
AGGCTTGGAATCTGCTGAG 
IL-27,p28 78 77 TCCTCTCCACCTACCGCCT 
TGGACAGCAGCAGCAACTC 
GAPDH 
 
57 60 GGTCGGAGTCAACGGATT 
ATCGCCCCACTTGATTTTG 
Dectin-1:  
 
55 54 GCTTAATTGGAAAGAAGAGAAGA 
GATTAAAGGGAAACAGGTATCTT 
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3.3.3. Time-lapse microscopy detection of phagocytosis of Candida albicans by 
THP-1 cells 
In addition to detecting cytokines expressed by the THP-1 cells after challenge with 
HKC, time-lapse microscopy was also used to examine the phagocytosis of C. 
albicans by THP-1 monocyte cells. THP-1 cells were seeded into the wells of a 24 
well plate at concentrations of 1103 cells/ml, 1104 cells/ml, 1105 cells/ml, and 
1106 cells/ml. The THP-1 cells were incubated overnight in RPMI 1640 medium at 
37∘C in a 5% (v/v) CO2 enriched atmosphere. To these cells, HKC (110
4 cells/ml, 
1105 cells/ml, and 1106 cells/ml) and/or curdlan (500 µg/ml, 50 µg/ml and 5 
µg/ml) was added prior to commencement of time-lapse microscopy. During time-
lapse microscopy, the cells were viewed for 3 h at 20x magnification with images 
taken every 2 min with a high-resolution microscope (Deltavision, GE healthcare 
lifesciences, Buckinghamshire, UK).  
3.3.4 In vitro cytokine expression by human peripheral blood monocytes 
following challenge with heat killed C. albicans (HKC) 
3.3.4.1 Peripheral blood monocyte cell (PBMC) isolation 
Collection and isolation of human PBMC from healthy volunteers was done 
following ethical approval by Cardiff University (DENTL 09/18) (Appendix III). 
Briefly, 20 ml of venous blood was taken from the volunteer into a heparin 
containing vacutainer after informed consent was obtained. Human PBMCs were 
then isolated using density gradient centrifugation using Ficoll-Paque (GE Life 
Science, UK). The blood was diluted with an equal volume of phosphate-buffered 
saline (PBS) and then layered onto Ficoll before centrifugation for 30 min. The layer 
of PBMCs was identified as the clear interface layer between the plasma phase and 
Ficoll phase. This layer of PBMCs was carefully removed and placed into serum free 
RPMI 1640 medium and washed (3). Cells were cultured (with or without 
stimulation) at 37°C in a 5% (v/v) CO2 enriched atmosphere in RPMI 1640 medium 
supplemented with 10% (v/v) FBS, containing penicillin and streptomycin 10,000 
U/ml (Invitrogen). 
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Once the cells were isolated, they were stimulated with 100 ng/ml of LPS (E. coli) 
and different HKC strains as described for the THP-1 cells (Section 3.3.2). Cytokine 
expression for IL-12p70, IL-23 and IL-27 was measured by ELISA as previously 
described and gene expression for the cytokine subunits was measured by RT-PCR 
and qPCR as described previously for THP-1 cells. 
3.3.4.2 Maturation of PBMC to dendritic cells 
In some experiments, the isolated human volunteer PBMCs were cultured with 25 
ng/ml granulocyte-macrophage colony-stimulating factor (GMCSF) (Immunotools, 
Germany) and 10 ng/ml of IL-4 (Immunotools) to drive them to DCs for 7 days. The 
DCs were then stimulated with either 100 ng/ml of LPS (E. coli) or HKC 1x106 
cells/ml for 0, 4, 6 and 24 h. The supernatant was collected for detection of 
cytokine expression by ELISA as previously described (section 3.3.2.1). The cells 
were collected for qPCR as described (section 3.3.2.2 and 3.3.2.3).  
3.3.5. Dectin-1 expression in THP-1 cells and human PBMC 
THP-1 cells or human PBMC were stimulated with increasing concentrations of E. 
coli LPS (Sigma Ltd., UK) followed by challenge with HKC or culture negative 
controls. In some experiments, the PBMC were driven for 7 days to become DCs 
with the addition of GMCSF (25 ng/ml) and IL-4 (10ng/ml). The cell medium was 
changed every 48 h over the 7-day period. Cells were then cultured for different 
time periods before harvesting and analysis for dectin-1 expression and cytokine 
production. 
3.3.5.1. Detection of Dectin-1 and CD14+ Expression in Human PBMCs and THP-1 
Cells 
To detect dectin-1 expression by human monocytes, with or without LPS 
stimulation, human PBMCs and THP-1 cells were cultured overnight with increasing 
concentrations of LPS (0, 10, 100, and 200 ng/mL). Cells expressing dectin-1 were 
then detected by staining with an anti-dectin-1 specific antibody (Abcam, 
Cambridge, UK) in combination with anti-human CD14 antibody (ImmunoTools) 
and isotype control antibodies. Cells were then washed (×3) with PBS and 
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subsequently fixed in 300 𝜇l of FACS buffer containing 2% (v/v) paraformaldehyde. 
Samples were analysed by collecting 10,000 events using a FACSCalibur flow 
cytometer (BD Biosciences, Oxford, UK). CD14+ cells in PBMC were gated and 
increased percentages of dectin-1 positive cells calculated and compared to cells 
without LPS stimulation. 
3.3.5.2 Cell Phagocytosis Assay and FACS Analysis.  
To examine DC and monocyte-mediated phagocytosis of HKC, the HKC were initially 
stained with propidium iodide (PI red fluorescent dye). Briefly, 10 𝜇l of 1 mg/ml PI 
was added to 200 𝜇l of 107 HKC/mL (counted using a haemocytometer) in PBS and 
incubated for 30 min on ice before washing (×3) with cold PBS. To analyse 
phagocytosis of the HKC by human PBMCs and THP-1 cells, the cells were 
stimulated overnight with increasing concentrations of E. coli LPS followed by 
addition of 1 x 105 HKC/ml which had been stained with PI. This preparation was 
then cultured for further 2 h. The cells were then washed (×3) with cold PBS before 
fixation of the cells with 2% (v/v) paraformaldehyde in PBS. Cells without addition 
of HKC served as negative controls. Phagocytosis of PI stained HKC was measured 
using fluorescent microscopy or FACS analysis. Negative controls were used for 
setting FACS gating to obtain the percentage of cells that had phagocytosed PI-
labelled HKC. An increased PI fluorescent signal would lead to a shift towards the 
right in FL2 histogram plots, and therefore indicate higher phagocytotic ability of 
cells. In some experiments, human PBMCs were stained with fluorescein 
isothiocyanate (FITC) conjugated anti-dectin-1 (Abcam). The association of dectin-1 
expression with HKC phagocytosis was then detected by FACS analysis. 
3.3.5.3 PBMC expression of IL-17A 
PBMCs were cultured with three different C. albicans strains (S1, S2 and S3) at 
1x106 cells/ml. Expression of IL-17A was measured in the supernatant at 1, 3 and 7 
days after stimulation with HKC. The BD™ Cytometric Bead Array (CBA; BD) Human 
Th1/Th2/Th17 Cytokine Kit was used to quantify IL-17A cytokine in the cell culture 
samples (minimum sensitivity estimated at 2 pg/ml for the cytokines). This was 
performed as previously described (Section 2.3.5.1).  
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3.3.6 Statistical analysis 
Summary statistics (means and standard deviation (SDs)) were determined where 
applicable. To analyse significance differences between various stimulations, values 
obtained were compared using student t tests. (Excel 2010). P-values of <0.05% 
were considered statistically significant. Heat maps for associations between 
variables for RT-qPCR analyses were created using R statistical software (version 
3.1.1).  
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3.4 Results 
3.4.1. Identification of Candida albicans for in vitro studies 
Nineteen clinical isolates of C. albicans (Appendix III) were used for experiments 
and prior to this had their identity confirmed by phenotypic and genotypic 
approaches.  
 
3.4.1.1 Presumptive identification of isolates using chromogenic agar  
Initial presumptive identification of C. albicans was undertaken with CHROMagarTM 
Candida culture medium. Figure 3.2 shows the typical green colouration of two C. 
albicans isolates on this chromogenic medium. Of the original 19 isolates, one (S3) 
did not show the expected green colour of C. albicans and was therefore not used 
in the cell stimulation experiments. 
 
 
: 
Figure 3.2: CHROMagarTM Candida medium illustrating the expected green/blue 
colour of C. albicans isolates. S1 and S2 represent two test isolates. 
 
3.4.1.2 Germ-tube test 
Of the 19 test isolates, all except isolate S3 were found to be positive for germ tube 
(Figure 3.3 and table 3.5). 
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Table 3.5: CHROMagarTM Candida identification, germ tube test and MLST analysis 
of 19 strains of C. albicans. 
Candida 
Strain 
 
Identification 
by 
ChromagarTM 
Candida 
Germ tubes Diploid 
sequence type 
Clade 
1 C. albicans Y 1807 8 
2 C. albicans Y 1808 8 
3 Candida spp N N/A N/A 
4 C. albicans Y 1809 singleton 
5 C. albicans Y 1810 9 
6 C. albicans Y 1811 singleton 
7 C. albicans Y 1812 1 
8 C. albicans Y 1813 8 
9 C. albicans Y 1814 1 
10 C. albicans Y 1815 2 
11 C. albicans Y N/A N/A 
12 C. albicans Y 1816 1 
13 C. albicans Y 1817 1 
14 C. albicans Y 1818 1 
15 C. albicans Y 1819 1 
16 C. albicans Y 1820 8 
17 C. albicans Y 1821 4 
18 C. albicans Y 1822 4 
19 C. albicans Y 1823 4 
n/a- not applicable, Y-yes, N-no  
149 
 
 
 
 
Figure 3.3: Germ tubes of C. albicans after incubation for 2-3 h at 37C in horse 
serum (TCS). All strains except S3 were germ tube positive. 
 
3.4.1.3 Molecular identification of C. albicans isolates 
DNA was successfully extracted from 18 test isolates (S3 was not included) and 
amplicons of the expected size were generated in all cases (Figure 3.4). Sequencing 
confirmed a C. albicans identity at >98% similarity for 15 isolates with C. albicans 
sequences archived in the Genbank database. Isolates S5, S8 and S12 were all 
identified as C. albicans with a 96% homology on sequence comparison (Appendix 
III). 
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     L     1     2    3     4    5    6     7     8    9    10   11  12  13 14   L 
 
Figure 3.4: Agarose gel 1.5% (w/v) showing PCR products from C. albicans strains 
S1-S18 amplified using primers ITS1 and ITS2. Electrophoresis was undertaken to 
confirm amplicon size. Purified amplicons were subsequently sequenced to confirm 
identity. All 18 test strains were confirmed as C. albicans. Lane L contains a 
molecular weight marker. 
 
3.4.1.4 Clade designation of isolates using Multilocus Sequence Typing (MLST)  
Most of the C. albicans isolates belonged to clades 1, 4 and 8 (Table 3.5 and Figure 
3.5). The clade designation was considered important to undertake to aid 
interpretation of any strain difference identified in subsequent experiments. The 
diploid sequence type was the number assigned to each unique combination of 
genotypes. MLST analysis revealed that S11 was in fact a non-C. albicans Candida 
species (C. dubliniensis) and it was not used in further experiments.  
Following identification of C. albicans, 8 of the original 19 isolates were 
subsequently progressed for the in vitro challenge experiments involving THP-1 
cells and peripheral blood mononuclear cells (PBMC). The isolates used and the 
individual clade designation and strain details for subsequent stimulation 
experiments are detailed in appendix III.  
540bp 
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Figure 3.5: Dendrogram constructed using Unweighted Pair Group Method with 
Arithmetic Mean (UPGMA) clustering showing relation and clade designation of 
different isolates. The singletons are marked by * and the C. albicans clinical 
isolates (n=17) are grouped by the different clades. Strains 1-6, 10, 11 and 12 were 
used in the majority of stimulation experiments form this control group of isolates. 
  
  
Clade 1
Clade 8
Clade 2
Clade 4
Clade 9
*
*
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3.4.2 In vitro cytokine expression by THP1 human monocytes following challenge 
with C. albicans 
3.4.2.1 ELISA detection of IL-12p70, IL-23 and IL-27 cytokines 
LPS (PG and E. coli) had a dose-dependent effect for 10, 100 and 1000 ng/ml 
concentrations of LPS on increasing the IL-23 and IL-27 cytokines in the culture 
supernatant (Figures 3.6 and 3.7). However, IL-12 was detected in extremely low 
concentrations and for LPS (PG) stimulation the level of detection was below or 
equal to the level detected in the supernatant by the cell only control with no LPS 
stimulation (Figure 3.8).  
When HKC strains (S1-S6) were added on their own to THP-1 cells, IL-27 (Figure 3.9) 
and IL-12 cytokines were not detected in the culture supernatant. IL-23 was 
detected at extremely low levels (Figure 3.10) after stimulation of THP-1 cells with 
HKC (S1-S6) and below the control level, so was deemed not significant and there 
was no dose dependent response detected. Curdlan also did not stimulate IL-12, IL-
23 or IL-27 at detectable levels at different concentrations (100 µg/ml, 10 µg/ml or 
1 µg/ml) (Figures 3.9 and 3.10). Of note, was that IL-12, IL-27 and IL-23 were not 
detected, or detected at low levels in the THP-1 cell supernatant if C. albicans was 
added without prior exposure to LPS (Tables 3.6-3.8). 
IL-23 was constantly expressed by THP-1 cells when stimulated with LPS for 24 h 
(both LPS-PG and LPS-E. coli) followed by different strains of HKC (S1, S2, S3, S5, 
S10 and S11) for 24 h, apart from an increase with the higher S4 concentration 
(5x106 cells/ml). There was also a low level constant expression evident with 
curdlan at both concentrations (100 µg/ml and 10 µg/ml) (Figure 3.11). IL-27 
showed mostly a constant expression with the different strains of HKC. S4 showed 
a dose related response. Certain C. albicans strains (S1, S5 and S11) only stimulated 
expression of IL-27 from THP-1 cells at higher concentrations (Figure 3.12). IL-12 
was not detected by ELISA in the culture supernatant.  
After initial addition of LPS (E. coli) (24 h) to THP-1 cells and then challenge with 
HKC (S1, S2, S3, S4, S5) for 2 h, significant detection of IL-23 for S1 in a dose 
dependent manner compared to the controls was evident (p<0.05) (Figure 3.13). 
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Candida albicans S2 and S3 also led to a significant increase in IL-23 expression 
compared to the controls (P<0.05), which was not evident with S4 and S5 (Figure 
3.14).  
IL-27 was constantly expressed with all HKC strains after challenge with LPS (E. coli) 
(Figure 3.15). IL-12 showed only minimal expression from THP-1 cells after 
challenge with HKC and LPS (E. coli) (Figure 3.16). 
Addition of GM-CSF and IL-4 to THP-1 cells to induce further maturation did not 
lead to a significant increase in IL-12, IL-23 and IL-27 expression following HKC (S1 
or S5) or curdlan challenge at different concentrations (Tables 3.6-3.8).  
3.4.2.2 RT-PCR analysis of cytokine expression by THP-1 cells 
Expression of mRNA for targeted cytokines was detected for THP-1 cells after 
stimulation with C. albicans or LPS (PG) using RT-PCR. (Figure 3.17). Candida 
albicans (S1) stimulated the highest EBi3 expression at 2 h from THP-1 cells. 
Expression of this gene was maintained at a high level until 24 h after stimulation. 
IL-27p28 gene expression occurred at a constant level. Whilst IL-12p40 was 
detected together with IL-12p35, the secretion of IL-12 heterodimer protein was 
not evident for both C. albicans and LPS stimulated cell culture. IL-23p19 was 
expressed following LPS addition on its own, but with HKC stimulation only.  
Constant IL-27a and IL27b receptor gene expression occurred with THP-1 cells at 2, 
6, 24 and 48 h as determined by RT-PCR (Figure 3.18). Expression of TLR2, TLR4 and 
dectin-1 mRNA was constant at 2, 6, 24 and 48 h compared with the house keeping 
β-actin gene (Figure 3.19). 
3.4.2.4 Time-lapse microscopy detection of phagocytosis of C. albicans by THP-1 
cells 
Time-lapse microscopy revealed that C. albicans cells were actively captured and 
phagocytosed by the THP-1 cells. Images of the time-lapse microscopy are shown in 
figures 3.20-3.22 and the movie of the phagocytosis of C. albicans by THP-1 cells is 
on the enclosed CD (back cover). 
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3.4.3 In vitro cytokine expression by PBMCs following challenge with C. albicans  
3.4.3.1 ELISA detection of IL-12p70, IL-23 and IL-27 cytokines 
IL-23 and IL-12 production from PBMCs (further matured by IL-4 and GMCSF) was 
detected when stimulated with LPS (E. coli) 100 ng/ml or HKC (S1) 1x106 cells/ml 
after 24 h only. No IL-23 expression was detected at earlier time points with LPS or 
C. albicans stimulation of PBMC derived dendritic cells (Figure 3.23). 
IL-27 was not expressed by mature PBMCs following C. albicans or LPS stimulation 
at any time point (data not shown).  
3.4.3.2 RT-qPCR analyses of cytokine expression by PBMCs 
Results for mRNA expression from PBMC after stimulation are shown in tables 3.9- 
3.10 and figures 3.24-3.25. There was an increase in EBi3 (4.77 % of GAPDH) and 
P40 (6.14 % of GAPDH) subunits gene expression following 24 h of C. albicans 
stimulation as measured by qPCR using SYBRGreen. This finding was also replicated 
using RT-qPCR (Perfectprobe) where EBi3 (47% of GAPDH) and P40 (162% of 
GAPDH) mRNA levels were increased after 24 h stimulation with C. albicans. The 
increase in the mRNA of these two protein subunits could indicate either IL-23 or 
IL-12 expression or both. 
Heat map associations are shown for EBi3 and P40 cytokine subunits when 
stimulated by C.albicans and LPS at 24 h for RT-qPCR using SYBRGreen (Figure 
3.26). There is a much higher value of P40 when PBMCs are stimulated with 
C.albicans and LPS at 4 and 24 h as detected by RT-qPCR (PerfectProbe) (Figure 
3.27). The other cytokines subunits are clustered with lower values and a lower 
association on this heat map (Figure 3.27). The increase of P40 subunit again 
supports IL-12 or IL-23 expression. 
3.4.4 Dectin-1 expression by THP-1 cells and PBMCs  
3.4.4.1 Detection of dectin-1 and CD14+ gene expression by Human THP-1 Cells 
and PBMCs 
LPS stimulation only was found to induce a dose-dependent increase in dectin-1 
expression by THP-1 cells as evident by RT-qPCR (Figure 3.28) and FACS staining for 
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cell surface protein expression (Figure 3.29 and 3.30). Challenge only with HKC did 
not produce a detectable level of dectin-1 mRNA expression from THP-1 cells 
compared to the control (Figure 3.28). The THP-1 cells cultured with GM-CSF and 
IL-4 showed a small up-regulation of dectin-1 mRNA levels at 2 h (CT=0.0005) post 
stimulation, and this was further increased after 24 h (CT=0.00076). This was 
however, only a relatively small increase compared with LPS stimulation alone 
(Figure 3.28). However, the levels of mRNA expression for dectin-1 with LPS were 
also marginal at 2 h (CT=0.003) and again increased at 24 h (CT=0.011).  
Without LPS stimulation, freshly isolated PBMCs showed low levels of dectin-1 
mRNA expression (data not shown). A rapid increase in dectin-1 mRNA levels were 
detected 2 h after LPS stimulation and increased dectin-1 expression was again 
seen after 24 h LPS stimulation (Figure 3.31). Dendritic cells derived from PBMCs 
had higher expression of dectin-1 mRNA than non-matured PBMCs.  
3.4.4.2 PBMC phagocytosis of HKC and FACS analysis  
After overnight culture of isolated human PBMCs in full medium, about 15% of 
CD14+ cells became dectin-1+ monocytes, and these were readily detected by anti-
dectin-1 antibody and FACS analysis. Further increases in the numbers of dectin-1 
positive cells occurred with increasing doses of LPS stimulation (LPS 10 
ng/ml=34.7%; 100 ng/ml=35.4%; 200 ng/ml=56% dectin-1+ monocytes) (Figure 
3.32). The PBMCs with increased dectin-1 expression appeared to be the cells 
associated with HKC phagocytosis (Figure 3.33).  
3.4.4.3 Detection of IL-17A expression by PBMC 
Addition of HKC (S1, S2 and S3) to PBMCs induced IL-17A production after 3 days of 
cell culture with S1, S2 and S3 different clinical strains of C. albicans. This was 
significantly increased further after 7 days of HKC challenge (Figure 3.34).  
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Figure 3.6: IL-23 production from THP-1 cells stimulated with LPS (E. coli) (A) and 
LPS (PG) (B) as measured by ELISA. 
The amount of IL-23 cytokine in the culture supernatant from stimulated THP-1 
cells increased in a LPS dose dependent manner. Bars are representative of mean 
and error bars of standard deviation. The results were representative of 2 
independent experiments. 
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Figure 3.7: IL-27 production from THP-1 cells stimulated with LPS (E. coli) (A) and 
LPS (PG) (B) as measured by ELISA. 
LPS (PG or E. coli) increased IL-27 cytokine levels from stimulated THP-1 cells in the 
culture supernatant in a dose dependent manner, as measured by ELISA. Bars are 
representative of mean and error bars of standard deviation. The results were 
representative of 2 independent experiments. 
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Figure 3.8: IL-12 production from THP-1 cells stimulated with LPS (E. coli) (A) and 
LPS (PG) (B) measured by ELISA.  
IL-12 was expressed at very low levels from THP-1 cells after LPS (PG) stimulation 
with a small increase with LPS (E.Coli)  stimulation Bars are representative of mean 
and error bars of standard deviation. The results were representative of 2 
independent experiments..   
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Figure 3.9: IL-27 production from THP-1 cells stimulated with heat killed C. albicans 
(S1-S6), LPS (PG) and curdlan as measured by ELISA. 
Different strains of HKC (S1-S6) did not stimulate IL-27 expression from THP-1 cells 
as detected in the culture supernatant. Curdlan also did not stimulate IL-27 
expression. Bars are representative of mean and error bars of standard deviation. 
The results were representative of 2 independent experiments.LPS-PG (series 1 
concentration LPS 100 ng/ml and series 2 LPS 10 ng/ml) did stimulate IL-27 
expression (Series 3 represents THP-1 cells only).  
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Figure 3.10: IL-23 production by THP-1 cells stimulated with HKC (S1-S6), LPS (PG) 
and curdlan, as measured by ELISA. 
Different strains of HKC (S1-S6) at different concentrations (5x104, 5x105, and 5 x 
106 cells/ml) did not stimulate IL-23 expression from THP-1 cells as detected in the 
culture supernatant. Bars are representative of mean and error bars of standard 
deviation. The results were representative of 2 independent experiments. 
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Table 3.6: Production of IL-12 by THP-1 cells after challenge with different stimuli  
Stimulation THP-1 cells IL-12 
expression (pg/ml) 
THP-1 cells (GMCSF and 
IL-4) IL-12 (pg/ml)  
HKC S1 5x104 (cells/ml) 1.26 0 
HKC S1 5x105 (cells/ml) 0 0 
HKC S1 5x106 (cells/ml) 0 0.94 (0.0 SD)0 
HKC S5 5x104 (cells/ml) 1.029 (0.0 SD) 0 
HKC S5 5x105 (cells/ml) 1.06 0 
HKC S5 5x106 (cells/ml) 1.96 0.98 (0.0 SD) 
Curdlan 100µg/ml 0 3.69 (0.94SD) 
Curdlan 10µg/ml 2.29 (0.0 SD) 0 
Curdlan 1µg/ml 0.51 (0.01SD) 0 
Medium only 0 0 
HKC= heat killed Candida albicans, S=strain, GMCSF=granulocyte macrophage 
colony stimulating factor, SD=standard deviation 
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Table 3.7:  Production of IL-23 by THP-1 cells after challenge with different stimuli  
Stimulation THP-1 cells IL-23 
expression (pg/ml) 
THP-1 cells (GMCSF and 
IL-4) IL-23 (pg/ml)  
HKC S1 5x104 (cells/ml) 5.11 (0 SD) 0 
HKC S1 5x105 (cells/ml) 4.81 (2.89SD) 5.43 (2.8 SD) 
HKC S1 5x106 (cells/ml) 1.88 (1.64SD) 1.94 (0.59SD) 
HKC S5 5x104 (cells/ml) 1.77 (0 SD) 0 
HKC S5 5x105 (cells/ml) 4.64 (0.95SD) 2.03 (0 SD) 
HKC S5 5x106 (cells/ml) 7.94 (2.18 SD) 0 
Curdlan 100µg/ml 0 5.62 (0SD) 
Curdlan 10µg/ml 0 0 
Curdlan 1µg/ml 15.55 (10.11SD) 0 
Medium only 6.47 (1.13 SD) 4.63 (0.45 SD) 
HKC= heat killed Candida albicans, S=strain, GMCSF=granulocyte macrophage 
colony stimulating factor, SD=standard deviation 
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Table 3.8:  Production of IL-27 by THP-1 cells after challenge with different stimuli   
Stimulation 
 
THP-1 cells IL-27 
expression (pg/ml) 
THP-1 cells (GMCSF and 
IL-4) IL-27 (pg/ml)  
HKC S1 5x104 (cells/ml) 0 12.46 (0 SD) 
HKC S1 5x105 (cells/ml) 0 0 
HKC S1 5x106 (cells/ml) 0 2.03 (0 SD) 
HKC S5 5x104 (cells/ml) 0 0 
HKC S5 5x105 (cells/ml) 53.08 (0 SD) 0 
HKC S5 5x106 (cells/ml) 9.78 (0 SD) 0 
Curdlan 100µg/ml 0 11.28 (4.97 SD) 
Curdlan 10µg/ml 0 20.81 (0 SD) 
Curdlan 1µg/ml 0 0 
Medium only 0 1.01 (0 SD) 
HKC= heat killed Candida albicans, S=strain, GMCSF=granulocyte macrophage 
colony stimulating factor, SD=standard deviation 
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Figure 3.11: IL-23 production by THP1 cells stimulated with different HKC strains 
(concentration cells/ml) (LPS 24 h followed by HKC 24 h). IL-23 was constantly 
expressed following challenge with all HKC strains apart from an increased 
production with HKC S4 (5x106 cells/ml). A low but constant level of IL-23 
production occurred with curdlan (100 µg/ml and 10 µg/ml) challenge. Bars are 
representative of mean and error bars of standard deviation. The results were 
representative of 2 independent experiments. 
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Figure 3.12: IL-27 production from THP1 cells with different HKC strains 
(concentration in cells/ml) (LPS 24 h followed by HKC 24 h).  
IL-27 showed mostly a constant expression with the different strains. S4 showed a 
dose related response. S5 only stimulated expression of IL-27 at the higher 
concentration of HKC (5x106 cells/ml). Bars are representative of mean and error 
bars of standard deviation. The results were representative of 2 independent 
experiments. 
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Figure 3.13 Human monocyte cell line (THP-1) produced IL-23 after stimulation by 
LPS and heat-killed Candida albicans (S1). 
Pre-challenge of THP-1 cells with LPS resulted in significantly (**p<0.01) higher IL-
23 production post HKC stimulation as measured by ELISA. Bars are representative 
of mean and error bars of standard deviation. The results were representative of 2 
independent experiments. 
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Figure 3.14: Production of IL-23 from THP-1 cells after challenge with different 
stimuli. Different levels of IL-23 were produced from THP-1 cells after stimulation 
with different strains of C. albicans (S1, S2, S3, S4 and S5) and challenged with LPS 
as measured by ELISA. HKC S1 led to IL-23 production in a dose dependant manner. 
Bars are representative of mean and error bars of standard deviation. The results 
were representative of 2 independent experiments. 
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Figure 3.15: Production of IL-27 from THP-1 cells after challenge with different 
stimuli. Similar levels of IL-27 were produced from THP-1 cells after stimulation with 
different strains of C. albicans (S1, S2, S3, S4 and S5) and challenged with LPS as 
measured by ELISA. Bars are representative of mean and error bars of standard 
deviation. The results were representative of 2 independent experiments. 
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Figure 3.16: Production of IL-12 from THP-1 cells after challenge with different 
stimuli. Similar low levels of IL-12 were produced from THP-1 cells after stimulation 
with different strains of C. albicans (S1, S2, S3, S4 and S5) and challenged with LPS 
as measured by ELISA. Bars are representative of mean and error bars of standard 
deviation. The results were representative of 2 independent experiments. 
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Figure 3.17: Expression of mRNA for targeted cytokine subunits for IL-12, IL-23, IL-
27 and IL-35 from THP-1 cells when stimulated with either HKC (S1) or LPS as 
measured by RT-PCR.  
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Figure 3.18: Expression of mRNA of IL-27 receptor expression in THP-1 cells. The 
expression of mRNA of IL-27 receptors, gp130 (IL-27Rα) and WSX-1 (IL-27Rβ), were 
detected by RT-PCR after challenge with HKC (S1). The constitutive expression of 
both chains of IL-27 receptor was detected.  
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Figure 3.19: Expression of mRNA of TLR 2, TLR 4 and dectin-1 by THP-1 cells after 
HKC stimulation. THP-1 cells were stimulated for 48 h with HKC (results are for HKC 
S1). Dectin-1 mRNA expression was increased at 2-24 h after stimulation (with a 
peak at 6 h).  
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Figure 3.20: Timelapse images of THP-1 cells phagocytosis of HKC (S1). Image A was 
taken from the start of the time-lapse experiment. Image B was taken after 1 h 
after the start of the experiment and image C was taken after 3 h and the majority 
of HKC have been phagocytosed. 
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Figure 3.21: IL-23 production from peripheral blood mononuclear cells (PBMCs) 
driven with IL-4 and GMCSF. Matured PBMCs produced IL-23 when stimulated with 
LPS (E. coli) 100 ng/ml or HKC (S1) 1x106 cells/ml after 24 h only. No IL-23 
expression was detected at earlier time points with LPS or C. albicans stimulation of 
PBMC derived dendritic cells. Bars are representative of mean and error bars of 
standard deviation. The results were representative of 2 independent experiments. 
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Table 3.9: The expression of IL-12 family cytokine subunit genes in PBMCs detected 
by RT-qPCR (SYBRGreen)  
 
Cytokine 
subunit 
Med 4h Med 24h LPS 4h LPS 24h HKC 4h HKC 24h 
P40 0.03 0.10 2.01 1.86 0.23 6.14 
P35 0.01 0.00 9.77 0.04 0.03 0.01 
EBI3 0.14 1.11 1.84 10.27 1.84 4.77 
P28 0.39 0.23 15.32 5.76 0.22 0.34 
P19 0.22 0.09 0.63 0.04 0.26 0.17 
Med= medium only negative control, LPS= lipopolysaccharide, HKC=Heat Killed 
Candida albicans, h=hour 
Values represent gene expression/GAPDH (% of GAPDH) 
 
Table 3.10: The expression of IL-12 family cytokine subunit genes in PBMCs 
detected by RT-qPCR (Perfect Probe)  
 
Cytokine 
subunit 
Med 4h Med 24h LPS 4h LPS 24h HKC 4h HKC 24h 
P40 0.19 1.66 41.95 88.89 31.06 162.72 
P35 0.00 0.01 0.06 0.11 0.33 0.02 
EBI3 0.24 1.42 11.16 64.77 1.58 47.00 
P28 0.01 0.02 9.39 9.24 0.66 0.28 
P19 1.02 2.13 2.75 1.86 2.80 1.52 
Med= medium only negative control, LPS= lipopolysaccharide, HKC=Heat Killed 
Candida albicans, h=hour  
Values represent gene expression/GAPDH (% of GAPDH)  
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Figure 3.22: The gene expression for the five different IL-12 cytokine subunits from 
PBMCs. The subunits included detection of p35, p19, EBi3, p40 and p28 from 
PBMCs stimulated with LPS or C.albicans detected by RT-qPCR (SYBRGreen) 
expressed as % of GAPDH. Bars are representative of mean and error bars of 
standard deviation. The results were representative of 2 independent experiments. 
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Figure 3.23: The gene expression for the five different IL-12 cytokine subunits from 
PBMCs. The subunits included detection of p35, p19, EBi3, p40 and p28 from 
PBMCs stimulated with LPS or C.albicans detected by RT-qPCR (Perfect probeTM) 
expressed as % of GAPDH. Bars are representative of mean and error bars of 
standard deviation. The results were representative of 2 independent experiments. 
(Ca=C.albicans, med= medium only) 
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Figure 3.24: Heat map (no scaling) showing the associations of the gene expression 
of the protein subunits of the IL-12 family with different stimulations of PBMCs as 
detected by RT-qPCR (SYBRGreen).In the columns C.albicans appears closely 
clustered as well as LPS 24h and C. albicans 24h. In the rows P28 and P35 are 
strongly clustered (driven by LPS 4 hours), and P19, EBI3 and P40 are strongly 
clustered (driven by LPS 24 hours). (Med= medium, h= hours, Ca=C. albicans and 
LPS=lipopolysaccharide). 
 
  
L
P
S
_
4
h
M
e
d
_
4
h
M
e
d
_
2
4
h
C
a
_
4
h
C
a
_
2
4
h
L
P
S
_
2
4
h
P28
P35
EBI3
P40
P19
Heat Map: No Scaling
179 
 
 
 
 
Figure 3.25: Heat map (no scaling) showing the associations of the gene expression 
of the protein subunits of the IL-12 family with different stimulations of PBMCs as 
detected by RT-qPCR (PerfectProbe). In the columns C.albicans 24h and LPS 24h are 
strongly clustered as well as C.albicans and LPS at 4 h. In the rows p40 appears a 
higher value compared to the other subunits stimulated by C. albicans and LPS at 
both 4 and 24 h. (Cells= medium only, h= hours, Ca=C. albicans and 
LPS=lipopolysaccharide). 
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Figure 3.26: Expression of Dectin-1 mRNA by THP-1 cells following LPS challenge. 
Dectin-1 mRNA expression increased in THP-1 cells at 2 and 24h after LPS 
stimulation as measured by RT-qPCR. HKC (S1) and GMCSF IL-4 and TNFα were also 
used to stimulate THP-1 cells however only minimal levels of dectin-1 were 
expressed. (HKC= heat killed C.albicans, med= medium only, GIT= GMCSF, IL-4 and 
TNFα). Bars are representative of mean and error bars of standard deviation. The 
results were representative of 2 independent experiments. 
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Figure 3.27: Cell surface expression of dectin-1 in THP-1 cells following challenge 
with increasing levels of LPS. Dectin-1 positive PBMCs were detected by 
fluorescence-activated cell sorting following staining with an anti-dectin-1 antibody. 
The number of dectin-1 positive cells increased in an LPS dose dependent manner. 
The results were representative of 2 independent experiments. (Med = medium 
only, no LPS) (FL1-H = relative intensity of the fluorescence).  
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Figure 3.28: Dectin-1 positive THP-1 cells after stimulation with increasing 
concentrations of LPS. Dectin- 1 positive THP-1 cells were detected by fluorescence-
activated cell sorting following staining with an anti-dectin-1 antibody. The number 
of dectin-1 positive cells increased in an LPS dose dependent manner. The results 
were representative of 2 independent experiments.  
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Figure 3.29: Dectin-1 expression by peripheral blood mononuclear cells after 
stimulation with LPS. Dectin-1 expression was detected by RT-qPCR at 2 and 24 h 
and the results were representative of three independent experiments. 
 
 
 
 
 
 
 
Figure 3.30: Dectin-1 presence on peripheral blood mononuclear cells following 
challenge with increasing levels of LPS. Dectin-1 positive PBMCs were detected by 
fluorescence-activated cell sorting following staining with an anti-dectin-1 antibody. 
The number of dectin-1 positive cells increased in a LPS dose dependent manner.  
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Figure 3.31: Phagocytosis of C. albicans by peripheral blood mononuclear cells 
following challenge with increasing levels of LPS. Phagocytosis of PI stained 
C.albicans by PBMCs was detected by fluorescence-activated cell sorting following 
staining with FITC. Phagocytosis of Candida albicans increased with higher LPS 
concentration. 
 
 
 
 
 
 
 
 
Figure 3.32: IL-17A production by peripheral blood mononuclear cells after 
stimulation with C. albicans. PBMCs showed an increased production of IL-17A after 
stimulation with 3 different strains of C. albicans (S1, S2 and S3) over 7 days as 
measured by cytometric bead analysis.   
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3.5 Discussion  
Oral candidosis is an important health problem that can progress to oesophageal 
candidosis, which may lead to decreased nutritional uptake and have a detrimental 
effect on general health (Conti et al., 2009). In severely immunosuppressed 
individuals, further progression to systemic infection and even death may occur. 
The IL-12 cytokine family is thought to play an important role in directing T-cell 
differentiation and the resulting host immune response during a candidal infection 
(Gee et al., 2009). 
Monocytes in peripheral blood are precursor cells produced in the bone marrow, 
and can differentiate into macrophages and dendritic cells (DCs) that produce 
cytokines, particularly those of the IL-12 family. These cells therefore bridge the 
innate and adaptive immunity. Monocyte and macrophage/DCs are major host 
innate immune cells that are considered to play an important role in controlling 
Candida infection. Candida albicans recognition by host innate immune cells will 
lead to the production of cytokines, which stimulate immune cells, such as 
macrophages, neutrophils and dendritic cells, for subsequent pathogen killing. To 
understand how Candida induces host immune cell recognition for cytokine 
production, in this chapter clinical strains of heat killed C. albicans were studied 
before addition to a culture of human monocytes (THP-1 cell line) and human 
peripheral blood mononuclear cells. 
In this study, ELISA data (Section 3.4.2.1 and Figures 3.9 and 3.10) suggested that 
the IL-12 family cytokines (IL-12, IL-23 and IL-27) were not produced by THP-1 cells 
after C. albicans only stimulation. It was only when the human monocyte cell line 
(THP-1 cells) was pre-challenged with LPS and then C. albicans added that some 
members of the IL-12 family were detected. In vivo, other cells undoubtedly will 
play a role in cytokine release including the production of other cytokines by T cells, 
and other lymphocyte subsets influencing the cytokines that will ultimately be 
released from the APCs to determine the Th cell response (Lykah et al., 2008). The 
presence of additional cytokines in vivo may be the reason why C. albicans on its 
own could not stimulate the THP-1 cells to produce members of the IL-12 cytokine 
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family in this in vitro experiment. It has also been shown that zymosan stimulation 
with IFNγ was needed to induce IL-12 production from DCs (Lykah et al., 2008).  
THP-1 cells when stimulated with C.albicans only or when pre-challenged with LPS 
before the addition of C.albicans, in both stimulation conditions, there was an 
absence of IL-12 production or non-significant levels of IL-12 were produced. This 
may suggest that IL-35 was being produced by THP-1 cells stimulated with either C. 
albicans or LPS rather than IL-12. IL-35 production by THP-1 and PBMC cells was 
inconsistent, and no conclusive findings could be made regarding its production in 
this chapter. IL-12 was not detected in the supernatant of THP-1 cell culture 
following stimulation with C. albicans and LPS. This may indicate that IL-12 does not 
play a significant role in controlling candidosis based on this cell culture model This 
finding would be supported by previous mouse models, where IL-12 knockout mice 
showed only a slight increase in fungal burden compared with IL-23 knockout mice 
(Conti et al., 2009). This could support the view that a Th17 pathway rather than a 
Th1 pathway is important in the immune response to candidal infection. However, 
it cannot be assumed that a mouse model will predict the same response that 
occurs in human’s (Shanks et al., 2009). 
Furthermore, it has been reported that IL-23 and the Th17 pathway negatively 
regulate Th1 responses, which may explain the low expression of IL-12 (Zelante et 
al., 2007). In an experimental colitis model, IL-23 was found to down-regulate IL-12 
production by DCs, which may have occurred in the present cell culture study 
(Becker et al., 2006). 
PBMCs further matured with GMCSF and IL-4 to become dendritic cells which were 
then stimulated with LPS or HKC were found to produce IL-12 at 24 h but not at 
earlier time points. This would fit with a Th1 response being elicited by PBMC 
derived DCs. This may fit with a model where a Th1 response to C. albicans has 
been found to be protective against secondary systemic candidal infections, but 
not mucocutaneous infections (Kashem et al., 2015). Levels of the p40 subunit 
mRNA in PBMCs after C.albicans stimulation appeared to be increased at 6 and 24 
h, which could indicate IL-12 or IL-23 cytokine expression as this subunit is common 
to both cytokines. 
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In the case of THP-1 cells pre-challenged with different clinical C. albicans strains 
and then LPS, IL-23 was detected in the supernatant by ELISA. This may support a 
Th17 driven response to candidal infection for mucosal host defence (Conti et al., 
2009, Schonherr et al., 2017, Conti et al., 2014). IL-23 is thought to expand the 
Th17 lineage resulting in elimination of Candida (Saunus et al., 2010).  
Detection of mRNA encoding for cytokine subunits after C. albicans stimulation was 
somewhat difficult to interpret given that the subunits are shared components for 
several of the cytokines. It could be hypothesised that an increase in the p40 mRNA 
was indicative of IL-23 release, rather than IL-12 as p40 is a common subunit to the 
two cytokines. In the current results, there was however weak expression of the 
p40 and p19 protein after stimulation of THP-1 cells with C. albicans detected by 
RT-PCR.  
In cultures of PBMCs that had been differentiated to DCs, IL-23 was detected in the 
supernatant by ELISA only at 24 h after HKC and LPS stimulation. RT-qPCR revealed 
an increase in p40 subunit mRNA, but not p19 mRNA. It is therefore difficult to 
state with certainty which cytokine incorporating the p40 subunit has been 
upregulated. From the literature, IL-23 is known to be necessary in Th17 
development and is produced from APCs after the recognition of C. albicans 
mannan (Smeekens et al., 2010, Richardson and Moyes, 2015). 
IL-27 was produced by THP-1 cells after C.albicans stimulation and showed a dose 
response with increasing concentrations of different HKC strains. IL-27 is known to 
suppress pro-inflammatory Th17 responses and prevents IL-2 release and Th2 
responses, thus having a dual role (Yoshida and Yoshiyuki, 2008). The inhibitory 
effect of IL-27 on mucosal Th2 responses is thought to be independent of its ability 
to enhance IFNγ production (Villarino and Hunter, 2004). 
The protein subunits for IL-27 mRNA were both expressed from THP-1 cells by both 
C. albicans and LPS stimulation. The presence of EBi3 and p28 at constant levels 
would support the view that IL-27 was constantly expressed. Expression of the IL-
27 receptors, gp130 and WSX-1, were detected by RT-PCR after challenge with C. 
albicans. Constitutive expression of both chains of the IL-27 receptor were 
detected and this could indicate that IL-27, produced from THP-1 cells, acts on the 
188 
 
cell in an autocrine manner. The binding of IL-27 to IL-27R activates the Jak/stat 
signalling pathway, which implies a role of the IL27R in regulating the immune 
process (Villarino and Hunter, 2004).  
IL-27 was not produced by PBMCs differentiated into DC at any time point with LPS 
or HKC stimulation. EBi3 mRNA was shown to be upregulated after both LPS and 
HKC at 24 h stimulation, but this subunit can form both IL-27 (together with p28) 
(Pflanz et al., 2002) and IL-35 (together with p35) (Niedbala and Wei, 2007) so it is 
difficult to interpret this result. It could be hypothesised that the lack of IL-27 
expression prevents its inhibitory role which would inhibit the expansion of Th17 
cells allowing a Th17 response to occur and control the candidal infection 
(Murugaiyan et al., 2009). 
The detection of small amounts of p35 mRNA when THP-1 cells were stimulated by 
C. albicans could indicate the role of IL-35 rather than IL-12 in the activation of the 
APC to drive the T cell response. IL-35 is thought to play a role in the production of 
a T-reg response preventing overstimulation of the inflammatory response to 
Candida and preventing tissue damage (Conti et al., 2009). EBi3 but not p35 was 
also expressed from PBMC which may also support a role of IL-35 and a Treg 
response in regulating the immune response to C. albicans infections although the 
role of IL-35 in immune regulation has been unclear in studies so far (Banchereau 
et al., 2012). An improvement to this part of the results and to strengthen the 
findings would have been to detect the IL-35 cytokine using ELISA however this was 
not successful and there wasn’t a commercial kit available. 
Pattern recognition receptors (PRRs) are important in activation and release of 
cytokines. The main receptors for the recognition of C. albicans are dectin-1, TLR2 
and TLR4 and these bind to different structures on the fungal surface inducing 
specific innate immune responses (Ferwerda et al., 2008) (Section 1.2.2).  
Dectin-1 is a C-type lectin receptor and key to C. albicans recognition by binding to 
the β-glucan component of the yeast cell wall. Dectin-1 expression by monocytes 
for recognition of Candida β-glucan plays a key role in controlling both mucosal and 
systemic Candida infection in humans, despite potential early masking. 
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Importantly, dectin-1 gene mutation in patients has been associated with Candida 
infection of mucosal skin (Ferwerda et al., 2009). 
Previous studies have shown that β- glucan in C. albicans cell wall may actually be 
masked during the early stages of infection and then later exposed (Wheeler et al., 
2008). Thus, host recognition of Candida via β-glucan interaction with dectin-1 and 
subsequent induction of immune responses and infection control may be less 
prominent in-early stages of Candida infection compared with later ones. In this in 
vitro study, the extent of potential β-glucan masking was unknown, and it may 
have been possible that heat treatment of the C. albicans would have increased β-
glucan exposure and thus enhanced the observed responses compared with the in 
vivo situation. Any enhancement of β-glucan exposure would have been consistent 
for all experiments. 
In the THP-1 cell line, both the TLRs and dectin-1 mRNA were expressed after 
stimulation with C. albicans. It has been shown that there is a synergistic effect 
with dectin-1 and TLR2 or TLR4 in human monocyte-derived macrophages resulting 
in increased production of the pro-inflammatory cytokine TNF- (Ferwerda et al., 
2008).  
The co-ligation of dectin-1 with multiple TLRs has been shown to suppress IL-12 
production but promote the production of IL-23 (Dennehy et al., 2009). This may 
explain the results where no IL-12 was detected after C. albicans stimulation but IL-
23 was present when determined by ELISA.  
PBMCs stimulated with LPS and addition of C. albicans were the cells with 
increased dectin-1 expression and were the cells associated with C. albicans 
phagocytosis. This result demonstrated that LPS could up-regulate dectin-1 
expression in human peripheral blood monocytes and this in turn enhanced 
phagocytosis of C. albicans. It has been reported that β-glucan particles bound to 
dectin-1 in macrophages to form a phagocytic synapse that initiates cell 
phagocytosis and cytokine production (Goodridge et al., 2011). These results 
further confirm that dectin-1 induced by LPS may therefore have a critical role in C. 
albicans control. 
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LPS and GM-CSF/IL-4 induced dectin-1 expression in THP-1 cells and PBMCs and the 
levels of LPS-induced Dectin-1 expression was also associated with the cells’ ability 
to phagocytose Candida in PBMCs. LPS induced dectin-1 expression led to IL-23 
production from human monocytes (THP-1) in a dose dependent manner. Human 
PBMCs stimulated with 3 different clinical strains of C. albicans produced higher 
level of IL-17A, hence again supporting a Th17 response.  
IL-17A detected after long periods of cell culture may indicate that dectin-1 and 
other receptors for Candida recognition are only elevated after cell culture since by 
FACS analysis only limited levels of dectin- 1 expression were detected in PBMC 
after overnight culture without LPS. Unfortunately, IL-23 production was not 
detected in those cell cultures which may indicate consumption of IL-23 by Th17 
cells and other cells with IL-23 receptor expression in human PBMC cultures, since 
PBMCs are a heterogeneous cell population. 
IL-17A production was detected in the cell culture following HKC stimulation, but 
not in controls at days 3 and 7. This may indicate that the Th17 recall response 
occurred, which can require days to become fully functional (Chapter 4). In this 
study, three different clinical isolates of C. albicans were added to the cell cultures, 
and no significant difference in terms of IL-17A production was evident between 
these three strains. 
In this present study, low levels of dectin-1 expression were found by THP-1 cells 
cultured in full culture medium. LPS induced a dose-dependent increase in dectin-1 
expression by these cells, as seen by both mRNA and protein levels. This was not 
only evident in THP-1 cells, but also in newly isolated human PBMC-derived 
monocytes. THP-1 cells are precursors of human macrophage/DC cell line which 
can be further matured by culture in cell medium containing GMCSF. LPS 
stimulation therefore appears to sensitise human monocytes for C. albicans 
recognition. It has previously been reported that β-glucan together with LPS 
stimulated a 6- fold higher IL-10 production by freshly isolated human monocytes 
(Chen et al., 2008). Stimulation by C. albicans together with LPS resulted in THP-1 
cells producing an increased quantity of IL-23, and this was dependent on HKC cell 
number. This result suggested that increased dectin-1 expression by LPS 
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subsequently resulted in higher IL-23 production following C. albicans challenge. IL-
23 is a critical cytokine that drives and maintains Th17 responses. Th17 cells are a 
subpopulation of CD4+ T cells which are differentiated from naïve T-cells in the 
tissue environment containing TGFβ1, IL-1β, and IL-23 (Iwasaki and Medzhitov, 
2015).  
Monocytes without full maturation expressed considerably lower levels of dectin-1, 
and a significantly increased dectin-1 expression was then observed after LPS 
stimulation. This contrasts with studies by other groups that have shown mouse 
and human matured macrophages and dendritic cells expressed higher levels of 
dectin-1, and reduced expression was seen with LPS stimulation (Willment et al., 
2005, Willment et al., 2003, Reid et al., 2004, Bonfim et al., 2009). The results in 
this chapter have shown increased dectin-1 expression after culture of human 
PBMC with GM-CSF/IL-4 (to generate typical PBMC-derived DCs). The different 
levels of dectin-1 mRNA expression for human PBMC and THP-1 cells (as shown by 
hDectin-1/hGAPDH ΔΔCT) may be explained by a relatively lower cell number in 
PBMCs. 
Although dectin-1 is the main PRR that induces expression and production of pro-
inflammatory cytokines. Dectin-2 and 3 also enhance ROS production and 
phagocytosis and killing of fungi and another explanation for the results in this 
study would be that dectin-2 and 3 played a role in the increased phagocytosis of 
HKC LPS stimulated cells (Netea et al., 2015). This would be an area worthy of 
further study to look at the role of these other PRRs in the recognition and 
phagocytosis of C. albicans. 
The findings from the experiments in this chapter indicated some variation 
between the amounts of IL-23 produced in the supernatant of THP-1 cells using the 
different clinical strains of C. albicans. There was found to be a significant increase 
in IL-23 expression when THP-1 cells were stimulated with C. albicans and LPS for 
strains 1, 2 and 3 but not 4 and 5. The other IL-12 family members did not show a 
significant difference between strains studied after stimulation of THP-1 cells or 
PBMCs. The strains were all from different oral conditions with different pathology 
so it could be hypothesised that there may be variation in the immune response 
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that would be expected with particularly virulent strains. The 17 strains of C. 
albicans in this study were found to belong to 5 different clades with 2 that were 
classed as singletons. The main clade groups of 3 or more isolates were from 
groups 1, 4 and 8.  It has already been demonstrated that flucytosine resistance is 
restricted to members of the group 1 clade and it may be that different phenotypic 
and virulence characteristics differ between clades (Pujol et al., 2004). 
IL-27 expression did vary slightly between strains with S1, S5 and S11 producing 
undetectable levels of expression of the cytokine from Thp-1 cells at the lowest 
concentration of C. albicans but all these strains expressed IL-27 at the highest 
concentration of C. albicans. Interestingly these three strains were also all from 
three different clades (S1 clade 8, S5 a singleton and S11 clade 1) and it has been 
reported that different clades have different properties such as clade 1 isolates 
being more often associated with superficial skin infections or it may emerge that 
some clades are more invasive (McManus and Coleman, 2014). The lack of IL-27 
expression may also indicate that these three strains are commensal and less likely 
to cause an immune response by the host and IL-27 production. IL-27 production 
has been associated with inhibition of fungal clearance by suppression of the 
protective immune response (Patin et al., 2016). In contrast IL-23 expression was 
induced by all C. albicans strains tested at all concentrations.  
Candida albicans can be used live or heat-killed in experimental cell culture models. 
Heat-killing C. albicans is beneficial in cell culture as it avoids the use of antifungals 
and the possible effects on the experimental model. It has been shown that the use 
of heat-killed Candida results in the exposure of β-glucan on the surface of the cell 
wall and subsequent recognition by dectin-1 (Gow et al., 2007). In contrast live C. 
albicans stimulated monocytes mainly act via recognition of cell surface mannans 
(Gow et al., 2007).  
A further difference between heat-killed and live Candida is that live Candida has 
been shown to suppress reactive oxygen species (ROS) production by the 
phagocyte (Wellington et al., 2009). This may suggest that heat-killed Candida is 
more likely to evoke an immune response than live Candida. This difference needs 
to be considered in interpreting the results of this study. Further work could 
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include repeating the results with live C. albicans strains and using different strains 
and clades of C. albicans in larger numbers to look for significant trends of the 
immune response by the host. 
Future work could also include investigating these in vitro results and repeating 
them in vivo as differences will exist between this and a cell culture environment. 
There may exist a lack of other cytokines, immune surveillance cells, chemokines 
and other cell signalling processes in an experimental model. By simplifying the 
process in vitro, the interpretation of the results may be missing interactions that 
would affect immune response in vivo. 
Further limitations and areas for future work in this study would include repeating 
RT-qPCR with different strains of C. albicans as this wasn’t carried out due to time 
constrains. The RT-qPCR was carried out using both an intercalating dye 
(SYBRgreen) and a designed primer probe (PerfectProbe). The results showed 
similar trends for both methods but there is always the potential in both these 
methods that the signal may not have been from a genuine amplification of the 
target signal. As the target was thought to be of low abundance then a target 
hydrolysis probe was used to overcome this problem. There is however still the 
possibility of primer dimers with this method. Further work to consider a wider 
number of experimental time intervals and an increase in repeats with different 
strains of HKC may have strengthened this area of work. 
Overall this study shows important areas worthy of future research with regards to 
the immune response, in particular related to the IL-12 family of cytokines, to C. 
albicans by monocytes and dendritic cells. The results from this chapter have 
indicated that LPS appears to be important in enhancing the immune response to 
C. albicans. This potentially occurs by enhancing dectin-1 expression resulting in 
increased phagocytosis of Candida and therefore clearance in a host environment. 
LPS may therefore be important at an early stage of C. albicans recognition and 
immune response to an infection. 
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3.6 Conclusions 
This chapter aimed to gain further understanding on how C. albicans is both 
recognised by specific immune cell types (monocytes and dendritic cells) and how 
this influenced subsequent immune cell responses (cytokine expression and 
phagocytosis). 
 
1. A significant dose related increase in IL-23 expression was detected from human 
monocytes (THP-1 cells) with prior stimulation by LPS. There was no significant 
production of the tested IL-12 family cytokines (IL-12, IL-23 and IL-27) from THP-1 
cells when C. albicans only was added. LPS may be therefore be required for early 
recognition of C. albicans and subsequent immune response. 
 
2. IL-23 showed a significant increase in expression when THP-1 cells were 
stimulated with C. albicans for certain strains which were from different clades. 
Different strains and clades of C.albicans may therefore lead to a differential effect 
on IL-23 expression from human monocytes although this was not seen for the 
other IL-12 family cytokine members.  
 
3. This study indicated that LPS could induce dectin-1 expression in human 
monocytes (THP-1 cells and PBMCs), and this resulted in enhanced C. albicans 
phagocytosis. LPS may thus alter innate immune cell function for C. albicans 
recognition and affect early stages of Candida infection. 
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Chapter 4: 
Recall response of T helper cells after 
stimulation of peripheral blood 
mononuclear cells with Candida 
albicans  
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4.1 Introduction  
The immune response differs at various times of an individual’s life, with health 
status and whether there has been prior exposure of the immune response 
(section 4.1.4). Different immune responses are clearly demonstrated when 
comparing the lymphocyte population found in cord blood compared with adult 
blood and the increased number of naïve Th cells in cord blood (Cicuttini and Boyd, 
1994). The immune system normally encounters Candida albicans early on in an 
individual’s life, with first contact potentially occurring when a neonate is exposed 
to C. albicans as a commensal coloniser of the mother’s vaginal mucosa (Ali et al., 
2012). The immune response to C. albicans will be multifactorial and will comprise 
of an innate response involving phagocytes (Section 1.2.3) and sentinel cells of the 
immune system present in blood and at epithelial surfaces. The innate response is 
traditionally thought of as a rapid response to infection (Iwasaki and Medzhitov, 
2015). The adaptive response (Section 1.2.4) is largely dependent on how naïve T 
helper (Th) cells are ‘driven’ by the pathogen to elicit one of several distinct Th cell 
responses (Richardson and Moyes, 2015). The naïve Th cell pool is considered to 
remain fairly constant throughout life, despite changes in the presented antigens 
and a decrease in production with age (Tanchot and Rocha, 1998). In addition to 
these T cell responses, there will also be memory T cell responses arising from 
previous exposure to the pathogen (Section 4.1.3). 
 
4.1.1 T helper cell lineage and their response to C. albicans 
CD4+ Th cells are critical to host defences and these cells can differentiate into 
specialised subsets (Nakayamada et al., 2012) (Section 1.2.4). These different 
subsets are distinct lineages of Th cells each exhibiting specific cytokine secretion 
profiles (Nakayamada et al., 2012, Helmstetter et al., 2015, Zhou et al., 2009). The 
different Th cells and the cytokines involved are presented in table 4.1. A certain 
amount of plasticity has been recognised between these Th cell types, as opposed 
to the classical view of them having limited flexibility (Zhou et al., 2009, 
Nakayamada et al., 2012). The Th cell lineage includes Th1, Th2, Th17, Treg, Th9, 
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Th22, and the newest cell type referred to as follicular helper T (Tfh) cells 
(Nakayamada et al., 2012). Th1, Th2, Th17 and Treg cells have previously been 
described in this thesis with regards to their cytokine release and function (Section 
1.2.4). The occurrence of distinct Th cell lineages enables the adaptive immune 
response to respond to different pathogens in an appropriate and distinct manner 
(Murphy and Stockinger, 2010).  
Th1 and Th2 CD4+ cell subsets were first described in 1986 by Mosmann et al 
(Mosmann et al., 1986). Th1 cells were thought to activate macrophages to release 
IFNγ and enhance the killing of pathogens (Murphy and Stockinger, 2010). Th1 cells 
are generated following exposure to IL-12 and the transcription factor T-bet, and 
these cells then release IFNγ, IL-2 and TNFα (Schmitt and Ueno, 2015). In oral 
candidosis, Th1 cells have a pro-inflammatory role and activate macrophages 
leading to phagocytosis and killing of the fungus. The importance of this effect is 
clearly evident in patients with immunodeficiency as evident in AIDs patients, 
where the extensive deficiency in Th1 cell numbers significantly increases 
susceptibility to oral candidosis (Schmitt and Ueno, 2015). It has also been found 
that in secondary systemic candidosis, Th1 rather than Th17 responses are 
protective (Kashem et al., 2015). 
Th2 cells were originally considered to be classical Th cells that help B cells 
generate antibodies (Murphy and Stockinger, 2010). Th2 cells have been shown to 
release IL-4, IL-5, IL-13 and IL-10 cytokines and develop from naïve CD4+ Th cells 
following exposure to IL-4 and the transcription factors STAT6 and Gata-3 (Zielinski, 
2014). In oral candidosis, Th2 cells are considered to play an anti-inflammatory role 
and are deemed to regulate the immune response against the organism (Romani, 
1999). More recently, Th2 cytokines have been shown to have conflicting roles in 
the host response to C. albicans (Netea et al., 2015). 
CD4+ Th cells producing IL-17 were first discovered in 2003 (Murphy et al., 2003) 
and were later named in 2005, as Th17 cells (Harrington et al., 2005, Park et al., 
2005). The Th17 cell subset is thought to be induced by TGFβ, IL-6, IL-1 and IL-21 
(Murphy and Stockinger, 2010). IL-23, which is part of the IL-12 family (Section 
3.1.3.1), is thought to be particularly important in Th17 cell expansion and function 
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(Conti et al., 2009). Evidence has associated human genetic deficiencies involving 
Th17/IL-17 pathways with candidosis (Hernandez-Santos and Gaffen, 2012). It has 
been found that genetic deficiencies in dectin-1, CARD9, IL-17RA and IL-17F may all 
increase the risk of chronic mucocutaneous candidosis (CMC) (Section 1.1.3.11). 
These deficiencies lower the number of Th17 cells or impair signalling by IL-17A and 
IL-17F (Ferwerda et al., 2009, Puel et al., 2011, Hernandez-Santos and Gaffen, 
2012). The role of IL-17 cytokine in the immune response to C. albicans is discussed 
in section 4.1.2. 
Treg cells are believed to be primed following exposure to IL-2 and TGFβ, and these 
cells express high levels of Foxp3 (Schmitt and Ueno, 2015). Treg cells can be 
categorised as resting or activated, and are deemed to have a diverse role in the 
immune response to infection (Whibley and Gaffen, 2014). It has been found that 
Treg cells behave differently depending on conditions. Treg cells have been shown 
to enhance the differentiation of naïve Th cells into Th17 cells and promote IL-17A-
dependent clearance of C. albicans during mucosal infection (Pandiyan et al., 
2011). The underlying mechanism for this is thought to involve IL-2 sequestering by 
Treg cells, which prevents inhibition of Th17 cell differentiation. This phenomenon 
has been shown in both in vitro and in vivo studies (Pandiyan et al., 2011). This role 
of Treg cells has also been demonstrated in disseminated murine C. albicans 
infection, where Treg cells enhanced the Th17 response, but inhibited the Th1 and 
Th2 responses (Whibley et al., 2014). 
IL-9 producing Th9 cells were discovered in 2008 (Veldhoen et al., 2008) and these 
cells are thought to differentiate from naïve Th cells in response to IL-4 and TGFβ 
(Schmitt and Ueno, 2015) (Table 4.1). IL-9 has several functions including 
pathophysiological and physiological roles. Th9 cells are able to recruit Th17 cells in 
autoimmunity, however there have been no specific studies looking at oral 
candidosis and Th9 cell responses (Schmitt et al., 2014). 
Th22 cells secrete IL-22 and the differentiation of naïve T-cells into Th22 cells is 
promoted by IL-23, IL-12 and IL-6 (Schmitt and Ueno, 2015). In a study of 
keratinocyte stimulation with IL-22 and TNFα, it was shown that the growth of C. 
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albicans was inhibited and this conserved the integrity of the epidermal barrier in a 
skin infection model (Eyerich et al., 2011). 
Tfh cells are thought to express IL-21 and are differentiated from naïve T-cells by 
the cytokines IL-12, IL-23 and TGFβ (Schmitt and Ueno, 2015) (Table 4.1). Tfh cells 
are thought to have a role in the differentiation of B cells into plasma and memory 
cells (Ueno et al., 2015). To date, there have been no studies examining the role of 
Tfh cells in response to human C. albicans infection. 
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Table 4.1: T helper cells and associated cytokines and transcription factors  
Th cell subset Cytokines 
involved in 
differentiation 
Main 
transcription 
factors 
Effector 
cytokines  
References 
Th1 IL-12 T bet 
STAT4 
IFNγ 
IL-2 
TNFα 
(Murphy and 
Stockinger, 
2010) 
Th2 IL-4 Gata-3 
STAT6 
 
IL-4 
IL-5 
IL-10 
IL-13 
(Mosmann et 
al., 1986) 
(Zielinski, 
2014) 
Th17 IL-1 
IL-6 
IL-21 
IL-23 
TGFβ 
RORγt IL-17A 
IL-17F 
(Conti et al., 
2016) 
Treg IL-2 
TGFβ 
Foxp3 IL-10 
IL-35 
(Schmitt and 
Ueno, 2015) 
Th22 IL-23 
IL-12 
IL-6 
unknown IL-22 (Schmitt and 
Ueno, 2015) 
Th9 IL-4 
TGFβ 
STAT6 
Gata-3 
IL-9 (Schmitt and 
Ueno, 2015) 
Tfh TGFβ 
IL-12 
IL-23 
Bcl-6 IL-21 (Schmitt and 
Ueno, 2015) 
Th=T helper cell, Treg=regulatory T cell, Tfh=follicular helper T cell, IL=interleukin, 
STAT=signal transducer and activator of transcription, ROR=retinoid orphan 
receptor, Foxp3= forkhead box protein 3, Bcl= B-cell lymphoma 
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4.1.2 IL-17 expression and function in C. albicans immunity 
Th17 cells express IL-17A and IL-17F (Section 4.1.1), although the IL-17 cytokine 
family is known to consist of a total of 6 cytokine members (Section 1.2.5.1). IL-17A 
and IL-17F are considered to play a protective role against oral candidosis (Conti 
and Gaffen, 2015), which is in direct contrast to IL-17C (Conti et al., 2015). IL-17A 
elicits its protective effect by stimulating cytokines, such as G-CSF and IL-8, which 
promote the expansion and recruitment of neutrophils to the infection site 
(Whibley and Gaffen, 2014). In oral epithelial cells, IL-17 receptor (IL-17R) signalling 
plays an important role in protection against oral candidosis and this has been 
demonstrated in murine infection models (Conti et al., 2016).  
In this chapter, measurement of IL-17A was determined in vitro as an indicator of 
whether a protective response was being recalled by Th17 cells resulting in 
clearance of C. albicans by a subsequent neutrophil response. 
 
4.1.3 T memory cell and recall response to C. albicans 
A key feature of the adaptive immune response is its ability to respond efficiently 
to antigens. It has been found that ‘experienced’ T cells respond to a stimulation 
more rapidly than a naïve T cell due to immunological memory (Bevington et al., 
2017). The memory T cell response allows a rapid recall response when antigens 
are re-encountered (Zediak et al., 2011). The fate of naïve T cells once they have 
been activated and the immune response resolved is that the vast majority (90-
95%) of responding T cells will die (Bevington et al., 2017) (Mueller et al., 2013). 
However, a small number of T cells return to a quiescent state and persist as 
antigen-specific memory T cells. The difference between the immune response of a 
naïve T cell and a memory T cell is that the former can take up to 24 h to mount a 
response, whilst memory cells respond to an antigen in as little as 1-2 h (Bevington 
et al., 2016).  
Continual reinforcement from various cytokines, in particular IL-7 and the TNF 
super family is required for the maintenance and survival of naïve and memory T 
cells, and this retains the appropriate number of these cells in the Th cell pool for 
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subsequent adaptive immune responses (Seddon et al., 2003). Memory CD4+ T cells 
support the adaptive immune response by ‘patrolling the periphery’ for signs of re-
infection and these cells are able to re-expand the Th cell population within 
lymphoid tissue if re-infection occurs, thus enabling a more efficient response to 
infection (Bevington et al., 2017). 
There have been three different memory T cell subsets defined. The central 
memory T cell (TCM) which can produce IL-2 and proliferates extensively, effector 
memory T cells (TEM) which are less proliferative and produce cytokines such as 
IFNγ, and a more recently identified population of tissue-resident memory cells 
(TRM) which reside in peripheral tissue after an infection has cleared (Mueller et al., 
2013). 
In T cell activation by dendritic cells (DCs) multiple signals are required to influence 
naïve CD4+ Th cells being driven into effector Th cells and later generation of T 
memory cells (Mueller et al., 2013). Higher levels of pathogen and inflammation 
have been shown to be more likely to drive the effector T cell response rather than 
T memory cell generation (Obar et al., 2011). 
For Th1 cells it has been shown that the extent of transcription factor expression 
controls the amount of IFNγ production and that the Th cell stably commits to 
produce a certain amount of a set cytokine. The memory Th cell then retains the 
‘memory of that cytokine’ release in subsequent immune responses (Helmstetter 
et al., 2015). This also indicates that the immune system regulates the production 
of cytokines and hence prevents an excessive inflammatory response to a pathogen 
(Helmstetter et al., 2015). 
The specific memory subset that contributes to playing a role in protection against 
candidosis in the oral mucosal tissue has yet to be established. This chapter aims to 
study the recall response following C. albicans stimulation and elicited by Th1, Th17 
and Treg cells. These studies will indicate if a particular memory recall Th cell 
response is being driven. 
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4.1.4 PBMC and circulating T cells 
The use of PBMCs as an experimental model to study the immune response has 
been discussed in section 3.1.4.2. There are a variety of cell types present in PBMC 
populations including monocytes and lymphocytes. Lymphocytes can be further 
categorised into T cells, B cells and natural killer cells (NK). There are small numbers 
of circulating T cells present in the blood and the percentage of these will vary 
depending on the local immune system of the individual and occurrence of 
infection/disease. This can be seen in patients with head and neck cancer where an 
elevation in the numbers of Treg cells present occurs during active disease 
compared to healthy volunteer blood (Schaefer et al., 2005). It has also been 
shown that there is an increase in the number of Th17 cells in patients with sepsis 
compared to healthy volunteers (Colo Brunialti et al., 2012). The age and maturity 
of the immune system may play a role in the population of lymphocytes as evident 
in differences between adult and cord blood. Some of the differences include the 
percentage of lymphocytes expressing CD3 and CD8 markers being lower in cord 
blood than adult blood; the absolute numbers of CD4+ cells being higher in cord 
blood and the cord blood CD4+ T cells being deficient in function compared to adult 
CD4+ T cells (Cicuttini and Boyd, 1994). Such differences in volunteer blood 
potentially effecting the T cell population of PBMCs needs to be considered in an 
experimental model and for the purposes of this study, only healthy adult 
volunteer blood was used. 
 
4.1.5 Characteristic surface markers of Th1, Th17 and Treg cells  
The cell surface molecules on lymphocytes that are recognised by monoclonal 
antibodies are designated as clusters of differentiation (CD). The different CD 
numbers can be used in flow cytometry to identify T cell subsets which are shown 
in table 4.2. 
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Table 4.2: Cluster of differentiation markers used to identify T cell subset panel  
CD= cluster of differentiation  
  
Cluster of differentiation markers Cell population identified in peripheral 
blood 
  
CD3 T cells 
CD4 T helper cells (CD3+) 
CD8 Cytotoxic T cells (CD3+) 
CD25 Regulatory T cells (CD3+) 
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4.1.6 Flow cytometry in the identification of T helper cells 
Flow cytometry is a well-established method of detecting extracellular antibodies 
and intracellular cytokines. The approach can therefore identify Th cell responses 
following stimulation or pathogen challenge (Jung et al., 1993, Pala et al., 2000, 
Elson et al., 1995). The advantage of flow cytometry is that it can be used to assess 
multiple characteristics on a single cell. However, the disadvantage is that the 
methods may affect the cell surface phenotype and therefore careful 
interpretation of results is required (Pala et al., 2000). Phorbol myristate acetate 
(PMA) and ionomycin are used in flow cytometry and have been shown to trigger a 
strong production of cytokines in vitro and has been used to evaluate intracellular 
detection of cytokines from different T cell subpopulations (Picker et al., 1995). 
 
4.2 Aims 
This in vitro work aimed to confirm if the recall Th cell response stimulated by C. 
albicans correlated with the expression of cytokines established in chapter 3, and 
to see if these findings supported a Th1, Th17 or Treg response. Specific aspects of 
study to achieve these aims were as follows: 
 
1. To identify the Th cell recall response when human PBMC were stimulated with 
C. albicans. 
2. To identify the IL-17A expression in the supernatant of the PBMC stimulated by 
heat killed C. albicans (HKC) to confirm if this supported the Th 17 cell recall 
response. 
3. To identify whether any differences occurred in the recall Th cell response 
against two HKC strains (S1 and S12).  
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4.3 Materials and Methods 
4.3.1 Isolation of Peripheral Blood Mononuclear Cells (PBMCs)  
Collection and isolation of human PBMCs from healthy a volunteer was done 
following ethical approval by Cardiff University (DENTL 09/18) (Appendix III). 
Human PBMCs were isolated using density gradient centrifugation using Ficoll 
Paque (GE Life Science, Buckinghamshire, UK). Briefly, after informed consent, 
20ml of venous blood was taken from the volunteer (n= 3 different volunteers 
used) into a heparin containing vacutainer. The blood was diluted with an equal 
volume of phosphate-buffered saline PBS and then layered onto Ficoll before 
centrifugation 252 x g for 30 min. The layer of PBMCs was identified as the clear 
interface layer between the plasma phase and Ficoll phase. The layer of PBMCs was 
carefully removed and placed into serum free RPMI 1640 medium (Lonza 
BiowhittakerTM, Castleford, UK) and then washed three times. The cells were 
cultured (with or without HKC (S1 and S12) stimulation; (section 4.3.2) at 37oC in a 
5% CO2 enriched atmosphere in RPMI 1640 medium supplemented with 10% (v/v) 
foetal bovine serum (FBS), containing penicillin and streptomycin (10,000 U/ml) 
(Invitrogen, California, USA). The PMBCs were cultured at a density of 4 x 105 
cells/ml per well. Cultured cells were passaged at regular intervals (every 48 h) 
throughout experiments. 
 
4.3.2 Cell stimulation for cell surface and intracellular staining 
PBMCs were stimulated with different strains (S1 and S12) of heat killed Candida 
albicans (HKC) at a concentration of 1 x 105 or 1 x 106 cells/ml. Cells were either 
unstimulated or stimulated with 50 ng/ml of phorbol myristate acetate (PMA) 
(Sigma, Poole, UK) and 500 ng/ml of ionomycin (Sigma) for 4 h, prior to harvesting. 
In further experiments, PBMCs were additionally stimulated with clinical isolates of 
HKC at either 1 x 105 or 1 x 106  cells/ml. or PMA (Sigma) and Ionomycin (Sigma) 
only for 4 h before harvesting as the positive control. The cells were harvested at 
the following time points: t=4h, 72 h, 120 h, and 168 h. 
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4.3.3 Detection of cell-surface and intracellular cytokines. 
Monensin (3 mM; BD Biosciences, Oxford, UK) was added to all the PBMCs at 4 h 
prior to harvesting. The PBMCs were transferred to separate Eppendorf tubes and 
centrifuged at 500 x g for 5mins and the resulting cell pellet resuspended in 50 µl of 
Fluorescence-activated cell sorting (FACS) blocker (5% (v/v); rabbit serum, Sigma) 
for 20 min. An additional 50 µl of FACS buffer (PBS, 0.5% (v/v) bovine serum 
albumin, 7.5 mM sodium azide, 5 mM EDTA) was added and the cells were then 
aliquoted into two tubes. One aliquot was treated with 1 µl anti-CD3 (0.25µg/test) 
(eBioscience, Aachen, Germany) and 1 µl anti-CD4 (0.125µg/test) (eBioscience) 
antibodies detailed with the fluorescent marker in tables 4.3 and 4.4. The second 
aliquot was treated with 1 µl anti-CD4 (0.125µg/test) and 1 µl anti-CD25 
(0.125µg/test) (eBioscience) antibodies (Table 4.5). These PMBC preparations were 
incubated at 40C for 1 h with the antibodies and then washed three times with 
FACS buffer. PBMCs were then centrifuged and resuspended in 100 µl of 
Cytofix/CytopermTM (BD biosciences) and left on ice for 20 min, prior to washing 
the cells twice with Perm/Wash bufferTM (BD biosciences). 2µL of each of the 
intracellular antibodies including IFNγ (0.5mg/ml), IL-17A (0.25µg/test) and EBi3 
(0.03ug/test) (all from eBioscience) and their isotype controls were then added 
(detailed with fluorescent marker in Tables 4.3, 4.4 and 4.5). These antibodies were 
incubated at 40C for 1 h before washing three times with Perm/Wash bufferTM (BD 
biosciences) and then resuspended in Cellfix (BD biosciences) ready for 
fluorescence-activated cell sorting (FACS) analysis. 
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Table 4.3:  FACS antibodies used for cell surface and intracellular staining for Th1 
panel 
Antibody Colour/Channel Isotype 
control 
Working 
concentration 
Antibody 
source 
CD3 Per CP CY5.5 Mouse 
IgG2aK  
0.25µg/test eBioscience 
CD4 Eflour 450 Mouse 
IgG2aK 
0.125µg/test eBioscience 
IFNγ FITC Mouse IgG1K 0.5µg/test eBioscience 
CD= cluster of differentiation, IFN=interferon, Ig=immunoglobulin, FITC= 
Fluorescein isothiocyanate, CY= cyanine. 
 
Table 4.4:  FACS antibodies used for cell surface and intracellular staining for Th17 
panel 
Antibody Colour/Channel Isotype 
control 
Working 
concentration 
Antibody 
source 
CD3 Per CP CY5.5 Mouse 
IgG2aK  
0.25µg/test eBioscience 
CD4 Eflour 450 Mouse 
IgG2aK 
0.125µg/test eBioscience 
IL-17A PE Mouse IgG1K 0.25µg/test eBioscience 
CD= cluster of differentiation, IL=interleukin, Ig=immunoglobulin, PE= 
PE=phycoerythrin CY= cyanine,  
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Table 4.5:  FACS antibodies used for cell surface and intracellular staining for Treg 
panel 
Antibody Colour/Channel Isotype 
control 
Working 
concentration 
Antibody 
source 
CD3 Per CP CY5.5 Mouse 
IgG2aK  
0.25µg/test eBioscience 
CD25 Eflour 450 Mouse 
IgG2aK 
0.125µg/test eBioscience 
Ebi3p27 PE Mouse 
IgG2bK 
0.03µg/test eBioscience 
 
CD= cluster of differentiation, EBi3= Epstein Barr virus induced gene 3, Ig= 
immunoglobulin, PE=phycoerythrin, CY= cyanine  
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4.3.4 Flow cytometric analysis  
The samples were transferred into a FACS tube in 200µl of wash buffer. The 
samples were analysed using a FACS Canto II machine (BD Biosciences). Flow-
cytometric data was analysed using FlowJo® software (Version 10). The 
lymphocytes were gated based on the forward scatter and side scatter (FSC/SSC) 
and were determined within the CD4+ and CD3+ gate. The prevalence of Th17 cells 
was determined as a percentage of IL-17A+ cells amongst the CD3+/CD4+ population 
of T cells. The prevalence of Th1 cells was determined as the percentage of IFNγ+ 
cells in CD3+/CD4+ T cells. The Treg cells were identified by gating CD4+ and high 
CD25+ staining and the percentage of EBi3+ cells in this population. 
 
4.3.5 Enzyme-Linked Immunosorbent Assay (ELISA) detection of cytokines 
following stimulation by HKC or PMA  
PBMCs (4 x 105 cells/ml per well) were stimulated with S1 and S12 HKC at 
concentrations of either 1 x 105 or 1 x 106 cells/ml. Cells were left unstimulated as a 
negative control and some were stimulated with 50 ng/ml PMA (Sigma, UK) and 
500 ng/ml Ionomycin (Sigma, UK) for 4 h before harvesting as a positive control. 
The culture supernatant was harvested at the following time points: t=4 h, 72 h, 
120 h, and 168 h. 
 
4.3.5.1 ELISA for IL-17A cytokine 
An ELISA (eBioscience) was used to quantify IL-17A in the culture supernatant of 
the PBMCs. Wells of NUNC Maxisorp 96 well ELISA plates were incubated with 100 
μl/well of capture IL-17A (homodimer) (eBioscience) antibody (48µL of 250X 
purified anti-human IL-17A capture antibody diluted in 12 mL of 1X coating buffer) 
in 1X coating buffer (eBioscience) as described in the certificate of analysis supplied 
by the company. The plate was sealed with a clear, polyester sealing film (Starlabs, 
Hamburg, Germany) and incubated for 12h at 4oC. The wells were aspirated and 
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washed 5 times with wash buffer (>250 μl/well) allowing time for soaking (1 min) 
during each wash step to increase the effectiveness of absorption of the washes. 
The plate was blotted on an absorbent plate to remove any residual buffer. The 
wells were blocked with 200 μl/well of assay diluent (1) (eBioscience) and 
incubated at room temperature for 1 h. The wells were aspirated and washed as 
previously described. Assay diluent (1) was used to dilute the standards as noted 
on the certificate of analysis. The top standard of IL-17A used was 500pg/mL. 
Standard concentrations of antigen were added (100 μl) to the appropriate wells in 
a 2-fold dilution series. 
The cell culture supernatant (100 μl) was added undiluted to the appropriate wells. 
The plate was sealed and incubated overnight for maximal sensitivity. The wells 
were aspirated and washed (5) as previously described.  Detection antibody 
(biotin-conjugated anti-human IL-17A, eBioscience or biotin-conjugated anti-
human IFNγ, eBioscience) was diluted (48µL of 250X detection antibody was 
diluted in 12mL of 1X assay diluent) in 1 assay diluent and added to each well (100 
μl/well). The plate was sealed and incubated at room temperature for 1 h. The 
wells were aspirated and washed as previously described for 5 washes. Avidin-
horseradish peroxidase (Avididn-HRP 250X enzyme was diluted in 12mL of 1X assay 
diluent) (100 μl/well) in 1 assay diluent was then added to each well. The plate 
was incubated at room temperature for 30 min after which the wells were 
aspirated and washed (7), allowing the wash buffer to soak in the wells for 1 min 
prior to aspiration. Substrate solution (1x TMB solution, eBioscience) (100 μl/well) 
was added to each well and the plate incubated at room temperature for 15 min. 
Stop solution (1MH3PO4) (50 μl/well) was added to each well and the absorbance 
read at 450nm and measured with a FLUOstar spectrophotometer (BMG, FLUOstar 
optima). 
 
4.3.5.2 ELISA for IFNγ cytokine 
An ELISA (eBioscience) was used to quantify IFNγ in the culture supernatant of the 
PBMCs. Wells of NUNC Maxisorp 96 well ELISA plates were incubated with 50 
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μl/well of purified anti-human IFNγ (homodimer)(eBioscience) antibody (10µL of 
0.5mg/ml purified anti-human IFNγ capture antibody diluted in 5 mL of PBS). The 
plates were sealed, incubated and blocked as described in section 4.3.5.1. Assay 
diluent (1) was used to dilute the standards as noted on the certificate of analysis. 
The top standard of IFNγ used was 1000pg/mL. Standard concentrations of antigen 
were added (100 μl) to the appropriate wells in a 2-fold dilution series. The cell 
culture supernatant (100 μl) was added undiluted to the appropriate wells. The 
plate was sealed and incubated overnight for maximal sensitivity. The wells were 
aspirated and washed (5) as previously described. Detection antibody (biotin-
conjugated anti-human IFNγ, eBioscience) was diluted (48µL of 250X detection 
antibody was diluted in 12mL of 1X assay diluent) in 1 assay diluent and added to 
each well (100 μl/well). The plates were then sealed and incubated and the 
methods were continued for the ELISA as described in Section 4.3.5.1. Unless 
otherwise stated the experiments were done in triplicate. 
  
4.3.8 Statistical analysis 
The FACS experiments each revealed one data set from each sample of PBMCs so 
trends were analysed rather than statistical analysis due to the variation between 
individuals. Student’s paired t-test was used to compare un-stimulated and 
stimulated cells within each group of data for FACS and ELISA results. A p value of 
<0.05 was considered significant. Statistical analysis was performed using Microsoft 
Excel (Version-2010). 
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4.4 Results 
4.4.1 Detection of Th17 cell-surface and intracellular cytokines by FACs in PBMC 
culture. 
FACS analysis showed that the percentage of CD4+/IL-17A+ (Th17) cells in PBMC 
culture after stimulation with heat killed C. albicans (S1 and S12; 5 x 105 cells/ml 
and 5 x 106 cells/ml) and 4 h stimulation of PMA, ionomycin and monensin, 
generally increased over the 7 day period. This was particularly evident with S12 C. 
albicans stimulation in blood sample one (Figure 4.1 and Table 4.6). 
In blood sample one, the lowest percentage of Th17 cells occurred at day 0 (0.47%) 
with C. albicans S12 (1 x 106 cells/ml) stimulation, and this was lower than evident 
with unstimulated PBMCs (0.63%) (Table 4.6). The highest percentage of Th17 cells 
over the 7-day period was at day 7 with C. albicans S12 (1 x 106 cells/ml) 
stimulation (10.8%). In the case of C. albicans S1 stimulation, the level of Th17 cells 
detected was 0.98% at the higher C. albicans concentration (1x106 cells/ml) at 7 
days. The increase in the percentage of Th17 cells from day 0 to 3 (p<0.007) and 
from day 0 to 5 (p<0.037) was statistically significant (p<0.05) when comparing 
both strains to the unstimulated cells. No significant difference was evident from 
day 0 to day 7 (p<0.106).  
In blood sample two there was a significant (p<0.021) increase in the percentage of 
Th17 cells from day 0 to 3, but not for other time periods (P<0.075) (Figure 4.2 and 
Table 4.6). The highest percentage of Th17 cells over the 7-day period was with C. 
albicans S12 (1 x 106 cells/ml) stimulation (23.2%) at day 7, which was the same as 
with blood sample one. The trend for a more rapid increase in the percentage of 
Th17 cells detected in blood sample two was evident. There was a low level of 
positive cells detected at day 0 after 4 h stimulation with the higher concentration 
of C. albicans stimulation (3.42% C. albicans S1, 1 x 106 cells/ml; 5.5% C. albicans 
S12, 1 x 106 cells/ml). This compared to the first blood sample PBMCs, where the 
same or lower percentage of Th17 cells was detected compared with unstimulated 
cells. The percentage of Th17 cells stimulated by S12 1 x 106 cells/ml was over 
double that of S1 at the same concentration of C. albicans at day 7 (Table 4.6). This 
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increased percentage with S12 at day 7 compared to S1 was seen in both 
experiments. 
A representative FACS plot for TH17+ cell gating is shown in Figure 4.3. 
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Figure 4.1: Percentage of CD4+/IL-17A+ (Th17) cells in PBMC culture after 
stimulation with C. albicans S1 or S12 (blood sample 1). Heat killed Candida 
albicans (S1 or S12) were used at two different concentrations (1x 105 cells/ml and 
1 x 106 cells/ml) with 4 h stimulation of PMA, ionomycin and monensin. Samples 
were analysed by FACS at different time points (day 0, 3, 5 and 7). U/S = 
unstimulated PBMCs; HkCa= Heat killed Candida albicans; S1 and S12 =strain 1 and 
12; PMA=Phorbol Myristate Acetate. (n=1) 
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Figure 4.2: Percentage of CD4+/IL-17A+ (Th17) cells in PBMC culture after 
stimulation with C. albicans (S1 or S12) (blood sample 2). Heat killed C. albicans (S1 
or S12) were used at two different concentrations (1x 105 cells/ml and 1 x 106 
cells/ml) with 4 h stimulation of PMA, ionomycin and monensin. Samples were 
analysed by FACS at different time points (day 0, 3, 5 and 7). U/S= unstimulated 
PBMCs; HkCa= Heat killed Candida albicans; S1 and S12 =strain 1 and 12; 
PMA=Phorbol Myristate Acetate.  
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Table 4.6: Percentage of Th17 cells in PBMC culture as determined by FACS  
 
Stimulation 
(cells/ml) 
 
IL-17A+/CD4+ cells (%) 
Blood sample 1 
 
IL-17A+/CD4+ cells (%) 
Blood sample 2 
Day 0   
HKC S1, 1 x105  0.63 0.45 
HKC S1, 1 x106  0.63 3.42 
HKC S12, 1 x105  0.53 0.97 
HKC S12, 1x106  0.47 5.50 
U/S 0.63 0.40 
Day 3   
HKC S1, 1 x105  1.41 2.35 
HKC S1, 1 x106  1.22 16.90 
HKC S12, 1 x105  1.85 9.75 
HKC S12, 1x106  1.85 13.80 
U/S 0.36 3.29 
Day 5   
HKC S1, 1 x105  3.32 3.61 
HKC S1, 1 x106  1.78 8.57 
HKC S12, 1 x105  2.75 11.60 
HKC S12, 1x106  6.95 4.76 
U/S 0.23 0.21 
Day 7   
HKC S1, 1 x105  2.18 0.76 
HKC S1, 1 x106  0.98 9.56 
HKC S12, 1 x105  2.66 5.51 
HKC S12, 1x106  10.8 23.20 
U/S 0.16 0.47 
U/S =unstimulated; HKC =heat killed C. albicans; S1 and S12 =strain 1 and 12; IL 
=interleukin, CD =cluster of differentiation.  
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Figure 4.3: Representative sample analysis of the gating strategy for Th1 and Th17 
cells in PBMCs. Lymphocytes were identified by typical forward scatter (FSC) and 
side scatter (SSC) (R1) (A). Th17 positive cells were identified by gating positive 
CD4+ and IL-17A+ cells (Q2) (B). Th1 positive cells were identified by gating positive 
CD4+ and IFNγ+ cells (Q10) (C). 
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4.4.2 Detection of Th1 cell-surface and intracellular cytokines by FACs in PBMC 
culture. 
Following FACS analysis, the percentage of CD4+/IFNγ+ (Th1) cells in PBMC culture 
after stimulation with C. albicans S1 and S12 (1x 105 cells/ml and 1 x 106 cells/ml) 
and 4 h stimulation of PMA and ionomycin, was higher at all time points compared 
with day 0 in blood sample 1 (Figure 4.4 and Table 4.7). In this first blood sample, at 
days 3, 5 and 7 the percentage of Th1 cells detected was constant for both C. 
albicans S1 and S12, and at both HKC concentrations. The lowest percentage of Th1 
cells was at day 7 in the unstimulated PBMCs (0%). At day 0, unstimulated PBMCs 
produced a background level of 3.13% Th1 cells. The highest level of Th1 cells 
(18.7%) was at day 3 following stimulation with C. albicans S1. When comparing C. 
albicans stimulated or unstimulated PBMCs, there was a significant increase in the 
percentage of Th1 cells from day 0 to 3 (p<0.0008), from day 0 to 5 (p<0.0031) and 
from day 0 to day 7 (p<0.0186) over the 7 day period.  
In blood sample two, the overall trend in detection of Th1 cells was noticeably 
different to blood sample 1 (Figure 4.5 and Table 4.7). The highest detection of Th1 
cells (54.9%) was at day 5 with C. albicans S1 (1x106 cells/ml). There was no 
significant difference in percentage of Th1 cells from day 0 to day 3, 5 or 7. There 
was a higher background expression of Th1 cells at day 0 in this PBMC experiment 
compared to the first, with 15.7% Th1 cells detected following stimulation with C. 
albicans S1 (1x106 cells/ml). A representative FACS plot for Th1+ gating is shown in 
figure 4.3. 
 
4.4.3 Detection of Treg cell-surface and intracellular cytokines by FACs in PBMC 
culture. 
CD4+ /CD25+ /EBi3+ (Treg) cells were not detected by FACs following stimulation by 
C. albicans S1 or S12 at either C. albicans concentration, or for the unstimulated 
negative control. This may have been caused by a difficulty in intracellular staining. 
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Figure 4.4: Percentage of CD4+/IFNγ+ (Th1) cells in PBMC culture after stimulation 
with C. albicans S1 or S12; (blood sample 1). Heat killed C. albicans (S1 or S12) were 
used at two concentrations (1 x 105 cells/ml and 1 x 106 cells/ml) and 4 h 
stimulation with PMA and Ionomycin. Samples were analysed by FACS at day 0, 3, 5 
and 7. U/S= unstimulated PBMCs; HkCa= Heat killed Candida albicans; S1 and S12 
=strain 1 and 12; PMA=Phorbol Myristate Acetate. (n=1)  
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Figure 4.5: Percentage of CD4+/IFNγ+ (Th1) cells in PBMC culture after stimulation 
with C. albicans S1 or S12 (blood sample 2). Heat killed C. albicans (S1 or S12) were 
used at two different concentrations (1x 105 cells/ml and 1 x 106 cells/ml) with 4 h 
stimulation of PMA and Ionomycin. Samples were analysed by FACS at day 0, 3, 5 
and 7. U/S= unstimulated PBMCs; HkCa= Heat killed Candida albicans; S1 and S12 
=strain 1 and 12; PMA=Phorbol Myristate Acetate. (n=1). 
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Table 4.7: Percentage of Th1 cells in PBMC culture as determined by FACS analysis 
Stimulation 
(cells/ml) 
IFNγ+/CD4+ cells (%) 
Blood sample 1 
IFNγ+/CD4+ cells (%) 
Blood sample 2 
   
Day 0   
HKC S1, 1 x105 3.64 4.29 
HKC S1, 1 x106 0.64 15.70 
HKC S12, 1 x105 0.31 4.58 
HKC S12, 1x106 0.31 0.90 
U/S 3.13 1.00 
Day 3   
HKC S1, 1x105 18.7 0.24 
HKC S1, 1x106 11.3 2.69 
HKC S12, 1x105 10.8 1.71 
HKC S12, 1x106 11.3 2.06 
U/S 0.43 0.17 
Day 5   
HKC S1, 1x105 9.47 7.42 
HKC S1, 1x106 8.83 54.9 
HKC S12, 1x105 10.2 6.93 
HKC S12, 1x106 12.3 1.78 
U/S 0.11 0.15 
Day 7   
HKC S1, 1x105 8.4 1.69 
HKC S1, 1x106 9.52 1.36 
HKC S12, x105 7.36 2.08 
HKC S12, 1x106 17.1 2.99 
U/S 0.029 15.01 
U/S =unstimulated, HKC =heat killed C. albicans, S1 and S12 =strain 1 and 12; IL 
=interleukin, CD =cluster of differentiation.  
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4.4.4 IL-17A cytokine production by PBMCs after stimulation  
IL-17A cytokine production as determined by ELISA was measured in the 
supernatant of PBMCs stimulated by C. albicans S1 or S12 (1x 105 cells/ml or 1 x 106 
cells/ml). In blood sample one the concentration of IL-17A increased significantly 
from day 0 to day 7 (p<0.0045) following stimulation by both C. albicans strains and 
concentrations. The overall trend of increasing production of IL-17A over time was 
similar to the previously reported percentage of Th17 cells detected (see earlier 
results in section 4.4.1).  
The highest production of IL-17A was 18.81 pg/ml (SD+/- 4.56) from PBMCs 
stimulated with C. albicans S12 (1x106 cells/ml) at day 7 (Figure 4.5 and Table 4.8). 
No IL-17A was evident at day 0 for all conditions. There was no significant increase 
in IL-17A production in blood sample one from day 0 to day 3 (p<0.055), but there 
was a significant increase from day 0 to day 5 (p<0.0078) and from day 5 to day 7 
(p<0.029).  
In blood sample two, a significant increase in production of IL-17A from PBMCs 
from day 0 to day 7 (p<0.016) occurred, which was not evident at day 3 (p<0.40) or 
day 5 (p<0.19). There was a low production of IL-17A at day 0, 3 and 5, with higher 
levels evident at day 7 (Figure 4.6 and Table 4.8). Highest production (133.45 pg/ml) 
of IL-17A occurred with C. albicans S12 (1x106 cell/ml) which was 7-fold higher that 
encountered with the PBMCs in blood sample two.  
Comparing stimulation with both C. albicans strains, C. albicans S12 (1 x 106 
cells/ml) at day 7 led to the highest production of IL-17A in both experiments 
(18.81 and 133.45pg/ml respectively). This higher production of IL-17A detected 
from PBMC stimulated with S12 is similar to the higher percentage of Th17 cells 
detected after S12 stimulation of PBMCs in the earlier FACS experiments (Section 
4.4.1). 
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4.4.5 IFNγ production from PBMCs after stimulation as detected by ELISA  
IFNγ production was measured by ELISA in the supernatant of PBMCs stimulated 
with C. albicans S1 and S12 (1x 105 cells/ml and 1 x 106 cells/ml) and compared to 
PMA (positive control) and unstimulated PBMC expression. Production of IFNγ was 
highest after PMA stimulation at day 7 (1.67 OD) (Figure 4.8). There was a slight 
increase in IFNγ production at day 7 following stimulation with the higher 
concentrations (1x106 cells/ml) of C. albicans S1 and S12, however there was no 
significant difference between these levels and unstimulated PBMCs at day 7.  
  
225 
 
 
 
Figure 4.6: IL-17A production from peripheral blood mononuclear cells after 
stimulation with C. albicans S1 or S12 (blood sample 1). PBMCs were stimulated 
with heat killed C. albicans (S1 or S12) at two different concentrations (1 x 105 
cells/ml and 1 x 106 cells/ml). Supernatant was collected at different time points 
(day 0, 3, 5 and 7) and the concentration of IL-17A measured by ELISA. U/S= 
unstimulated PBMCs; HkCa= Heat killed Candida albicans; S1 and S12 =strain 1 and 
12; PMA=Phorbol Myristate Acetate. 
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Figure 4.7: IL-17A production from peripheral blood mononuclear cells after 
stimulation with C. albicans S1 or S12 (blood sample 2). PBMCs were stimulated 
with two different strains of heat killed C. albicans (S1 or S12) and at two different 
concentrations (1 x 105 cells/ml and 1 x 106 cells/ml). The supernatant was 
collected at different time points (day 0, 3, 5 and 7) and the concentration of IL-17A 
measured by ELISA. U/S= unstimulated PBMCs; HkCa= Heat killed Candida albicans; 
S1 and S12 =strain 1 and 12; PMA=Phorbol Myristate Acetate. 
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Table 4.8: Production of IL-17A by PBMCs after stimulation with HKC as determined 
by ELISA 
Stimulation  
(cells/ml) 
Mean IL-17A 
production 
(pg/ml) 
(Blood 
sample1) 
Standard 
deviation 
(pg/ml) 
(Blood 
sample1) 
Mean IL-17A 
production 
(pg/ml) 
(Blood 
sample2) 
Standard 
deviation 
(pg/ml) 
(Blood 
sample2) 
Day 0     
PMA 1.12 0.51 4.52 2.96 
HKC S1, 1 x105 0 0 1.69 0 
HKC S1, 1 x106 0 0 1.03 0.59 
HKC S12, 1x105 0 0 0 0 
HKC S12, 1x106 0 0 0 0 
U/S 0 0 10.17 0 
     
Day 3     
PMA 0 0 1.40 1.48 
HKC S1, 1x105 2.10 0.52 0 0 
HKC S1, 1x106 6.88 4.60 2.58 2.16 
HKC S12, 1x105 0.59 0 0.90 0 
HKC S12, 1x106 2.56 0.94 0 0 
U/S 0 0 0 0 
 
  
  
Day 5 
  
  
PMA 0 0 0 0 
HKC S1, 1x105 2.59 0.58 0 0 
HKC S1, 1x106 6.68 1.52 3.28 1.63 
HKC S12, 1x105 6.51 3.24 0 0 
HKC S12, 1x106 4.01 1.08 7.99 8.28 
U/S 0 0 0 0 
 
  
  
Day 7 
  
  
PMA 0 0 1.69 0 
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HKC S1, 1x105 10.37 0.71 65.02 14.83 
HKC S1, 1x106 10.26 3.29 64.92 19.06 
HKC S12, 1x105 10.90 0.84 42.38 5.037 
HKC S12, 1x106 18.81 4.56 133.46 39.69 
U/S 0 0 0 0 
U/S =unstimulated, HKC= heat killed C. albicans, S1 and S12 =strain 1 and 12, 
PMA=Phorbol myristate acetate; IL =interleukin. 
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Figure 4.8: IFNγ production from peripheral blood mononuclear cells after stimulation with 
C. albicans S1 or S12 (blood sample 2). PBMCs were stimulated with two different strains of 
heat killed C. albicans (S1 or S12) and at two different concentrations (1x 105 cells/ml and 1 
x 106 cells/ml). The supernatant was collected at different time points (day 0, 3, 5 and 7) 
and the concentration of IFNγ measured by ELISA. U/S= unstimulated PBMCs; HkCa= Heat 
killed Candida albicans; S1 and S12 =strain 1 and 12; PMA=Phorbol Myristate Acetate. 
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4.5 Discussion 
The adaptive immune response of the host to C. albicans is important in 
determining whether clearance or colonisation of the microorganism occurs 
(Richardson and Moyes, 2015). In the research presented in this Chapter, the type 
of Th-cell recall response to C. albicans generated by PBMCs was assessed together 
with determination of whether C. albicans resulted in an early recall/memory Th 
cell response when PBMCs were stimulated with two different strains of C. 
albicans. It was hypothesised that a recall/memory response may be generated, 
particularly from memory Th17 cells, since these cells have previously been 
documented as being pivotal in mucosal candidal infections (Hernandez-Santos et 
al., 2013). Treg cells are thought to have a protective role in oral candidosis 
(Pandiyan et al., 2011) and can promote a Th17 inflammatory response in 
disseminated candidosis (Whibley and Gaffen, 2014). 
In determining the Th17 memory response from PBMCs when stimulated with C. 
albicans, it was found that for both blood samples the Th17 cell response was 
higher at day 7 than day 0 for S12 C. albicans. There was, however, a significantly 
increased positive cell response for both strains of C. albicans from day 0 to day 3, 
which may imply the initiation of the memory Th17 response. This fits with 
previous findings where it has been shown that C. albicans induced a Th17 
response after 6 days culture (Tóth et al., 2013). This finding would also support the 
work in Chapter 3, where IL-23 expression was detected from PBMCs in response 
to C. albicans stimulation indicating that C. albicans drives a Th17 response, as IL-
23 is important in the differentiation of Th17 cells (Conti et al., 2009). There was no 
increased percentage of Th17 cells evident after 4 h stimulation with C. albicans 
compared to the unstimulated cells. As this early memory response can occur in 1-
2 h (Bevington et al., 2017) it indicates that no early memory response to the two 
strains of C. albicans was generated by the PBMCs from blood sample one. This 
could indicate that this individual had not previously or recently encountered a 
Candida infection or more likely that the memory response in this cell culture 
model required a longer time period than 4 h. An adaptive immune response can 
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be supported by the memory Th cells by re-expanding the effector Th-cell 
population after re-infection (Bevington et al., 2017), although this is highly unlikely 
to have played a role in the detection of the increase in Th17 numbers by day 7 in 
this individual in this cell culture model. For an effector Th17 cell response to be 
generated, there is a requirement for involvement of antigen presenting cells 
(APCs) and cytokines, such as GMCSF and TGFβ to drive activation and 
differentiation of naive CD4+ Th-cells into the Th17 cell subset (Richardson and 
Moyes, 2015). Therefore, the effector Th cell response would not be expected to 
be evident in this cell culture model of PBMC as APCs such as dendritic cells (DCs) 
and the required cytokines were not included as part of this experimental model. 
The percentage of Th17 cells detected by FACS in the pool of PBMCs from blood 
sample two increased more rapidly compared to blood sample one. There was a 
low level of positive cells detected at day 0 after 4 h stimulation with the higher 
concentration of C. albicans S1 and S12 compared to blood sample one, where a 
similar percentage of Th17 cells were detected for stimulated and unstimulated 
situations. This could indicate that this second volunteer’s PBMCs had Th17 
memory cells able to recognise C. albicans, which were already present in the 
peripheral blood circulation, hence being detected in the first 4 h of stimulation. 
Helmstetter et al found that memory T cells retained their individual cytokine 
memory for a Th lineage in subsequent immune responses (Helmstetter et al., 
2015). Pathogen specific memory T cells can also improve immune efficiency, 
which may improve the immune response to subsequent infections (Mueller et al., 
2013).  
The difference in the rate of Th17 expansion may be explained by the immune 
system’s prior exposure to C. albicans. It may have been that the individual 
donating the second blood sample had recently been exposed to a Candida 
resulting in a more rapid Th17 recall response.  
To date, there are limited studies on the memory response to C. albicans and the 
finding that the blood from the two volunteers studied here has responded with 
different recall Th17 responses to two different strains of C. albicans is a novel one. 
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This result needs to be confirmed in further studies using greater numbers of 
volunteers and C. albicans strains. 
In future work, it would be interesting to also include initial time points at 2, 4 and 
6 h to determine the immediate memory T cell response in more detail, as well as 
the later time points at days 3, 5 and 7, which may detect the memory Th cell 
expansion. This may have more accurately detected differences in Th cell 
expansion, rather than only assessing at 4 h post stimulation. Such an approach 
would also avoid the limitations of flow cytometry, which is a ‘snapshot’ of the 
immune response and will fail to identify any rapid switching of Th cells 
(Helmstetter et al., 2015). A limiting factor to increasing the number of time points 
is the number of cells in a volume of blood that can be taken from a single 
volunteer. 
Measuring IL-17A expression in the supernatant of the PBMCs stimulated with C. 
albicans showed a similar increasing trend over the studied time period in 
expression of the cytokine as measured by ELISA from both blood samples. As 
previously discussed (Section 4.1.2 and Table 4.1), IL-17A is expressed by Th17 cells 
and has a role in recruiting neutrophils to promote phagocytosis of C. albicans, 
resulting in clearance of infection and host protection (Schonherr et al., 2017). 
Interestingly, there was no IL-17A detected in the supernatant at day 0 of the 
PBMCs from blood sample one. This finding may indicate the absence of any 
circulating Th17 cells in this population of PBMC, or if present, they were in such 
small numbers that the IL-17A expression was not detectable at this early stage. 
This corresponds with the FACS result where a low percentage of Th17 cells were 
detected suggesting a limited recall Th17 response at day 0. The significant increase 
in expression of IL-17A at day 7 indicates the increased amount of cytokine 
expressed into the cell culture by the memory Th17 cells. Blood sample 2 PBMCs 
showed a low level of IL-17A at day 0 which could have been expressed from the 
memory Th17 cells that were detected at 4 h, however the level was below that of 
the unstimulated cells so no conclusions can be reliably be drawn. 
There was a significant increase in IL-17A expression from day 0 to day 7 by the 
PBMCs of blood sample 1 and 2, indicating the increasing number of memory Th17 
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cells expressing IL-17A, which is essential in defence against C. albicans (Schonherr 
et al., 2017). The expression of IL-17A was 7-fold higher from the stimulated PBMCs 
of blood sample 2, which may be explained by the higher percentage of Th17 cells 
(determined by FACS) in this sample. This may indicate a recent exposure to the 
pathogen by the donor of this blood.  
IL-17A can be expressed by cells other than Th17 cells (Cua and Tato, 2010) and this 
needs to be considered when interpreting the results of this study. IL-17A can be 
produced by γδT-cells, natural killer T-cells and innate lymphoid cells and can 
eliminate fungi by inducing antimicrobial peptides such as defensins (Kuwabara et 
al., 2017).  
In blood sample 1, the Th1 expression was more constant after day 3 for both heat 
killed C. albicans S1 and C. albicans S12. There were a significantly higher 
percentage of memory Th1 cells at days 3, 5 and 7, compared with unstimulated 
PBMCs at day 0. The overall average percentage of memory Th1 cells was higher 
than Th17 cells.  
In the case of blood sample 2, there was no significant difference in the Th1 
response from day 0 onwards for stimulated and unstimulated PBMCs. The large 
increase in percentage of Th1 cells at day 5 following stimulation with C. albicans 
S1 may have been an erroneous finding, possibly arising from an antibody staining 
error, as it is difficult to explain such a large percentage increase at only one time 
point.  
PBMCs have been used in this study, which may be more representative of a 
systemic infection response rather than a mucosal tissue response. An increased 
percentage of Th1 cells detected by FACS in this study may suggest that the recall 
Th1 cell response plays a protective role in systemic candidosis (Kashem et al., 
2015).  
In contrast to the previous recall Th17 response detected, the Th1 response 
detected was not strain specific. At day 0, the percentage of Th1 cells was not 
higher than detected for unstimulated conditions, thereby indicating a Th1 memory 
cell response to C. albicans was not present in blood sample 1 at day 0. The lack of 
a Th17 recall response generated by the PBMCs correlates with this finding. The 
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experiment may again have been improved by increasing the number of early time 
points to detect memory responses generated after a few hours. Switching 
between Th cells or plasticity can occur (Murphy and Stockinger, 2010), which may 
not have been detected with one early time point. 
A Th1 response is considered important in the control of systemic candidosis, but 
Th17 cells are thought to be more important during cutaneous candidosis (Kashem 
et al., 2015). Both of the studied C. albicans strains (S1 (DW1/93) and S12 (PTR/94)) 
originated from the oral cavity (Malic et al., 2007), but systemic infection may 
originate from an endogenous C.albicans strain that has resided on the oral 
mucosal surface and therefore potentially inducing a Th1 pro-inflammatory 
response.  
Each C. albicans clade contains strains that have evolved differently (MacCallum et 
al., 2009). Clade 1 consists mainly of strains that are resistant to flucytosine by the 
mechanism of an amino acid change (Tavanti et al., 2005). No demonstrable 
difference in virulence between the different clades has, however, been shown in 
murine models (MacCallum et al., 2009). It is still not clear what the role of 
virulence of the C. albicans strain or clade has versus the host role in resistance to 
the fungi by mounting an immune response. There is a difference between some C. 
albicans strains and their ability to resist intracellular killing, replicate, and escape 
from macrophages (Tavanti et al., 2006). This would be expected to influence the 
immune response mounted by the host and the recall response, if that particular C. 
albicans strain was reencountered. 
Different individuals may respond differently to different clades and strains of C. 
albicans. The two strains used in this experiment were S1 (DW1/93), a commensal 
strain, clade 8 (Table 3.5) and S12 (PTR/94) which was a pathogenic strain (CHC) 
(Malic et al., 2007) belonging to clade 1. Strain S12 showed an overall trend of 
causing an increased number of CD4+/IL-17+ cells at day 7 compared to day 0. It is 
tempting to speculate that this finding reflects the pathogenic background of the 
S12 strain being able to induce a higher Th17 immune response from PBMCs 
compared to the commensal S1 strain. The limitations of this experiment were that 
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only trends could be observed and larger numbers of C. albicans strains and clades 
would need to be analysed to substantiate the result. 
Treg surface and intracellular markers were used to characterise the Th cell subset 
in the PBMC culture, however, no positive staining was evident. Whilst this finding 
implies there were no Treg cells in the PBMC population, it is more likely that the 
antibodies were not effective. It may have also been that the antibodies were not 
able to target the cytokine in the nucleus through poor permeabilisation. Future 
study using different antibodies and volunteers is therefore warranted.  
What has not been determined by this research is the specific type of memory 
response arising from C. albicans stimulation of PBMCs. There have been several 
different types of memory cells reported; central memory T cell (TCM), effector 
memory T-cells (TEM) and tissue-resident memory cells (TRM), which can reside in 
peripheral tissue after an infection (Mueller et al., 2013). It would be predicted that 
the TRM cells would reside in the oral mucosal tissue at a potential site of 
reinfection and would be ready to co-ordinate an immune response at an early 
stage in oral candidosis (Chang et al., 2014). This current study has, however, not 
looked at a tissue model of oral candidosis infection and the type of memory T cell, 
and this would be an area for future work. 
As previously highlighted, the approach used in these studies only provides a 
measure of cytokines at a single time point and therefore could miss any rapid 
switching between cytokine producing and non-producing states (Helmstetter et 
al., 2015). A different methodology may be conducive to the study of shorter time 
intervals to account for any rapid switching between Th states and cytokine 
produced. Such an approach may have given a more accurate memory recall 
response as this is generally acknowledged as being a rapid response within 1-2 h 
(Bevington et al., 2016).  
Different individuals were used to collect PBMCs following ethical approval 
received for this project. As such resulting variation could arise between the blood 
of these individuals based on different immunological memory to the C. albicans 
stimulus and the way in which their immune system responded to the pathogen. To 
limit variation between samples a larger number of blood samples from healthy 
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volunteers may have enabled an average result that was potentially more in line 
with a population response and wider conclusions could be drawn. It would also 
have been interesting to compare the recall response by experienced adult T-cells 
and naïve T-cells from an infant; however this was not undertaken given time and 
ethical considerations. 
Further consideration needs to be given to the method of initially gating CD3+ cells 
for the lymphocyte population. Using this technique, natural killer T-cells are not 
excluded from the cell population and these cells may have contributed to the IL-17 
producing cell population, in addition to Th17 cells (Colo Brunialti et al., 2012). 
The use of flow cytometry has been widely used for the characterisation of Th 
subsets, but in vitro stimulation of PBMCs may lead to cell division or death that 
can differ between healthy volunteers and with the individual’s immune system. A 
viability marker could be used in future studies to address this issue, and would 
exclude dead or early stage apoptosis cells in the flow cytometry analysis (Colo 
Brunialti et al., 2012).  
This study has demonstrated a varied immune response by the PBMCs from 
different individuals in terms of the memory Th-cell response by day 7 for both the 
Th1 and Th17 cells detected. Such findings may explain why certain individuals are 
more susceptible to superficial and systemic candidal infections. This chapter has 
identified areas that warrant further research. The work also may have implications 
for future treatment of systemic candidosis and how individuals may respond to 
treatment through enhancement of the body’s own immune host response. 
Overall this study indicated a memory Th17 response was detected in PBMCs after 
C.albicans stimulation which was supported by the detection of IL-17A at day 7 in 
the supernatant by ELISA. This finding supports both the results from the DS 
patients (Chapter2) where Th17 cytokines were detected in the palatal secretions 
and the result from the stimulation of human monocytes with C.albicans and LPS  
and the detection of IL-23 (Chapter 3). These combined results so far further 
support a Th17 response to C.albicans. These findings will be further investigated in 
the subsequent chapter by identifying the immune cells in biopsy samples of 
chronic hyperplastic candidosis (Chapter 5).  
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4. 6 Conclusions 
This in vitro work investigated whether the recall Th cell response stimulated by C. 
albicans correlated with expression of cytokine profiles established in chapter 3, 
and to see if these findings supported a Th1, Th17 or Treg recall response.  
 
1. Overall there was a significant Th17 recall response by the cells stimulated with 
C. albicans in both PBMCs from blood sample one and two between day 0 and 3. In 
blood samples one and two as detected by FACS, the highest percentage of Th17 
cells was at day 7 following stimulation with C. albicans S12.  
There was a significant Th1 recall response from day 0 to days 3, 5 and 7 by PBMCs 
from blood sample one when stimulated by C. albicans compared to the 
unstimulated cells. However this finding was not evident using PBMCs from blood 
sample two. 
Treg cells were not detected and no conclusions could be drawn.  
 
2. IL-17A expression in the supernatant of the PBMC stimulated by HKC showed a 
significant increase in blood samples one and two as detected by ELISA at day 7 
compared to the unstimulated cells. 
IFNγ showed no significant increased expression in the supernatant of PBMCs 
stimulated by C. albicans. 
 
3. Differences occurred between the two HKC strains (S1 and S12) particularly at 
day 7 for the percentage of Th17 detected and expression of IL-17A at the higher 
concentration of S12.  
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Chapter 5: 
Candida albicans colonisation and 
inflammatory response in chronic 
hyperplastic candidosis   
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5.1 Introduction  
Candida albicans is a fungal microorganism and a frequent coloniser of mucosal 
surfaces in humans, where it can exist as a commensal or pathogen (Feller et al., 
2014). The microorganism is most often associated with superficial infections in 
debilitated individuals but can cause systemic disease in severely 
immunocompromised individuals which has high morbidity and mortality (Brown et 
al., 2012).  
Our understanding of the mechanism(s) by which the host recognises and responds 
to C. albicans is still incomplete, particularly with regards to the immune response 
in the oral mucosa.  
There are four main clinical presentations of oral candidosis, and chronic 
hyperplastic candidosis (CHC) (Section 1.1.3.9) is one that is of particular interest as 
it has been associated with an increased risk of dysplasia (Section 5.1.1) (Sitheeque 
and Samaranayake, 2003). In the oral cavity, tissue biopsy samples for diagnostic 
purposes of CHC are taken as part of routine clinical care.  
 
5.1.1 Chronic hyperplastic candidosis 
CHC has been used as a descriptor of candidal infections associated with 
leukoplakia in the mouth since the 1960s (Sitheeque and Samaranayake, 2003). 
CHC can be categorised, based on clinical appearance, as either plaque-like or 
nodular (Samaranayake and MacFarlane, 1990). The characteristic appearance of 
CHC is typically seen as the occurrence of white plaque lesions, which in contrast 
with other primary oral candidosis lesions, cannot be removed by gentle scraping 
(Figure 5.1).  
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A 
 
 
Figure 5.1: Clinical presentation of chronic hyperplastic candidosis at the right 
buccal commissure. Figure A shows the typical appearance and site of CHC.   
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CHC lesions are most frequently encountered at the commissure regions of the oral 
cavity, although they can also be located on the buccal mucosa, palate, lateral 
border of tongue or dorsal surface of the tongue (Williamson, 1969, López et al., 
2012).  
A detailed review of the predisposing host factors associated with oral candidosis is 
provided in section 1.1.3.12 of this Thesis. There are several host factors that 
specifically relate to CHC, including smoking, age and gender (CHC is more 
prevalent in middle aged men) and a high level of alcohol consumption (Arruda et 
al., 2016). Smoking has been frequently linked to CHC and in one study it was found 
that all CHC patients (n=53) were smokers (Arendorf et al., 1983). Smoking may 
favour candidal colonisation by inducing increased epithelial keratinisation 
(Mosadomi et al., 1978) or reducing levels of salivary immunoglobulin A levels 
(Bennet and Reade, 1982, Sitheeque and Samaranayake, 2003). A possible 
depression of polymorphonuclear leukocyte (PMNs) function has also been 
described in smokers compared to non-smokers in particular the ability of PMNs to 
phagocytose (Güntsch et al., 2006, Kenney et al., 1977). 
The histopathological features of CHC include hyperplasia and hyperparakeratosis 
of the surface epithelium and in contrast to other superficial forms of oral 
candidosis, CHC involves hyphal invasion into the epithelial surface with associated 
neutrophil polymorphs (Cawson, 1973). 
Diagnosis of CHC requires microscopic examination of formalin-fixed lesional tissue 
and examination of the tissue for features of dysplasia. CHC has arguably a higher 
potential for malignant change to squamous cell carcinoma (SCC) (López et al., 
2012). Candidal infection as a risk factor in terms of malignant transformation may 
be through the ability of certain candidal strains to form nitrosamines which are 
known carcinogens, from salivary precursors, (Sanjaya et al., 2011). CHC lesions 
therefore need to be closely monitored by a clinician, as up to 15% may undergo 
dysplastic change (Samaranayake and MacFarlane, 1990). A study in 2012, assessed 
the presence of markers associated with malignancy (including p53, p21 cyclin-
dependent kinase inhibitor 1A and proliferating cell nuclear antigen) in CHC 
patients using immunohistochemistry, and found an increase in p53 compared to 
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control samples which could explain the higher potential for malignant change in 
CHC (Darling et al., 2012). Most of these markers however can be upregulated in 
reactive conditions such as ulceration and p53 can be increased in any proliferating 
cell.  
 
5.1.2 Immune response in chronic hyperplastic candidosis 
The host-Candida interaction and details of the immune response have been 
discussed in section 1.2. Briefly, pathogen associated molecular patterns (PAMPs) 
on C. albicans are recognised by pattern recognition receptors (PRRs) on immune 
surveillance cells such as dendritic cells. The recognition receptor, phagocytic cell, 
site and type of candidosis will all play a role in how the host responds to the 
infection (Krysan et al., 2014). 
Candida albicans is recognised by PRRs such as TLRs, of which TLR2, TLR4 TLR6 and 
TLR9 have been linked to the immune response against Candida (Section 1.2.2.2) 
(Netea et al., 2010, Wagener et al., 2014). In a study by Ali et al, biopsies from 
patients with CHC were stained using immunohistochemistry to assess differences 
in TLR expression between CHC and controls. This was a small study with only 5 
patients in each group, and the main finding was that in two of the five CHC 
samples there was a higher number of hyphae compared to yeast, decreased 
staining of TLR2 and increased staining of TLR4 (Ali et al., 2008). There have been 
very few other recent studies looking at the specific cell-mediated immune 
response in CHC (section 5.1.4). 
The type of Th cell response driven by the interaction of the APC with C. albicans 
will determine if a pro-inflammatory or anti-inflammatory response is raised when 
C. albicans is encountered by the circulating immune surveillance cells in the 
tissues (Section 1.2.4). To date, IL-17 immunity has been found to be important in 
the mucosal defence against C. albicans (Schonherr et al., 2017). IL-17 is expressed 
by Th17 cells, which drive a pro-inflammatory response to reduce the mucosal C. 
albicans infection.  
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5.1.3 Detection of Candida in formalin fixed histopathological specimens 
Candida are poorly stained by routine haematoxylin/eosin processing and 
therefore special staining techniques are used to show the presence of Candida 
(Sitheeque and Samaranayake, 2003). The periodic acid-Schiff (PAS) technique can 
detect Candida due to interaction of carbohydrates in the cell wall with the Schiff 
reagent, leading to pink/red colouration of the fungus. PCR can be used to identify 
Candida species directly in formalin fixed biopsy sections (Williams et al., 2001). 
Williams et al (2001) demonstrated a case of CHC that underwent malignant 
change over a 7 year period and the isolated strain of C. albicans was classed as a 
high invader in in vitro tissue models. This finding may indicate that there is an 
inherent difference between C. albicans strains in terms of virulence and, 
potentially therefore, the immune response.  
 
5.1.4 Characterisation of the inflammatory infiltrate in CHC using 
immunohistochemistry 
Immunohistochemistry can be used to characterise the inflammatory cells present 
in formalin fixed biopsy samples. This technique has previously been applied to 
CHC tissues (Williams et al, 1997) and these researchers stained for 
immunoglobulin light chains and found that T lymphocytes were the dominant cell 
type (53.9%), with fewer B lymphocytes and macrophages indicating a T-cell 
mediated immune response (Williams et al., 1997).  
In a study by Ali et al, biopsies from CHC patients (n=10) were stained for IL-8 and 
IL-8A receptors and reported that IL-8 was strongly expressed in both vascular and 
mucosal epithelium, and many of the inflammatory cells including neutrophils 
stained positively for IL-8A (Ali et al., 2006). This would fit with a pro-inflammatory 
response to the C. albicans hyphae invading the epithelium in CHC patients. No 
studies to date have looked in detail at individual cytokines and Th cell responses in 
CHC tissues.  
In this study, I have analysed expression of cluster of differentiation markers CD3, 
CD4, CD8 and CD20 using immunohistochemical staining. These markers are 
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appropriate for identification of different immune cell populations within tissues 
(Table 4.2). In this respect, CD3 positive cells are T cells, CD4 positive cells are Th 
cells, CD8 positive cells are cytotoxic T cells and CD20 cells are B cells. To further 
help specify the type of Th cell response specific proteins and cytokines can be 
determined as detailed in table 5.1.  
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Table 5.1: Proteins and cytokines used in immunohistochemistry of tissues and 
associated Th cell responses 
Protein subunit or 
cytokine 
Cytokine 
incorporating 
subunit 
Cell expressing the 
cytokine  
Th cell response 
associated with 
cytokine 
EBi3 IL-35 
IL-27 
Treg 
Naïve Th cell or 
APC 
Treg 
Th1 
P35 (IL-12A) IL-35 
IL-12 
Treg 
Naïve Th cell or 
APC 
Treg 
Th1 
IFNγ IFNγ Th1, NK, Tc or APC Th1 
Foxp3 N/A Treg Treg 
IL-17 IL-17 Th17 Th17 
IL-22 IL-22 Th17 or Th22 Th17 or Th22 
Th=T helper cell, Treg=regulatory T cell, IL=interleukin, EBi3= Epstein Barr virus 
induced gene 3, Foxp3= forkhead box protein 3, NK= natural killer T cell, Tc=CD8+ 
cytotoxic T cell, APC=antigen presenting cell, IFN=interferon, N/A=not applicable 
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5.1.4.1 Scoring systems to quantify immunohistochemistry patterns 
Quantification methods in immunohistochemistry need to be reliable, easy to use 
and reproducible (Walker, 2006). The localisation of the antigen is important as this 
may be in the nucleus, cytoplasm or in the cell membrane (van Diest et al., 1997). 
There are a number of factors that can affect reliability of results related to the 
method of staining, including, fixation of the tissue, duration and type of antigen 
retrieval, antibody specificity and detection systems (Walker, 2006). When 
calculating the extent of staining, a variety of methods can be used including 
counting all stained cells or determining a subjective estimation of the overall 
proportion of positive cells. A percentage calculation has been reported to be a 
useful approach for comparisons between different tissues of the same type and 
when the method is standardised for all samples (Walker, 2006). The H score is a 
method that was initially proposed by Hirsch et al and involves scoring on a scale 
between 0 to 400 (percentage of positive cells x staining intensity) (Hirsch et al., 
2003). This score has been used in clinical trials to assess benefit of medication 
versus placebo (Mazieres et al., 2013). 
 
Through detecting inflammatory cells and particularly the Th cell expression in 
clinical biopsy samples containing Candida, it may be possible to increase our 
understanding of the mechanism by which host’s respond to C. albicans and how 
this might lead to either colonisation or infection. The research in this Chapter was 
designed to support the in vitro (chapters 3 and 4) and in vivo studies (chapter 2) 
performed previously in this Thesis. 
 
5.2 Aims 
This research aimed to compare the T cell response in different human tissue 
samples including those from chronic hyperplastic candidosis. The purpose of this 
chapter was to support the work previously performed in DS patients (Chapter 2) 
that showed a Th17 and Th1 cell response to Candida (Rogers et al., 2013). Tissue 
samples studied included chronic hyperplastic candidosis, tonsil tissue, 
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fibroepithelial polyp, and squamous papilloma with superficial Candida, and oral 
lichen planus as a comparison. 
 
The specific aims of this Chapter were: 
 
1. To evaluate the sub-populations of CD4+ T cells detected by 
immunohistochemistry staining with anti-CD3, CD4, CD8, CD20, Foxp3, IL-35 (p35 
and EBi3 subunits), IFN and IL-17A antibodies in different tissue samples.  
 
2. To compare the Th cell response in CHC tissue to that evident in different control 
tissues. 
 
The results from this part of the study, in combination with the clinical data from 
the denture stomatitis study (Chapter 2), will highlight the role of certain T cell sub 
populations in controlling oral mucosal Candida infection in humans.  
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5.3 Methods 
5.3.1 Ethical approval 
Ethical approval was obtained (IRAS Project ID 136258) and permission granted 
from the Cardiff and Vale University Health Board R&D (14/DEN/5953) (Appendix 
IV).  
 
5.3.2 Biopsy specimens  
Tissue samples were obtained from archived formalin-fixed diagnostic biopsy 
specimens, which had previously been consented from living patients for routine 
diagnostic purposes, held in the School of Dentistry, Cardiff University. All clinical 
pathology samples were reviewed by A. V. Jones (Consultant Pathologist) to 
confirm the diagnosis and anonymised using an alphanumeric coding system 
comprising an alpha code for the diagnostic type and the sample number. This 
system kept the principle assessor blind to the diagnosis and allowed 
reproducibility and correlation between the different immunohistochemical stains 
for the same specimen as well as diagnostic subtypes. With the exception of 
diagnosis, no other patient-related information was included. 
 
The following tissue samples were used: 
• Chronic Hyperplastic Candidosis (CHC) (Code A, n=19) comprised test 
samples used to investigate the nature and distribution of T cell response to 
Candida infection. 
• Tonsil (n=1) was used as a positive control for normal immune cells.  
• Fibroepithelial polyp (FEP) (Code C, n=3) represented reactive fibrous 
proliferations with little inflammation that were used as a negative control 
for inflammation and Candida infection. 
• Squamous papilloma with superficial Candida infection (SP) (Code B, n = 5) 
represented a non-Candida related epithelial proliferation, that are 
frequently secondarily colonised by Candida. These were used to determine 
the specificity of the immune response for a Candida induced lesion.  
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• Oral lichen planus (OLP) (Code D, n= 10) was used as an immunological 
process unrelated to Candida to determine the specific findings in CHC 
tissues.  
 
5.3.3 Tissue processing and sectioning 
Prior to tissue processing, all specimens had previously been fixed in 10% (v/v) 
neutral buffered formalin solution for a minimum of 24 h. All tissues were 
subjected to automated tissue processing (as detailed in Table 5.2) for 16 h period 
using a Leica ASP300 tissue processor (Leica, Milton Keynes, UK). Following 
processing, tissues were orientated into cassettes, covered with hot paraffin wax, 
cooled on ice and 4 µm sections were cut using a microtome (Leica Biosystems Ltd, 
Newcastle upon Tyne, UK). Sections were floated in a 46°C water bath, separated 
and placed on Dako FLEXTM IHC microscope slides (Dako, Glostrup, Denmark) and 
incubated in an oven (Binder, Tuttlingen, Germany) for 1 h at 60oC.  
 
5.3.4 Antigen retrieval for all antibodies 
The Dako FLEXTM IHC microscope slide was placed into a PT links module chamber 
(Dako) containing an EnVision™ FLEX Target Retrieval Solution (pH 9). The chamber 
heated the sections to 97oC for 20 mins, before cooling to 65oC. The sections were 
then immediately placed into the EnVision™ FLEX Wash Buffer (x 1) (Dako) for 5 
min. 
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Table 5.2: Automated tissue processing steps for the ASP300 tissue processor 
(Leica) 
NBF = 10% Neutral Buffered formalin, IDA = Industrial denatured alcohol (IDA) i.e 
ethanol, h=hours, m=minutes 
  
Reagent Time (h:m) Temperature oC 
10% NBF 00:05 Ambient 
90% IDA 01:00 Ambient 
95% IDA 01:00 Ambient 
100% IDA 01:00 Ambient 
100% IDA 01:00 Ambient 
100% IDA 01:00 Ambient 
100% IDA 01:00 Ambient 
Xylene 01:00 Ambient 
Xylene 01:00 35 
Xylene 01:00 45 
Wax 01:00 60 
Wax 01:30 60 
Wax 02:00 60 
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5.3.5 Immunohistochemistry (IHC) protocol for automated system for CD3, CD4, 
CD8 and CD20 
Antibodies used for both the automated system and manual staining are detailed in 
table 5.3. The Dako FLEXTM IHC microscope slides were placed into the Dako 
Autostainer Link 48 ™ staining machine. The correct programme for the antibodies 
used was selected on the computer and the machine completed several stages, as 
detailed, to stain the samples for antibodies CD3, CD4, CD8 and CD20.  
Briefly, endogenous peroxidase was initially blocked using EnVision™ FLEX 
Peroxidase-Blocking Reagent (Dako) for 5 min. The sections were then washed 
twice for 5 min in EnVision™ FLEX Wash Buffer (x 1) and then incubated with the 
primary antibody (CD3, CD4, CD8 or CD20 Table 5.3) for 20 min. Sections were then 
washed twice for 5 mins in the EnVision™ FLEX Wash Buffer (x 1) (Dako) before 
placing in the EnVision™ FLEX /HRP (Dako) detection reagent for 20 min. Sections 
were washed twice again, as described previously. 3,3'-diaminobenzidine (DAB)-
containing EnVision™ FLEX Substrate Working Solution was prepared by mixing it 
thoroughly with 1 drop of EnVision™ FLEX DAB+ Chromogen per 1 mL EnVision™ 
FLEX Substrate Buffer. The sections were placed in the EnVision™ FLEX Substrate 
Working Solution for 5 min before washing as previously described. Sections were 
counterstained using EnVision™ FLEX Haematoxylin (Dako) for 5 min and finally 
rinsed with distilled water. The slides were removed from the Autostainer Link 
machine, dehydrated and cleared as described in section 5.3.6.  
A negative control was carried out using all steps detailed apart from the primary 
antibody (CD3, CD4, CD8 or CD20).  
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Table 5.3: Primary antibodies used for immunohistochemistry 
 
      
Antibody 
target 
(human) 
Source 
of 
antibody 
Antibody 
working 
concentration 
(µg/ml) 
Incubation 
Antibody 
manufacturer 
Manufacture 
Number 
      
      
CD3 Rabbit Ready to use  20 min Dako IR50361 
CD4 Mouse Ready to use  20 min Dako IR64961 
CD8 Mouse Ready to use 20 min Dako IR62361 
CD20 Mouse Ready to use  20 min Dako IR60461 
EBi3 Rabbit 10.0 1 h Abcam 83896 
FOXp3 Rabbit 2.5 1 h Abcam 4728 
IL-17A Rabbit 1.0 1 h Abcam 79056 
IL-12A Rabbit 0.97 1 h Abcam 131039 
IFNγ Rabbit 0.5 1 h Abcam 9657 
 
CD=cluster of differentiation, IL=interleukin, EBi3=Epstein Barr virus induced gene 
3, Foxp3= forkhead box P3, IFNγ=interferon gamma, min= minutes, h= hours. 
Incubation was all carried out at ambient temperature.  
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5.3.6 Immunohistochemistry protocol for manual staining for all other antibodies 
After antigen retrieval (Section 5.3.4) tissue sections were treated with EnVision™ 
FLEX Peroxidase-Blocking Reagent (Dako) for 5 min. Sections were then washed 
twice for 5 min in the EnVision™ FLEX Wash Buffer (x 1) and then incubated with 
primary antibody (EBi3, FoxP3, IFNγ, IL-17A or IL-12A) (Table 5.3 for antibody 
concentrations) for 1 h. Sections were washed twice for 5 min in the EnVision™ 
FLEX Wash Buffer (x 1) (Dako) before incubating with the EnVision™ FLEX +Rabbit 
(Linker) (Dako) for 15 min, and then washed twice as previously described. Sections 
were placed in EnVision™ FLEX /HRP (Dako) detection reagent for 20 min and 
washed twice as previously described. DAB-containing EnVision™ FLEX Substrate 
Working Solution was prepared as described previously and sections were 
incubated in the solution for 10 min prior to washing as previously described. 
Sections were counterstained with EnVision™ FLEX Haematoxylin (Dako) for 5 min 
and finally rinsed with distilled water. Tissues were dehydrated in a series of 
ethanol solutions (x3) for 2 min at each stage before being cleared in xylene (x3) 
(Genta medical, York, UK) for 2 min. A coverslip was mounted on the stained 
sections using DPX mounting medium (CellPath).  
A negative control was carried out using all steps detailed apart from the primary 
antibody (EBi3, FoxP3, IFNγ, IL-17A or IL-12A).  
 
5.3.7 Analyses and scoring of the immunohistochemistry stained samples 
All histology slides were scanned at x20 magnification using UPlanSApo lens 
(Olympus, Japan) and converted to digital images using an Aperio Scanscope® 
(Leica Biosystems). Each specimen was assessed for quality (tangential sectioning, 
representative of the lesion, degree of background staining) using x10 or x20 
Aperio image scope (Version 12.3.2) (Leica Biosystems) and 6 representative 
images taken and saved as jpeg files. These were repeated for all antibodies and for 
each diagnostic case. Each slide was compared to the positive control tonsillar 
tissue. 
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In each image the number of positively stained immune cells was calculated as a 
percentage of three areas: the epithelium, the superficial lamina propria and the 
overall total percentage of immune cells in both the epithelium and lamina propria. 
To determine intra-examiner reliability 20% of the total samples were reassessed 
using the same scoring method as described. 
 
5.3.8 Statistical analysis 
Intra-class correlation coefficient (ICC) was carried out to determine the intra-
examiner reliability in scoring the slides on a repeat 20% of the sample using SPSS 
(Version 23).  
Descriptive statistics were determined for the mean, median, standard deviation 
and 95% confidence intervals for the individual CD’s and cytokines for each of the 
different groups using Excel (2010) and SPSS (version 23)  
The data was tested and the squamous papilloma (SP) group was found to be 
difficult to test if the data was normally distributed for CD’s due to the small 
sample size (n=4), likewise for the fibroepithelial polyp (FEP) group for the cytokine 
analysis (n=3). The data for the CHC and OLP groups were generally normally 
distributed. The one-way ANOVA (parametric) and Kruskal-Wallis (non-parametric) 
test were used to determine significance. A p value below 0.05 was considered 
significant. The null hypothesis was that all groups were the same and the 
alternative hypothesis was one group is significantly different to the other two 
groups. A T test was used to determine significance between the CHC group and 
the controls. 
Clustering analyses was carried out by principal component analyses using function 
1 and function 2 as principal components of a covariance matrix that included 
within group and between- group elements using SPSS (version 23). 
No formal power calculation was done as this was a pilot study. 
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5.4 Results 
5.4.1 Immunohistochemistry (IHC) staining of tissue sections 
5.4.1.1 Distribution and quantification of CD positive cells in CHC 
In the majority of chronic hyperplastic candidosis (CHC) (group A) tissue sections, 
CD3+ cells were detected and these were primarily located in the basal layer of the 
epithelium (15.58% mean) (Figure 5.2 and Table 5.4). There appeared to more in 
the stratum spinosum compared to oral lichen planus (OLP) tissue sections. In the 
lamina propria of the CHC tissues, CD3+ stained cells were more diffusely spread. 
CHC tissues had a statistically higher number of CD3+ cells in the connective tissue 
(p=0.014) compared with squamous papilloma tissues, but not when comparing 
the tissue in its entirety (p>0.05) (Table 5.4). There were significant differences 
between the tissue groups for CD3+ cell staining. This was true for the entire tissue 
(p=0.002), the epithelium (p=0.032), and the connective tissue (p<0.001) (Figure 
5.3). 
For CHC tissues, the CD4+ cells were diffusely scattered in both the lamina propria 
and epithelium, and the total mean number of CD4+ cells was lower (13.46%) than 
CD3+ stained cells (25.58%) (Tables 5.5 and Figure 5.4). The CHC group had a 
statistically higher number of CD4+ cells in the connective tissue (p=0.003) 
compared with the squamous papilloma tissues, but not when numbers in all three 
areas were analysed (p>0.05). A significant difference between the tissues was 
evident for the number of CD4+ cells with regards to entire tissue sections 
(p=0.013) and the connective tissue (p<0.001). The number of these cells in the 
epithelia of the different tissues did not differ significantly (p=0.155) (Table 5.5 and 
Figure 5.5). 
CD8+ positive cells in CHC were mainly sparsely dispersed in the lamina propria 
(7.58%) with a low number also in the basal layer of the epithelium (2.88%) (Figure 
5.6. and 5.7 and Table 5.6). There was no significant difference between CHC and 
squamous papilloma tissues with regards to numbers of CD8+ cells. In CHC tissues 
CD20+ positively stained cells tended to be dispersed throughout the lamina 
propria compared to the OLP group where they were more often found localised 
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below the epithelial junction (Figure 5.8) CD20+ cells appeared low in number in the 
epithelium (0.27%) and lamina propria (1.88%) overall in CHC tissues (Table 5.7 and 
Figure 5.9). 
 
5.4.1.2 Distribution and quantification of CD positive cells in control tissue 
sections 
The tissue sections of squamous papillomas (group B) generally had noticeably 
fewer total CD3+ cells present (10% median value) than for CHC (22.5%) and OLP 
tissues (32.5%) (P=0.008) (Table 5.4). CD3+ staining of cells in OLP tissues (group D) 
was evident in the basal layer of the epithelium and these cells were tightly 
aggregated just below the epithelial junction in the lamina propria for these tissues 
(Figure 5.2). Figure 5.3) indicates that squamous papilloma tissues (group B) had 
the lowest numbers of cells in all areas (mean 11.25%). Highest numbers of these 
cells occurred in the entire tissue (38.75%) and the lamina propria (60.5%) 
component of OLP tissues (group D). 
For squamous papilloma tissues, CD4+ stained cells were generally dispersed in the 
epithelium, although these were very few in numbers (5%) (Table 5.5). When 
detected in squamous papilloma tissues, CD4+  cells were in the lamina propria just 
below the epithelial junction. In the case of OLP, the overall distribution of CD4+ 
cells was very similar to that of CD3+ cells (Figure 5.4). Figure 5.5 indicates that the 
squamous papilloma (group B) had the lowest values for the total, epithelium and 
connective tissue CD4+ staining and that the total and connective tissue had the 
largest values in OLP (group D).  
Squamous papilloma CD8+ cells were also present in low numbers and were 
dispersed throughout the lamina propria. In contrast, OLP tissues had a higher CD8+ 
cell infiltrate associated with basal cell destruction and these were concentrated in 
the lamina propria just below the epithelial junction (Figure 5.6). There was a 
significant difference between the groups with regards to numbers of CD8+ cells in 
the entire tissue section (p<0.001), the epithelium (p=0.02) and the connective 
tissue (p<0.001) (Table 5.6). Figure 5.7 showed that squamous papilloma (group B) 
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tissues had the lowest number of CD8+ cells in the entire tissue, in the epithelium 
and in the connective tissue. Highest numbers of these cells were found in the 
entire tissue, the epithelium and connective tissue of OLP (group D).  
CD20+ stained cells were noticeably fewer in all three tissue types (Figure 5.8) and 
no CD20+ cells were evident in the epithelium. When present in the lamina propria 
the CD20+ cells were located close to the epithelial junction. The groups showed 
significant differences for the total (p=0.001) and connective tissue (p=0.003) areas 
for CD20+ staining (Table 5.7). Figure 5.9 showed that the squamous papilloma 
(group B) had the lowest values for total and connective tissue CD20+ staining and 
that the total and connective tissue had the largest values in OLP (group D). There 
was no evidence of a significant difference between the groups for epithelial 
staining.  
The sample sizes for the squamous papilloma’s (group B) were very low (n=4), so 
any inferences from these results were treated with caution. 
 
5.4.1.3 Distribution and quantification of positive cells for the different cytokine 
staining in CHC tissue samples 
The cytokine staining of the tissue sections overall was more difficult to interpret 
than the CD’s correctly due to background staining and false positivity. This varied 
between sections and antibodies used but tended to be worse in the epithelial 
component generally. Anti-IL-12A+ (p35) and anti-EBi3 antibodies were the most 
problematic to interpret as there was generally a high level of background staining 
with these antibodies (Figure 5.10 and 5.18).  
In CHC and OLP tissues, IL-12A+ (p35) stained cells were more often detected in the 
lamina propria compared with the epithelium (Figure 5.10). IL-12A+ cells had a 
dispersed distribution in CHC tissues, whilst in OLP these cells were typically 
present in tight aggregates below the epithelial junction (Figure 5.10, A and B). 
There was significant differences between the four groups for the total (p<0.001), 
epithelium (p=0.003), and lamina propria (p<0.001) for IL-12A+ staining (Table 5.8). 
The highest value for IL-12A for CHC (group A) was in the epithelium (mean 6.72%) 
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(Figure 5.11). CHC had a significantly higher value of IL-12A for the connective 
staining (mean 24.3%) (p=0.015) but not when comparing all three areas to the 
fibroepithelial polyp as the control. 
For IFNγ+ stained cells in CHC tissues, these were most prominent at the basal layer 
rather than dispersed throughout the connective tissue component (Figure 5.12). 
The IFNγ+ cells for CHC tended to be scattered through the connective tissue, but in 
OLP the IFNγ+ cells were clearly evident in the lamina propria, just below the 
epithelial junction (Figure 5.12, A and D).There was no evidence of significant 
differences (p> 0.05) between the four groups for the total, epithelium, and 
connective tissue for IFNγ staining (Table 5.9). Figure 5.13 shows that the results 
across the groups are indeed very similar.  
IL-17A+ stained cells were prominent in the basal layer of the epithelium and 
throughout the lamina propria in CHC tissues (Figure 5.14A). There was significant 
differences between the groups for the connective tissue (p<0.001) of IL-17A 
staining only (Table 5.10) and the largest mean (32.63%) and median (30%) values 
were in CHC (group A) (Figure 5.15). This was statistically significant when 
comparing CHC and fibroepithelial polyp groups for IL-17A staining in the 
connective tissue (p=0.015). 
Foxp3+ cells generally exhibited minimal positive staining in all four tissues, 
particularly in the epithelium (Figure 5.16). There was evidence of some positively 
stained Foxp3 cells in the lamina propria of OLP tissues and to a lesser extent in 
CHC. 
Low levels of EBi3+ cells were detected in CHC tissues and when positive cells were 
seen they tended to be dispersed through the lamina propria or at the level of the 
basal layer (Figure 5.18A). There was evidence of significant differences between 
the groups for the total (p=0.005), epithelium (p=0.005), and connective tissue 
staining (p=0.002) for EBi3+ staining (Table 5.12 and Figure 5.19).  
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5.4.1.4 Distribution and quantification of positive cells for the different cytokine 
staining in control tissue samples 
IL-12A+ (p35) cells were sparsely dispersed in the squamous papilloma and 
fibroepithelial polyp tissues (Figure 5.10 B and C).The squamous papilloma’s (group 
B) and fibroepithelial polyp (group C) had the lowest values of IL-12A for the total, 
epithelium, and connective tissue and the values were largest in OLP (group D) for 
the total and connective tissue (Table 5.8).  
IFNγ+ cells in squamous papilloma and fibroepithelial polyp tissues were most 
prominent in the basal layer rather than dispersed through the connective tissue 
component (Figure 5.12 B and C) The IFNγ+ cells in OLP the IFNγ+ cells were clearly 
evident in the lamina propria, just below the epithelial junction (Figure 5.12 D). 
The squamous papilloma and fibroepithelial polyp tissues appeared similar to each 
other in overall distribution of positive IL-17A cells, but these cells were present in 
lower numbers compared to CHC, which was particularly noticeable in the 
connective tissue component (Figure 5.14 B and C). In OLP tissues, IL-17A+ cells 
were most apparent in the lamina propria below the epithelial junction, although 
these were not as tightly aggregated as seen with CD4+ cells (Figure 5.14D).The 
squamous papilloma (group B) and fibroepithelial polyp (group C) had the lowest 
mean values for the total, and connective tissue staining for IL-17A (Figure 5.15 and 
Table 5.10) . 
There were significant differences between the groups for the total (p=0.001), 
epithelium (p=0.002) and connective tissue (p<0.001) for Foxp3 staining (Table 
5.11). The squamous papilloma (group B) and fibroepithelial polyp (group C) had 
the lowest values for total, epithelium, and connective tissue staining of Foxp3 
which were close to 0 (Figure 5.17). The largest mean and median values were in 
OLP (group D). CHC group was not significantly higher in value than the 
fibroepithelial polyp group. 
EBi3+ cells were rarely seen in fibroepithelial polyp tissue. There was a slightly 
higher number of EBi3+ cells which were widely scattered through the epithelium 
and lamina propria for the squamous papilloma and OLP groups (Figure 5.18 B and 
D).The squamous papilloma (group B) and fibroepithelial polyp (group C) had the 
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lowest values for EBi3 staining for the total, epithelium, and connective tissue 
(Figure 5.19). The largest values were in CHC (group A) and there was a significantly 
higher value in all areas in this group compared to the fibroepithelial polyp group 
(p=0.002) (Table 5.12).  
Sample sizes for the fibroepithelial polyp group (C) were very low (n=3), so any 
inferences were treated with caution as the power was likely to be low, especially 
where the null was accepted. 
 
5.4.2 Clustering between the groups for immunohistochemistry staining 
There was some evidence of clustering using CD3, CD4, CD8, and CD20 and the 
total, epithelium and connective tissue staining values which is shown by the circles 
in the different groups (A,B and D) being clustered together (Figure 5.20). The 
dendrogram showed strong evidence of clustering into the groups  CHC, squamous 
papilloma, and OLP using CD3, CD4, CD8, and CD20 (Figure 5.21). Clustering was 
shown by the fact that D’s (OLP) are all clustered together at the bottom on the 
left-hand side (LHS) side of the dendrogram, A’s (CHC) are shown in the middle on 
the LHS, and B’s are at the top on the LHS. There was no evidence of clustering by 
“slide” number though, which would be expected as each datum in the 
spreadsheet for the CD’s was from a different subject.  
There was evidence of clustering using IL-12A, IFNγ, IL-17A, Foxp3 and EBi3 and the 
total, epithelium and connective tissue staining values (Figure 5.22). Clustering was 
again shown by the coloured circles (from the different given group A, B, C and D) 
all being clustered closely together. Function one (principal component one) 
separated the squamous papilloma and OLP group’s from the CHC and OLP group. 
The dendrogram also showed some clustering with some of the groups (Figure 
5.23). The C (FEP) and D (OLP) groups were fairly well mixed-together, though there 
appeared to be more A’s (CHC) on the top on the LHS of the figure. The squamous 
papilloma group were quite strongly clustered (close together on the dendrogram 
on the LHS). 
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5.4.3 Intra examiner consistency in slide measurements 
It was found the “consistency” (reliability) of the measurements was excellent in all 
cases of the CD staining (between 0.75 and 1.00) (Table 5.13), except CD20, 
epithelium staining result where it was fair (possibly poor) and IFNγ total, 
epithelium, and connective tissue result where it was good (possibly fair in one 
case). 
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Figure 5.2: Immunohistochemical staining of tissue sections using an anti-human 
CD3
+
 antibody. Chronic hyperplastic candidosis (A); squamous papilloma (B); oral 
lichen planus (C) and Tonsillar tissue (positive control) (D) (x10 magnification). 
  
A B 
C D 
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Table 5.4: Summary statistics for CD3+ immunohistochemistry percentage staining 
of different tissue types 
Percentage of stained 
CD3 cells 
n Mean Median 
Standard. 
Deviation 
95% Confidence 
Interval for Mean 
Lower 
Bound 
Upper 
Bound 
Total 
CHC 13 25.58 22.5 13.55 17.39 33.76 
SP 4 11.25 10.00 6.29 1.24 21.26 
OLP 10 38.75 32.50 16.21 27.15 50.35 
ANOVA F = 6.02,  dof=2,24,  P(2-tailed) = 0.008.  
K-W test P(2-tailed; exact) = 0.002. 
Epith 
CHC 13 15.58 12.50 5.78 12.08 19.07 
SP 4 9.37 7.50 5.91 0.03 18.77 
OLP 10 10.60 10.00 4.01 7.73 13.47 
ANOVA F (Welch) = 3.20,  dof=2,8,  P(2-tailed) = 0.094 
K-W test P(2-tailed; exact) = 0.032. 
CT 
CHC 13 32.88 30.00 14.78 23.95 41.82 
SP 4 13.75 10.00 11.08 3.89 31.39 
OLP 10 60.50 62.50 16.57 48.64 72.35 
ANOVA F = 16.72,  dof=2,24,  P(2-tailed) < 0.001 
K-W test P(2-tailed; exact) < 0.001 
 
n=number in each group, Epith=epithelium, CT=connective tissue, ANOVA= Analysis 
of variance, K-W=Kruskal-Wallis, CHC = chronic hyperplastic candidosis, SP= 
squamous papilloma, OLP = oral lichen planus, Results are all based on the one 
measurement per subject (i.e., median over measurements for all six slides for 
each subject).  
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Figure 5.3: CD3+: (left-hand side) scatterplot showing results of all subjects in each 
group; (right-hand side) bar chart of the mean and standard deviation for each 
group. Group A= chronic hyperplastic candidosis, B= squamous papilloma, and D= 
oral lichen planus.  
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Figure 5.4: Immunohistochemical staining of tissue sections using an anti-human 
CD4
+
 antibody. Chronic hyperplastic candidosis (A); squamous papilloma (B); oral 
lichen planus (C) and Tonsillar tissue (positive control) (D) (x10 magnification). 
  
A B 
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Table 5.5: Summary statistics for CD4+ immunohistochemistry percentage staining 
of different tissue types  
 
Percentage of stained 
CD4 cells 
n Mean Median 
Std. 
Deviation 
95% Confidence 
Interval for Mean 
Lower 
Bound 
Upper 
Bound 
Total 
CHC 13 13.46 10.00 6.25 9.68 17.24 
SP 4 6.37 4.25 5.88 2.98 15.73 
OLP 10 26.35 22.50 18.16 13.35 39.34 
ANOVA F (Welch) = 4.87, dof=2,8,  P(2-tailed) = 0.037 
K-W test P(2-tailed; exact) = 0.013 
Epith 
CHC 13 9.08 10.00 3.25 7.11 11.04 
SP 4 5.500 5.00 3.32 0.223 10.78 
OLP 10 8.050 10.00 3.1574 5.79 10.31 
ANOVA F = 1.89,  dof=2,24,  P(2-tailed) = 0.172 
K-W test P(2-tailed; exact) = 0.155 
CT 
CHC 13 18.65 15.00 9.93 12.65 24.65 
SP 4 8.00 4.25 8.03 4.78 20.78 
OLP 10 47.00 47.50 23.71 30.04 63.96 
ANOVA F(Welch)  = 9.93,  dof=2,10,  P(2-tailed) = 0.004 
K-W test P(2-tailed; exact) < 0.001 
 
n=number in each group, Epith=epithelium, CT=connective tissue, ANOVA= Analysis 
of variance, K-W=Kruskal-Wallis, CHC = chronic hyperplastic candidosis, SP= 
squamous papilloma, OLP = oral lichen planus, Results are all based on the one 
measurement per subject (i.e., median over measurements for all six slides for 
each subject).  
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 Figure 5.5: CD4+: (left-hand side) scatterplot showing results of all subjects in each 
group; (right-hand side) bar chart of the mean and standard deviation for each 
group. Group A= chronic hyperplastic candidosis, B= squamous papilloma and D= 
oral lichen planus.  
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Figure 5.6: Immunohistochemical staining of tissue sections using an anti-human 
CD8
+
 antibody. Chronic hyperplastic candidosis (A); squamous papilloma (B); oral 
lichen planus (C) and Tonsillar tissue (positive control) (D) (x10 magnification). 
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Table 5.6: Summary statistics for CD8+ immunohistochemistry percentage staining 
of different tissue types  
 
Percentage of stained 
CD8 cells 
n Mean Median 
Std. 
Deviation 
95% Confidence 
Interval for Mean 
Lower 
Bound 
Upper 
Bound 
Total 
CHC 13 5.54 5.00 4.33 2.92 8.15 
SP 4 2.37 1.75 1.80 0.48 5.23 
OLP 10 13.90 15.00 5.36 10.06 17.74 
ANOVA F (Welch) = 17.31, dof=2,14,  P(2-tailed) < 0.001 
K-W test P(2-tailed; exact) < 0.001 
Epith 
CHC 13 2.88 2.00 2.76 1.21 4.55 
SP 4 1.37 0.25 2.42 -2.48 5.24 
OLP 10 6.60 5.00 3.17 4.33 8.87 
ANOVA F (Welch) = 6.14, dof=2,9,  P(2-tailed) = 0.020 
K-W test P(2-tailed; exact) = 0.003 
CT 
CHC 13 7.58 5.00 5.56 4.22 10.93 
SP 4 3.62 4.25 1.89 0.62 6.63 
OLP 10 27.00 28.75 12.68 17.93 36.07 
ANOVA F (Welch) = 16.51, dof=2,15,  P(2-tailed) < 0.001 
K-W test P(2-tailed; exact) < 0.001 
 
n=number in each group, Epith=epithelium, CT=connective tissue, ANOVA= Analysis 
of variance, K-W=Kruskal-Wallis, CHC = chronic hyperplastic candidosis, SP= 
squamous papilloma, OLP = oral lichen planus, Results are all based on the one 
measurement per subject (i.e., median over measurements for all six slides for 
each subject).   
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Figure 5.7: CD8+: (left-hand side) scatterplot showing results of all subjects in each 
group; (right-hand side) bar chart of the mean and standard deviation for each 
group. Group A= chronic hyperplastic candidosis, B= squamous papilloma and D= 
oral lichen planus. 
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Figure 5.8: Immunohistochemical staining of tissue sections using an anti-human 
CD20
+
 antibody. Chronic hyperplastic candidosis (A); squamous papilloma (B); oral 
lichen planus (C) and Tonsillar tissue (positive control) (D) (x10 magnification). 
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Table 5.7: Summary statistics for CD20+ immunohistochemistry percentage staining 
of different tissue types  
 
Percentage of stained 
CD20 cells 
n Mean Median 
Std. 
Deviation 
95% Confidence 
Interval for Mean 
Lower 
Bound 
Upper 
Bound 
Total 
CHC 13 1.15 0.50 1.54 0.22 2.09 
SP 4 0.25 0.00 0.50 -0.55 1.04 
OLP 10 4.55 2.25 3.74 1.88 7.22 
ANOVA F (Welch) = 7.08, dof=2,15,  P(2-tailed) = 0.007 
K-W test P(2-tailed; exact) = 0.001 
Epith 
CHC 13 0.27 0.00 0.97 -0.31 0.85 
SP 4 0.00 0.00 0.00 0.00 0.00 
OLP 10 0.00 0.00 0.00 0.00 0.00 
ANOVA N/A 
K-W test P(2-tailed; exact) > 0.999 
CT 
CHC 13 1.88 0.50 2.52 0.36 3.41 
SP 4 0.25 0.00 0.50 -0.54 1.04 
OLP 10 5.60 3.50 4.46 2.41 8.79 
ANOVA F (Welch) = 8.55, dof=2,15,  P(2-tailed) = 0.003 
K-W test P(2-tailed; exact) = 0. 003 
 
n=number in each group, Epith=epithelium, CT=connective tissue, ANOVA= Analysis 
of variance, K-W=Kruskal-Wallis, CHC = chronic hyperplastic candidosis, SP= 
squamous papilloma, OLP = oral lichen planus, Results are all based on the one 
measurement per subject (i.e., median over measurements for all six slides for 
each subject).  
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Figure 5.9: CD20+: (left-hand side) scatterplot showing results of all subjects in each 
group; (right-hand side) bar chart of the mean and standard deviation for each 
group. Group A= chronic hyperplastic candidosis, B= squamous papilloma and D= 
oral lichen planus. 
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Figure 5.10: Immunohistochemical staining of tissue sections using an anti-human 
IL-12A+ (p35) antibody. Chronic hyperplastic candidosis (A); squamous papilloma 
(B); fibroepithelial polyp (C) oral lichen planus (D) and Tonsillar tissue (positive 
control) (E) (x10 magnification).  
A B 
C D 
E 
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Table 5.8: Summary statistics for IL-12A (p35) immunohistochemistry percentage 
staining of different tissue types 
Percentage of stained 
IL-12A cells 
n Mean Median Std. 
Deviation 
95% Confidence 
Interval for Mean 
Lower 
Bound 
Upper 
Bound 
Total CHC 18 17.75 17.50 12.52 11.52 23.97 
SP 5 4.20 3.50 3.91 -0.66 9.06 
FEP 3 1.83 2.00 1.75 -2.53 6.19 
OLP 10 28.25 27.50 22.61 12.07 44.42 
ANOVA F (Welch) = 11.50,  dof=3,14,  P(2-tailed) < 0.001 
K-W test P(2-tailed; exact) < 0.001 
Epith CHC 18 6.72 8.75 3.84 4.81 8.63 
SP 5 1.90 1.00 1.94 -0.52 4.32 
FEP 3 1.00 1.00 1.00 -1.48 3.48 
OLP 10 5.75 5.00 3.09 3.54 7.96 
ANOVA F (Welch) = 11.48,  dof=3,12,  P(2-tailed) = 0.001 
K-W test P(2-tailed; exact) = 0.003. 
CT CHC 18 24.31 25.00 13.03 17.83 30.78 
SP 5 4.90 5.00 3.97 -0.04 9.84 
FEP 3 3.33 5.00 2.88 -3.84 10.50 
OLP 10 40.75 42.50 26.14 22.05 59.45 
ANOVA F (Welch) = 16.45,  dof=3,13,  P(2-tailed) < 0.001 
K-W test P(2-tailed; exact) < 0.001 
n=number in each group, Epith=epithelium, CT=connective tissue, ANOVA= Analysis 
of variance, K-W=Kruskal-Wallis, CHC = chronic hyperplastic candidosis, SP= 
squamous papilloma, FEP=fibroepithelial polyp, OLP = oral lichen planus, Results 
are all based on the one measurement per subject (i.e., median over 
measurements for all six slides for each subject). 
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Figure 5.11: IL-12A+ (p35 subunit): (left-hand side) scatterplot showing results of all 
subjects in each group; (right-hand side) bar chart of the mean and standard 
deviation for each group. Group A= chronic hyperplastic candidosis, B= squamous 
papilloma, C= fibroepithelial polyp and D= oral lichen planus. 
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Figure 5.12: Immunohistochemical staining of tissue sections using an anti-human 
IFNγ+ antibody. Chronic hyperplastic candidosis (A); squamous papilloma (B); 
fibroepithelial polyp (C) oral lichen planus (D) and Tonsillar tissue (positive control) 
(E) (x10 magnification). 
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Table 5.9: Summary statistics for IFNγ immunohistochemistry percentage staining 
of different tissue types  
Percentage of 
stained IFNγ cells 
n Mean Median Std. 
Deviation 
95% Confidence Interval 
for Mean 
Lower 
Bound 
Upper 
Bound 
Total CHC 19 28.16 25.00 12.38 22.19 34.13 
SP 5 26.00 30.00 5.47 19.20 32.80 
FEP 3 21.67 20.00 12.58 -9.59 52.92 
OLP 9 22.50 20.00 12.37 12.99 32.01 
ANOVA F = 0.614,  dof=3,32,  P(2-tailed) = 0.611 
K-W test P(2-tailed; exact) = 0.711 
Epith CHC 19 31.84 30.00 15.65 24.30 39.39 
SP 5 32.00 30.00 8.36 21.61 42.39 
FEP 3 23.33 20.00 5.77 8.99 37.67 
OLP 9 18.89 15.00 6.97 13.53 24.25 
ANOVA F = 2.431,  dof=3,32,  P(2-tailed) = 0.083 
K-W test P(2-tailed; exact) = 0.488 
CT CHC 19 23.95 20.00 11.25 18.52 29.37 
SP 5 19.00 20.00 8.94 7.89 30.11 
FEP 3 13.33 10.00 5.77 -1.01 27.68 
OLP 9 25.00 20.00 13.46 22.05 59.45 
ANOVA F = 1.06,  dof=3,32,  P(2-tailed) = 0. 38 
K-W test P(2-tailed; exact) = 0.21 
N=number, Epith=epithelium, CT=connective tissue, ANOVA= Analysis of variance, 
K-W=Kruskal-Wallis, Results are all based on the one measurement per subject (i.e., 
median over measurements for all six slides for each subject), Group A= chronic 
hyperplastic candidosis, B= squamous papilloma, C= fibroepithelial polyp and D= 
oral lichen planus. 
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Figure 5.13: IFNγ+: (left-hand side) scatterplot showing results of all subjects in 
each group; (right-hand side) bar chart of the mean and standard deviation for 
each. Group A= chronic hyperplastic candidosis, B= squamous papilloma, C= 
fibroepithelial polyp and D= oral lichen planus. 
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Figure 5.14: Immunohistochemical staining of tissue sections using an anti-human 
IL-17A+ antibody. Chronic hyperplastic candidosis (A); squamous papilloma (B); 
fibroepithelial polyp (C) oral lichen planus (D) and Tonsillar tissue (positive control) 
(E) (x10 magnification). 
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Table 5.10: Summary statistics for IL-17A immunohistochemistry percentage 
staining of different tissue types  
Percentage of 
stained IL-17A 
cells 
n Mean Median Std. 
Deviation 
95% Confidence Interval 
for Mean 
Lower 
Bound 
Upper 
Bound 
Total CHC 19 25.13 20.00 14.54 18.12 32.14 
SP 5 16.00 20.00 5.47 9.20 22.80 
FEP 3 13.33 10.00 10.41 -12.52 39.19 
OLP 10 17.70 20.00 13.11 8.32 27.07 
ANOVA F = 1.42,  dof=3,33,  P(2-tailed) = 0.254 
K-W test P(2-tailed; exact) = 0.202 
Epith CHC 19 29.08 30.00 17.74 20.53 37.63 
SP 5 20.00 20.00 10.00 7.58 32.42 
FEP 3 26.67 20.00 11.55 -2.01 55.35 
OLP 10 19.35 15.00 16.20 7.76 30.94 
ANOVA F = 0.97,  dof=3,33,  P(2-tailed) = 0.417 
K-W test P(2-tailed; exact) = 0.633 
CT CHC 19 32.63 30.00 15.58 25.12 40.14 
SP 5 11.00 10.00 2.23 8.22 13.78 
FEP 3 11.67 10.00 7.64 -7.31 30.64 
OLP 10 23.50 25.00 13.55 13.81 33.19 
ANOVA F (Welch) = 11.54,  dof=3,8,  P(2-tailed) = 0.003 
K-W test P(2-tailed; exact) < 0.001 
n=number in each group, Epith=epithelium, CT=connective tissue, ANOVA= Analysis 
of variance, K-W=Kruskal-Wallis, CHC = chronic hyperplastic candidosis, SP= 
squamous papilloma, FEP=fibroepithelial polyp, OLP = oral lichen planus, Results 
are all based on the one measurement per subject (i.e., median over 
measurements for all six slides for each).  
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Figure 5.15: IL-17A+: (left-hand side) scatterplot showing results of all subjects in 
each group; (right-hand side) bar chart of the mean and standard deviation for 
each group. Group A= chronic hyperplastic candidosis, B= squamous papilloma, C= 
fibroepithelial polyp and D= oral lichen planus.  
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Figure 5.16: Immunohistochemical staining of tissue sections using an anti-human 
Foxp3
+
 antibody. Chronic hyperplastic candidosis (A); squamous papilloma (B); 
fibroepithelial polyp (C) oral lichen planus (D) and Tonsillar tissue (positive control) 
(E) (x10 magnification apart from D- x20 magnification).  
A B 
C D 
E 
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Table 5.11: Summary statistics for Foxp3 immunohistochemistry percentage 
staining of different tissue types  
Percentage of 
stained Foxp3 
cells 
n Mean Median Std. 
Deviation 
95% Confidence Interval 
for Mean 
Lower 
Bound 
Upper 
Bound 
Total CHC 16 2.34 1.00 1.62 1.48 3.21 
SP 5 0.40 0.00 0.89 -0.71 1.51 
FEP 3 0.00 0.00 0.00 0.00 0.00 
OLP 9 3.50 4.00 1.58 2.28 4.72 
ANOVA F = 7.14,  dof=3,29,  P(2-tailed) = 0.001 
(Homogeneity test has P < 0.05. However, Welch test cannot be 
used here as one group C has a variance of zero). 
K-W test P(2-tailed; exact) = 0.002 
Epith CHC 16 1.44 2.00 0.79 1.01 1.86 
SP 5 0.20 0.00 0.45 -0.35 0.75 
FEP 3 0.00 0.00 0.00 0.00 0.00 
OLP 9 2.06 2.00 1.10 1.21 2.90 
ANOVA F = 8.02,  dof=3,29,  P(2-tailed) < 0.001 
K-W test P(2-tailed; exact) = 0.001 
CT CHC 16 3.75 5.00 2.81 2.25 5.25 
SP 5 0.90 0.00 2.01 -1.60 3.40 
FEP 3 0.00 0.00 0.00 0.00 0.00 
OLP 9 6.11 7.50 2.58 4.12 8.09 
ANOVA F = 6.81,  dof=3,29,  P(2-tailed) = 0.001 
(Homogeneity test has P < 0.05. However and again, Welch test 
cannot be used here as one group C has a variance of zero). 
K-W test P(2-tailed; exact) = 0.001 
n=number in each group, Epith=epithelium, CT=connective tissue, ANOVA= Analysis 
of variance, K-W=Kruskal-Wallis, CHC = chronic hyperplastic candidosis, SP= 
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squamous papilloma, FEP=fibroepithelial polyp, OLP = oral lichen planus, Results 
are all based on the one measurement per subject (i.e., median over 
measurements for all six slides for each subject). 
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Figure 5.17: Foxp3+: (left-hand side) scatterplot showing results of all subjects in 
each group; (right-hand side) bar chart of the mean and standard deviation for 
each group. Group A= chronic hyperplastic candidosis, B= squamous papilloma, C= 
fibroepithelial polyp and D= oral lichen planus.  
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Figure 5.18: Immunohistochemical staining of tissue sections using an anti-human 
EBi3
+
 antibody. Chronic hyperplastic candidosis (A); squamous papilloma (B); 
fibroepithelial polyp (C) oral lichen planus (D) and Tonsillar tissue (positive control) 
(E) (x10 magnification). 
A B 
C D 
E 
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Table 5.12: Summary statistics for EBi3 immunohistochemistry percentage staining 
of different tissue types  
Percentage of 
stained EBi3 cells 
n Mean Median Std. 
Deviation 
95% Confidence Interval 
for Mean 
Lower 
Bound 
Upper 
Bound 
Total CHC 19 8.29 7.50 8.04 4.42 12.16 
SP 5 3.50 0.00 4.87 -2.55 9.55 
FEP 3 0.33 0.00 0.57 -1.10 1.77 
OLP 9 3.56 2.00 4.19 0.34 6.77 
ANOVA F (Welch) = 7.18,  dof=3,12,  P(2-tailed) = 0.005 
K-W test P(2-tailed; exact) = 0.184 
Epith CHC 19 9.47 7.50 6.92 5.01 13.94 
SP 5 4.00 0.00 9.26 -2.80 10.80 
FEP 3 0.33 0.00 5.47 -1.10 1.77 
OLP 9 3.56 2.00 0.58 0.34 6.77 
ANOVA F (Welch) = 7.27,  dof=3,12,  P(2-tailed) = 0.005 
K-W test P(2-tailed; exact) = 0.209 
CT CHC 19 8.58 10.00 7.62 4.91 12.25 
SP 5 3.00 0.00 4.47 -2.55 8.55 
FEP 3 0.17 0.00 0.29 -0.55 0.88 
OLP 9 3.89 5.00 4.17 0.69 7.09 
ANOVA F (Welch) = 9.45,  dof=3,12,  P(2-tailed) = 0.002 
K-W test P(2-tailed; exact) = 0.081 
n=number in each group, Epith=epithelium, CT=connective tissue, ANOVA= Analysis 
of variance, K-W=Kruskal-Wallis, CHC = chronic hyperplastic candidosis, SP= 
squamous papilloma, FEP=fibroepithelial polyp, OLP = oral lichen planus, Results 
are all based on the one measurement per subject (i.e., median over 
measurements for all six slides for each subject).  
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Figure 5.19: EBi3+: (left-hand side) scatterplot showing results of all subjects in each 
group; (right-hand side) bar chart of the mean and standard deviation for each 
group. Group A= chronic hyperplastic candidosis, B= squamous papilloma, C= 
fibroepithelial polyp and D= oral lichen planus   
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Figure 5.20: Linear discriminant analysis for the CD’s. This shows CD3, CD4, CD8, 
and CD20 and total, epithelium and connective tissue staining in the calculation and 
there is some evidence of clustering using CD3, CD4, CD8, and CD20. Clustering is 
shown by the coloured circles (from the different given group A, B, D) all being 
clustered closely together. The average (x, y) coordinate for each group A, B, and D 
is called the group centroid. Function 1 and function 2 are principal components of 
a covariance matrix that includes within-group and between-group elements 
showing a form a principal components analysis. (Group A=chronic hyperplastic 
candidosis, B=squamous papilloma, C= fibroepithelial polyp and D=oral lichen 
planus.) 
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Figure 5.21: Dendrogram to show hierarchical clustering of the CD’s. This used CD3, 
CD4, CD8, and CD20 and also total, epithelium and connective tissue in the 
calculations. There is strong evidence of clustering into the groups A, B, and D using 
CD3, CD4, CD8, and CD20. (Group A=chronic hyperplastic candidosis, B=squamous 
papilloma, C= fibroepithelial polyp and D=oral lichen planus.) 
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Figure 5.22: Linear discriminant analysis for the cytokines. This shows IL-12A, IFNγ, 
IL-17A, Foxp3 and EBi3 and total, epithelium and connective tissue staining in the 
calculation and there is evidence of clustering using IL-12A, IFNγ, IL-17A, Foxp3 and 
EBi3. Clustering is shown by the coloured circles (from the different given group A, 
B, C and D) all being clustered closely together. The average () coordinate for each 
group A, B, and D is called the group centroid. Function 1 and function 2 are 
principal components of a covariance matrix that includes within-group and 
between-group elements showing a form a principal components analysis. Function 
one (principal component one) separates groups B and D from groups A and D. 
(Group A=chronic hyperplastic candidosis, B=squamous papilloma, C= 
fibroepithelial polyp and D=oral lichen planus.) 
  
293 
 
 
 
Figure 5.23: Dendrogram to show hierarchical clustering of the cytokines. This used 
IL-12A, IFNγ, IL-17A, Foxp3 and EBi3 and also total, epithelium and connective 
tissue in the calculations. There is some evidence of clustering into the groups A, B, 
C and D using IL-12A, IFNγ, IL-17A, Foxp3 and EBi3. (Group A=chronic hyperplastic 
candidosis, B=squamous papilloma, C= fibroepithelial polyp and D=oral lichen 
planus.)
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Table 5.13: Intraclass correlation coefficients (ICC) for analysis of the 
immunohistochemistry staining 
 Data using 6 measurements per 
subject directly  
(i.e. data from all 6 slides)  
Data using just a single 
measurement  
per subject  
(i.e. the median over the 6 slides) 
CD3, Total 0.946 (0.894, 0.972) 0.926 (0.474, 0.990) 
CD3, Epith 0.817 (0.641, 0.907) 0.936 (0.543, 0.991) 
CD3, CT 0.954 (0.910, 0.977) 0.962 (0.730, 0.995) 
CD4, Total 0.938 (0.878, 0.968) 0.949 (0.635, 0.993) 
CD4, Epith 0.809 (0.625, 0.903) 0.880 (0.140, 0.983) 
CD4, CT 0.966 (0.934, 0.983) 0.977 (0.833, 0.997) 
CD8, Total 0.953 (0.907, 0.976) 0.994 (0.955, 0.999) 
CD8, Epith 0.877 (0.759, 0.937) 0.938 (0.559, 0.991) 
CD8, CT 0.955 (0.911, 0.977) 0.991 (0.935, 0.999) 
CD20, Total 0.952 (0.906, 0.976) 0.968 (0.768, 0.995) 
CD20, Epith 0.427 (-0.123, 0.708) 0.000 (-60.146, 0.860) 
CD20, CT 0.941 (0.884, 0.970) 0.918 (0.415, 0.989) 
EBi3, Total 0.925 (0.867, 0.958) 0.981 (0.907, 0.996) 
EBi3, Epith 0.941 (0.896, 0.967) 0.958 (0.790, 0.992) 
EBi3, CT 0.932 (0.879, 0.962) 0.999 (0.997, 10.000) 
Foxp3, Total 0.764 (0.560, 0.873) 0.755 (-0.222, 0.951) 
Foxp3, Epith 0.845 (0.712, 0.917) 0.941 (0.703, 0.988) 
Foxp3, CT 0.849 (0.719, 0.919) 0.895 (0.474, 0.979) 
IFNγ, Total 0.620 (0.293, 0.796) 0.585 (-10.413, 0.929) 
IFNγ, Epith 0.661 (0.369, 0.818) 0.773 (-0.318, 0.961) 
IFNγ, CT 0.785 (0.601, 0.885) 0.490 (-10.971, 0.912) 
IL-12A, Total 0.967 (0.940, 0.981) 0.938 (0.688, 0.988) 
IL-12A, Epith 0.715 (0.492, 0.840) 0.893 (0.466, 0.979) 
IL-12A, CT 0.978 (0.961, 0.988) 0.768 (-0.156, 0.954) 
IL-17A, Total 0.815 (0.670, 0.896) 0.900 (0.498, 0.980) 
IL-17A, Epith 0.858 (0.746, 0.920) 0.840 (0.198, 0.968) 
IL-17A, CT 0.885 (0.794, 0.935) 0.718 -(0.409, 0.944) 
ICCs, where brackets indicate the 95% CI, Epith-epithelium, CT-connective tissue, IL-
interleukin, IFNγ, Interferon, EBi3- Epstein-Barr virus induced gene 3, Foxp3- 
forkhead box protein 3.  
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5.5 Discussion 
Chronic hyperplastic candidosis (CHC) is a chronic oral mucosa Candida related 
pathology. This condition is more prevalent in smokers (Arendorf et al., 1983) 
which may cause a reduction in the salivary immunoglobulin A levels (Bennet and 
Reade, 1982) or possibly cause depression of the polymorphonuclear leukocyte 
function (Güntsch et al., 2006, Kenney et al., 1977, Sitheeque and Samaranayake, 
2003). It is, however, still unclear what the local immune response to the candidal 
pathogen is in this condition, in particular the T helper (Th) cell response. It would 
be expected that a local immune response was being raised by the resident 
immune cells but it is unknown whether this is either ineffective or an 
immunosuppressive response is prominent allowing the chronic oral mucosal 
infection in CHC to persist. 
In this chapter I aimed to look specifically at the Th cell response in CHC biopsy 
samples and compare it to three different common oral mucosal conditions 
namely; squamous papilloma, fibroepithelial polyp and oral lichen planus (OLP).  
The cluster of differentiation (CD) markers used in the three groups showed a 
significant difference between the three groups for CD3+, CD4+, CD8+ and CD20+. 
The oral lichen planus (OLP) group had the highest values and squamous papilloma 
the lowest of the three. OLP is a chronic inflammatory disease that is known to be 
driven by activation of CD8+ cells leading to destruction of basal cells (Walsh et al., 
1990). It would therefore be expected to have higher values of CD3+, being a T cell 
marker, CD4+ as a marker for Th cells and CD8+ as a marker of cytotoxic T cells. 
With regards to the visual appearance of the OLP slides the lymphocytes where 
generally in the upper lamina propria consistent with previous reports (Scully et al., 
1998). Interestingly CD20+ cells were comparatively raised in the OLP group 
although the values were low in all four groups compared to the other CD staining. 
Squamous papilloma is frequently secondarily infected by Candida but usually with 
a limited immune response, which is supported by this study with the lowest values 
for all four CD markers. 
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The CHC group had a statistically higher level of CD3+ and CD4+ in the connective 
tissue component compared to the squamous papilloma but not in the epithelial 
layer. This result provides evidence that the Candida within CHC produces a 
modified host response compared to those conditions where Candida acts a 
secondary infecting agent. Some of these changes may be related to the effects 
Candida have on the epithelium as malignant oral keratinocytes can produced 
factors such as EBi3 that can modify the host response (personal communication). 
An abundance of T lymphocytes have previously been reported in the lamina 
propria in both denture stomatitis (Johannessen et al., 1986) and in chronic 
hyperplastic candidosis (Williams et al., 1997). In both these human oral candidosis 
studies the specific Th cell response was not characterised. 
The different cytokines detected in the four groups characterised which Th cell 
response was likely to drive the inflammatory process. As discussed in section 1.2.4 
and detailed in table 4.1 each Th cell secretes a specific cytokine profile. The slides 
were not double stained therefore the results need to be interpreted with caution 
as the cytokines may have been secreted from other immune cells, such as innate 
lymphoid cells (ILCs) or neutrophils, in addition to the Th cells (Gladiator et al., 
2013, Huppler et al., 2014). Most neutrophils found in CHC are seen in the keratin 
layer rather than the lamina propria hence are unlikely to be the cause of cytokine 
release observed in this study. Double staining can be unreliable as the intensity of 
the alkaline phosphatase (red staining) is not as great as the diaminobenzidine 
(DAB) (brown staining) and is a more useful technique when staining different 
regions.  
IL-17A is an effector cytokine secreted from Th17 cells and shown to induce 
resistance to oropharyngeal candidosis (Conti et al., 2009). This study confirms IL-
17A was significantly higher in the lamina propria in CHC compared to controls. This 
indicates a Th17 pro-inflammatory response is driven by CHC although IL-17A can 
also be secreted from ILCs and neutrophils which may in themselves play a role in 
immunity against mucosal candidosis (Huppler et al., 2014, Gladiator et al., 2013). 
IL-17A also has been shown to play a role in recruiting more neutrophils to the site 
of candidal infection (Becker et al., 2015) however, as mentioned previously, 
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although neutrophils are present in the lamina propria, neutrophils are mostly 
found in the keratin layer in CHC. The Th17 response in CHC would support the 
findings in the denture stomatitis study (Chapter 2) where there was an increase in 
the Th17 cytokines (IL-17A, IL-22 and TGFβ) compared to the control group. The 
OLP group had lower values of IL-17A+ cells compared to the CHC group in this 
study. A study by Javvadi et al. comparing an OLP group to a non-specific 
inflammatory control group using IHC on archival biopsy samples found that IL-
17A+ cells were lower in the OLP group than the control (Javvadi et al., 2016). 
In contrast to the pro-inflammatory response driven by Th17 cells detected in CHC 
samples, Foxp3 showed a significant difference in the lamina propria between the 
four groups studied with the largest values identified in the OLP group. There was a 
trend of increased Foxp3 in CHC, but this was not significantly different to controls, 
which showed low expression in all groups. Foxp3 is a transcription factor required 
by Treg cells which are thought to have a predominantly immunosuppressive role 
and have been shown to suppress both Th1 and Th17 differentiation (Sutmuller et 
al., 2006). The balance between Th17 and Treg cells may be the determining factor 
in whether colonisation or Candida infection occurs (Bonifazi et al., 2009). The 
results from this chapter demonstrate a trend of increased Treg numbers in CHC 
compared to controls, resulting in suppression of the pro-inflammatory response 
and chronic oral candidal infection.  
There was evidence of significant differences between the four groups for IL-12A 
(p35) and EBi3 protein subunits. The CHC group values were significantly increased 
compared to the FEP group for both these protein subunits in the lamina propria. 
The EBi3/p35 heterodimeric protein forms the cytokine IL-35 (Collison et al., 2007). 
IL-35 is thought to suppress IL-17 from Th17 cells and promote IL-10 secretion from 
Treg cells (Niedbala and Wei, 2007). The significantly increased level of both 
individual subunits may indicate an increased level of IL-35 promoting a Treg 
response in the CHC patients. The results need to be interpreted with caution as 
both these protein subunits can combine to form other cytokines. IL-12A (p35) can 
combine with p40 (not measured) to form IL-12 (Chapter 3) which drives a Th1 pro-
inflammatory cytokine and EBi3 can combine with p28 (also not measured) to form 
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IL-27 which is thought to have dual roles in oral candidosis. Double staining (using 
DAB (brown) and alkaline phosphatase (red)) could be used as a method to stain 
the two cytokine protein subunits however this is a difficult technique especially 
when staining similar areas and is better when the product of interest is in two 
different areas i.e. nucleus and cell membrane. The mRNA expression level of the 
different genes of the cytokines could be included in further study however this 
would have been difficult in the tissue samples in this chapter as they have been 
formalin fixed which can cause RNA fragmentation. 
There was no evidence of significance between the four groups for IFNγ+ staining 
although the values in CHC were higher than the control group but did not reach 
significance. IFNγ is secreted by Th1 cells and induces a pro-inflammatory response 
(Murphy and Stockinger, 2010). The lack of a significant increase of IFNγ in CHC 
biopsy samples may indicate that there is not a marked Th1 response in this 
chronic candidal condition. In a murine model of cutaneous candidosis, the pro-
inflammatory cytokines IFNγ, IL-17 and IL-12 were detected at an initial acute 
phase of cutaneous candidosis infection but anti-inflammatory cytokines (IL-13, Il-4 
and IL10) were detected after 4 days (Campois et al., 2015). This may indicate that 
IFNγ is detected at an acute phase in candidosis but to a lesser extent in a chronic 
condition such as CHC. 
The different Candida species in the biopsy samples from the oral cavity were not 
identified in this study. There may have been other Candida species affecting the 
localised immune response in addition to C.albicans. The species of Candida 
present in the CHC study group therefore would be expected to include the hyphae 
forming species of Candida of which C.albicans and C.dubliniensis are oral 
commensals (Brand, 2012). In CHC, Candida will adhere to the epithelial cell, invade 
and damage oral epithelial cells (Swidergall and Filler, 2017).  
Previous studies have shown that C.albicans is the most prevalent species in the 
oral cavity in oral candidosis at around 60% whereas C.dubliniensis is estimated at 
2-3% prevalence (Muadcheingka and Tantivitayakul, 2015, De-la-Torre et al., 2016) 
(Section 1.1.3.4) therefore most of the immune response could be hypothesised to 
be caused by C.albicans in the biopsy samples. In further studies it may be useful to 
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identify the species of Candida in the oral biopsy samples, using fresh and fixed 
tissues, in addition to identification of the cytokines and T cell markers to see if 
there is a difference between the Candida species and between different clades.  
The tissue samples in the CHC could have been categorised into the concentration 
of candidal hyphae to see if there was a correlation between the higher 
concentration of hyphae and the inflammatory response. Although in the study by 
Williams et al. the inflammatory cell infiltrate was relatively consistent within the 
samples even though there was a great variation in the number of Candida hyphae 
in the different CHC samples (Williams et al., 1997). 
A number of different factors can lead to a false-positive signal being detected on 
the immunohistochemistry (IHC) slide. These can include; an inappropriately high 
antibody concentration and signal that is in the wrong compartment of the cell 
(Allen, 2016). Positive and negative controls were used in this experimental chapter 
to try to avoid some of these pitfalls. The cytokine antibodies were polyclonal 
rather than monoclonal like the CD antibodies which may explain some of the 
background staining seen with some of the tissue samples with the cytokine 
antibodies. 
Due to a high level of background staining, particularly with EBi3 and IL-12A (p35) 
antibodies, semi-automated image analysis software was not used to count the 
cells due to potential errors being introduced with the software analysis 
overestimating the number of positively stained cells. This could also have occurred 
with the manual counting of cells as the person interpreting the slides can 
misinterpret the result and this can be a source of error (Allen, 2016). This variable 
was attempted to be overcome in this study by one examiner (myself) doing all the 
interpretation and calculating an intra-observer reliability score to test for variation 
in the scoring method used at two different time points. The same photographs of 
each condition and each different antibody were used on both occasions to avoid 
any selection bias. This result showed that overall there was an excellent or good 
consistencies of the measurements in the rescoring of the slides indicating the 
results were reliable. This reliability score could be further improved in future work 
by having a second examiner and carrying out an inter class consistency score. 
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False negative immunostaining may have also have affected the results in this 
study. There are several factors that can cause this including; poor tissue fixation, 
antibodies that are too dilute or not properly optimized, and epitope retrieval 
method not optimized for individual antibodies (Allen, 2016). Therefore the 
absence or low values and even high values of the cytokines and CD’s in this study 
needs to be interpreted with caution and with these issues in mind and there are 
some studies that report IHC findings cannot be formally concluded (Fritschy, 
2008).  
Commercial antibodies may lack the specificity and sensitivity for an application, 
which may lead to problems of purity of an antibody and affect the results 
(Schonbrunn, 2014). All antibodies will cross react to some extent which will lead to 
non-specific binding and false positive results (Fritschy, 2008). Negative controls 
without the primary antibody were used in this chapter to try to demonstrate 
specificity of the antigen targeted by the antibody. 
IHC can be interpreted as evidence that the target of interest, in my studies the 
cytokine and CD positive staining, is present in the tissues that have been examined 
assuming that the primary and secondary antibodies are selectively bound to their 
targets (Fritschy, 2008). In further work it would be interesting to also include the 
Th2 cytokines such as IL-4, IL-5, IL-10 and IL-13 in the IHC analysis but in this thesis I 
have concentrated on the IL-12 family (Chapter 3) and the Th1, Th17 and Treg 
responses hence these cytokines were not include in this CHC tissue staining. To 
further study the individual IL-12 family member’s protein subunits p40, p28 and 
p19 could have been included. 
Due to ethical stipulations for this study the tissue samples were anonymised and 
no information regarding the biopsy samples was known apart from the clinical 
diagnosis. This may have influenced the results as the samples may have been from 
different mucosal sites, the patients may have been medically compromised, had 
an immunodeficiency disorder or be taking immunosuppressant medications 
(topical or systemic). There may have therefore been confounding factors in the 
interpretation of the results of this study. 
301 
 
Because of the ethical considerations of the tissue samples in this study it was not 
known how old the formalin fixed tissue sections were that were used for the IHC 
staining. Although solutions of formalin are now standardised from ISO accredited 
laboratories, it has been previously shown that IHC detection and retrieval of some 
antigens could be impaired by storage of the paraffin slides over 3 months 
(Bertheau et al., 1998). This has also been shown for both monoclonal and 
polyclonal antigen retrieval (van den Broek and van de Vijver, 2000). A longer 
storage time can result in false negative findings particularly affecting loss of 
nuclear, cytoplasmic and membranous biomarkers and it can impact on whole 
tissue sections (Economou et al., 2014).  
Blinding of the slide groups until after all the counting and statistical analysis was 
carried out for the CD and cytokine staining on the IHC slides. This aimed to 
eliminate any bias that may have been introduced by unintentional over or under 
scoring certain CD’s and cytokines in the tissue of interest i.e. CHC.  
Further studies to support the work in this chapter could include using fresh biopsy 
tissue to look for the mRNA of genes using QPCR for CHC tissue compared to a 
control tissue group. The other inflammatory cells in the infiltrate such as 
neutrophils and macrophages (M1 or M2 types) could be also be determined. M1 
macrophages are associated with the release of pro-inflammatory cytokines 
compared to M2 macrophages which are associated with anti-inflammatory 
cytokines (Zheng et al., 2013). It could be hypothesised from the findings in this 
study that in CHC the M1 macrophages may have been higher in number as mainly 
a Th17 pro-inflammatory response was detected in CHC. However due to the 
presence of IL-35 protein subunits found in this chapter indicating a Treg anti-
inflammatory response, M2 macrophages may also be present in CHC. This would 
be an interesting area of further study. In addition, further markers could be used 
to determine the presence of other immune cells present in the epithelium and 
lamina propria compartments in CHC such as the use of S100 on dendritic cells. 
To date there have been limited studies on CHC and the immunological aspects of 
this condition. Of interest are the varying clinical presentations of oral candidosis 
with a single known aetiological agent. It could be proposed that hyperplastic 
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candidosis is a superficial cellular reaction to the fungal pathogen which the local 
and systemic host immune response cannot eradicate (Sitheeque and 
Samaranayake, 2003). In the CHC biopsy samples the main cellular response 
appeared to be an increased T helper cell infiltrate in the lamina propria rather 
than the epithelium. In differentiating the type of Th response, it would appear 
CHC promotes a pro-inflammatory Th17 response, indicated by IL-17A, which was 
observed in the lamina propria. A Treg response was also detected in CHC as 
indicted by the presence of the IL-35 protein subunits, which may suggest Treg cells 
suppress and regulate the pro-inflammatory nature of Th17 cells that may allow 
the chronic nature of this condition to continue without the appropriate antifungal 
treatment or elimination of trigger factors such as smoking. 
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5.6 Conclusions 
This part of work aimed to compare the T cell response identified in different 
human tissue samples including those from chronic hyperplastic candidosis (CHC), 
fibroepithelial polyp, squamous papilloma with superficial Candida, and oral lichen 
planus (OLP) as a comparison. 
 
1. There was a significant difference between the three groups for CD3+, CD4+, CD8+ 
and CD20+. The OLP group had the highest value and squamous papilloma group 
the lowest percentage staining. The CHC group had a statistically higher level of 
CD3+ (p=0.014) and CD4+ (p=0.003) staining in the lamina propria compared to 
squamous papilloma but not in the epithelium. This indicates the increased 
presence of T helper cells in CHC compared to the control. 
 
2. For the cytokine IHC staining there was evidence of significant differences 
between the four groups for IL-12A (p35) and EBi3 protein. There was no evidence 
of significance between the groups for IFNγ+. IL-17A showed a significant increase 
in the lamina propria in the CHC group (p=0.015). The CHC group showed a 
significant increase in the lamina propria for IL-12A+ and IL-17A+ cells and for 
lamina propria and epithelium for EBi3+ compared to the FEP control group. The 
cytokine findings indicate an increased Th17 response in the CHC group. The 
individual cytokine subunits are more difficult to interpret but could indicate both 
IL-35 and IL-12 cytokines, indicating a Treg and Th1 response respectively. 
 
 
The results from this part of the study in combination with the clinical data from 
the denture stomatitis study (Chapter 2) suggest the role of certain T cell sub 
populations, in particular Th17 and Treg, in controlling oral mucosal Candida 
infection.  
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Chapter 6: 
General discussion 
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6.1 General discussion 
Most human carriers of Candida are asymptomatic, indicating that Candida 
primarily exists as a commensal in healthy individuals. Infections with Candida are 
mostly superficial and affect mucosal surfaces, but systemic infection in 
immunocompromised patients can occur and these have high morbidity and 
mortality rates (Rajendran et al., 2016). Several different clinical presentations of 
superficial oral candidosis are recognised and these are associated with a multitude 
of different local and systemic factors (Section 1.1.3.12).  
Understanding the mechanism by which the host recognises and responds to 
Candida is still incomplete. In particular, relatively little is known about T helper 
(Th) cell responses to Candida in the oral mucosa. This research has examined the 
type of Th host immune response to C. albicans, in two different forms of oral 
candidoses, namely denture stomatitis (DS) and chronic hyperplastic candidosis 
(CHC) employing in vivo and in vitro investigations. 
Candida albicans is recognised by host immune cells via pattern recognition 
receptors (PRRs), including toll-like receptors (TLRs) and C-type lectin receptors 
(CLRs) (e.g. dectin 1) (Netea et al., 2010). Such recognition can trigger phagocytosis 
and cytokine production. Antigen presenting cells (APCs) such as dendritic cells 
(DCs) release cytokines that drive different Th cell responses which can either 
promote eradication of Candida, or allow asymptomatic colonisation or persistence 
of infection. 
The type of Th cell subsets involved in the control of oral candidosis in both in vitro 
and in vivo has been the focus of this research. A clinical investigation with denture 
stomatitis (DS) patients revealed the presence of Th1 and Th17 cytokines in the 
palatal secretions at significantly higher levels than non DS patients (Chapter 2). 
This appeared to have a beneficial effect in reducing the Candida levels on the 
palate but not on the denture surface. This balance of increased Candida load on 
the denture surface and the raised pro-inflammatory cytokines (IFNγ, IL-2, TNFα, IL-
17A and IL-22) may result in the chronic palatal erythema and inflammation that is 
seen clinically in DS patients with DS (Chapter 2).  
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Interestingly, the anti-inflammatory cytokines, IL-10 and TGFβ1, were also elevated 
in DS patients compared to controls. IL-10 and TGFβ1 can both originate from T 
regulatory (Treg) cells, which supress Th1 and Th17 responses (Sehrawat and 
Rouse, 2017). In contrast, a study in mice has shown that Treg cells can promote 
Th17 cells in oral candidosis (Pandiyan et al., 2011). IL-10 and TGFβ1 cytokines can 
be generated by other resident cells in the oral mucosa, such as fibroblasts, 
keratinocytes and macrophages (Sanjabi et al., 2009). It is not known from this DS 
study, what the influence of the interplay of the immune cells with non-immune 
cells is, and how this will change the response and outcome to the Candida 
invasion at mucosal surfaces (Netea et al., 2015). The DS study determined the 
local palatal cytokine response and although other patient factors were considered, 
these were not taken into detailed account in the analyses of the results. Other 
local patient factors, such as a low salivary flow (Glazar et al., 2010) and pH 
(Martori et al., 2014) are known to increase the risk for DS. These factors could, in 
future studies, be measured to ascertain if they influence local host and Th cell 
responses. Although the general health of patients was evaluated in the DS study 
and patients on immunosuppressant medication were excluded, patient’s 
haematological investigations were not undertaken.  
A further interesting study would be to consider the species of bacteria present in 
the DS patient group studied. In a small group of DS patients studied in chapter 2, 
no Candida were recovered from any of the three sites (tongue, palate or denture). 
This would support other microorganisms such as S. aureus and S. epidermis 
contributing to DS as found in previous studies (Budtz-Jorgensen, 1990, Pereira et 
al., 2013).  
In chapter 3, lipopolysaccharide (LPS) appeared to play an important role in 
upregulating the host response and the cells’ ability to recognise C. albicans leading 
to IL-23 expression and a Th17 response. It could be hypothesised that in DS 
patients with higher Th17 responses, that there would be an increased co-infection 
with bacterial species that promote host cell responses to C. albicans. Although 
studies of bacterial- candidal interactions have shown that bacteria can either 
modulate the virulence of C.albicans (Bor et al., 2016) or promote candidal 
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virulence upregulating the host inflammatory response (Cavalcanti et al., 2015, Xu 
et al., 2014). 
In chapter 5, the medical details of patients from whom the archive CHC tissues 
originated from were not available due to ethical considerations. This is an aspect 
that could be addressed in future studies to rule out influence of any previously 
undiagnosed haematological deficiencies or abnormalities that may affect the 
host’s response to Candida. It is already well described how patients with AIDS are 
predisposed to oropharyngeal candidosis and similarly with diabetes mellitus 
(section 1.1.3.12.2) (Patton et al., 2013, Willis et al., 2000). 
DS causes an erythematous form of oral candidosis and hyphae are found invading 
into the stratum spinosum. In contrast, chronic hyperplastic candidosis (CHC) 
presents as white plaques and the condition is characterised by invasion of the oral 
mucosal tissues by hyphae (Hebecker et al., 2014). There are several known host 
factors contributing to CHC including smoking, increased age, gender and increased 
alcohol consumption (Arruda et al., 2016). However, there is relatively little known 
about the local host immune response in CHC. Chapter 5 of this thesis describes 
study of the inflammatory cell infiltrate in CHC compared to control tissues. Overall 
CHC tissues had statistically higher levels of CD3+ and CD4+ cells (indicative of Th 
cells) in the lamina propria component compared to the control group, but not in 
the epithelium. The Th cells were differentiated further by cytokine IHC staining. A 
significant increase in IL-17A+ positive cells was evident in the lamina propria of 
CHC tissues compared with controls. Candida within CHC therefore produced a 
modified host response compared to those conditions where Candida acted as a 
secondary infecting agent i.e. squamous papilloma biopsy samples.  
IL-17A is part of the IL-17 family of cytokines and is released from Th17 cells in 
addition to innate lymphoid cells (ILCs) and neutrophils (Section 1.2.5.1). IL-17A 
plays a critical role in host protection against C. albicans (Schonherr et al., 2017). 
Th17 has a pro-inflammatory role in oral candidosis and increases phagocytosis of 
Candida thus promoting clearance of the invading pathogen in conditions such as 
CHC (Conti et al., 2014). The Th17 response detected in CHC reflects the previous 
findings in chapter 2 in DS patients. These studies of two distinct types of oral 
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candidoses both support a local Th17 pro-inflammatory response. This has 
previously been demonstrated in murine models (Schonherr et al., 2017, 
Hernandez-Santos et al., 2013, Conti et al., 2014), but this gives further support for 
the same response in humans.  
In the CHC tissue samples, there was no evidence of a significant increase in IFNγ+ 
staining compared to controls. This implies that the Th17 response played a more 
critical role than Th1 responses in CHC (Chapter 5), although Th1 cytokines were 
significantly elevated in the palatal secretions of DS patients (Chapter 2). A murine 
model demonstrated that Th17 cells, and not Th1 cells were protective against 
mucocutaneous infection, whereas Th1 and not Th17 cells were protective in 
systemic infections (Kashem et al., 2015). The models of oral candidoses in the 
human in vivo work in this present research were both superficial mucosal models; 
hence a Th17 response would be expected. The results from chapter 5 in 
combination with the clinical data from DS patients suggested the role of Th17 cell 
sub populations in controlling oral mucosal Candida infection.  
It has previously been shown that a Th17 cell memory response is specific to C. 
albicans, whereas a Th1 memory cell subset response has been shown in response 
to Mycobacterium tuberculosis in a mouse model (Acosta-Rodriguez et al., 2007). In 
chapter 4, the recall response of T helper cells in healthy individuals after 
stimulation of PBMCs with C. albicans in vitro was determined. Overall there was a 
significant Th17 recall response by cells stimulated with C. albicans in two PBMCs 
blood samples. The Th1 recall response was however not consistent in both PBMC 
blood samples. The memory response may therefore vary between individuals, or 
the Th17 recall response may be more apparent, as would fit with the findings in 
chapter 2 and 5 where a significant Th17 response to Candida was found rather 
than Th1.  
This present research also considered the response of immune cells, in particular 
human monocytes and dendritic cells to C. albicans in vitro (Chapter 3). The main 
finding from the in vitro studies showed that LPS was able to induce dectin-1 
expression in human monocytes and this resulted in IL-23 production with 
enhanced C. albicans phagocytosis. LPS may thus alter innate immune cell function 
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for Candida recognition and affect early stages of Candida infection. The 
production of IL-23 further indicates a Th17 driven host response to Candida 
infection in cell culture. Again this would support the findings of the increased Th17 
immune response found in DS and CHC patients. 
The IL-12 family of heterodimeric cytokines have been shown to have diverse roles 
in immune responses and members of the IL-12 cytokine family (IL-12 (p35/p40), 
IL-23 (p19/p40), IL-27 (p28/EBi3) and IL-35 (p35/EBi3)) have recently been 
expanded to include IL-Y (p28/p40) and IL-39 (p19/EBi3) (Hasegawa et al., 2016).  
Three of the IL-12 cytokines, IL-12, IL-23, and IL-27 are primarily produced by 
activated antigen-presenting cells (APCs), such as dendritic cells (DCs) and 
macrophages, whilst IL-35 is produced by Treg cells and activated B cells and has an 
immunosuppressive function (Hasegawa et al., 2016). IL-12 promotes a Th1 
immune response, IL-23 drives pro inflammatory Th17 cells and IL-27 is thought to 
play a dual role in both Th1 cell differentiation and induction of Treg cells 
(Hasegawa et al., 2016, Yoshida and Hunter, 2015). Given these roles, it can be 
predicted that the IL-12 cytokines will play an important role during infection 
through protecting the host and increasing the inflammatory response. This was 
indeed evident in the present research (Chapter 3) where an increase in IL-23 but 
not IL-12 or IL-27 cytokines was found indicative of a Th17 pro inflammatory 
response.  
Interestingly, the individual cytokine proteins subunits of the IL-12 family have 
recently been shown to have a self-standing function in addition to the role of the 
heterodimeric cytokines of the IL-12 family (Hasegawa et al., 2016). This would be 
an area to consider in future study of responses to candidal infections and may 
explain why in chapters 3 and 5, the individual cytokine subunits of the IL-12 family 
were significantly increased, without necessarily forming a known IL-12 cytokine 
with a second raised protein subunit. 
Detection of individual cytokine subunits present in CHC tissues were more difficult 
to interpret (Chapter 5), but could indicate production of both IL-35 and IL-12 
cytokines, suggesting a Treg and Th1 response, respectively. A Treg response in 
CHC would support the findings of the research of DS patients, where the Treg 
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cytokines IL-10 and TGFβ1 were both significantly increased. The primary function 
of Treg cells is to restrict an excessive inflammatory response that could be 
damaging to the host (Whibley and Gaffen, 2014). However, Treg cells in an 
oropharyngeal candidosis murine model have been shown to promote Th17 cell 
production (Pandiyan et al., 2011) and thus indicate a protective function in C. 
albicans oral mucosal infection. 
IL-35 is a heterodimeric anti-inflammatory cytokine consisting of two protein 
subunits (Section 1.2.5.2.4) (Banchereau et al., 2012). There is a paucity of 
literature on IL-35 and involvement in human oral candidosis. Since IL-35 consists 
of two cytokine subunits, it cannot be concluded that the presence of significantly 
increased positive staining of EBi3 and p35 in CHC tissue (Chapter 5) are indicative 
of IL-35 presence. Detection of IL-35 was not apparent in chapter 3, and this would 
be an area that requires further study. 
Strains of C. albicans associated with the studied CHC tissue biopsies (Chapter 5) 
could hypothetically be regarded as being more invasive than commensal strains. It 
could be proposed that in order to have caused CHC they have to possess the 
necessary virulence factors to enable epithelial invasion. In doing so, the damage to 
the epithelium could have stimulated release of pro-inflammatory cytokines 
(Swidergall and Filler, 2017). The CHC findings may reflect the presence of a more 
virulent form of C. albicans and may not therefore be extrapolatable to all forms of 
oral candidosis. Tavanti et al reported that C .albicans oral isolates had different 
virulence phenotypes influencing their interaction with macrophages, ability to 
resist intracellular killing, and to undergo transition from yeast to hyphal forms 
(Tavanti et al., 2006). It would be interesting to further characterise the Candida 
strains from CHC tissues, and consider their virulence characteristics in relation to 
immune responses.  
In chapters 3 and 4, the C. albicans strains 5 (S5) and S12 were used in in vitro 
experiments and both were originally recovered from CHC patients, compared to 
C.albicans S1 which was a non-pathogenic commensal strain. However, C. albicans 
S5 did not stimulate IL-23 expression from THP-1 cells, unlike the commensal 
originating C. albicans S1 (Chapter 3). When compared with C. albicans S1, C. 
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albicans S12 led to an increased number of CD4+/IL-17+ cells at day 7 of challenge 
compared to day 0 (Chapter 5). It is tempting to speculate that these findings 
reflect differences in the pathogenic background of the strains. The C. albicans S12 
strain also induced a higher Th17 recall immune response from PBMCs compared 
to the commensal C. albicans S1 strain. Candida albicans S5 did not stimulate 
increased expression of IL-23 compared with the commensal strain. The limitations 
of these experiments were that only trends could be observed, and larger numbers 
of C. albicans strains and clades would need to be analysed to substantiate results.  
The C. albicans strains used in the in vitro studies were of different clades. Candida 
albicans S1 and S12 were from clade 8 and clade 1 respectively. Results of chapter 
4 revealed that there was a difference in the Th recall response between these two 
strains. Studies have indicated that there may be a link between differences in C. 
albicans clade types and their ability to infect or colonise different anatomical 
locations (Tavanti et al., 2005). A significant difference was detected between C. 
albicans S1 and C. albicans S2 (both clade 8), compared with C. albicans S4 (clade 9) 
for IL-23 expression when THP-1 cells were stimulated with C. albicans and LPS. 
Interestingly, when comparing the features associated with the clades; clade 8 
strains were most commonly isolated from the bloodstream, and clade 1 strains 
are associated with superficial infections and oral carriage (McManus and Coleman, 
2014). This clade association may explain some of the differences in the associated 
responses reported in these present studies, however further investigation with 
increased strain numbers is required. 
The presence of other oral microorganisms may impact how the immune cells 
respond to C. albicans. There was an enhanced response to C. albicans by THP-1 
cells when LPS was used to pre-stimulate the cells prior to stimulation with C. 
albicans. An increase in IL-23 expression was found compared to LPS only, or HKC 
only stimulation of THP-1 cells. This may indicate a synergistic role in an oral 
candidal infection, also confirmed by the upregulation of dectin-1 by LPS, allowing 
increased phagocytosis of C. albicans (Chapter 3). Previous studies have in contrast 
found bacterial-candidal interactions to modulate C.albicans virulence and the 
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subsequent host immune response to promote commensal carriage (Bor et al., 
2016).  
Biofilms, such as those present on denture prostheses, can contribute to DS and 
protect Candida from the host immune cells (Sardi et al., 2013). Within a biofilm 
environment, a variety of microorganisms would be encountered and it has been 
shown that biofilms containing both bacteria and Candida promote Candida 
virulence (Cavalcanti et al., 2015).  
In an oral environment, C. albicans typically exists as a commensal without 
provoking a localised immune response. It could be proposed that it is only when C. 
albicans and bacteria species co-exist in the oral cavity that a host response is 
generated and cytokines released from local immune cells such as DC, monocytes 
and memory T cells driving the clearance of the pathogen. From the results of 
chapter 3, it could be predicted that IL-23 would be released which in turn would 
promote a Th17 response. This pathogenic synergy has also been shown in a 
murine study, between oral commensal bacteria and C. albicans (Xu et al., 2014). 
Xu et al. found that oral commensal bacteria modify the virulence of C.albicans, 
resulting in upregulation of neutrophils and the host inflammatory response. 
Anti-IL-17A specific target therapy is already used in patients with psoriasis and 
autoimmune diseases (Patel et al., 2013). From the results of chapters 2, 4 and 5, 
where IL-17A appeared to be increased in response to C. albicans, IL-17A and the 
Th17 response appear to play an important role in the immune response to C. 
albicans resulting in phagocytosis and clearance. It would therefore be expected 
that in patients treated with anti-IL-17A therapy, an increased prevalence of oral 
candidosis would occur. Whibley et al studied oropharyngeal candidosis in a 
murine model and treated mice with anti–IL-17A therapy and these subsequently 
developed increased susceptibility to infection (Whibley et al., 2016). IL-17A, IL-
17AF, and IL-17F appear to have a cooperative role in this murine study (Whibley et 
al., 2016). In this research, I have just studied IL-17A, and in future studies of oral 
candidosis it would therefore be intriguing to also consider other members of the 
IL-17 family.  
313 
 
Another group of patients that present with chronic mucosal and skin fungal 
infections are those suffering from chronic mucocutaneous candidosis (CMC) and 
this group would be interesting to include in future study. Some of the deficiencies 
associated with CMC include deficiencies relating to dectin-1, CARD9 (caspase 
recruitment domain-containing protein 9), p 40 (IL-12/23), IL-12/23 receptor 
(IL12Rβ1 deficiency), STAT3 (signal transducer and activator of transcription 3), IL-
17A, IL-17F and IL-17RA (Huppler et al., 2012). It could be extrapolated from the 
findings in chapter 3 that IL-23 would not be increased in a cell culture PBMC study 
from CMC patients as was found in my study after stimulation with C. albicans. 
In this study, I have endeavoured to consider how C. albicans is recognised by the 
host in the oral mucosa. This study has built on the growing body of evidence that 
shows that the Th17 response plays a primary role in controlling oral mucosal 
candidosis (Conti et al., 2016, Gladiator et al., 2013, Hernandez-Santos et al., 2013, 
Huppler et al., 2014, Netea et al., 2015). This has become more apparent since 
commencement of this PhD in 2009. Most of the current literature supporting 
involvement of a Th17 response in immune protection against oral candidosis has 
been in murine models. A limitation of using mice is that they are naïve to Candida 
(Conti et al., 2014) and therefore results may not accurately predict responses in 
humans as most humans are exposed to Candida at an early age (Ali et al., 2012). 
The findings of this present study (particularly the results presented in Chapters 2 
and 5) are supportive of those previously reported. Importantly, however 
investigations of the immune responses in DS and CHC have previously been 
limited. Elucidating the role of the host immune system in these common forms of 
oral candidosis may have further implications in how oral candidosis is managed 
and there would appear to be potential to exploit the Th17 pathway as a potential 
therapeutic target. 
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6.2 Conclusions 
The overall aim of this project was to study the potential of C. albicans, to regulate 
host immune response in different forms of oral candidoses, using in vivo and in 
vitro studies. The conclusions that have been drawn from this research are as 
follows: 
1. Candida colonisation was significantly higher on the tongue and fitting 
surface of the denture stomatitis (DS) patients. However, colonisation in this 
group of patients was lower on the palatal mucosa than in non-DS controls. 
Candida albicans was the most prevalent species in both patient groups. 
2. The local cytokine response in patients with DS showed that there was a 
significant increase in Th1 (IFNγ, TNF-α, IL-2), Th17 (IL-17A, IL-22 and TGF-β1), 
IL-10 and TGFβ1 cytokines in DS patients compared with non-DS controls. 
Results showed that whilst Th1/Th17 local mucosal immune responses may 
be of benefit in controlling Candida levels at mucosal sites in DS, these 
responses alone did not facilitate resolution of infection. 
3. Increased numbers of CD3+ and CD4+ cells in CHC indicated higher presence of 
Th cells in the lamina propria of CHC compared to controls. CHC tissues had 
significantly more IL-12A+ and IL-17A+ cells, and EBi3+ staining compared to 
controls. These cytokine findings indicate increased Th17 responses in CHC 
tissues. The individual cytokine subunits could indicate both IL-35 and IL-12 
cytokines, suggesting Treg and Th1 responses, respectively. 
4. With prior stimulation by LPS (24 h) there was a significant dose related 
increase in IL-23 expression from THP-1 cells following C. albicans stimulation 
(S1). No increased expression was evident for IL-27 or IL-12 from THP-1 cells. 
Human PBMCs further matured with IL-4 and GMCSF and stimulated with C. 
albicans expressed IL-23 at 24 h but not IL-27. This study indicated that LPS 
could induce dectin-1 expression in human monocytes (THP-1 cells and 
PBMCs), and this resulted in enhanced C. albicans phagocytosis. LPS may thus 
alter innate immune cell function for C. albicans recognition and affect early 
stages of Candida infection. 
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5.  The recall response of T helper cells in healthy individuals after stimulation of 
PBMCs with C. albicans in vitro showed a significant Th17 recall response. The 
Th1 recall response was less evident. 
.   
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Appendix II i: Criteria and clinical measures used in clinical study of chronic 
erythematous candidosis patients 
 
IIi a: Diagnosis and Inclusion Criteria 
Subjects aged 18 or above with a full upper conventional denture, approximately 
half of whom have pre-existing stomatitis and approximately half who won’t have 
pre-existing stomatitis. 
 
Inclusion Criteria 
1. Consent 
Demonstrates understanding of the study and willingness to participate as 
evidenced by voluntary written informed consent and has received a signed 
and dated copy of the informed consent form. 
2. Age 
Aged at least 18 years. 
3. Compliance 
Understands and is willing, able and likely to comply with all study 
procedures and restrictions. 
4. General Health 
Good general health with (in the opinion of the investigator) no clinically 
significant and relevant abnormalities of medical history or oral 
examination. 
5. Diagnosis 
Edentulous with a full upper conventional denture 
 
Exclusion Criteria 
1. Pregnancy 
Women who are known to be pregnant or who are intending to become 
pregnant over the duration of the study. 
2. Breast-feeding 
3. Allergy/Intolerance 
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Known or suspected intolerance or hypersensitivity to the study materials 
(or closely related compounds) or any of their stated ingredients. 
Polident Antibacterial contains the following ingredients: Sodium 
bicarbonate, citric acid, sodium carbonate, potassium monopersulfate, 
sodium perborate, sodium lauryl sulfoacetate, sodium benzoate, 
Polyethylene Glycol-180, Proteolytic enzyme (Everlase 6.0T), 
Tetraacetylethlenediamine (TAED), peppermint oil, PVP/VA copolymer, 
FD&C Blue #1 Lake, FD&C Blue #2. 
4. Use of an antibiotic or antifungal within 30 days of the Screening and/or Baseline     
visit. 
5. Use of concomitant medications which, in the opinion of the investigator, will 
interfere with the study treatment or interpretation of the results e.g. daily use of 
Steroid Inhaler, systemic steroids or immunosuppressant drugs. 
6. Clinically dry mouth. (Lack of pooling of saliva in the floor of the mouth observed 
during clinical examination). 
7. Dentures with extensive soft (silicone) relines or cold cure relines. Dentures that 
are in need of repair. 
8. Clinical Study/Experimental Medication 
a) Participation in another clinical study or receipt of an investigational drug 
within 30 days of the screening visit. 
b) Previous participation in this study. 
9. Substance abuse 
Recent history (within the last year) of alcohol or other substance abuse. 
10. Personnel 
An employee of the sponsor or the study site or members of their 
immediate family. (The site for this protocol is the Cardiff University School 
of Dentistry Clinical Trials Unit within the University Dental Hospital, Cardiff.  
Employees of Cardiff University and the University Dental Hospital not 
associated with the School of Dentistry Clinical Trials Unit are eligible to 
participate). 
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IIi b: Study Treatment, Dose and Mode of Administration Polident Antibacterial – 
overnight soak (treatment) 
 
Each evening, before retiring to bed, the subject will dissolve one Polident 
Antibacterial tablet in at least 150 millilitres (ml) of warm (not hot) tap water 
(enough to cover the denture) within a denture bath. They will allow their denture 
to soak overnight then brush the denture with the Polident solution for 1 timed 
minute. The denture will then be rinsed thoroughly with running water. The 
remaining solution will be discarded after brushing. 
Note: If the subject also has a lower denture, they will repeat the above procedure 
using one Polident tablet in a separate denture bath. 
Polident Antibacterial – 15 minute soak (prevention) 
Each evening before retiring to bed, the subject will dissolve one Polident 
Antibacterial tablet in at least 150 ml of warm (not hot) tap water (enough to cover 
the denture) within a denture bath. They will allow their denture to soak for 15 
timed minutes then brush the denture with the Polident solution for 1 timed 
minute. The denture will then be rinsed thoroughly with running water. The 
remaining solution will be discarded after brushing. 
Note: If the subject also has a lower denture, they will repeat the above procedure 
using one Polident tablet in a separate denture bath. 
 
Other 
Additional data was collected to assist in the understanding and interpretation of 
the results. These included salivary assessment, assessment of denture fit, 
assessment of denture cleanliness, total hours wearing the denture, age of 
denture, smoking status and denture adhesive use. A subject questionnaire at the 
conclusion of the study was used to assess overall subject satisfaction with the 
denture cleanser product. 
 
Subject Withdrawal Criteria 
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Subjects had the right to withdraw from the study at any time for any reason. The 
investigator also had the right to withdraw subjects from the study in the event of 
intercurrent illness, AEs or treatment failure after a prescribed procedure, protocol 
deviations, administrative reasons or other reasons 
 
Subject Replacement 
Subjects who did not complete the study were not replaced. 
 
Subject Restrictions 
 
 
 Lifestyle 
Subjects were asked to refrain from eating or drinking (except water) for at least 2 
hours before they attended the clinic. Subjects were required to only use the study 
product provided or water to clean their dentures throughout the study. They were 
allowed to brush their natural teeth (if applicable) using the standard toothbrush 
and toothpaste provided. Subjects indicated how and when they cleaned their 
upper denture as well as how many hours they wore their dentures each day on a 
diary card. Subjects assigned to the Polident overnight soak, soaked their dentures 
in Polident. Subjects randomised to the corresponding water control soaked their 
dentures in water overnight. All remaining subjects soaked in Polident or water for 
15 minutes and followed their normal denture wearing habits. 
 
Medications and treatments 
Subjects were not allowed to take any of the medications prohibited in the 
exclusion criteria throughout the course of the study. 
  
IIi c Screening and Baseline Methods, Measurements and Evaluations 
 
Screening 
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Informed consent 
Written (signed and dated by the subject) informed consent from each subject or a 
legally acceptable representative, participating in the study after adequate 
explanation of the aims, methods, objectives, and potential hazards of the study 
was obtained.  
 
Medical history 
A medical and dental history from each subject was taken. Subjects were also 
asked about the age of their denture. Details of any relevant medical or surgical 
history, including allergies or drug Sensitivity, were recorded. Any concomitant 
medications were also recorded. 
 
 
Baseline Measurements 
Salivary Survey 
 
The subject was asked the following questions: 
 Does the amount of saliva in your mouth seem to be too little, too much or 
don’t notice it? 
 Does your mouth feel dry while eating a meal? Yes or no. 
 Do you need to sip liquids to aid in swallowing dry foods? Yes or no. 
 How would you rate your feeling of comfort under your denture? 
o  No discomfort 
o Mild discomfort 
o  Moderate discomfort 
o  Very uncomfortable 
o  As uncomfortable as possible 
 
Oral Soft Tissue Examination 
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The OST exam performed at the Screening visit (if separate Screening and Baseline 
visits) was a gross oral exam. The OST exam performed at the Baseline visit 
included the labial mucosa (including lips), buccal mucosa, mucogingival folds, 
gingival mucosa, hard palate, soft palate, tonsilar area, pharyngeal area, tongue, 
sublingual area, submandibular area and salivary glands. Observations were made 
of any erythema, desquamation and ulcerations, and other relevant clinical 
observations. The results of the examination were recorded as either normal or 
abnormal. The location and brief description of any abnormalities were also 
recorded. The OST exam performed at the Baseline visit was considered as the 
baseline assessment. The Day 28 (+/- 1 day) OST exam was performed after all 
other study procedures had been completed. Abnormal findings considered to be 
clinically significant at this visit not noted at the Baseline visit were recorded as an 
AE. 
 
 
 
Sample Size Determination 
 
No formal sample size calculation was performed due to the exploratory nature of 
this study. Twenty subjects per treatment in each stratum were considered 
sufficient for the purpose of this study.  
 
Ingredients of polident 
Polident Antibacterial contains the following ingredients: Sodium bicarbonate, citric 
acid, sodium carbonate, potassium monopersulfate, sodium perborate, sodium 
lauryl sulfoacetate, sodium benzoate, Polyethylene Glycol-180, Proteolytic enzyme 
(Everlase 6.0T), Tetraacetylethlenediamine (TAED), peppermint oil, PVP/VA 
copolymer, FD&C Blue #1 Lake, FD&C Blue #2. 
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Appendix II ii: PATIENT INFORMATION SHEET 
 
A Clinical study investigating the Effects of a Clean Denture on Gum Health 
 
Clinical Protocol L3830643 
You are being invited to take part in a research study.  Before you decide it is 
important for you to understand why the research is being done and what it will 
involve.  Please take time to read the following information carefully and discuss it 
with others if you wish.   
 Part 1 tells you the purpose of the study and what will happen to you if you 
take part.   
 Part 2 gives you more detailed information about the conduct of the study.   
Ask us if there is anything that is not clear or if you would like more information.  
Take time to decide whether or not you wish to take part.  Thank you for your 
interest in this research study. 
 
PART 1 
What is the purpose of the study? 
GlaxoSmithKline Consumer Healthcare are the sponsor and funder for this study. 
This means that they are responsible for the design, management and financing for 
this study. 
The aim of this study is to investigate the effect of Polident Antibacterial (a denture 
cleansing tablet commercially available in France) on the prevention and treatment 
of stomatitis (inflammation of the mucous lining of the mouth) when compared to 
using water. 
 
Why have I been chosen? 
You have been chosen because you meet the study entry criteria of having a full 
upper conventional denture and are at least 18 years of age.  You may also be 
experiencing clinical signs of stomatitis. 
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Altogether, a maximum of 120 subjects will take part in this study (approximately 
half of whom will have clinical signs of stomatitis and approximately half of whom 
will not have stomatitis), which will last approximately 16 weeks.   
 
Do I have to take part in this study? 
No.  You are entirely free to choose whether or not to take part.  If you do decide 
to take part, you will be asked to sign a consent form, of which you will be given a 
copy along with this information sheet to keep.  You are still free to withdraw at 
any time without giving a reason.  Although unusual, the study dentist also has the 
right to stop your participation in the study in the event of you experiencing illness, 
or for administrative or other reasons. 
 
We will also keep you informed of any new information that may become available 
during the trial that may affect your willingness to continue participation in the 
trial. 
 
What will happen to me if I take part in this study? 
If you agree to participate in this study, you must read this Patient Information 
Sheet and then sign and date the Informed Consent Form before any study 
procedures begin.   
This is an examiner blind, randomised, clinical study in denture wearing subjects 
both with and without clinical signs of denture stomatitis.  
Upon review of your mouth and if you qualify for the study, you will be randomly 
(like the flip of a coin) assigned to receive/use either one of the four study 
treatments. 
1. Polident Antibacterial to use daily (15 minute soak) OR  
2. Tap water to use daily (15 minute soak) if you don’t have stomatitis 
3. Polident Antibacterial to use daily (overnight soak) OR 
4. Tap water to use daily (overnight soak) if you do have stomatitis 
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If you are assigned to use either one of the water treatments, you won’t be 
provided with a product, but will be asked to use your own tap water. 
 
If you also possess a lower denture, you will be asked to follow the same cleansing 
procedure for your lower denture as you did for your upper denture.  If you are 
assigned to either of the 15 minute treatment regimes, you will be asked to follow 
your routine denture wearing habits overnight. If this includes soaking you 
denture(s), you must do so in water only. 
 
Because this is an ‘examiner blind’ study, the examiner will not know which 
treatment you have been assigned to use and it is therefore important that you do 
not discuss which treatment you have been assigned to use when you speak to the 
examiner or any of the other study site staff.   
To complete this study you will need to attend the clinic (School of Dentistry) on up 
to 6 occasions over a maximum of 6 weeks.  These visits are for screening, baseline 
(or these 2 visits may be combined), then at weekly intervals (on Day 7, 14, 21 and 
28 all +/- 1 day).  
The activities to be performed at each of these visits are detailed below: 
1. Visit 1 - Screening Visit - approximately 1 hour 
Pre-Visit restrictions 
On the morning you attend the Clinic: 
 You must not use any denture adhesive products. 
Within 2 hours of attending the Clinic: 
 You must refrain from eating or drinking (except water)  
This visit may take place up to 14 days before your Baseline visit (or the Screening 
and Baseline visit may be combined).  After you have provided your written 
informed consent to participate in this study your date of birth, gender, race and 
smoking status will be recorded in your study booklet.  The examiner will also ask 
you about your medical and dental history, (including the age of your denture) and 
whether or not you use denture adhesive and record this in your study booklet, 
along with any medications you may be taking.  Assuming you meet the study 
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eligibility criteria, the examiner will then take a look inside and carry out an 
examination of your mouth. 
You may not enter into the study if you have a history of alcohol or drug abuse, or 
have an allergy to the study materials or any of their stated ingredients.  You may 
not participate in this study if you have been on another clinical study in the 30 
days (1 month) before attending for the screening visit. 
If you satisfy all the necessary criteria, you will either move straight onto the 
Baseline visit activities or will be given a date to return to the Clinic for your 
Baseline visit.  Before you leave the clinic you will be asked about non treatment 
emergent events you may have experienced. 
2. Visit 2 – Baseline Visit - up to 1 hour 
If this visit is on a separate day to the Screening visit, you will be asked about any 
medications you have taken/are taking and the examiner will check that you are 
still eligible to continue in the study by asking you a few questions.  Assuming you 
continue to meet the study eligibility criteria, the examiner will then carry out a full 
examination of your mouth and ask you about any non treatment emergent events 
you may have experienced.  The examiner will then remove your upper denture to 
determine whether or not you have clinical signs of stomatitis (as it is very unlikely 
that you will know whether or not you have it), and if you do have it, how much 
you have. 
Depending on whether you do or don’t have stomatitis, you will be randomly 
assigned to receive either one of the four treatments as detailed above. 
You will then undergo the following procedures/assessments: 
 
Procedure 
No. 
Procedure/assessment 
name 
Why is the 
procedure / 
assessment being 
performed? 
What will 
procedure/ 
assessment 
involve 
1 Denture stability and 
retention 
To assess the 
stability and 
retention of your 
denture(s) 
The examiner 
moving your 
upper denture 
whilst in place 
(and lower 
denture also if 
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applicable) 
2 Denture bearing tissue 
score 
To assess the tissues 
which support your 
denture(s) 
The examiner 
removing your 
upper denture 
(and lower 
denture also if 
applicable) 
3 Salivary survey To assess how much 
saliva you produce 
The examiner 
asking you a few 
questions 
4 Clinical photography To photograph the 
inside of your mouth 
The examiner 
placing a retractor 
in your mouth 
and using a mirror 
to take a 
maximum of 5 
images 
5 Erythema index To measure any 
erythema (flushing of 
the skin) inside your 
mouth 
The examiner 
inserting a small 
probe inside your 
mouth which will 
measure any 
erythema on a 
total of 6 
occasions (3 on 
each side of the 
palate) 
6 Inflammation index To measure and 
score the upper oral 
soft tissue inside 
your mouth 
The examiner 
looking inside 
your mouth 
7 % palate covered by 
erythema 
To estimate the 
proportion of the 
right and left halves 
of your palate which 
are covered by 
The examiner 
looking inside 
your mouth 
359 
 
erythema 
8 Imprint culture To assess candidal 
colonisation from 
cultures of your 
palate, fit surface of 
the denture and 
tongue 
The examiner 
placing three 
separate sterile 
2cm2 foam 
squares 
(moistened in 
saline) on either 
the fit surface of 
your denture, 
palate and tongue 
for 30  seconds 
9 Denture cleanliness 
index 
To assess the 
cleanliness of your 
denture 
The examiner 
removing your 
denture(s) and 
assessing their 
cleanliness 
 
9 Denture cleanliness 
index 
To assess the 
cleanliness of your 
denture 
The examiner 
removing your 
denture(s) and 
assessing their 
cleanliness 
10 Inflammatory marker 
collection 
To detect and assess 
the production of 
protein markers of 
inflammation in fluid 
collected from the 
sites of infection and 
inflammation from 
your palatal mucosa 
The examiner 
placing a piece of 
filter paper on 
your palatal 
mucosa with your 
denture in situ for 
5 mins. 
 
After all the above procedures have been completed you will be provided with a 
script to go to the pharmacy and collect your study product kit.  The kit will include: 
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 Standard toothpaste to use on your natural teeth (if applicable) throughout 
the study, 
 2 denture baths in which to soak your denture(s) – upper and lower (if 
applicable).   
 Countdown timer to measure soak time of your denture and/or 1 minute 
brushing time of your denture using the product solution 
 Measuring cylinder to measure out the volume of water to add to the 
denture bath(s) to soak the denture(s) 
 4 standard toothbrushes – 1 to clean your upper denture, 1 to clean your 
lower denture (if applicable), 1 to clean your natural teeth (if applicable) 
and 1 spare 
You will also be issued with a diary card to complete on a daily basis to indicate 
how and when you cleaned your upper denture as well as how many hours you 
wore your denture(s) each day. 
3. Day 7, Day 14 and Day 21 (all +/- 1 day) - approximately 1 hour 
During these visits, you will undergo procedures 4-10.  The examiner or Clinic staff 
will ask you whether you have felt unwell or taken any medication since your last 
visit.  A member of the site staff will also review your diary card to make sure you 
are completing it correctly. 
4. Day 28 (+/- 1 day) - approximately 1 hour 
During this visit, you will undergo procedures 4-10 and the examiner will carry out 
a full examination of your mouth.  The examiner or Clinic staff will ask you whether 
you have felt unwell or taken any medication since your last visit.  You will be asked 
to return all unused product and complete a post study cleansing questionnaire.  At 
the end of the study you will be offered a professional (ultrasonication) denture 
cleaning. 
Expenses and payment 
In recognition of any inconvenience which you may incur, you will be receive £150 
for completing the study.  This money will be given to you at the end of the study If 
you do not qualify during the Screening visit you will be given £15. 
The money obtained from this study is subject to tax and participants must declare 
it as such.  If for any reason you do not complete the study, the sum you receive 
will be pro rated. 
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What do I have to do? 
 Attend all visits at the allocated time. 
 Complete all study assessments as directed. 
 You are required to refrain from consuming food or drinks (except water) 
for the 2 hours prior to visiting the clinic 
 You must not use denture  adhesive on the day you attend the clinic 
 It is important that you report all symptoms that you experience to the 
study staff immediately both during the study and for 5 days after your last 
study visit.  The contact numbers are at the end of this information sheet. 
Inform one of the study staff if you are taking part in another clinical study at 
present. 
What are the products to be tested? 
There are two study treatments being tested, these are:- 
1.Polident Antibacterial, a commercial denture cleansing product marketed in 
France 
2. Tap water 
What are the possible disadvantages and risks of taking part? 
The procedures and assessments that you will undergo are similar to those you 
would experience during a routine dental check-up. 
The main disadvantage of taking part in the study is the inconvenience of attending 
the study visits. 
Are there any side effects? 
Polident Antibacterial is a commercial product available to purchase in France.  The 
following precautionary labels are stated on the Polident Antibacterial product: 
• Keep tablets out of reach of children and elderly needing care 
• Do not place tablets in mouth 
• Keep tablet solution out of mouth 
• Do not use if you are sensitive to any of the ingredients.  If you experience 
irritation due to cleanser use, discontinue and consult a healthcare professional. 
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The Polident Antibacterial product will be supplied in limited quantities and 
assuming you follow the instructions provided there should be minimal or no side 
effects associated with using the product. 
IF YOU EXPERIENCE AN ADVERSE REACTION, SIDE-EFFECT OR INJURY YOU 
SHOULD CONTACT THE CLINIC PROMPTLY. 
Are there any benefits in taking part? 
A possible benefit from participating in this study is that your clinical signs of 
stomatitis may improve over the course of the study.  In addition, you have the 
opportunity to contribute to a scientific investigation that may benefit others.  
There is also the possibility that you may not benefit from your participation in this 
study.  No guarantees have been made to you. 
Are there any alternative procedures/treatments? 
Other denture cleansing tablets are available, but none of them are known to have 
any effect on preventing or treating stomatitis. 
What will happen to any samples I give? 
The inflammatory marker samples taken at the Baseline visit and during the Day 14 
(+/- 1 day) and Day 28 (+/- 1 day) visits will be transferred to a laboratory where 
they will be stored at -70ºC until testing  to determine what levels of certain 
cytokines they contain, they will then be destroyed.  The inflammatory markers 
taken on Day 7 (+/- 1 day) and Day 21 (+/- 1 day) will be frozen at -70ºC and stored 
until after the study has been completed and results of the study have been 
reported.  If they are not used within 2 months of the study report being available, 
they will be destroyed.  Only clinic staff and staff at the laboratory will have access 
to the samples. 
What happens when the research study stops? 
When the research stops you will be referred back to your dentist. 
What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any 
possible harm you might suffer will be addressed.  The detailed information on this 
is given in part 2. 
Will my taking part in the study be kept? 
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Yes.  All the information about your participation in this study will be kept 
confidential.  These details are included in Part 2. 
Contact details 
If you have any further questions concerning the study, or in case of any difficulty 
during the study please contact: 
Professor Mike Lewis  Tel: 02920 742541 (office hours only) 
    Tel: TBC (mobile) 
Mrs Rita Walker   Tel: 02920 742439 (office hours only) 
School of Dentistry, Cardiff University, Heath Park, Cardiff, CF14 4XY, UK. 
This completes Part 1 of the Information Sheet. 
If the information in Part 1 has interested you and you are considering 
participation, please continue to read the additional information in Part 2 before 
making a decision. 
 
PART 2 
What if relevant new information becomes available? 
Sometimes during the course of a research project, new information becomes 
available about the treatment that is being studied.  If this happens, your study 
dentist will tell you about it and discuss whether you want to or should continue in 
the study.  If you decide to continue in the study you will be asked to sign an 
updated consent form.  Also, on receiving new information your study dentist 
might consider it to be in your best interests to withdraw you from the study.  He 
will explain the reasons why.  If the study is stopped for any other reason, you will 
be told why. 
What will happen if I don’t want to carry on with the study? 
You can withdraw from the study at any time without your medical/dental care or 
legal rights being affected.  If you withdraw from the study we will use the data 
collected up to your withdrawal.  
What happens if something goes wrong? 
If you are harmed due to someone’s negligence, then you may have grounds for a 
legal action but you may have to pay for it.  Regardless of this, if you wish to 
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complain, or have any concerns about any aspect of the way you have been 
approached or treated during the course of this study, the normal National Health 
Service complaints mechanisms should be available to you. 
If you experience any side effects that are study related, which is unlikely, 
compensation for any injury caused will be in accordance with the guidelines of the 
Association of the British Pharmaceutical Industry (ABPI).  Broadly speaking the 
ABPI guidelines recommend that ‘the sponsor’ (GlaxoSmithKline Consumer 
Healthcare (GSKCH)), without legal commitment, should compensate you without 
you having to prove that it is at fault.  This applies in cases where it is likely that 
such injury results from giving any new drug or any procedure carried out in 
accordance with the protocol for the study.  ‘The sponsor’ (GSKCH) will not 
compensate you where such injury results from any procedure carried out which is 
not in accordance with the protocol for the study.  Your right at law to claim 
compensation for injury where you can prove negligence is not affected.  Copies of 
the ABPI guidelines are available on request. 
Will my taking part in this study be kept confidential? 
The results will be analysed by GSKCH, and in due course may be reviewed by the 
regulatory and claims approval authorities.  This may involve inspection of all 
study-related information but your identity will always remain strictly confidential.  
Your name or initials will not appear on any information collected.   
Your data will be made available (within and outside the European Union) to the 
sponsor’s employees, investigators, members of the ethics committee and/or 
employees of the competent supervisory authorities exclusively in anonymised 
form for the purposes of examining data.  Your participation in the study will be 
treated as confidential, that is, any personally identifiable information will be held 
and processed under secure conditions at GSKCH (or an agent of GSKCH) with 
access limited to appropriate GSKCH staff or other authorised agents having a 
requirement to maintain the confidentiality of the information.  Data will be kept 
on file for 15 years.  You will not be referred to by name in any report or 
publication (in a scientific journal) of the study.  Your identity will not be disclosed 
to any person, except in the event of a medical emergency or if required by law.  
You may be entitled under law to access your personal data and to have any 
justifiable corrections made.  If you wish to do so, you should request this from the 
investigator conducting the study.  A representative from the sponsor company 
may observe the study in progress. 
Your anonymised data will be processed electronically to determine the outcome 
of this study, and to provide it to health authorities/drug regulatory agencies.  The 
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data will be transferred to GlaxoSmithKline Consumer Healthcare Biostatistics and 
Data Management department in Parsippany, New Jersey, USA and also their site 
in Gurgaon, New Delhi, India, for analysis.  For these purposes, GSKCH complies 
with internal procedures to protect personal information even in countries whose 
data privacy laws are less strict than those of this country.  Your data, which is 
anonymised, will not be used for any other research.   
A representative of the sponsor company may observe the study procedures at one 
or more study visits. 
If you consent to take part in this study we will notify your general practitioner (GP) 
of your participation. 
Who is organising and funding the research? 
The sponsor organising and funding this study is GlaxoSmithKline Consumer 
Healthcare. 
What will happen to the results of the research study? 
It is possible that the results of the study will be made available in the public 
domain through scientific publications and/or presentations as appropriate.  
Should this be the case any information about you will be anonymised as detailed 
in ‘Confidentiality’ above.   
Who has reviewed the study? 
This study has been reviewed and given favourable ethical approval by a Research 
Ethics Committee.   
 
Intellectual property statement: 
The information and any materials or items that you are given about or during the 
study - such as information regarding the study drug(s) or the type of study being 
performed - should be considered the confidential business information of the 
study sponsor.  You are of course, free to discuss with your friends and family while 
considering whether to participate in this study or at any time when discussing 
your present or future healthcare. 
 
Thank you for your help. 
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Appendix III: 
In vitro study 
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Appendix III  
Table III i: Candida albicans strains 1-19 (Malic et al., 2007)  
 
Strain no. 
Laboratory reference  Isolate source 
S1 DW1/93 Normal, oral mucosa 
S2 PB1/93 Normal, oral mucosa 
S3 WK1/93 Normal, oral mucosa 
S4 LR1/93 Normal, oral mucosa 
S5 408/99 SCC tongue 
S6 135bm2/94 CHC, SCC buccal mucosa 
S7 289t/00 SCC, tongue 
S8 480/00 SCC, oral mucosa 
S9 819/00 Keratosis, sublingual 
S10 970/00 CAC, oral mucosa 
S11 40/01 PMC, palate 
S12 243/00 Lichen planus 
S13 Ptr/94 CHC, buccal mucosa 
S14 705/93 CHC, buccal mucosa 
S15 848/99 CHC, tongue 
S16 458r/94 CHC, buccal mucosa 
S17 324la/94 CHC, commissure 
S18 455rgh/94 CHC, tongue 
S19 1190/97 CHC, buccal mucosa 
CHC -chronic hyperplastic candidosis, SCC –squamous cell carcinoma, CAC –chronic 
atrophic candidosis, PMC –pseudomembranous candidosis  
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Appendix III ii: Letter confirming ethical approval for collection of volunteer blood 
(Chapters 3 and 4) 
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Appendix III iii: Letter confirming extension of ethical approval for collection of 
volunteer blood (Chapters 3 and 4) 
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Appendix III -Table III ii: Candida albicans strains with original and strain number 
used in stimulation experiments 
Original  Clade New strain 
number 
Laboratory 
reference  
Isolate source 
S1 8 S1 DW1/93 Normal, oral mucosa 
S2 8 S2 PB1/93 Normal, oral mucosa 
S3 N/A Not used WK1/93 Normal, oral mucosa 
S4 singleton S3 LR1/93 Normal, oral mucosa 
S5 9 S4 408/99 SCC tongue 
S6 singleton S5 135bm2/94 CHC, SCC buccal 
mucosa 
S7 1 S6 289t/00 SCC, tongue 
S8 8 S7 480/00 SCC, oral mucosa 
S9 1 S8 819/00 Keratosis, sublingual 
S10 2 S9 970/00 CAC, oral mucosa 
S11 N/A Not used 40/01 PMC, palate 
S12 1 S10 243/00 Lichen planus 
S13 1 S11 Ptr/94 CHC, buccal mucosa 
S14 1 S12 705/93 CHC, buccal mucosa 
S15 1 S13 848/99 CHC, tongue 
S16 8 S14 458r/94 CHC, buccal mucosa 
S17 4 S15 324la/94 CHC, commissure 
S18 4 S16 455rgh/94 CHC, tongue 
S19 4 S17 1190/97 CHC, buccal mucosa 
CHC -chronic hyperplastic candidosis, SCC –squamous cell carcinoma, CAC –chronic 
atrophic candidosis, PMC –pseudomembranous candidosis  
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TableIII iii: Sequencing results for PCR products from candidal DNA 
Candida 
sample 
ITS 1 primer 
result (genes 
for ITS1, 5.8S 
rRNA,) 
Percentage 
identity 
ITS 2 primer 
result 
Percentage 
identity 
1 Candida albicans 98 Candida albicans 97 
2 Candida albicans 100 Candida albicans 96 
3 Candida albicans 99 Candida albicans 98 
4 Candida albicans 99 n/a n/a 
5 Candida albicans 96   
6 Candida albicans 99 Candida albicans 98 
7 Candida albicans 99 Candida albicans  100 
8 Candida albicans 96 n/a n/a 
9 Candida albicans 99 Candida albicans 98 
10 C albicans 
C dubliniensis 
90 
99 
C albicans 
C dubliniensis 
98 
88 
11 Candida albicans 99 Candida albicans 95 
12 Candida albicans 96 n/a n/a 
13 Candida albicans 99 Candida albicans 99 
14 Candida albicans 100 Candida albicans 99 
15 Candida albicans 99 Candida albicans 98 
16 Candida albicans 99 Candida albicans 98 
17 Candida albicans 97 Candida albicans 93 
18 Candida albicans 99  n/a 
Search done using blast search NCBI/nucleotide sequence on 11/3/09,Sample 4- 24 
letters in sequence, non-specific, Sample 5 no sequence for ITS 2 primer, Sample 7, 
its 2 primer only 44 letters long, Sample 8 its 2 primer only 21 letters, Sample 12 its 
primer 2 only 25 letters., Sample 19 its primer2 only 22 letters 
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Appendix IV: 
Ethical approval for CHC study 
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Appendix IV: IRAS approval for the use of archived biopsy samples (Chapter 5). 
 
